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ABSTRACT 
Importance:  In Africa most P. falciparum malaria infections during pregnancy remain asymptomatic 
yet are associated with maternal anaemia and low birthweight. WHO recommends intermittent 
preventive therapy in pregnancy during the second and third trimester with Sulphadoxine-
Pyrimethamine (IPTp-SP). However, SP efficacy is threatened by high-level parasite resistance. 
Thesis objectives:  
The objectives of this thesis were three fold: 
Efficacy and safety of ISTp-DP 
To evaluate the efficacy and safety of scheduled intermittent screening with malaria rapid diagnostic 
tests (RDTs) and treatment of RDT-positive women with Dihydroartemisinin-piperaquine  (ISTp-DP) 
as an alternative strategy to IPTp-SP in an area of high malaria transmission and SP resistance. 
Effect of asymptomatic malaria infections 
To investigate the effect of asymptomatic malaria infections, specifically evaluating the role of 
asymptomatic infections missed by a malaria rapid diagnostic test (mRDT) on pregnancy and birth 
outcomes.  
Diagnostic sensitivity of HRP2/pLDH RDT for active placental malaria 
To determine the sensitivity of an mRDT to detect active malaria infection sequestered in the 
placenta. 
Design, setting, and participants: This was an open-label two-arm individually randomised 
superiority trial in 3 sites with high SP resistance in Malawi. Between July 2011 and March 2013, 
1873 HIV-seronegative women at 16-28 weeks of gestation were recruited (1155 primigravidae and 
secundigravidae [paucigravidae], 718 multigravidae). 
viii 
 
Interventions: IST and IPTp-SP were administered at 3 or 4 scheduled visits in the 2nd and 3rd 
trimester, 4 to 6 weeks apart. The IPTp-SP arm received SP at each visit. The ISTp-DP arm were 
screened for malaria at every visit and treated with DP if RDT-positive.  
Main outcomes and measures:  
Efficacy and safety 
The primary outcomes of interest to evaluate the efficacy and safety of ISTp-DP were gravidity 
dependent. Amongst paucigravidae these were any adverse live birth outcome (composite of small-
for-gestation age, low birthweight or preterm birth) whilst amongst multigravidae, any P. falciparum 
infection at delivery was of primary interest. Analysis was by modified intention to treat.  
Effect of asymptomatic malaria infections 
Outcomes of interest in this analysis were composite adverse live birth outcome, individual adverse 
live birth outcomes (small for gestational age, preterm birth and low birthweight) and maternal 
anaemia. Analysis was restricted to only women in the IST arm fulfilling the modified intention to 
treat criteria.  
Diagnostic sensitivity of HRP2/pLDH RDT for active placental malaria 
The diagnostic sensitivity of mRDT on peripheral maternal venous blood at delivery for active 
placental malaria against placental histology as the gold standard was the primary outcome of 
interest. Analysis included women from both trial arms at delivery.    
Results:  
Efficacy and safety 
The prevalence of adverse birth outcome was similar in both arms: ISTp-DP=29.9%, IPTp-SP=28.8%, 
Risk-Difference: 1.08%, 95% confidence interval (CI): -3.25 to 5.41; Relative Risk (RR) =1.04 (0.90-
1.20), p=0.625, (paucigravidae: RR=1.10 [0.92-1.31], p=0.282; multi-gravidae RR=0.92 [0.71-1.20], 
p=0.543). The prevalence of malaria at delivery was higher in the ISTp-DP arm (48.7% vs 40.8%):  
Risk-Difference=7.85 (3.07-12.63); RR=1.19 (1.07-1.33), p=0.007 (paucigravidae: RR=1.16 [1.04-
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1.31], p=0.011; multi-gravidae: RR=1.29 [1.02-1.63], p=0.037). Foetal loss was more common with 
ISTp-DP (2.6% vs 1.3%; RR=2.06 [1.01-4.21], p=0.046) and highest among non DP-recipients (3.1%) 
in the ISTp-DP arm. 
Effect of asymptomatic malaria infections by RDT 
46.2% of women had malaria infection by either RDT or PCR at their first antenatal visit. The 
prevalence of sub-RDT infection was consistently higher in multigravidae than paucigravidae 
throughout pregnancy. The risk for any placental malaria was higher with asymptomatic missed RDT 
parasitaemia than never having had any detected parasitaemia at study visits: 38.8% vs 20.4%; RR= 
1.90; 95% CI 1.28, 2.82; p=0.002. This was consistent when stratified by gravidity. Missed infections 
were also associated with higher risk for composite any adverse live birth outcome (26.5% vs 12.8%; 
RR=2.06; 95%CI 1.23, 3.42; p=0.005) which was driven by the strong association with preterm birth: 
19.1% vs 4.1%; RR=4.7; 95% CI 2, 11.1; p<0.001. Asymptomatic patent RDT infections were 
associated with increased risk for maternal anaemia, placental malaria, composite adverse live birth 
outcome, preterm birth and low birth weight. 
Diagnostic sensitivity of HRP2/pLDH RDT for active placental malaria 
Peripheral blood RDTs at delivery were 48% sensitive (95% C.I 39.6, 56.4%) to diagnose active 
placental malaria infection. This was lower than PCR (64% vs 48%; difference=16.4%; 95% CI 8.4, 
24.5%; p<0.001) but higher than LM (48% vs 16%; difference=31.5%; 95% CI 22.4, 40.6%; p<0.001). 
The sensitivity of RDTs on placental blood to diagnose active placental infection was lower than in 
peripheral blood: 34% vs 48%; difference=-13.7%; 95% CI -21.1, -6.3%, p<0.001. Peripheral blood 
RDT had a low diagnostic sensitivity at 70% (95% CI 47.1, 86.8%) in detecting an active placental 
infection density of above 100parasites/500 RBCs, associated with an increased risk of low birth 
weight. 
Conclusion and relevance: Scheduled screening for malaria parasites with RDTs provided 3 to 4 
times during pregnancy as part of focused antenatal care was not superior to IPTp-SP in a setting of 
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high SP resistance, being associated with higher foetal loss and more malaria at delivery. This may 
be attributable to the effect of asymptomatic parasitaemia that are left to persists in the peripheral 
blood without treatment due to  low rate of detection of infection by RDTs through subsequent 
antenatal visits, and/ or the low sensitivity to detect active infection sequestered in the placenta. As 
such, in areas with high SP resistance, ISTp-DP is not a viable option. There remains an urgent need 
to identify alternative drugs that can replace SP for antenatal malaria prevention.  
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 Research overview 
1.1.1 Background 
 Women bear a greater disease burden in regards to reproductive health than their male 
counterparts. Pregnancy predisposes women to greater health adversities. In developing countries, 
infections and nutritional deficiencies pose a constant impediment to the wellbeing of both the 
woman and unborn child. Malaria in pregnancy remains a major public health challenge in areas of 
malaria endemicity with significant risks for morbidity and mortality to mother-fetal pairs. By 
absolute numbers, Plasmodium vivax which is endemic in mostly south-east Asia, the Indian 
subcontinent and Latin America is responsible for the greater burden of malaria in pregnancy (1). 
However, by severity of morbidity and mortality, a greater burden is witnessed in areas endemic to 
the most virulent species of the causative agent, P. falciparum. 
 Maternal anaemia as a result of malaria in pregnancy is a well-documented adverse outcome 
(2). Unlike infant mortality, there is relatively little evidence for the effect of malaria related maternal 
mortality other than indirectly through anaemia related morbidity. Low birth weight as a 
consequence of malaria induced intrauterine growth restriction (IUGR) or preterm delivery is a well 
characterised consequence of malaria in pregnancy through direct action at the placental level or 
independently through malaria-associated maternal anaemia (3-6). In addition, infant mortality has 
been demonstrated to be aggravated by malaria exposure during pregnancy (6, 7). Increasing 
evidence now suggests that pregnancy associated malaria may impact on subsequent neurocognitive 
(8, 9) and growth (10) trajectories in early childhood independent of low birth weight. 
 The World Health Organization (WHO) currently advocates a universal two pronged 
approach for the control of malaria in pregnancy in endemic regions. This framework constitutes 
prompt and effective case management and use of long lasting insecticide treated bed nets (LLITNs). 
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is an additional 
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third prong recommended for areas with moderate to high malaria transmission in sub-Saharan 
Africa (11).     
1.1.2 Study rationale 
 The growing trend in resistance to Sulphadoxine-Pyrimethamine culminated in the 
discontinued use of SP for the management of symptomatic malaria, having been replaced by 
artemisinin combination therapies in recent recommendations (12). However, SP continues to 
remain the only  drug recommended for intermittent preventive treatment for the control of malaria 
in pregnancy (13). The WHO recently revised its policy guidelines for IPTp-SP to be instituted to all 
pregnant women as early as possible in the second trimester at each scheduled antenatal visit as part 
of focused antenatal care until delivery, with at least one month between doses (11).   
 Several studies have demonstrated that IPTp-SP continues to remain effective despite 
growing resistance (14). Evidence from a recent study by Kayentao et al was integral to influencing 
the new recommendations by the WHO. This systematic review and meta-analysis of 7 trials with a 
total of 6,281 pregnancies demonstrated that increased dosing of SP was superior to the previous 2 
dose recommendation (15). However, this has been in overall consideration in areas of no more than 
moderate malaria transmission and SP resistance. Findings in areas of higher resistance suggest that 
with growing resistance the current observed benefits of SP as IPTp-SP is waning (16-18). These 
findings represent extremes of a spectrum of the impact of SP resistance on the effectiveness of IPTp-
SP. More recent unpublished findings by ter Kuile et al submitted to the WHO Evidence Review Group 
on malaria, demonstrated that the effectiveness of IPTp-SP decreased as the prevalence of resistant 
parasite genotypes increased (19).  
Alternative drugs and control strategies are urgently needed for the continued efforts to 
successfully control pregnancy associated malaria. Several trials have been and are currently 
underway to evaluate various mono- and combination therapies to replace SP for IPTp. Many that 
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have been completed have demonstrated little or no success due to poor performance in 
efficacy and/ or tolerability. Increasing interest has grown for alternative strategies that 
involve intermittent screening and treatment (ISTp) has received particular interest. The 
concept of ISTp involves screening pregnant women from the second trimester, at regular 
scheduled antenatal visits at least a month apart, with a malaria rapid diagnostic test (RDT). 
Women who have a positive RDT result are then treated with an efficacious antimalarial.  
We conducted a trial comparing ISTp with dihydroartemisinin-piperaquine (ISTp-DP) 
against IPTp-SP. The study was designed to provide the required evidence base to support 
policy makers with the development of potential alternative strategies that could replace IPTp-
SP in areas with high SP resistance in Malawi as well as contribute to the greater body of 
evidence toward global recommendations for alternative control measures for malaria in 
pregnancy. Furthermore, because of scant and often conflicting evidence of the effect of 
asymptomatic malaria infections, more so those missed by RDTs, on pregnancy outcomes, and 
the unclear efficiency of RDTs in diagnosing infections sequestered in the placenta, the study 
would be able to additionally evaluate the potential impact of low density sub-patent (PCR 
positive, RDT negative) infections on maternal and newborn outcomes.  
1.1.3 Objectives 
1.1.3.1 Primary objective: 
 To compare the efficacy and safety of scheduled intermittent screening with malaria rapid 
diagnostic tests (RDTs) and treatment of RDT-positive women with Dihydroartemisinin-piperaquine  
(ISTp-DP) against intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) 
in the second and third trimesters on adverse birth outcomes and malaria infection at term among 
HIV-negative women protected by insecticide–treated bed nets. Specifically, 
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1. To determine if ISTp-DP compared with IPTp-SP in the second and third trimesters of 
pregnancy is associated with at least a 25% reduction in adverse birth outcome as composite 
endpoint of low birth weight, preterm birth and small for gestational age in paucigravidae. 
2. To determine if ISTp-DP compared with IPTp-SP in the second and third trimesters of 
pregnancy is associated with at least a 50% reduction in placental malaria in multigravidae. 
1.1.3.2 Secondary objectives: 
 The principle secondary objective from this trial that is covered in this thesis is as follows: 
1. To evaluate the tolerability and safety of ISTp-DP in the second and third trimesters of 
pregnancy.    
 In addition, the following secondary objectives will also be evaluated for purposes of this 
manuscript, though not specified in the original trial protocol: 
2. Investigate the effect of sub-patent parasitaemia by RDT on pregnancy outcomes  
3. To evaluate the reliability of malaria rapid diagnostic test for the detection of active placental 
malaria independent of detectable peripheral parasitaemia. 
 Outline of this thesis 
 This thesis covers 3 main research discussions topics and has been arranged in 3 broad 
sections. 
1.2.1.1 Section 1: Introduction and methods 
Chapter 1 provides the a brief context in which this work has been based 
Chapter 2 addresses the literature review of the research topic in greater detail and  
Chapter 3 gives a description of the methods of the study from which this thesis is based. 
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1.2.1.2 Section 2: Results chapters 
Chapter 4 describes the findings of the clinical trial that evaluated the efficacy and safety of 
intermittent screening and treatment with Dihydroartemisinin-piperaquine compared to 
intermittent preventive treatment with Sulphadoxine-Pyrimethamine for the control of malaria in 
pregnancy. 
Chapter 5 evaluates the role of sub-diagnostic parasitaemia of common diagnostic tests on maternal 
anaemia and fetal outcomes. 
Chapter 6 seeks to   investigate the reliability of a pLDH/HRP2 combination malaria rapid diagnostic 
test for the detection of active placental malaria. 
1.2.1.3 Section 3: Discussion, further research, overall conclusion and recommendations 
Chapter 7 brings into context the brief individual discussion in the respective chapters in order to 
provide a perspective on the outcome of the performance of ISTp-DP against IPTp-SP and set the 
stage for future research. The chapter ends with an overall conclusion and policy recommendations 
from this work. References and annexes follow thereafter.  
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 General Introduction: Malaria in pregnancy 
2.1.1 Global epidemiology 
 Owing to the significant human capital and economic costs inflicted by malaria (20), control 
continues to remain a pertinent agenda of the global health community, philanthropists and 
multilateral development institutions alike, such as the World Health Organization (WHO), The Bill 
and Melinda Gates Foundation (BMGF) and the World Bank (WB) respectively. Global concerted 
efforts are embodied in the declaration of Millennium Development Goal 6C: To have halted by 2015 
and begun to reverse the incidence of malaria and other major diseases (20). The impact of malaria 
percolates into the very fabric of the economic development of nations where malaria remains 
endemic (21), contributing to the continuous cycle of poverty. Such is the economic cost of malaria 
that Africa losses an estimated US$ 12 billion annually, accounting for almost 50% loss in per capita 
gross domestic product (22, 23). Substantial economic gains have been evident where malaria has 
been successfully eradicated following the efforts of the 1960’s.    
 According to 2014 estimates (24), 3.3 billion people in 97 countries remained at risk of 
malaria with 36% at high risk (at least one malaria case per 1,000 persons). Approximately 125.2 
million pregnancies globally are at risk of the adverse effects of malaria in pregnancy (1). The burden 
of pregnancy associated malaria is concentrated in the geographical areas of Latin America, the 
Indian subcontinent and south-east Asia, accounting for 70.5 million pregnancies in low transmission 
or of predominantly Plasmodium vivax. Sub-Saharan Africa, with 54.7 million pregnancies, bears the 
brunt of intense malaria transmission, mainly by P.falciparum, the most virulent strain causing 
malaria disease. Though the former three areas account for an estimated 56% of the populations at 
risk, sub-Saharan Africa accounts for the vast majority of the morbidity and mortality burden of 
malaria per pregnancy. Malaria is estimated to account for between 19% and 43% of infant Low Birth 
Weights (LBW), with 6% of LBW related infant deaths occurring as a consequence of malaria induced 
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LBW (2, 25) as well as a higher perinatal mortality rate (26). Twenty-five percent of severe anaemia 
in pregnancies in sub-Saharan Africa are attributed to malaria infection, with an estimated 38% 
complicated by any degree of anaemia instigated by malaria infection. The effect of malaria in 
pregnancy accounts for about 10,000 maternal deaths, and 75,000 to 200,000 infant deaths annually 
(27).  
 Pregnancy increases a woman’s susceptibility to malaria infection (28), with those living in 
rural areas, in their first or second pregnancy, infected with HIV, and adolescents at particularly high 
risk. In endemic countries with stable malaria transmission, such as Malawi and much of sub-Saharan 
Africa, most malaria infections in pregnant women remain asymptomatic or have only mild 
symptoms, and are therefore undetected and untreated. Symptomatic or asymptomatic falciparum 
malaria infection affects the placenta and is associated with unfavourable outcomes for both mother 
and baby, including maternal anaemia, low birth weight (due to intra-uterine growth retardation or 
pre-term birth) and an increased risk of neonatal death (2). There is also increasing evidence that 
babies born to mothers with placental malaria infection are at increased risk of malaria infection in 
their first and second years of life, (29-32), and anaemia (33-35). Placental malaria has also been 
associated with reduced mother to child transfer of protective antibodies to infectious diseases such 
as measles (36). The control of malaria in pregnancy is therefore important for the health of mothers 
and babies and an important element of antenatal care in endemic areas.  
 Malawi country profile 
Covering an area of approximately 118,000 square kilometers, Malawi is a small land locked 
country in south-east Africa.  It is divided into 3 regions; North, Center and South, with 28 
administrative districts. Recent estimates by the United Nations Children’s Fund (37) peg the 
population at just under 16 million with more than half the population under the age of 18 years of 
age. Total fertility rate is estimated at 5.5 with 640,000 births per annum. Maternal and under five 
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mortality rates are relatively high, at 680/100,000 live births and 71/1,000 live births 
respectively though these are substantial improvements from previous years under survey. 
The national HIV prevalence is estimated at 10.8% with 13.6% of women in the reproductive 
age group being infected (38). Approximately 55% of households own an insecticide treated 
bed net and 94.7% of pregnant women attend at least one antenatal care visit. 
2.2.1 Transmission settings 
Lying between latitudes 9° and 18°S, and longitudes 32° and 36°E, the climate is 
generally of a tropical disposition with maritime influences, giving a strongly seasonal 
characteristic with the rainy season spanning between November and April, a colder dry 
season between May and August and a hot dry season between September and October. 
Between the drier and wetter months, humidity ranges from 50% to 87%. Positioned within 
the Great Rift Valley system, the topography of the country is characterised by undulating 
surface features of varying elevation, from predominant plateaus in the north of the country to 
plains, dotted highlands and valleys toward the south thus conferring variable weather 
patterns between regions which bear a strong influence on malaria transmission and infection 
risk. The highest risk is conferred in the low lying areas along the lakeshore, Shire Valley and 
central plains, that tend to be hotter, wetter and more humid, with lower risk in the highland 
areas (39). Malaria transmission occurs throughout the year with marked seasonal increases 
in malaria related morbidity and mortality. 
2.2.2 Vector ecology and pyrethroid resistance 
 Four main species of anopheline vectors serve as principle transmission agents namely; An. 
arabiensis, An. funestus, An. gambiae s.s. and An. Quadriannulatus (40, 41). With human blood indices 
of 99.2% and 96.3% respectively, An. funestus, An. gambiae s.s are highly anthropophilic. In tandem 
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with the well-recognised perennial transmission pattern, the presence of these vectors surge during 
the rainy season. 
 Pyrethroid resistance in Malawi is classified as moderate to high. Though few, previous 
insecticide resistance studies have demonstrated increasing levels of resistance by main vector 
actors to pyrethroids and, increasing worrying, to Dichlorodiphenyltrichloroethane (DDT), (42). 
Despite the trend in increasing insecticide selection pressure, recent evidence demonstrates a lack 
of a commensurate increase in malaria transmission with continued beneficial effect of pyrethroid  
LLITNs, though additional implementation of insecticide based control measures appears not confer 
any additional benefit within the current levels of vector resistance (43, 44).  
2.2.3 Parasite ecology and sulphadoxine–pyrimethamine resistance 
 The predominant species of Plasmodium is P.falciparum, occurring usually as monoinfections 
with the intermittent occurrence of mixed infections with other species, mainly P.malariae (45).  Non-
falciparum monoinfections are extremely rare. Resistance to Sulphadoxine-Pyrimethamine is wide 
spread with near saturation of quintuple mutants (46). 
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Figure 2.1 Map of proportion of the population under highest transmission intensity by district (predicted PfPR2-10, 40-50%. 
2010) 
 
 
(Bennett et al., 2013) 
 
 Malaria and HIV coinfection in pregnancy 
 Malaria and HIV infection commonly overlap in their geographic distribution (47) and whose 
intersection is more pronounced in pregnancy with significant consequences owing to the synergy 
in effects between the two diseases. An estimated 1 million pregnancies are complicated by 
coinfection with Malaria and HIV infection in sub-Saharan Africa every year (48). 
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 By compromising the immune system though the reduction in CD4 + cells and thus the cell 
mediated immunity, HIV infection substantially increases susceptibility to infection and severity of 
disease in pregnancy with greater adverse pregnancy and birth outcomes such as maternal anaemia 
and low birth weight (48). HIV infection consequently annuls the gravidity dependant immunity 
against malaria, rendering women of higher gestational orders vulnerable to the severity and risk of 
malaria infection as paucigravidae (49, 50). A review of the burden of HIV-1 and malaria co-infection 
found that HIV infected pregnant women consistently experienced higher placental and peripheral 
parasitaemia as well as malaria related morbidity and adverse birth outcomes (51).   
 Malaria in the face of co-existing HIV infection has been demonstrated to confer greater viral 
replication (52, 53) and resultant higher maternal viral loads (54).This confers the possibility of 
increasing the risk of mother to child transmission of HIV prenatally (52), though the body of 
evidence around this effect remains polarized with some studies not showing any additional risk 
conferred for mother to child transmission of HIV-1 (52, 55). In-vivo studies have however suggested 
that a possible mechanism for the facilitation of HIV transmission perinatally may be mediated 
through increased HIV-1 replication in placental cells instigated by TNF – alpha following a cell 
mediated response to VAR2CSA – CSA binding of infected erythrocytes in the intervillous vasculature 
of the placenta (56). 
 Maternal undernutrition and malaria in pregnancy 
 Nutritional status is a key determinant in pregnancy outcomes (57-59). Acute malnutrition 
demonstrates marked seasonality with higher incidence during the rainy season, which coincides 
with cultivation and food insecurity, as compared to the post rainy and dry season that coincide with 
harvests (60). The impact of this seasonal variability confers a similar seasonal trend on low birth 
weight. Peaks in LBW due to small for gestational age are evident at the end of the rainy season, 
culminating from low maternal energy intake during the cultivating season. However, this 
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observation may also arise as a result of chronic sub-patent malaria infections over the same period 
which also is characterised by high malaria transmission.  
 Studies of the relationship between maternal nutritional status and malaria susceptibility in 
pregnancy are few. In children under the age of five years, micronutrient deficiencies and gross 
undernutrition increase the burden of malaria related morbidity and mortality (61). Maternal 
undernutrition and malaria have been noted to interact in increasing the risk of IUGR (62) suggesting 
adverse birth outcomes could be improved through a coupled approach to nutrition and malaria 
intervention during pregnancy.  
 Malaria in pregnancy as a direct cause of maternal mortality 
 Traditionally, malaria in pregnancy has not been considered as a major direct cause of 
maternal mortality. However, evidence from a previous study by Menendez and colleagues in 
Mozambique has challenged this prevailing doctrine (63) by concisely evaluating the role of malaria 
which has lacked in previous maternal mortality autopsy studies. In this prospective autopsy study 
on causes of maternal deaths, evaluation for malaria parasitaemia, including CNS examinations and 
histology of multiple organs, were conducted and found evidence of malaria infection in 66.2% of the 
autopsies. 10.1% of the women (n = 14) were determined to have died due to severe malaria, more 
than a third of whom were due to cerebral malaria. 
 A more recent nationwide autopsy study conducted in Mozambique by Singh et al 
demonstrated a higher direct contribution of malaria to maternal mortality (64). Malaria accounted 
for 23.1% of maternal deaths in a setting where only 42.3% of pregnant women slept under an 
insecticide treated net and 19.6% received at least two doses of Sulphadoxine-Pyrimethamine for 
intermittent preventive treatment.  
 These two studies provide the most concise findings of the direct contribution of malaria to 
maternal mortality which has lacked in previous publications. Their findings highlight the 
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preventable contribution of malaria to maternal mortality which has been otherwise grossly 
underestimated. 
 Aetiology and pathophysiology of malaria in pregnancy 
 Of the known 120 species of Plasmodium, to date there are only 5 species known to cause 
malaria in humans: P.malariae, P.falciparum, P.ovale, P.vivax and more recently, a previously 
predominantly simian species, P.knowlesi, reported from Asia. With the exception of P.knowlesi, each 
species has a characterised virulence in the general population and particularly in pregnancy, with 
falciparum being the most aggressive, followed by vivax. The method of transmission of P.knowlesi 
from simian hosts has remained elusive but the impact by this strain is set to increase due to 
transmission within the human pool (65, 66). It has been postulated that P.knowlesi is likely to confer 
similar adverse pregnancy outcomes as P.falciparum and P.viax but the magnitude of risk and 
severity are subject to further investigation (67). 
2.6.1 Host malaria immunological responses in pregnancy 
 Immune responses to P.falciparum, which harbors the greatest virulence and confers the 
greatest burden of malaria morbidity and mortality globally, are the best characterised of all 
Plasmodium species causing malaria. The natural acquisition of protective immunity to P.falciparum 
is largely dependent on transmission intensity and develops as a result of the slow attainment of a 
broad spectrum of immune responses to several antigens, including members of the Plasmodium 
falciparum erythrocyte membrane protein 1 (PfEMP1) family. In pregnancy, this acquired immunity 
to blood stage malaria is reduced and further susceptibility to severe P.falciparum malaria infection 
is conferred, especially in the placenta due to a lack of immunity to placenta specific cytoadherence 
proteins. Immunity to placental cytoadherence only develops over the course of subsequent 
pregnancies which results in the reduced occurrence of malaria associated adverse outcomes in the 
mother and foetus over several pregnancies (68-70). 
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2.6.1.1 Cellular mediated responses 
 Due to the need to taper immune responses in pregnancy so as not to reject the fetal allograft, 
Th2 subset of T helper cells, supported by the hormones progesterone and oestrogen (71),  modulate 
a predominantly systemic anti-inflammatory response. This is mainly achieved through transforming 
growth factor β (TGF-β) and interleukins - 4, 5, 10 and 13. An initial pro-inflammatory sequence by 
Th1 cells via  interleukin (IL)-2, tumour necrosis factor α (TNF-α), and interferon gamma (IFN-γ) is 
essential being essential in the early phases of pregnancy to facilitate implantation (72) but is later 
dampened by the predominance of the anti-inflammatory response.  
 A high prevalence of malaria parasitaemia between weeks 10 and 12 of pregnancy (73) 
coincides with peak Th2 cytokine levels suggesting that the anti-inflammatory milieu during this 
period confers a state of temporary reduced immunity. Infection with malaria stimulates a Th1 
mediated immune response, which is elicited in the acute phase of the infection to clear the parasites 
(74). These responses when localised in the placenta as a result of  sequestration of infected 
erythrocytes (75) via the binding of the VAR2CSA antigen expressed on the surface of IEs, and 
chondroitin sulphate antigens expressed on the walls of the intervillous vasculature, stimulates 
localized expression of TNF-α (76) by macrophages. This initial reaction, coupled with expression of 
Migration Inhibitory Factor (MIF) from the syncytiotrophoblast, further stimulates macrophage 
recruitment leading to a vicious cycle of inflammation, consequently compromising the structural 
integrity of the placenta.  
 Unlike   TNF-α,  IFN-γ produced in response to malaria infection is not associated with 
adverse pregnancy outcomes (77). IFN-γ is postulated to confer a gravidity dependant protection 
reliant on the maternal ability to limit levels within non-pathological concentrations (78). 
Multigravidae undergo a rapid peak of IFN-γ levels in response to malaria infection that subsequently 
drops as opposed to sustained peaks seen in primigravidae (79).  
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2.6.1.2 Humoral mediated responses 
 Humoral response mechanisms are orchestrated by cell mediated immune responses to 
malaria infection via the activation of B cells by Plasmodium specific CD4 + T cells during blood stage 
infection (80), leading to the production of antibodies that prevent erythrocyte infection, block 
cytoadherence and promote phagocytosis by macrophages (74, 81). The placental cytoadherence 
phenomenon exhibited by P.falciparum is mediated by ligands expressed on the surface of infected 
red blood cells and surface adhesion molecules expressed on the placental vascular endothelium such 
as intercellular adhesion molecule 1 (ICAM-1), CD36, chondroitin sulphate A (CSA) and hyaluronic 
acid (82, 83). 
 Immunity against malaria in pregnancy, in particular, against placental sequestration 
mediated by VAR2CSA, is largely mediated by the evolution of humoral immunity over subsequent 
pregnancies with exposure to malaria (84). Immunity acquired prior to pregnancy is not protective 
against placental sequestration (85). This pregnancy-specific humoral mediated protection is 
conferred by immunoglobulin G (IgG) subclass of antibodies specific to the VAR2CSA ligand (86). 
However, antibodies to merozoite antigens, which are not specifically associated with pregnancy, 
also follow a parity dependent trend in conferring malaria protection.    
2.6.2 Effect of malaria infection on pregnancy outcomes 
2.6.2.1 Early peripheral parasitaemia and its impact on placental development 
 With peak malaria prevalence in pregnancy occurring prior to the full establishment of the 
placenta between 10-12 weeks of gestation (73), the induction of pro-inflammatory cascade may 
adversely impact the subsequent growth and expansion of placental vasculature between 16-18 
weeks through abrogated trophoblast invasion and migration (87). Recent in-vitro models have 
demonstrated reduced trophoblast invasion and migration when exposed to plasma from women 
infected with P.falciparum than plasma from uninfected women (87). These findings were further 
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suggested by the lower levels of trophoblast promoting hormones and higher concentration of 
inhibitory factors in P.falciparum infected plasma. In the same study, the well characterised virulence 
of P.falciparum infection was further evidenced as retarded trophoblast migration was not observed 
with plasma from women infected with P.vivax.  
 In mid-gestation, malaria infection results in the dysregulation of vascular development and 
angiogenesis regulated by Angiopoietins 1 and 2 (ANG-1 and ANG-2) in murine models (88). 
Furthermore evidence from a case controls study in 492 women showed that malaria in pregnancy 
was associated with derangement of the complement C5a system which, when blocked in mouse 
models, was associated with improved placental development and function (89). 
2.6.2.2 Placental sequestration and infection 
 The hallmark of Plasmodium falciparum infection in pregnancy after the placenta is 
established is the sequestration of infected erythrocytes in the placenta. This is mediated by the 
binding of VAR2CSA proteins expressed on the surface of infected erythrocytes to chondroitin 
sulphate-A receptors expressed in the placental vasculature (90). Pro-inflammatory mediators 
elicited in response to the expressed antigens lead to infiltration by inflammatory cells with 
consequent pathological changes to the placental architecture characteristic of placental malaria on 
histological examination (91-93). Recently, P.vivax has also been shown to bind to placenta ligands 
in-vitro (94) though thus has not been demonstrated in placental autopsies. Placental lesions are less 
pronounced in women infected with P.vivax, lacking the presence of the characteristic placental 
sequestration or hemozoin pigment of P.falciparum infection (95). 
 Localized inflammatory reactions in response to the sequestration of P.falciparum infected 
erythrocytes result in adverse birth outcomes (96) thought to be mediated through impaired 
nutrient invasion, dysregulation of growth regulating hormones and retarded placental vascular 
development (6, 97, 98). Furthermore, the propensity of this act of sequestration makes the diagnosis 
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of malaria infection based on peripheral blood examination difficult and thus leads to missed malaria 
infections (99). 
 As with systemic malaria antigen exposure, immunity to placental sequestration is largely 
unsterelising but develops with repeated exposures, conferring some degree of protection. As such, 
the consequences of placental infection are greater in paucigravidae than multigravidae (100) with 
this relationship being more pronounced in high transmission settings (101).  
2.6.2.3 Malaria induced anaemia in pregnancy 
 An estimated 400,000 pregnancies in sub-Saharan Africa are complicated by moderate to 
severe malaria-anaemia (102). Physiological adaptations during pregnancy predispose toward 
unfavorable fluid and iron balance, and consequentially to a higher risk of anaemia. Fluid retention 
mediated by argenine vasopressin (AVP) (103)  results in an increased intravascular volume which 
leads to hemodilution and physiological anaemia.  The increased metabolism of iron and folate 
mediated by fetal hepcidin (104, 105) further increases the demand for iron to sustain the maternal 
intrinsic requirements for erythropoiesis and fetal metabolism, which in instances of intake below 
the recommended daily allowance in pregnancy leads to iron deficiency anaemia (106) with 
consequent adverse pregnancy and birth outcomes. 
 Malaria induced anaemia is characterised by two main disease processes; parasite 
mechanisms infringing on erythropoiesis, iron metabolism, and infected erythrocyte sequestration 
in the spleen and placenta. The inflammatory cytokines induced by parasite infection has been well 
recognised in inhibiting erythropoiesis, with further suppression caused by the accumulation of 
heamozoin, a parasite by-product of haem metabolism, in the bone marrow (107).   Red cell 
destruction as the parasite migrates from the schizont to merozoite stages of the life cycle appears to 
play a less significant role in the pathogenesis of malaria anaemia (108). 
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 Organ sequestration plays a significant role in the genesis of anaemia syndromes in malaria 
in pregnancy. The red pulp zone of the spleen demonstrates intense phagocytic and free radical by 
macrophage activity in trapping and destroying parasitised erythrocytes much in a similar manner 
as senescent and aberrant red blood cells (109). This action may be mediated as a result of membrane 
and cellular transformations in the red blood cell following parasitisation, which may include loss of 
self-surface markers such as CD47, or the expression of foreign antigens on the red cell surface that 
promotes recognition, cytoadherence and phagocytosis in the spleen, with this high functionality of 
the spleen in acute infection characterised by spenomegaly (110). 
2.6.2.4 Adverse fetal outcomes 
 Low birth weight (birth weight less than 2.5kg) is one of the most well recognised 
consequences of malaria in pregnancy on the foetus, with a significant bearing on latter survival and 
development in childhood. This arises as a consequence of two different mechanism that may occur 
simultaneously or independently as a result of malaria infection in pregnancy. Due to the associated 
immunological mechanisms of each pathway, the relative contribution to LBW evidently follows the 
distribution of malaria transmission. In areas of unstable transmission where pregnant women have 
not developed a robust immunity to malaria, systemic malaria infection is characterised by fever, 
precipitating preterm birth and consequently, low birth weight (111, 112). In contrast, the burden of 
LBW in areas of stable malaria transmission is largely due to intrauterine growth restriction due to 
placental insufficiency and maternal anaemia induced by chronic and largely asymptomatic malaria 
infection (113). As such, there is a higher proportion of LBW characterised by small for gestational 
age (SGA). 
2.6.2.5 Post-birth ramifications of malaria in pregnancy independent of low birth weight 
 There is mounting, albeit inconclusive, evidence that maternal malaria infection increases 
infants’ susceptibility to malaria infection through the pre-natal exposure to malaria antigens and 
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possible immune-sensitisation. An early study conducted in Cameroon found no significant 
difference in the frequency of malaria between infants born to mothers with placental malaria and 
infants born to mothers without placental malaria during the first twenty four months of life (114).  
Findings from an analysis of a sub-set of the cohort suggested that increased infant susceptibility to 
malaria may be due to immunologic tolerance or congenital transmission of parasites (115), the later 
hypothesis which was supported by findings from a later study in Kenya where  children exposed to 
malaria in-utero acquire a tolerant phenotype to blood-stage antigens that persists into childhood 
and is associated with an increased susceptibility of the child to malaria infection and anaemia (116). 
Importantly, these effects are independent of low birth weight; i.e. they also occur in term children 
with normal birth weight. 
 A subsequent study conducted in Muheza District in Tanzania found that infants born to 
mothers who had evidence of placental malaria at delivery were 41% more likely to experience their 
first parasitaemia at a younger age compared to those who were born from mothers who did not 
have placental malaria at delivery (117). However, the increased risk was confined to infants born to 
multigravid women and not primi and secundigravid women which was surprising considering the 
known high risk of malaria in primigravidae and high incidence of post-neonatal infant mortality of 
infants born to malaria infected primigravid mothers with malaria (118-120). A more recent study 
from Gabon provided further evidence suggesting that malaria in pregnancy increases early 
childhood susceptibility to malaria infection. It found that offspring of mothers with placental P. 
falciparum malaria infection were about twice more likely to have clinical malaria in the first 30 
months of life than those born to uninfected women. In addition, the median parasite density was 
more than three times higher in infants born to malaria-infected mothers (121, 122).  
 Despite these suggestive findings of a biological mechanism conferring an increased risk of 
malaria morbidity in early childhood stemming from in-utero exposure, this association has been 
alternatively attributed to being a function of economic status and transmission intensity. Findings 
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from an infant cohort study conducted in a high transmission area in Ghana, born to mothers with 
and without evidence of placental malaria at delivery, showed no difference in the incidence of 
malaria in the first 12 months of life irrespective of gravidity, with the exception of infants from 
primigravid mothers who did not have placental malaria (a proxy for localised low transmission), 
who had a lower incidence of malaria infection and morbidity than the 3 other groups. There was 
however a marked association of economic status with the risk of malaria infection, with infants from 
poor households having a doubled higher risk than their counterparts from better socioeconomic 
classes (123). However, this comparison does not take into account the older age of children in the 
prior studies and thus may be a reflection of risk factors in the first 12 months of life, with the 
immunomodulatory mechanisms stemming from in-utero exposure playing a significant role in the 
later years of childhood. More so, additional recent findings from a study done in Cameroon points 
back to biological mechanisms that may stem from intrauterine exposure with IPTp-SP use and 
month of birth having increasing the risk of later susceptibility effect (124).   
 Malaria in pregnancy has been demonstrated to be a significant factor in early childhood 
survival in malaria endemic areas. Due to the direct effects on conferring higher risk of low birth 
weight, malaria in pregnancy indirectly increases the risk of infant mortality mediated by low birth 
weight (7, 125) . Owing to increased susceptibility to malaria infection as a result of in-utero exposure 
to malaria antigens, children exposed to malaria in pregnancy also succumb to a greater risk of 
malaria anaemia (9). Post birth anthropometric development has also been elucidated to be 
influenced by malaria exposure in-utero through the dependent effect of increased malaria 
susceptibility in childhood (126). Invariably, a vicious cycle exists, with malnutrition playing a 
further role in conferring higher risk of malaria infection and overall mortality in infants born to 
mother with malaria during pregnancy (127, 128). 
 Stimulation of the pro-inflammatory cytokine cascade due to exposure to malaria antigens 
directly (in congenital malaria though rare) or indirectly (in placental and maternal peripheral 
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malaria) as well as placental inflammatory cytokines produced in pregnancy associated malaria, may 
have a potentiating effect to adverse neurocognitive outcomes in infants in pregnancy associated 
malaria other than low birth weight (8). To this extent, it is estimated that infants born to primigravid 
and secundigravida mothers are at greater risk of neurocognitive impairment through this pathway 
as such mothers are more susceptible to malaria infection. Indirectly related to the occurrence of 
malaria n pregnancy, antimalarial therapies in chemoprophylaxis and treatment programmes in 
pregnancy have been widely studied to determine the safety and efficacy of antimalarials in 
pregnancy, reduction of maternal malaria associated morbidity and mortality and adverse birth 
outcomes. However, there is little evidence that has evaluated the impact of prolonged in-utero 
exposure to antimalarials on neurocognitive development. 
2.6.3 Malaria effect outcomes for clinical research endpoints 
 In the absence of HIV co-infection, clinical outcomes to measure the effect of interventions 
against malaria in pregnancy must take into consideration the sensitivity of the outcome by the 
influence of gravidity through acquired immunity (129, 130). Paucigravidae are more susceptible to 
aggressive pathophysiological consequences of malaria infection leading to greater risk of adverse 
fetal outcomes including, low birthweight, preterm birth and intrauterine growth restricted 
mediated small for gestational age (2), making them ideal indicators for effect. Malaria infection in 
multigravidae remains largely low density and asymptomatic with a lower significance on adverse 
fetal outcomes. However, persistent infections, both in the peripheral blood and sequestered in the 
placenta, have a strong significance on ex-utero consequences of new born morbidity and mortality 
(31, 131). As such, peripheral and placental malaria infection is an ideal indicator for effect amongst 
multigravidae. 
 Owing to the significance of these gravidity dependent outcomes, the magnitude of effect 
change to influence policy would differ. Conservative changes, such as a 25% effect size, in immediate 
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effect indicators in paucigravidae may be sufficient to influence policy owing to the weight of these 
outcomes. In comparison, the later effects of malaria infection, more pronounced in multigravidae, 
may require larger arbitrary effect sizes, such as a 50% effect change, to influence policy. Taking into 
consideration that individual outcomes are clinically meaningful, are of similar importance to 
pregnancy outcomes and do not exert any negative influence between each other , pooling them into 
respective gravidity specific primary composite endpoints would provide for greater statistical 
efficiency with respect to the anticipated effect size.        
 Implications of different malaria transmission intensities on the 
distribution and burden of malaria in pregnancy  
 Owing to the diverse transmission spectrum of malaria transmission, implications for 
consequences of malaria infection in pregnancy are equally diverse mainly dictated by the acquisition 
of antimalarial immunity through episodes of exposure (132). Pregnant women in low and unstable 
transmission regions have less developed antimalarial immunity and thus morbidity is mainly 
characterised by acute severe malaria syndromes such as severe anaemia and cerebral malaria, with 
the consequent high occurrence of adverse pregnancy outcomes and fetal and maternal mortality 
due to malaria (133).  
 Though sterilizing immunity is not obtained, repeated malaria exposure often confers a more 
robust antimalarial immune system in pregnant women in areas of more stable transmission (134) 
except in instances of immune suppression syndromes such as HIV infection (51, 135). In such 
scenarios, malaria infection is less patent and exists as a more chronic infection with low grade 
parasitaemia or often sub-patent and recurring. Though clinical syndromes are less acute, such 
infection status is sufficient to cause significant morbidity in pregnancy and adverse birth outcomes 
(25, 136, 137)  
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 Pregnancy: A possible reservoir for malaria transmission 
 Mature gametocytes are the sole transmission entity of malaria from human hosts to 
mosquito vectors. Commensurate with their greater susceptibility to malaria infection, there has 
been growing interest in the facilitation of malaria transmission by pregnant women especially in the 
growing context of Sulphadoxine – Pyrimethamine resistance. A recent study conducted in Blantyre, 
Malawi demonstrated significant gametocyte carriage by pregnant women at their first antenatal 
visit with IPTp-SP having no effect on the subsequent risk of gametocytemia in the later course of 
pregnancy (138). 
 The use of Sulphadoxine – Pyrimethamine has been demonstrated to be associated with 
increasing gametocyte carriage in both pregnant and non-pregnant populations. From 1998 to 2002, 
a study conducted in Mpumalanga Province, South Africa demonstrated a more than 7-fold increase 
in the duration of gametocyte carriage associated with the increasing prevalence of  
dhfr and dhps Sulphadoxine-Pyrimethamine resistance mutations (139).  A more recent study in a 
cohort of pregnant Nigerian women showed that IPTp-SP may actually predispose toward 
gametogenesis and gametocyte carriage (140) and recommended increased use of (LL)ITNs for the 
reduction of malaria transmission facilitated by pregnant women in malaria endemic regions where 
IPTp-SP is one of the strategies of choice for the control on malaria in pregnancy. 
 Current recommended use of artemisinin combination therapies for malaria case 
management ameliorates the risk of pregnant women in facilitating gametocyte transmission.  Based 
on guidelines for the management of uncomplicated malaria, published in 2010 by the WHO, 
artemisinin combination therapies are pivotal for the management of uncomplicated malaria (141) 
from the second trimester of pregnancy. Beside their efficacy in clearing asexual parasitaemia, ACTs 
also have gametocidal properties, reducing carriage 4-fold (142).  However, largely persistent 
asymptomatic infections in pregnancy mean that the majority of gametocyte carriage will not be 
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treated with ACTs and thus continued exposure of asymptomatic parasitaemia to SP during IPTp 
largely means pregnant women may become significant reservoirs for malaria transmission in the 
current era of growing SP resistance.  
 Control of pregnancy associated malaria: Current Recommendations, 
Strategies and Challenges 
 The World Health Organization (WHO) currently recommends a three pronged approach for 
the control of malaria in pregnancy; case-management of symptomatic malaria; providing long 
lasting insecticide-treated bed nets (LLITNs) to reduce exposure to infective mosquito bites; and 
intermittent preventive treatment of malaria in pregnancy (IPTp).   
2.9.1 Insecticide Treated Bed nets (ITNs) 
 Early individual and cluster randomised trials have established the benefits and cost 
effectiveness of insecticide treated bed nets in reducing the impact of malaria infection in pregnant 
and non-pregnant populations, and reducing malaria transmission, with several meta-analyses 
consolidating these conclusions. Early trials conducted in Africa from the late 1980’s to the early 
1990’s unequivocally demonstrated the protective efficacy of ITNs against malaria morbidity and 
mortality in children of up to 62% (143-145), findings which were further strengthened in more 
recent studies (146).  Consolidation of these findings in a meta-analysis further supported the 
evidence of ITNs as a cost-effective strategy for the prevention of malaria in children (147, 148). ITNs 
not only reduced malaria associated morbidity and mortality in children but also reduced malaria 
transmission at the population level through reduced vector populations (149-152). The protective 
effect of ITNs however may be transmission dependent as demonstrated by a recent study conducted 
in Myanmar, in an area with unstable and highly seasonal transmission, where no additional benefit 
was conferred by the use of  ITNs  (153). Additional concerns have been raised of the risk of rebound 
mortality in older child hood age groups with extended ITN use and the concomitant overall cost 
27 
 
effectiveness of ITNs (154) but these concerns have largely remained unsubstantiated in further 
studies (151, 155, 156). 
 Following the encouraging efficacy findings of ITNs on malaria morbidity and mortality in 
children, several subsequent trials were conducted, evaluating the impact of ITNs on malaria 
associated pregnancy outcomes. An early study amongst primigravidae eastern Kenya, characterised 
by lower malaria transmission with an estimated entomological inoculation rate of 10 infective bites 
per person per year, demonstrated no beneficial impact on several outcomes including birthweight 
and severe anaemia (157). However, a later study in western Kenya with more intense transmission 
showed ITNs had significant protective efficacy on anaemia, low birthweight, placental malaria and 
maternal malaria at delivery, with reduced incidences of malaria infection (158). The contradiction 
in findings between the two studies strongly suggested the influence of local transmission intensity 
on the efficacy of ITNs on pregnancy outcomes, similarly to paediatric populations. Evidence from 
several meta-analyses have demonstrated that ITNs overall are beneficial for the protection of 
pregnant women against malaria and improvement of pregnancy outcomes (159). One of the most 
recent and comprehensive meta-analyses undertaken on the protective effect of antimalarial 
interventions in pregnancy and related pregnancy and infant outcomes collated data from 32 African 
countries. The study demonstrated significant reductions in malaria associated morbidity and 
adverse birth outcomes with the use of ITNs under operational conditions (160). These results were 
supportive of findings from an earlier systematic review of five ITN trials (161) which demonstrated 
reduced adverse live birth outcomes as well as maternal parasitaemia and anaemia with ITN use. 
Despite concerns of rapidly expanding pyrethroid resistant vectors, the ITNs appear to provide 
continued benefit against the adverse effects of malaria in children and pregnant women as 
evidenced from recent findings from a study in Malawi where non-ITN users were 1.5 times more 
likely to have malaria infection and ITNs reduced the incidence of malaria infection by 30% (162). 
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 Long Lasting Insecticide Treated Bed nets for the prevention of malaria in pregnancy 
continue to be aggressively advocated by the WHO (163) and have been the subject of greater 
resource mobilization in malaria prevention efforts. An estimated 214 million LLITNs were 
distributed in 2014 (24) with a large proportion in the decline in malaria associated morbidity and 
mortality in pregnancy being attributed to LLITNs in light of rising SP resistance (164, 165). Indeed 
owing to this efficacy, the WHO strongly advocates for universal coverage of LLITNs instead of 
previous limitations only to vulnerable populations (under 5 children and pregnant women) (165). 
2.9.2 Effective case management  
 Despite robust efforts to prevent malaria infection by use of ITNs, cases of clinical malaria are 
inevitable. It is within such incidents that prompt and effective case management with an efficacious 
antimalarial drug is required. Effective case management entails two principles; accurate diagnosis 
and treatment with an efficacious antimalarial. 
 Proven parasitaemia is a prerequisite for the prescription and administration of antimalarial 
drugs (141, 166, 167) to prevent unwarranted drug pressure that would cultivate drug resistance of 
current first line antimalarial agents. Examination of thick blood films was previously the 
recommended standard for diagnosing malaria. However, due to poor infrastructure, limited 
expertise and being time consuming, light microscopy has posed a significant hindrance to access to 
effective case management in many resource limited settings.  The advent of lateral flow 
immunochromatographic assays for malaria has provided the much needed reprieve for poor 
resource settings, mostly characterised by high caseloads, allowing equitable access to effective 
malaria treatment. More commonly known as malaria Rapid Diagnostic Tests (mRDTs), these novel 
assays are quick and simple to use, having proven to be as reliable as traditional microscopy for the 
diagnosis of malaria (168) and suitable in settings where microscopy presents a bottleneck to access 
to effective management of clinical malaria. 
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 Current treatment guidelines for uncomplicated malaria in the first trimester of pregnancy 
by the WHO recommend a seven day course of quinine and clindamycin or artesunate in place of 
quinine if the initial regimen fails, with an ACT permitted if it is the only treatment available (141). 
Within the second and third trimesters, a regionally appropriate ACT is recommended or 
alternatively, first trimester regimens may be prescribed. ACTs have been shown to be efficacious for 
treatment of falciparum and non-falciparum species of Plasmodium (169, 170). However, despite the 
wide spread use of ACTs in pregnancy, clinical data on safety and efficacy in early pregnancy is limited 
and inconclusive (171). Recently completed treatment trials in pregnancy in Africa are expected to 
provide further insight into the safety and efficacy the 4 fixed-dose combination ACTs available to 
date in the 2nd and 3rd trimester  (172). 
2.9.2.1 Dihydroartemisinin-piperaquine (DHA-PQ) in pregnancy 
 Treatment trials in non-pregnant adults and children have shown DHA-PQ to be highly 
effective and well tolerated (173). Minor adverse events associated with DHA-PQ included nausea, 
vomiting, loss of appetite, diarrhoea, abdominal pain, and headache, dizziness, and sleep disturbance 
(173). A case series study in Thailand using DHA-PQ to treat pregnant women after treatment failure 
with quinine suggested that DHA-PQ was effective in pregnancy at the standard adult dose (174). 
Significant experience with DHA-PQ in the second and third trimester from southern Papua New 
Guinea and Indonesia, where the drug has been used as first line treatment in the second and third 
trimesters of pregnancy, has shown dihydroartemisinin-piperaquine to be very effective, safe and 
well tolerated in the second and third trimesters of pregnancy.  
 Despite animal studies having demonstrated artemisinins to be embryotoxic and potentially 
teratogenic in very early pregnancy in all animal species tested, similar findings have not been noted 
in humans as there remains a paucity in documented effects of exposure in the first trimester. In over 
1,000 documented pregnancies, no adverse effects on the mother or foetus were noted when 
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dihydroartemesinin-piperaquine was administered in the second or third trimester of pregnancy 
(12).  
 Reproductive toxicity studies in Australia (Davis, unpublished observations) and more 
recently by Sigma Tau (Medicine for Malaria Venture, personal communication) have not raised 
safety concerns with piperaquine. A lengthening in the duration of labour in rat models has been 
observed (Medicine for Malaria Venture, personal communication), but this has not been confirmed 
in humans in Thailand (Nosten, personal communications). Despite raising bioavailability and 
antimalarial efficacy (175), concerns of piperaquine cardiotoxicity have been raised following either 
co-administration with fat or repeated dosing that may result in elevated risks of prolongation of the 
QT interval (QTc) (176, 177).These concerns have not been validated in studies conducted in 
paediatric, non-pregnant and pregnant populations when administered at recommended doses (178-
180). However, significant QTc prolongation with a grade 1 cardiac event has been observed in a 
sample of healthy male volunteers when the treatment regimen was shortened from 3 to 2 days 
owing to the effective rapid raise of the piperaquine plasma concentration (181).    
2.9.3 Intermittent preventive treatment with sulphadoxine-pyrimethamine 
 Intermittent preventive treatment in pregnancy (IPTp) is currently recommended for HIV-
negative women in all areas with stable moderate to high transmission of malaria (13). The strategy 
consists of administration of treatment doses of an efficacious antimalarial drug at predefined 
intervals at least a month apart during the second and third trimesters of pregnancy, regardless of 
the presence of malaria parasitaemia. The previous policy was to provide two doses as part of routine 
antenatal care but this has since been revised by the WHO to a dose at every antenatal visit from 
quickening up to 36weeks, at least 4 weeks apart (182) . The strategy is thought to work by providing 
intermittent clearance or suppression of parasites in the placenta, and preventing new infections 
from occurring.  
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 Sulphadoxine-Pyrimethamine (SP) is the only drug currently used for IPTp. It has a profile 
that makes it highly suitable for this use. SP is very well tolerated and safe in the second and third 
trimester of pregnancy for mother and foetus (14). SP is also widely available, cheap, and can be given 
as a single dose. IPTp-SP is not recommended for HIV-positive women. WHO recommends that HIV-
positive women receive co-trimoxazole prophylaxis for HIV-related infections (183). As co-
trimoxazole and SP are both sulpha-containing drugs, SP is contra-indicated in HIV-positive women 
receiving co-trimoxazole. However, co-trimoxazole itself has some antimalarial properties and 
therefore serves to protect pregnant women with HIV infection from malaria infection (183).  
 As part of efforts to halt and reverse the incidence of malaria by 2015, and achieve a further 
90% reduction by 2030 as outlined in the previous Millennium Development Goals and current 
Sustainable Development Goals respectively, coverage of malaria interventions, including IPTp-SP, 
were earmarked for at least 80% coverage (184). Despite the simplicity of the strategy, operational 
delivery has largely remained ineffective in many countries with an estimated 48% of pregnant 
women in endemic settings not receiving any dose of IPTp-SP in 2013 (24). Findings from a synthesis 
and meta-analysis of national survey data between 2009 and 2011 from 27 countries showed that 
despite relative improvements in coverage of 2 dose IPTp-SP, the achieved levels remained below 
international recommendations (185). Estimates from Malaria indicator surveys in Malawi in 2012 
and 2014 have shown 54% and 64% of eligible pregnant women receiving at least 2 doses of IPTp-
SP (186, 187).  In light of the recent amendment of recommendations by the WHO for IPTp-SP to be 
administered at each antenatal visit from the 16 week of gestation, at least 4 weeks apart, indicating 
an upward recommended dosing of 3 or more doses (3, 11), there remains concern on the ability of 
national control programmes to scale up the coverage of the new recommendations stemming from 
a background of below par coverage of the prior lower dosing regimen as reflected by coverage of 
less than 10% in a recent systematic analysis of 58 household surveys from sub-Saharan Africa (188).  
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2.9.4  Other strategies for the control of malaria in pregnancy: Unsanctioned policies, 
a sign of desperation  
 The WHO has no other recommendations for the control of malaria in pregnancy other than 
the three pronged approach. However, this renders prevention policy in areas of unstable 
transmission, where P.vivax is predominant or areas of reducing transmission, vulnerable to lack of 
guidance where IPTp-SP may not be applicable. Growing resistance to SP in areas of stable 
transmission has also brought the sustainability of IPTp-SP into question.  
 To date, Indonesia is the only country that has implemented Single Screen and Treat in 
pregnancy (SSTp) as a policy in place of IPTp-SP. The strategy involves screening all pregnant women 
at their first antenatal visit and treating those with malaria. Thereafter, passive case detection is 
employed and women are only treated for symptomatic malaria. The efficacy of this strategy has no 
supportive evidence and currently for the first time in Asia, a clinical trial evaluating IPTp with 
Dihydroartemisinin-piperaquine and Intermittent Screening and Treatment with 
Dihydroartemisinin-piperaquine  are being evaluated as alternative options in this region (189), the 
result of which are anticipated in 2016. 
 As a result of declining malaria transmission and subsequent reductions in the prevalence of 
placental malaria or concerns over SP resistance, some countries have abandoned IPTp–SP.  Despite 
WHO recommendations, Rwanda discontinued IPTp–SP as a policy in 2008 due to increasing SP 
resistance and declining malaria prevalence. A recent study in Zanzibar has questioned the continued 
implementation of IPTp–SP in light of low prevalence of peripheral parasitaemia (190), with 
intensified surveillance, continued vector and transmission control with LLITNs and effective case 
management being recommended. 
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 Determinants of the effectiveness of Intermittent Preventive Treatment 
with Sulphadoxine-Pyrimethamine 
 The frequency of dosing has been unequivocally demonstrated to improve IPTp–SP efficacy 
across transmission settings. In a randomized control trial comparing 2 vs 3 doses of IPTp–SP in an 
area of highly seasonal malaria transmission and low SP resistance,  adding a third dose of IPTp–SP 
halved the risk of adverse pregnancy outcomes in all gravidities (191). A meta-analysis of 7 trials 
with over 6,000 pregnancies concluded 3 or more doses of IPTp–SP improved birth outcomes 
significantly in comparison to 2 doses (15). 
 In areas of high transmission with moderate SP resistance, at least two doses of IPTp-SP were 
associated with significant protective efficacy which was more pronounced in paucigravidae (192). 
In this retrospective birth outcomes study in Mansa, Zambia, at least two doses of IPTp–SP showed a 
reduction in LBW and any malaria infection.  
 A comparative study of the effect of IPTp–SP in two different transmission settings in 
Tanzania comprehensively underscores the transmission dependency of the efficacy of IPTp–SP. 
Using a prospective observational study design in two areas of differing transmission, one high and 
one low, IPTp–SP was effective in lowering the risk of placental malaria in the high transmission 
setting with no significant effect in the low transmission area (OR 0.2; CI 0.06-0.7; P = 0.015 vs OR 
0.4; CI 0.04-4.5; P = 0.478 respectively). However, IPTp–SP use did not confer any protection to 
maternal anaemia or LBW (193). 
 Work in HIV sero-positive pregnant women has however remained controversial.  Earlier 
work in Malawi comparing 2 doses against monthly dosing of IPTp–SP in HIV sero-positive and 
seronegative women demonstrated greater efficacy of monthly dosing than the standard 2 doses in 
the HIV sero-positive cohort (194). However, a study in Zambia showed no significant effect of 
increased dosing on any maternal or birth outcomes (75). These differences may be attributable to 
differing transmission intensities in the two study settings.  
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 Sulphadoxine –Pyrimethamine resistance: mechanism and drivers of an 
ever growing challenge for malaria control in pregnancy 
 Drug resistance has been a recurring impediment to malaria control efforts, in particular for 
the control of malaria in pregnancy.  Prior to the advent of IPTp-SP, weekly chloroquine 
chemoprophylaxis was the mainstay of malaria prevention in pregnancy (195).   The rapid spread of 
chloroquine resistance over the next two decades from the 1950’s, following emergence of resistance 
along the Thailand – Cambodia border (196) rendered chloroquine inefficient for case management 
or prophylaxis in pregnancy in malaria endemic areas. Following notable improvements in 
pregnancy and birth outcomes through several randomized trials and observational studies in the 
1990’s (197, 198), IPTp–SP was adopted as a replacement strategy.  
 However, rapidly expanding resistance, like its predecessor chloroquine, rendered SP 
ineffective for case management, with subsequent recommendations for withdrawal of SP for active 
case management and replaced with ACTs. Despite high treatment failure rates due to resistance, SP 
has remained a critical component for malaria control in pregnancy strategy advocated by the WHO 
as being the drug of choice for IPTp. This continued role has however been greatly overshadowed by 
the growing body of evidence that with an the advancement across a spectrum of severity and 
prevalence of SP resistance, IPTp-SP may gradually no longer present a viable option in malaria 
control efforts in pregnancy (164, 199, 200) despite incremental dosing showing additional benefits 
(3).   
2.11.1 Molecular mechanisms of sulphadoxine-pyrimethamine resistance  
 Random genetic mutations are responsible for conferring mechanisms of antimalarial drug 
resistance. These mutations in eukaryotic cells occur in the order of 1 in 106 mitosis cycles and viable 
mutations are subsequently selected out under pre-existing environments (201). In addition to 
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mutations, gene duplication, which occur more readily than mutations, may play a significant role in 
the development of drug resistance.  
 Anti-folate resistance by P.falciparum is conferred by point mutations in the dihydrofolate 
reductase (dhfr) and dihydropteroate synthase (dhps) genes.  Anti-folate class of drugs, of which 
Sulphadoxine - Pyrimethamine, Cotrimoxazole and Chlorproguanil-Dapsone are included, exert their 
action through inhibiting parasite enzymes essential to parasite folate biosynthesis through 
decreased production of folate precursors which irreversibly inhibits the parasite life cycle (202).  
 Mutations in the dhfr genome have been associated with increased resistance to 
Pyrimethamine (203) with triple mutations conferring high resistance to Pyrimethamine in-vivo and 
associated with clinical treatment failure (204, 205). Aberrations in dhps accord resistance to 
Sulphadoxine and commonly occur as a double mutant genotype A437G, K540E. In concert with 
triple dhfr mutations S108N, N51I and C59R, they form a quintuple mutant haplotype that is 
associated with high levels of SP resistance, though not associated with a total failure of IPTp–SP 
(206) or exacerbation of adverse consequences of malaria in pregnancy (207). However, a sextuple 
mutant phenotype that incorporates an additional mutation at the dhps 581 condone (A581G 
mutation) exhibits high IPTp–SP failure rates (208, 209) and is a strong predictor of IPTp–SPfailure. 
 A previous study in the Muheza district of Tanzania demonstrated that the additional A581G 
mutation was strongly associated with increased parasitaemia and placental inflammation that could 
worsen pregnancy outcomes (16, 199). In the same area, the continued administration of IPTp–
SPwas associated with an earlier time to first parasitaemia and a greater odds of severe anaemia in 
children born to mother who used IPTp–SP (16). These findings suggested that the additional 
dhps A581G conferred a selective advantage to parasites harboring this mutation under SP drug 
pressure and thus exacerbating malaria mediated placental pathology. This conclusion was however 
not supported by observations by a later study (210). 
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 Irrespective of the presence of the sextuple mutation, the very existence of the quintuple 
mutation also renders IPTp–SP ineffective in some areas, occurring along a spectrum of 
ineffectiveness which is largely dependent on the prevalence of resistant haplotypes (19). A cross-
sectional study in Tororo, Uganda, where the sextuple mutation is low but malaria transmission is 
high, showed that even more than 2 doses of IPTp–SP were not protective against individual adverse 
pregnancy outcomes   (211).  In Malawi, improvements in pregnancy outcomes have been ascribed 
to greater coverage of ITNS and not the continued efficacy of IPTp–SP (164). These observations may 
be related to the differential prevalence of the quintuple mutation compared to other areas where 
IPTp–SP remains effective transmission as the WHO prescribed guideline  for implementation of IPT 
in infants (IPTi) makes the consideration that IPTi with SP should not be implemented in areas with 
a greater than 50% prevalence of the dhps K540E mutation as a marker for the quintuple haplotype 
(212). 
 Due to the regional differences in the prevalence of A581G associated mutations conferring 
super resistance and the dhps A437G mutation, which is prevalent in conferring SP resistance in west 
Africa (213), the continued monitoring of P. falciparum dhps A581G and K540E mutations remains 
essential to inform policy adaptation in respective settings (214). 
2.11.2 Drivers of drug resistance and the consequent development trajectory of SP 
resistance  
 Recent observation of the re-emergence of chloroquine naïve P.falciparum after an extensive 
period of the absence of chloroquine use strongly indicated the potentiating effect of drug pressure 
in driving sustained drug resistance (215-217) and igniting hope for renewed use of chloroquine for 
malaria treatment interventions in light of SP resistance.  
 The use of SP in IPTp has been associated with the competitive facilitation of drug resistant 
strains of P.falciparum. IPTp–SP was noted to select for increased fractions of parasites exhibiting 
A581G mutation in Tanzania (18). However, recent findings from a study in Malawi shows that the 
37 
 
relative reduction in drug pressure is not an adequate factor in fostering the return of SP 
susceptibility. Samples from patients with clinical malaria  spanning periods of high, transitional and 
low SP use, following the switch in first line treatment policy in Malawi in 2007 to ACTs, showed an 
 
Figure 2.2 Countries where prevalence cut-off values of major SP resistance mutations are exceeded 
 
 
 
(Naidoo and Roper, 2013) 
 
increase in the quintuple phenotype even during the period of reduced SP use (218). These 
observations may be due to sustained drug pressure from IPTp–SP (219), though minimal in 
comparison to population pressure exerted by use in case management, but in the absence of which 
may present a significant drug pressure, or cross resistance due to the extensive use of trimethoprim-
sulfamethoxazole (Cotrimoxazole) in HIV management for prophylaxis against opportunistic 
infections (220).  
  Drug pressure does not appear to be the sole driver for drug resistance. Entomological 
studies have suggested the role of the Anopheline vector in selecting P.falciparum resistant 
phenotypes as suggested by vector control studies (221, 222). A recent study conducted in Southern 
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Zambia demonstrated a reduction in transmissible chloroquine resistant P.falciparum  despite high 
chloroquine resistant mutants in the human population (223). This has been similarly observed for 
Pyrimethamine resistance (222) and associated with a restoration of SP sensitivity (224) as a result 
of the re-expansion of sensitive strains as in the case of the re-emergence of chloroquine sensitivity 
(225). Consequently, continued and aggressive vector control resulting in vector selection may 
facilitate the resurgence of wild type dhfr and dhps codons sensitive to SP. 
2.11.3 Sulphadoxine-Pyrimethamine resistance and declining effectiveness of IPTp-
SP in Malawi 
 Malawi was the first country to introduce IPTp-SP in 1993, and the strategy initially appeared 
effective. Monitoring by the Queen Elizabeth Central Hospital in Blantyre showed that between 1997 
and 2006 the prevalence of placental malaria detectable by microscopy decreased five-fold from 
21.2% to 4.2% in first pregnancies and ten-fold from 18.9% to 1.9% in second and subsequent 
pregnancies (164). At the same time there was a steady increase in ITN use from 18% to 60%; while 
IPTp-SP use increased from around 20% in 1997 to 78% in 2002, but dropped again to less than 50% 
by 2006, suggesting that the increased use of ITNs was responsible for the continued fall of placental 
malaria rates (164).  
 The same study observed that the effectiveness of IPTp-SP in Malawi appeared to reduce 
dramatically between 2002 and 2006, to the extent that it appeared to be no longer be protective. 
After 2002, women who received two or more doses of IPTp-SP were equally likely to have placental 
malaria, anaemia, or low birth weight babies compared to women who had not received any IPTp. 
During the same period, ITNs were strongly associated with higher birth weights and decreased 
infection rates.  
 These finding are consistent with an increasing impact of SP resistance on IPTp effectiveness. 
The degree of SP resistance in 2001-2004 was high; over 90% of parasites had the ‘quintuple mutant’ 
(dhfr mutations N511, C59R and S108N, and dhps mutations A437G and K540E) associated with SP 
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resistance.(226) However, previous trials have also shown that IPTp-SP provides less benefit in 
women who are also protected by ITNs (227); therefore the reduced efficacy of SP probably reflects 
the combination of high concurrent ITN use and high levels of SP resistance.  
 More recent observational studies of the impact of SP resistance on IPTp-effectiveness have 
been cause of further concern about the longevity of SP, with further evidence that at the current 
levels of resistance (year 2010). Preliminary analysis of the in-vivo follow-up module showed that by 
June 2010, 43 of 87 (49.4%) asymptomatic parasiteamic women receiving SP in their first or second 
pregnancy were parasiteamic again between days 7 and 42, compared to only 6 of 72 (8.3%) women 
in their third or subsequent pregnancies. At delivery pregnant women were equally likely to be 
parasitaemia when they had received the full course of SP or no SP at all (Relative risk 0.99) (Kalilani-
Phiri, L and ter Kuile F, personal communication). However the risk of LBW was lower among SP 
recipients. 
 Alternative approaches to IPTp-SP in light of declining effectiveness 
 The problem of declining IPTp effectiveness requires urgent investigation and consideration 
of studies for alternative approaches to IPTp-SP. The two possible options for consideration are 
replacing SP alone with other drug combinations for IPTp, or alternative strategies to replace IPTp. 
2.12.1 Same strategy, different drug: Alternative drugs to Sulphadoxine-
Pyrimethamine for IPTp 
 A series of studies have evaluated several alternative drugs that could replace SP for IPTp. 
Any ideal drug would require to possess the characteristics outlined in the table below. The 
emergence of chloroquine sensitivity in Malawi (215) has inspired the consideration of chloroquine 
alone as a substitute for SP in IPTp (228). The results of this trial are yet to be published. Chloroquine 
has additionally been considered in combination with azithromycin as a viable substitute for SP in 
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IPTp (229, 230). However, a multicenter trial of fixed dose chloroquine-azithromycin for IPTp was 
terminated (231).   
 Azithromycin has been combined with SP to provide synergism of anti-malarial effect in IPTp 
as well as additional benefits of clearing reproductive tract infections associated with preterm birth 
and adverse pregnancy outcomes. An early trial conducted from 2003 of monthly SP with two doses 
of azithromycin (SPAZ) in Malawi showed a significant reduced risk of preterm delivery (RR=0.66, P 
= 0.01) and LBW (RR = 0.61, P = 0.02). However, this period when the trial was conducted had a low 
prevalence of SP resistance and as such findings may not be reproducible in the current era of near 
saturation of quintuple mutations (232). The postulation that SPAZ may be viable in settings of low 
SP resistance is further evidenced by findings from a recently published trial in Papua New Guinea 
(PNG) where high and super resistance phenotypes are absent (233). In this trial, SPAZ was 
efficacious in reducing LBW, preterm births, maternal parasitaemia and active placental malaria. A 
study in Ghana showed IPTp with amodiaquine or a combination of amodiaquine and SP to have 
comparable effects to SP (234). Findings from SP combination trials strongly suggest that any SP 
based combinations would likely be inappropriate in areas of high or super SP resistance.    
 A study in Benin showed mefloquine was more efficacious than SP for preventing placental 
malaria, clinical malaria, and maternal anaemia at delivery (235). However, these findings were not 
consistent in a trial conducted in Mozambique that found IPTp with mefloquine not to confer any 
additional benefit on placental infections and birth outcomes than IPTp-SP in both HIV uninfected 
and infected women (236, 237) and thus not supportive of a policy change. 
 None of the new IPTp candidates have the same favourable profile as SP alone; they are more 
complicated to give (azithromycin-chloroquine and amodiaquine-based regimens need to be taken 
once daily for three days, compared with a single dose for SP) and are not as well tolerated (such as 
mefloquine based regimens), which are important considerations in a strategy that targets otherwise 
healthy asymptomatic women.  
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 Dihydroartemisinin–Piperaquine has also been enlisted into the band wagon of potential 
candidates to replace SP for IPTp. A recently concluded trial conducted in Kenya (238) has evaluated 
the efficacy of IPTp–DP against IPTp–SP and ISTp–DP, the results of which will only be available later 
in the year.  A similar trial is also being conducted in Indonesia to evaluate efficacy against 
predominantly P.vivax (189). 
 
Table 2.1 Optimal IPTp drug profile  
The optimal IPTp therapy would be a combination of two molecules that: 
✓ Exhibit similar time above minimum inhibitory concentrations 
✓ Support a once per month dosing regimen (≤ 2 doses) 
✓ Have different mode of actions to reduce resistance selection 
✓ Are active against asexual & sexual stages 
✓ Are not necessarily rapid acting 
✓ Are either a fixed dose or loose combination 
✓ Different from first line treatment for symptomatic malaria 
✓ Ideally active against other treatable maternal health problems, e.g. STI/RTI, maternal-fetal 
transmission of infection 
✓ Are safe during all the pregnancy, although pregnant women are unlikely to receive the first dose of 
IPTp in the first trimester 
✓ Cost as little as possible per pregnancy with prices that are in line with current price estimates for 
artemisinin combination therapy (218) 
  
  Note: There are no new classes of medicines with plasma exposures above MIC for 28 days. Such exposure is most likely to be 
achieved by slow release depot formulations which would require molecules with doses of less than 10 mg/day. No such 
compounds currently exist. 
 
Adapted from “Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually 
transmitted infections in pregnancy. Chico and Chandramohan, 2011. (230) 
  
 Malaria transmission among pregnant women has reduced considerably following increased 
control measures including indoor residual spraying (IRS), widespread ITNs and use of ACTs in the 
community (ACTs kill gametocytes and can therefore help reduce transmission). This reduces the 
number of women at risk of malaria and the potential impact and cost-effectiveness of presumptive 
approaches such as IPTp. The marked reduction in exposure risk and the need for change to an 
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alternative drug regimen has changed the risk-benefit profile for IPTp as a strategy of choice. 
Furthermore the dynamic changes in malaria transmission between geographical locations negates 
the value of IPTp as a ‘one size fits all’, with alternative strategies tailored to specific transmission 
dynamics being required. 
2.12.2 Alternative strategies to IPTp for the control of pregnancy associated malaria 
 In light of the diminishing prospects of IPTp being an overarching strategy for malaria in 
pregnancy control policy owing to the dynamic transmission landscape and lack of an ideal candidate 
drug, new approaches tailored to specific transmission and resistance settings are currently under 
consideration. In areas with high resistance but reducing transmission, interest has grown on 
intermittent screening and treatment as a feasible replacement to IPTp-SP. The strategy entails 
screening women at each antenatal visit for malaria using a malaria rapid diagnostic test and 
administering a treatment course with an efficacious antimalarial if the woman tests positive.  
 Submicroscopic parasitaemia in pregnancy: The danger that lurks in the 
shadows 
 To date the United States Food and Drug Administration (FDA) regards microscopy 
confirmed parasitaemia as the only approved endpoint to evaluate interventions and new 
diagnostics (239). Though remaining as the gold standard in many research settings, the limit of 
detection of malaria parasitaemia in field conditions ranges from 50 – 100 parasite per microliter of 
whole blood with increased rate of false negatives at low parasite densities (240). Consequently the 
effects of parasitaemia below the limits of detection by microscopy have been better elucidated by 
the use of nucleic acid amplification techniques which are highly sensitive and specific (241), 
providing a means of evaluating the effect of low burden parasitaemia below the threshold of 
conventional microscopy (242). Low density parasitaemia is common in pregnancy, with a 
predisposition for early pregnancy (243).  
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2.13.1 Pathophysiological impact of submicroscopic in pregnancy 
2.13.1.1 Immune responses in pregnancy 
 It is well recognizes that exposure to malaria antigens is essential in the development of 
malaria specific immunity (244-246), however the factors determining the rate of development of 
this immunity are not clear, including whether in addition to exposure frequency, immunity is 
stimulated in a dose dependant manner to the level of parasitaemia at exposure. If and how 
submicroscopic parasitaemia influences the development of immunity to malaria in pregnancy 
remains unknown. Findings from a study in non-pregnant individuals demonstrated that low level 
parasitaemia inhibited dendritic cell function by induction of apoptosis (247) thus reducing malaria 
antigen presentation which is integral in the development of cell mediated and humoral anti-malaria 
immunity.    
 Submicroscopic parasitaemia has been associated with elevated levels of IL – 10 compared 
to uninfected pregnant women (248).  This observation was postulated to be due to chronic low level 
infection detected at enrolment as similar infection at delivery did not yield any significant 
differences in IL – 10, possible due to the acute nature of the observed parasitaemia at that time point. 
Elevated IL – 10 with submicroscopic malaria has also been demonstrated in earlier work conducted 
in Ghana (249).  
 The significance of IL – 10 to malaria immunity and immunopathology appear to be 
dependent on the levels of IL - 10. As a member of the Th – 2 cytokine family, the effects of IL – 10 are 
predominantly anti-inflammatory and regulate Th – 1 responses, in particular, the regulation of TNF 
levels. High levels of IL – 10 reduce pro-inflammatory responses and so are protective from severe 
malaria disease but may be hinder cellular mediated inflammatory responses to such a degree that 
may allow the unchecked progression of malaria infection to severe disease. Both extremes of levels 
of IL – 10 have been associated with poor malaria outcomes in children (250, 251) but this remains 
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to be established in pregnancy.   As such, the influence of submicroscopic parasitaemia on pregnancy 
outcomes may be dependent on the levels of IL – 10 that may be induced. 
 Findings from a study in Colombia has shown submicroscopic parasitaemia in the placenta 
to be associated with the upward regulation of pro-inflammatory cytokines, inflicted increased 
hypoxia and tissue damage (252). This cross sectional study at delivery compared 25 placentas with 
submicroscopic placental malaria against 25 sterile placenta and found elevated TNF – alpha and INF 
– gamma in the peripheral blood of PM + group. Higher apoptotic indexes and Fas expression were 
noted in the PM + group, denoting higher tissue damage, with markers of inflammation, HIF and 
VEGF, and hypoxia (COX – 1 and 2) being significantly higher in PM + samples. No conclusions were 
drawn on pregnancy outcomes from these results.    
2.13.1.2 Placental integrity and pregnancy outcomes 
 Low density infections under the threshold of microscopy are associated with placental 
malaria independent of the occurrence of patent parasitaemia (243). However the association with 
adverse pregnancy outcomes has largely remained contradictory. In a prospective cohort study by 
Cohee eta al (243), submicroscopic parasitaemia was not associated with adverse birth outcomes or 
maternal anaemia, findings that have been corroborated by a cross sectional study in India (253) 
which rather found patent parasitaemia to be associated with maternal anaemia and LBW. An earlier 
study conducted from Cameroon likewise found microscopically detectable parasitaemia, and not 
submicroscopic levels, to be associated with maternal anaemia (254).  
 Contrary to these conclusions, a recently published longitudinal study from Benin found 
submicroscopic malaria to be a significant risk factor for maternal anaemia and LBW (255). An earlier 
study in Ghana demonstrated submicroscopic infections to be associated with raised C-reactive 
protein (CRP) and mild anaemia, indicating low level parasitaemia may induce a pro-inflammatory 
cascade (256). However, this inflammation has not been associated with adverse birth outcomes. 
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Rather, the presence of the parasitaemia itself has been ascribed as an independent factor 
contributing to LBW (113). Despite the lack of association of inflammation induced with low level 
parasitaemia, evidence from Colombia has implicated submicroscopic parasitaemia in causing 
placental villitis and intervillitis but again, this was not associated with LBW (257). 
2.13.2 Impact of IPTp on submicroscopic parasitaemia 
 IPTp with SP clears sub patent parasitaemia although it fails to provide protection against 
reoccurrence of low level infection (243). The use of antimalarials for the control of malaria in 
pregnancy such as SP and chloroquine have been associated with submicroscopic parasitaemia 
(256). There is limited evidence as to the true association of IPTp and submicroscopic parasitaemia 
which may also be influenced by a function of the degree of maternal immunity and prevailing SP 
resistance.  
 Malaria diagnostics and their role in the control of malaria in pregnancy 
 The principle utilities of malaria diagnostics lie in routine case management and surveillance 
in control and elimination settings. The diagnostic techniques range across a variety of methods, each 
with their own strengths and weaknesses. 
2.14.1 Clinical diagnosis 
 Determination of malaria disease is based on the elucidation of symptoms associated with 
malaria infection. However, these symptoms are usually non-specific and overlap with many other 
infections especially characterised by fever, vomiting and chills. Transmission intensity has great 
implications for the sensitivity and specificity of clinical diagnosis of malaria though the non-specific 
nature of malaria symptoms gives clinical diagnosis very poor specificity due to the overlap many 
symptoms with other infections especially those commonly characterised by fever.  A study 
conducted in a low and unstable transmission setting in Kenya found, fever to have 88.9% sensitivity 
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and 15.4% specificity in children under  5 years of age, with 55.8% and 54.4% respectively in older 
children (258) with the addition of a second clinical criteria increasing the sensitivity but reducing 
the specificity. Previous studies have shown that the diagnostic performance of clinical assessment 
for the diagnosis of malaria   varies widely over transmission intensity (259). The use of clinical 
diagnosis for treatment decisions remains largely unreliable and leads to inefficient syndromic 
management (260, 261).  
2.14.2 Light microscopy with Giemsa stain 
 Light microscopy examination of Geimsa stained blood films has been the mainstay of malaria 
diagnosis for clinical care and disease surveillance, and has been regarded as the gold standard 
against which new malaria diagnostic tests are evaluated. Though operational costs are low, making 
it suitable for resource constrained environments, with added advantages of being able to provide 
speciation and quantification of parasitaemia, the method suffers several draw backs in the need for 
robust technical expertise which may not always be readily available (262), is time consuming (263) 
making it less ideal in settings of high disease burden, and requires vigorous equipment maintenance, 
quality control and quality assurance.    
 Under ideal conditions, light microscopy examination of thick blood film is able to detect 
parasitaemia as low as 4 parasite per microliter (264), with this detection threshold being higher in 
field settings up to 100 parasites per microliter. Thick blood film is more sensitive to detection of 
malaria parasitaemia than thin blood films, with the latter usually used for species identification. 
 Preparation of a blood film for examination under light microscopy involves spreading a 
sample of the blood as a thick or thin film, staining with a Romanovsky stain, commonly Geimsa, and 
examining the slide with a 100 x objective under oil immersion. Thick film microscopy has been 
shown to underestimate parasite densities likely as a result of staining process conferring them with 
a  reduced sensitivity compared to PCR in terms of detection and quantification  (265).  
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Figure 2.3 Examination of malaria parasitaemia under a light microscope 
 
 
 
 
Adapted from “Malaria diagnosis”. Centers for Disease Control and Prevention, 2015. (266) 
 
 False positive results with light microscopy arise commonly due to artifact inclusion due to 
poor preparation as well as poor technical expertise by the microscopist (267). Conversely, the 
false negative rate increases with declining parasite density (268). This underscores the need for 
greater expertise and time to diagnose malaria by microscopy to ensure a reduction in missing 
infections. Errors in species identification are largely under reported which is reflected in the under 
reporting of mixed infections, especially of P.falciparum and P.vivax, where differentiation between 
the species is not done (267, 269). Misclassification of P.knowlesi as P.malariae have been observed 
(270, 271), further stressing the weakness of microscopy especially where this distinction would be 
critical such as in south-east Asia where P.knowlesi malaria is fast spreading. Under reporting of the 
quality of microscopy has been noted even in published manuscripts where microscopy is regarded 
as the reference standard (168). 
 Methods to further enhance microscopic detection of parasitaemia have been developed. The 
quantitative buffy coat (QBC) technique involves staining the parasite DNA with fluorescent dyes 
such as acridine orange, with reading conducted by epi-fluorescent microscopy (272). These 
enhanced microscopy techniques have demonstrated higher sensitivity than conventional Geimsa 
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microscopy (273) even at low parasitaemia (274) but specificity is compromised due to staining of 
white cell DNA. In addition, speciation and quantification of parasitaemia is not feasible. 
Notwithstanding, this technique has been strongly considered as a feasible replacement to Geimsa 
microscopy for qualification of malaria infection in the routine case management diagnosis of malaria 
(273) and has become a growing diagnostic method of choice for field epidemiology studies due to 
the added advantage of sensitivity at low parasitaemia levels. 
2.14.3 Immunochromatographic diagnostic techniques 
 Malaria antigen based tests were initially pioneered by the development of 
immunoflorescent antibody and enzyme linked immunosorbent assays (IFA and ELISA respectively) 
with commercial application remaining scarce and use largely relegated to research purposes (275-
277). 
 Immunochromatographic assays, commonly known as malaria rapid diagnostic tests 
(mRDTs) were developed based on bound antibodies detecting specific malaria antigens such as 
histidine rich protein 2 (HRP – 2), plasmodium lactate dehydrogenase (pLDH) or aldolase which 
would elicit a chromatographic response, in the form of a colored line, if the specific antigen is present 
in the blood sample (278).  The WHO  sets a required sensitivity for rapid diagnostic tests used for 
active case management of malaria of at least 95% at a parasite density of 100 parasites per 
microliter  (279, 280).  
 The efficiency of RDTs is largely dependent on the intensity of transmission that dictates the 
mean parasite density associated with clinical symptoms as well as the prevalence of infections that 
has an impact on the sensitivity of the test (281, 282). Evidence from performance analysis in 
children show that RDTs demonstrate a drastic decline in sensitivity at parasite densities below 200 
parasites/μL (283). Target antigen expression is crucial in determining the calibre of RDTs 
appropriate in particular settings. In areas in Latin America and India, the existence of HRP2-deleted 
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strains of Plasmodium have been identified (284-286) and as such HRP2 based RDT would have 
dismal performance in these areas and would largely be inappropriate.  Polymorphism of HRP2 and 
3 surface antigens may impact negatively on HRP-based RDTs in areas with HRP-expressing 
parasites (287), though a previous study that conducted a pooled analysis of HRP2 antigens of 
P.falciparum isolates from 38 countries did not demonstrate the sequence variation as a cause for 
sensitivity variation. However, performance of HRP-2 based RDTs may be further compromised by 
high titres of HRP-2 antibodies (288). 
 Further complicating the reliability of malaria RDTs is the observation of cross reactivity of 
autoimmune factors and bacterial antigens leading to false positives and consequentially an 
overestimation of parasitaemia and treatment. Iqbal and colleagues demonstrated that P.falciparum 
HRP2 tests gave a false positive result in 26% of patients with rheumatoid factor but were 
aparasitaemic by microscopy and PCR (289). In tropical settings where both malaria and bacterial 
infections, individually or as co-infections, abound, false positivity due to cross reactivity possesses 
a considerable concern. Non-Typhiodal Salmonella bacteraemia   has been associated with increased 
RDT positivity in the presence of a negative gold standard malaria test (290) and a recent case report 
documented a positive malaria rapid diagnostic tests with Salmonella typhi without evidence of co-
malaria infection (291). 
 A plethora of studies have been conducted evaluating the performance of several rapid 
malaria diagnostic tests in field settings and controlled laboratory environments. The evidence is 
well summed in a systematic review and meta-analysis by Abba et al in 2011 and a later publication 
by Maltha et al in 2013. Abba and colleagues categorized RDTs based on antigen combinations 
incorporated in the test for diagnosis of malaria with classes 1 – 3 having HRP-2 alone or in 
combination with other antigens and types 4 and 5 being anchored by pLDH (168). Of 74 studies 
incorporated in the analysis, 73% were types 1 – 3. The pooled performance estimates of the HRP-2 
based tests demonstrated high sensitivity and specificity of 95.0 % (95% C.I, 93.5% - 96.2%) and 
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95.2% (95% C.I, 93.4 % - 99.4 %). The meta-analytical averages for type 4 and 5 tests had lower 
sensitivity but higher specificity, at 93.2% (95% C.I, 88.0 % – 96.2%) and 98.5% (95% C.I, 96.7 % - 
99.4%) respectively. Conclusively, HRP-2 assays would miss less cases but pLDH tests would 
correctly diagnose more cases. 
 
Figure 2.4 A positive rapid malaria diagnostic test 
 
 
 
 
Adapted from “Malaria Diagnosis – Rapid Diagnostic Test”. Centers for Disease Control and Prevention, 2014. (292) 
   
 The majority of RDTs on the market are tailored toward the diagnosis of P.falciparum and 
P.vivax, demonstrating poor detection of P.ovale and P.malariae (293, 294). RDTs targeting 
conventional malaria antigens expressed by P.falciparum and P.vivax have been utilized for the 
detection of the newest identified species of Plasmodium causing malaria in humans, P.knowlesi. 
Some RDTs have been able to diagnose P.knowlesi infection (295) but with sensitivities markedly 
below the WHO recommended cut off of 95%.  RDTs with greater diagnostic reliability, preferably 
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based on an antibody specific for P.knowlesi, present a pressing niche in product development in light 
of the proliferation of P.knowlesi malaria disease in south-east Asia (296, 297). 
 In a review by Maltha et al (298), the reliability of RDTs was concluded to be mainly 
compromised by poor detection at low parasitaemia due to design limitations.  Paradoxically, tests 
were also susceptible to the hook/prozone effect, precipitating false negative results in instances of 
extremely high parasitaemia. Deficiencies in the expression of target antigens such as HRP-2 or the 
cross reactivity with other antigens has rendered test performance vulnerable to either poor or 
exaggerated performance indicators respectively.  Other factors such as end user errors and product 
packaging were also faulted in contributing to poor field performance of RDTs.  
 The WHO, in conjunction with the Centers for Disease Control and Prevention (CDC), TDR 
and FIND, conduct routine rounds of test performance for commercially available RDTs 
manufactured under ISO 13485:2003 quality system standard. The most recent round of RDT 
performance testing, Round 5, was conducted in 2013 (299). The panel detection score (PDS) is the 
main test score used to evaluate RDT performance. Of note is the great emphasis that has been placed 
on greater expectation of robust test performance at lower parasite concentrations, reflecting the 
growing need for more sensitive diagnostics at lower parasite densities (< 200 parasites/μL) that 
may still render clinically significant disease owing to reductions in parasite transmission in light of 
current eradication efforts in many endemic countries.  
 Results from the fifth WHO round of RDT performance evaluations showed that HRP2 based 
tests had the highest detection rates with pLDH only tests registering some of the poorest results. 
This was particularly evident at parasite densities of under 200 parasites/μL, with all evaluated 
tests having high detection at parasite densities greater than 2,000 parasites/μL. The proportion of 
tests that achieved a PDS greater than 75% at 200 parasites/μL were 78.6% and 42.4% for 
P.falciparum and P.vivax respectively. This highlights the marked deficit and the unmet need for 
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reliable tests for P.vivax (300), the implications of which could result in difficult administration of 
parasitaemia confirmed treatment guidelines in areas endemic to vivax malaria. Most of the 
evaluated tests demonstrated heat stability, an important factor in the confidence in test results as 
they are mostly used in tropical climates which register high temperatures, and are easy to use with 
the majority of tests being in cassette form.  
2.14.4 Molecular techniques 
 Molecular techniques based on the amplification of parasite DNA to detect malaria infection 
are more sensitive than RDTs and microscopy (301, 302), especially in low transmission settings and 
have gained increasing popularity in   epidemiological and drug efficacy studies (303). Since the 
advent of these techniques in the 1980’s and 1990’s (304), several variants of these molecular 
techniques have been developed with varying reliabilities. 
 Molecular diagnostic methods for malaria include mass spectrophotometry, automated blood 
cell counters, flow cytometry assays, microarrays, loop-mediated isothermal amplification (LAMP) 
and polymerase chain reaction (PCR) assays. Of all, PCR assays have emerged as the most useful in 
malaria epidemiology registering the highest sensitivity and specificity even at low parasite 
densities.  PCR is able to detect parasitaemia as low as 1 – 5 parasite per microliter, conduct species 
characterization and more importantly, evaluate for markers of drug resistance. The importance of 
these utilities for practical malaria epidemiology have become evident as PCR is the only currently 
reliable diagnostic modality for the fast emerging P.knowlesi malaria complex (305, 306) and the 
detection of mutations conferring resistance to anti-malarials such as artemisinin, SP and 
chloroquine (307-310) .Several variations of PCR methods have been developed such as nested PCR, 
real-time PCR, reverse transcriptase PCR  and polymerase chain reaction-single strand 
conformational polymorphism (PCR-SSCP). PCR remains limited to research purposes and high 
performance diagnostic laboratories due to the extensive demand on expertise, time and equipment. 
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As such PCR has not yet been modified for field use though this would be an ideal development for 
the optimization of malaria diagnosis for routine treatment and surveillance.  LAMP and microarrays 
have however demonstrated significant potential for field deployment (311) and may provide more 
sensitive diagnostic modalities than current thick smear microscopy and RDTs. 
 
Figure 2.5 Calculation of PDS for the evaluation of test performance 
 
 
 
Adapted from “Summary results of WHO product testing of malaria RDTs: Round 1-5 (2008-2013)”. World 
Health Organisation. 2013. (299) 
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2.14.5 Placental histology 
 To date there are no reliable diagnostics for the detection of placental malaria in-vivo. The 
growing need for in-vivo applicable diagnostics would greatly revolutionize the diagnosis and 
management of malaria in pregnancy and has been identified as an unmet need in malaria control 
efforts (300) and for the improvement of maternal and child health in malaria endemic settings.  
 Sequestration of erythrocytes infected by P.falciparum in the placenta is currently only 
diagnosable “post-mortem” by histological examination of placental sections after delivery and 
insults already rendered. This is too late for any meaningful interventions to be implemented to 
improve pregnancy outcomes that may have been adversely affected by placental malaria. As such, 
the histological diagnosis of placental infection has been relegated to research purposes as an 
endpoint of malaria in pregnancy studies. 
 Previously, placental malaria on histological examination of placental sections has been 
characterised by sequestered infected erythrocytes only (acute infection), infected erythrocytes with 
co-existing hemozoin in fibrin lattice (chronic infection) and hemozoin only in macrophages and / or 
fibrin (past infection) (92). Active malaria infection was associated with basal membrane thickening, 
fibrinoid necrosis and syncytial knotting.  A semi-quantitative grading system has been previously 
developed by Muehlenbachs and colleagues (93) in which a novel grading scheme was utilized to 
quantify inflammation and hemozoin deposition in placental malaria and evaluate the associations 
with pregnancy outcomes. Scores were demonstrated to be associated with decreased birthweight 
in samples from both high and low transmission settings, indicating the versatility of the method 
across divergent transmission intensities.  The utility of the method was underlined as enabling the 
comparison and standardization of results between studies where placental malaria is an endpoint. 
 The importance of diagnostics for in-vivo diagnosis of active placental malaria are 
underscored by histological findings of the placental architecture in active placental malaria 
described by histological examination. In a study of the morphometric and histological changes 
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observed in P.falciparum and P.vivax infections, Chaikitgosiyakul and colleagues demonstrated that 
the area for nutritional delivery is significantly reduced in active placental malaria due to a reduced 
number, size and vascularity of villi (92, 312). This distorted architecture has been observed to be 
reversible after efficacious treatment, implying that the detrimental effects of active placental 
infection can be reversed insitu if placental malaria can be reliably diagnosed and appropriately 
treated prior to delivery. 
2.14.6 Measures of diagnostic test performance    
2.14.6.1 The notion of the Gold Standard 
 The continued consideration of light microscopy as the gold standard for malaria diagnosis 
has been subject to heavy criticism in light of more sensitive diagnostic tests such as nucleic acid 
amplification based tests especially with the increased unreliability in expanding low transmission 
settings. A systematic review that employed a statistical analysis avoiding the dependence of a gold 
standard against which other tests would be evaluated found increased reliability of non-microscopy 
tests for the diagnosis of malaria (274).  
2.14.6.2 Evaluation of test performance 
 The performance of a diagnostic tests lies in its ability to discriminate between diseased and 
healthy conditions and correctly detect the disease of interest. Diagnostics in screening 
environments have to demonstrate the ability to detect pre-disease conditions or markers that are 
harbingers of disease in order for interventions to be administered to  prevent the full realization of 
the disease state. Several parameters are employed to assess the reliability of diagnostic tests for 
their chosen scope of utility. The rapid progress in the development of diagnostic tests presents a 
revolutionary prospect for personalized medicine and as such, the importance of the reliability of 
diagnostic tests will be imperative  (313). 
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2.14.6.2.1  Sensitivity, specificity, positive predictive values and negative predictive values 
 A comparison between an index test and a gold standard tests is the commonest used method 
to assess performance of an index test. This is accomplished by deriving parameters indicative of the 
index test performance from a 2 x 2 table: 
 
Figure 2.6 2x2 table for calculation of measures of diagnostic performance 
 
 
 
 
Adapted from “Understanding and using sensitivity, specificity and predictive values”. Parikh et al, 2008. 
(314) 
 
 The sensitivity of the index test is its ability to correctly classify diseased individuals. This is 
derived as a proportion of the (true) positives by the gold standard identified by the index test 
(a/a+c). The specificity is the index test’s ability to correctly discriminate un-diseased individuals. 
This is expressed as the proportion of (true) negatives by the gold standard identified by the index 
tests (d/b+d). The ideal test would have 100% sensitivity and 100% specificity but realistically, there 
is a trade-off between sensitivity and specificity. It is recommended that estimates for the precision 
of the index test be reported for studies evaluating performance of diagnostic tests (315). The 95% 
confidence interval limits for sensitivity and specificity can be calculated (315) but cannot exceed 
100%  (316). 
 The positive predictive value (PPV) of the index test is the efficiency of the test in having 
correctly identified diseased individuals who have been diagnosed by the test as having the disease. 
This is calculated as the probability of a patient having the disease when tested positive by the index 
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test and is given by (a/a+b). The negative predictive value is the efficiency by which the test correctly 
identifies an un-diseased individual and is given by the probability of a patient being negative when 
tested negative by the test (d/c+d). Both the PPV and NPV are a function of the prevalence of the 
disease in the population. The prevalence of a disease in the population has a positive association 
with PPV and a negative association with NPV. 
 The likelihood ratios for positive results (LR+) and negative results (LR-) are additional 
performance measures of the efficiency of the index test in a specified population. The LR+ is 
dependent on the sensitivity of the index test and the proportion of false positives, and is given by: 
sensitivity/ (100% – specificity) 
A value greater than 1 indicates the test is associated with the disease and describes the strength of 
the association of the test with actually having the disease compare not having the disease. Values 
greater than 10 are indicative of a high performance diagnostic. Conversely, the LR- is dependent on 
the specificity and is given by: 
(100% – sensitivity)/ specificity 
Figure 2.7 PROC curve as a function of disease prevalence 
 
 
 
 
Adapted from “The predictive receiver operating characteristic curve for the joint assessment of the positive 
and negative predictive values. Shiu and Gatsonis, 2008. (317) 
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Figure 2.8 PPV and NPV at different levels of urinary tract infection prevalence in children 
 
 
 
 
Adapted from “Quantifying how tests reduce diagnostic uncertainty”. Coulthard, 2007. (318) 
 
An LR- of less than 1 shows that the test is associated with the absence of the disease. The value 
describes the probability of a diseased individual being tested negative (319). Values less than 0.1 
are indicative of a good diagnostic test. As the LRs are derived from parameters not dependant on 
the prevalence of disease, they can be compared across studies provided the disease definition is 
constant between studies (320). Ancillary measures of diagnostic accuracy include ROC curves and 
Area Under the Curve (AUC), Diagnostic Odds Ratio (DOR), Diagnostic effectiveness and Youden's 
index. 
2.14.6.2.2 Ancillary measures of diagnostic accuracy  
 The ROC curve is a plot of the values of the diagnostic sensitivity and specificity pairs with 1 
– specificity against sensitivity. The discriminative power of the test is evident by the shape of the 
curve as well as the area under the curve. The greater the area under the curve is by virtue of the 
curve approximating the upper left hand corner of the graph, the greater the diagnostic accuracy of 
the test.   
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Figure 2.9 The ROC curve and AUC 
 
 
 
 
Adapted from “Measures of diagnostic accuracy: basic definitions”. Šimundić, 2008. (320) 
 
 The AUC is useful in comparison of two or more tests to assess which is more appropriate 
diagnostic as interpretation of the sensitivity and specificity of individual tests is not possible. The 
comparison of the AUC between tests requires statistical inference evaluating the difference between 
AUCs. 
The diagnostic odds ratio (DOR) is a ratio of the odds of a test indicating a true positive against the 
odds of the test indicating a false positive. It is given by: 
                                                             (TP/FN) / (FP/TN) = (a/c) / (b/d) = (ad/bc) 
It does not rely on the prevalence of the disease but is rather dependent on the sensitivity and 
specificity of the test. 
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Table 2.2 Relationship between the area under the ROC curve and diagnostic accuracy  
Area  Diagnostic accuracy 
0.9 - 1.0 Excellent 
0.8 - 0.9 Very good 
0.7 - 0.8 Good 
0.6 - 0.7 Sufficient 
0.5 - 0.6 Bad 
< 0.5 Test not useful 
Adapted from “Measures of diagnostic accuracy: basic definitions”. Šimundić, 2008. (320) 
 
  The diagnostic accuracy defines the percentage of index test results that agree with 
the gold standard test. This is a measure of the effectiveness of the index test and is given by:   
                                                                 (TP + TN) / N = (a + d)/ (a + b + c + d) 
The DOR is inversely related to the prevalence of the disease meaning the test will give more correctly 
classified individuals as the prevalence of the disease decreases (320). It is advised that the DOR be 
interpreted in the context of other measures of accuracy such as the predictive values. 
 The Youden’s index is a whole number derived from the sensitivity and specificity as: 
(sensitivity + specificity ) - 1 
The closer to 1 the index score is, the better the test. However, the index is unreliable in inferring 
the diagnostic accuracy between tests as tests may have the same score but different measures of 
sensitivity and specificity (320) and thus us not a reliable measure to discriminate the accuracy 
between tests. 
2.14.6.3 Reporting of diagnostic accuracy studies: The STARD Statement 
 The Standards for the Reporting of Diagnostic Accuracy studies (STARD) were developed in 
2003 to address the less than optimal reporting of studies evaluating the diagnostic accuracy of tests 
(321). The statement comprises a checklist of 25 items to ensure all relevant information is reported 
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in the manuscript (Annex 1). Much is still expected in the adoption of  the STARD protocol (322)  
though no revision of the statement have been undertaken since first publication. 
 Disease screening 
 The concept of disease screening as a strategy for the reduction of disease associated 
morbidity and mortality is based on the potential benefits of early detection of asymptomatic 
preclinical disease or disease precursors and administration of an effective intervention. 
Accordingly, the ten point Wilson-Jungner criteria for appraising the validity of a screening 
programme is essential in considering the viability of a screening strategy (323) though recent 
alternatives have been proposed after a review of the  Wilson-Jungner criteria in the current scientific 
dispensation (324-327). 
 The following criteria are considered in evaluating if a disease screening strategy is 
warranted (323): 
1. The condition sought should be an important health problem 
2. There should be an accepted treatment for patients with recognised disease 
3. Facilities for diagnosis and treatment should be available 
4. There should be a recognisable latent or early symptomatic stage 
5. There should be a suitable test or examination 
6. The test should be acceptable to the population 
7. The natural history of the condition, including development from latent to declared 
disease, should be adequately understood 
8.  There should be an agreed policy whom to treat as a patient 
9. The cost of case finding (including diagnosis and treatment of patients diagnosed) 
should be economically balanced in relation to possible medical expenditure as a whole 
10. Case finding should be a continuing process and not a “once and for all” project  
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 Innovation for the control of malaria in pregnancy 
 The extensive burden of malaria infection in pregnancy amongst the world’s poorest 
populations, coupled with the myriad of challenges faced in its control begs for a renewed drive 
for innovative strategies.   With the faltering of IPTp-SP as an effective strategy in P.falciparum 
endemic regions due to expanding SP resistance, potential strategies are faced with the 
challenge of achieving optimal target population coverage whilst ensuring safe and efficacious 
dose delivery for optimal protection and the prevention of the emergence of drug resistance. It 
would be expected that new strategies would work in synergy with LLITNs for the prevention of 
infections, reducing the burden of maternal, fetal and newborn morbidity and mortality.  
Significant gaps in knowledge remain in the safety of dihydroartemisinin-piperaquine in 
pregnancy and the role of low density infections not detected by diagnostic tests in routine 
clinical practice in low resource settings on pregnancy outcomes. Furthermore, though 
extensively used in routine clinical care for symptomatic malaria infection, the efficiency of RDTs 
in diagnosing asymptomatic infection, many largely persisting as low density infections, 
presents a significant challenge to the reliability of RDTs as part of control strategies for the 
control of malaria in pregnancy. This trail and its subsequent analyses therefore provide the 
opportunity evaluate targeted treatment of asymptomatic infection in pregnancy in a setting of 
declining transmission, the significance of low density infections on pregnancy outcomes and 
the efficiency of RDTs as a screening tool in asymptomatic malaria infection.  
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3 CHAPTER THREE: OVERVIEW OF STUDY DESIGN AND METHODS  
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 Background 
In the context of the existing body of evidence for the decreasing efficacy of IPTp–SP and 
the need for alternative drug and strategy interventions, this study was designed to evaluate 
the efficacy of 3 or 4 courses of ISTp – DP in comparison to a similar number of courses with 
IPTp–SP. The study was designed before the revised 2012 guidelines for IPTp–SP by the WHO.  
The primary objectives of the trial were: 
1. To determine if ISTp-DP compared with IPTp-SP in the second and third trimesters of 
pregnancy is associated with at least a 25% reduction in adverse birth outcome as composite 
endpoint of low birth weight, preterm birth and small for gestational age in paucigravidae. 
2. To determine if ISTp-DP compared with IPTp-SP in the second and third trimesters of 
pregnancy is associated with at least a 50% reduction in placental malaria in multigravidae. 
The sections that follow describe the specific design considerations for the trial as well as study 
procedures and statistical methods of analysis employed. A brief overview of statistical methods of 
the derived analyses from the main trial in the two subsequent analyses is presented, with further 
descriptions of specific methods provided in the respective chapters.  
 Trial design 
3.2.1 Overview 
This was an open-label, two-arm, individually randomized controlled superiority trial 
conducted at three sites in southern Malawi with high levels of SP resistance and ITN coverage. 
A stratified enrolment design by gravidity was employed with one strata for primi and 
secundigravidae (G1+2) and one for multigravidae (G3+). The study required 1665 women 
overall, comprising of 1155 paucigravidae and 500 multigravidae.  
Participants were randomly allocated to receive either at least three doses of IPTp with SP or at least 
three scheduled screenings with an RDT and treatment with DHA-PQ if they are RDT-positive. All 
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participants were given an insecticide-treated bed net. Women enrolled in the trial made at least 
three scheduled visits to the clinic, including the enrolment visit, spread over the second and third 
trimesters at least four weeks apart, approximately mirroring the appointment schedule for 
‘focussed antenatal care’ in Malawi which consists of four scheduled visits including one in the first 
trimester. Women who were enrolled by 25 weeks of gestation were asked to attend 4 scheduled 
visits in the 2nd and 3rd trimester with those enrolled after 25 weeks being requested to attend 3 
scheduled visits. Dating ultrasound scans were performed to assess gestational age.  
 Other than the investigational interventions, all participants received the standard antenatal 
care according to local policy, including standard clinical examinations, tests (section 3.8.1.2) and 
treatment as required (section 3.7.3). Administration of dihydroartemisinin-piperaquine (DHA-PQ) 
was done under direct supervision, with follow-up visit on day 3 and 14 post the first dose to assess 
tolerability and safety. Women were encouraged to attend the study clinic for assessment if they felt 
unwell during the study period, and to deliver in the maternity wards of the study sites to facilitate 
collection of delivery outcome data. In the event that they delivered outside of the study facilities, 
women were encouraged to notify staff as soon as possible, preferably within 24 hours but with a 
leeway of up to 7 days post-delivery. Maternal infant pairs were seen at approximately seven days 
and six weeks after delivery, to assess the postnatal health of both mother and infant before fully 
exiting the study.    
3.2.2 Study design 
3.2.2.1 Design considerations 
3.2.2.1.1 Superiority design 
 It was anticipated that ISTp would be more complex to implement and potentially more 
expensive than IPTp and, unlike with IPTp, sub-patent infections would not be prevented or 
suppressed, thus concomitant use of ITNs was important. Countries with moderate transmission 
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would only consider switching to a new strategy if it was clearly superior to the current policy of 
IPTp-SP, either because of SP failure or because SP would become potentially harmful. 
3.2.2.1.2 Efficacy versus effectiveness 
 The trial was designed primarily to assess the efficacy of ISTp when implemented as 
intended. This proof of concept was needed as a logical step before further assessments of 
effectiveness in practice were undertaken, as it was not yet established in this context. In addition, as 
any effect will usually tend to be greater under conditions of optimal implementation, the sample size 
required would be smaller for an efficacy trial than for an effectiveness trial. Therefore efforts were 
made to maximise participant adherence to the study protocol, including active follow-up of 
participants who missed scheduled appointments. Data was collected to assess the tolerability of the 
intervention and levels of adherence under the trial conditions.  
3.2.2.1.3 Open label design 
 Participants were informed of the intervention they are assigned to as the processes for IPTp 
and ISTp were visibly different and thus blinding would not have been possible. Blinding was 
however undertaken for diagnostic tests performed by laboratory personnel. 
3.2.2.1.4 Exclusion of HIV-positive women 
 Women who were HIV seropositive were not included as all HIV-positive women would have 
been eligible to receive co-trimoxazole prophylaxis of HIV-related infections, as recommended by 
WHO. Co-trimoxazole itself provides some protection from malaria infection, and SP is contra-
indicated in women receiving co-trimoxazole. It would therefore not have been possible to include 
HIV-positive women in the current trial, as they could not be included in the IPTp-SP arm.  
 With an estimated HIV prevalence of around 12% in pregnancy, it would be important to 
evaluate the potential effectiveness of ISTp in HIV-positive women, but this would require a different 
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trial answering a different question i.e. comparing co-trimoxazole prophylaxis alone with co-
trimoxazole prophylaxis plus ISTp.       
3.2.2.1.5 Intervention schedules 
 The study intervention was delivered at intervals of four to eight weeks and as far as possible 
corresponding to the usual schedule of ‘focused’ antenatal care visits during the second and third 
trimesters of pregnancy which are scheduled at approximately 24-28 weeks, 30-32 weeks, and 34-
36 weeks. Women attending between 16 and 23 weeks received an additional RDT screening or SP 
dose, as with IPTp this is what tends to happen in practice in Malawi. The last intervention in both 
arms occurred at approximately 34 to 37 weeks of gestation, to ensure clearance of the placenta 
before delivery. As per usual standard of care, women who had not delivered by 40 weeks were seen 
weekly up to 42 weeks gestation and if not yet delivered, would have labor induced as part of the 
clinical obstetric care in accordance with clinical guidelines. These visit were not classed as study 
visits, and had no influence on the administration of study interventions or procedures.  
 The regimen for IPTp in Malawi used to be at least two doses of SP during the second and 
third trimesters of pregnancy. However, Malawi switched to a more pragmatic approach providing 
SP at each scheduled visit as part of focussed antenatal care, with many women now receiving three 
or four doses of SP prior to the 2012 revised guidelines by the WHO. As the trial was designed to 
determine the superiority of a new, more expensive and complex intervention (ISTp) to current 
practice (IPTp), it was imperative that the current intervention be implemented in its most effective 
form possible.  
3.2.2.1.6 Inclusion of women with uncomplicated malaria at enrolment 
 Women with symptoms of malaria at enrolment were not excluded, but were randomized to 
the study groups, and treated with the case-management drug for the respective trial arm. Women 
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in the IPTp–SP group were treated with Artemether-Lumefantrine (CoArtem) and did not receive SP 
that month due to Lumefantrine being anticipated to provide post-treatment prophylaxis 
comparable with SP (3 to 4 weeks). SP was then be provided at the next scheduled visit. Women 
randomized to the ISTp arm received DHA-PQ as the treatment drug. This was done to reflect 
standards of practice of treatment of uncomplicated malaria in the current dispensation of IPTp-SP 
and the proposed ISTp-DP strategy within routine healthcare provision at the antenatal clinic. DHA-
PQ and CoArtem have comparable efficacy in treating malaria.    
3.2.2.1.7 Additional blood tests not part of the point of care testing and treatment   
In addition to the use of RDTs in the ISTP group, all participants in both arms had 
blood samples taken at enrolment and during each scheduled visit for peripheral malaria 
using standard microscopy of blood smears and PCR. The results of these tests were not 
available until the end of the trial and were not used to inform the care of the women. In this 
way, information on incidence of malaria infection was collected without contaminating the 
intervention in either arm. A blood sample was taken at the last visit in the third trimester 
for haemoglobin measurement and  a second HIV screening test in line with current WHO 
guidelines for repeat HIV testing in the third trimester (328). 
3.2.2.1.8 Stratified sampling of women with different gravidities  
 Based on systematic review of previous trials with IPTp-SP and ITNs (14, 159), it was 
anticipated that most or all of the impact on birth outcomes and morbidity would be in women in 
their first and second pregnancies.  However, the impact on placental malaria infection was expected 
to occur across all pregnant women, including those in their third and subsequent pregnancies. 
Placental malaria and malaria at term are recognised to be important endpoints in themselves as 
they have been found to be risk factors for malaria, anaemia and other infections in infants up to the 
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age of two years, independent of the effect of malaria on gestational age low birth weight (96, 329). 
This effect appears to be particularly evidence in multigravidae (123).  
 Furthermore, as IPTp is currently recommended for, and provided to women of all 
gravidities, and it was anticipated that any alternative strategies to IPTp may also be provided to all 
pregnant women, if any potential benefit is identified. The trial therefore focused on morbidity 
endpoints in women in their first and second pregnancies, and on malaria infection at term and 
delivery in women in their third to fifth pregnancies (active or past infection).  
3.2.2.1.9 Use of a composite birth outcome as the primary trial endpoint 
 In women in the first and second pregnancies, the study aimed primarily to assess the effect 
of the intervention on birth outcomes. A composite primary outcome of SGA, low birth weight or pre-
term birth was used because more births would fall into one of these categories than into a single 
category. In addition, malaria during pregnancy is associated with increased risk of all these three 
measures, including an increase in the risk of SGA in children born at term and with birth weight > 
2500 g. Therefore a smaller sample size would be required to detect a significant difference between 
study intervention arms than if a single outcome were used. SGA is a risk factor of neonatal and infant 
mortality, also in those both at term or with normal birthweights (330). 
 Early neonatal deaths were not included within the composite endpoint measure because the 
aetiological fraction of deaths due to malaria was anticipated to be small; most early postnatal deaths 
result from events occurring during delivery (e.g. prolonged labour).   
 Outcome measures 
3.3.1 Primary outcome 
In paucigravidae the primary outcome was a composite endpoint of adverse birth outcomes, defined 
as any of:  
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 Small for gestational age defined as a binary outcome of <10th percentile of fetal weight for 
attained gestational age 
 Preterm birth (spontaneous birth before 37 weeks gestation) 
 Low-birth-weight (birth weight under 2,500 grams) 
For women in their third to fifth pregnancies, malaria infection at term and delivery were the primary 
endpoint. These were defined as evidence of current or recent infection assessed at delivery by 
placental histopathology, a positive malaria RDT or PCR. 
3.3.2 Secondary outcomes 
3.3.2.1 Secondary efficacy outcomes 
1. Placental malaria (any species):  
a. Past infection detected by histopathology 
b. Active infection detected by: 
ii. Histopathology  
iii. Microscopy  
iv. Rapid diagnostic test 
v. Polymerase chain reaction (PCR) 
2. Maternal malaria infection (peripheral blood) at delivery, detected by: 
a. Microscopy  
b. RDT 
c. PCR  
3. Peripheral malaria infection during pregnancy detected by: 
a. Microscopy  
b. PCR  
4. Birth weight  
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a. Mean birth weight (grams) 
b. Low birth weight (<2,500 grams)  
5. Gestational age 
a. Mean gestational age at birth (grams) 
b. Pre-term birth (<37 weeks)  
6. Small for gestational age  
7. Maternal haemoglobin and anaemia: 
a. At delivery 
i. Mean maternal haemoglobin (g/dL) 
ii. Anaemia (Hb ≤ 11 g/dL) 
iii. Moderate to severe anaemia (Hb ≤ 8g/dL)  
b. During third trimester 
i. Mean maternal haemoglobin (g/dL) 
ii. Anaemia (Hb ≤ 11 g/dL) 
iii. Moderate to severe anaemia (Hb ≤ 8g/dL) 
8. Miscarriage (loss of foetus before 28 weeks gestation)  
9. Stillbirth (birth at 28 weeks or later showing no signs of life) 
10. Composite endpoint of the primary endpoint plus fetal loss (miscarriage or stillbirths) 
11. Infant death 
a. Perinatal death (stillbirth or death within 7 days of birth) 
b. Neonatal death (death within 28 days of birth) 
12. Malaria infection of the newborn, detected by analysis of umbilical cord blood with: 
a. RDT 
b. Microscopy 
c. PCR 
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13. Foetal haemoglobin and anaemia by sampling of umbilical cord blood at birth: 
a. Mean foetal haemoglobin (g/dL) 
b. Foetal anaemia (Hb ≤ 12.5 g/dL)   
c. Moderate to severe foetal anaemia 
14. Incidence of documented clinical malaria episodes during the second and third trimesters of 
pregnancy (history of fever in last 24 hours and documented malaria microscopy or RDT 
positive) 
15. Presence of any evidence of malaria infection at term (last antenatal visit), identified through 
microscopy or PCR, or at delivery, identified through peripheral and placental RDT, microscopy 
or PCR, or placental histopathology (active or past infection).  
16. Incidence of other illness episodes apparent at scheduled antenatal clinic visits or resulting in 
unscheduled clinic visits 
17. Incidence and prevalence of clinical malaria in infants by seven days and six to eight weeks 
determined by: 
a. RDT 
b. Microscopy 
c. PCR 
18. Prevalence of symptomatic infant anaemia at seven days and six to eight weeks 
a. Anaemia  
b. Moderate to severe anaemia 
19. Incidence of other illness episodes in the infants, apparent at scheduled postnatal clinic visits or 
resulting in unscheduled postnatal clinic visits 
3.3.2.2 Safety outcomes 
1. Severe cutaneous skin reaction in the mothers within 30 days of drug intake 
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2. Other serious adverse events in the mothers 
3. Congenital malformations identified by six weeks after birth 
4. Neonatal jaundice within 24 hours and at seven days 
5. Laboratory test results outside of normal range 
3.3.2.3 Tolerability outcomes 
1. Non-serious adverse events in the mothers 
2. Adherence to study medication 
 Study sites 
 The study was conducted in three research centers in southern Malawi with moderate to high 
malaria transmission (331). The first site, located 10 kilometers south of Blantyre in the Shire 
Highlands, the study was conducted at Mpemba health centers which serves a predominantly rural 
populace and characterised by mild temperature and humidity.  
 Further south, approximately 30 and 50 kilometers from Blantyre respectively, the study was 
conducted at Madziabango health center, under the administrative jurisdiction of Blantyre district 
though close to the Shire valley, and Chikwawa District Hospital located in the Shire Valley, both sites 
having characteristic high temperatures and humidity due to the topographic influences of the Shire 
valley. 
 Sample size 
 The trial utilised a stratified design with one strata for primigravidae and secundigravidae 
and one strata for multigravidae. It was designed to detect a 25% reduction (RR 0.75) in composite 
adverse birth outcomes (SGA, low birth weight and pre-term birth) in women in their first and second 
pregnancies with an 90% power and a 2-sided significance level of 0.05, if the rate of placental 
malaria in the control group was similar to that found ongoing observational studies of women 
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receiving routine care in the same area of Malawi. The proposed difference was based on four 
previous trials of IPTp which jointly reduced low birth weight by 29%.(14). Thus the efficacy of ISTp 
was expected to be similar to the efficacy of IPTp before the emergence of widespread SP resistance. 
In an ongoing IPT-mon study at the time, the incidence of SGA, low birth weight or preterm birth was 
40.3% (N=494) (Kalilani, personal communication). Therefore the study was designed to detect a 
25% difference between 40.3% in the control (IPTp) group and 30.2% in the intervention (ISTp) 
group. The study would still have 80% power (instead of 90%) to detect a 25% reduction if the risk 
were at least 33.3% instead of 40.3%. 
 For this primary endpoint, 491 participants were required in each arm or 982 in total. To 
allow for a 15% loss to follow-up, 1155 women in their first and second pregnancies were recruited. 
The sample size had an 81% power to detect a 25% or greater reduction in placental malaria (active 
or past infection), with a significance level of 0.05. If a power of 80% were used, the study would 
detect a difference of 21.8% or greater in the primary endpoint.   
 The trial was also designed to detect a 50% reduction in past or present placental malaria 
infection at delivery in multigravidae, based on previous studies of IPTp,(14) assessed by placental 
histopathology and RDT. The rate in women in Malawi who were taking IPTp-SP was estimated from 
an observational IPTp–SP study at 20.5% (Kalilani, personal communication). A reduction by 50% to 
10.25% would require 213 women per arm or 426 in total. To allow for a 15% loss to follow-up a 
total of 500 multigravidae were to be recruited.  The total sample size was therefore 1655. 
 Enrolment and Randomization 
3.6.1 Screening and eligibility assessment 
 Potential participants were screened for eligibility when attending their first routine 
antenatal appointment. If they met the inclusion criteria they were offered enrolment following 
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informed consent. Women who did not meet the inclusion criteria, or who did not wish to participate 
in the trial received the usual antenatal care, including the standard IPTp-SP schedule. 
 Eligibility screening was conducted by clinic nurses and midwives and supported by study 
staff. Screening data was recorded in a log kept in the investigators site file. One screening log was 
kept for each site. The record reported how many women attended their first antenatal visit over the 
enrolment period, how many were potentially eligible, how many were enrolled into the study and 
reasons for non-eligibility of those not enrolled. It was used to ensure that women were selected for 
the study without bias. Each screened woman was assigned a screening registration number in 
sequential order by the study clinic. Screened attendees who did not meet the eligibility criteria for 
the trial were considered as screening failures. Screening registration numbers were not re-used. 
Women were allowed to enter the study at a later date upon meeting the eligibility criteria if she was 
previously unable to do so at the prior visit.  
 Gestational age was initially estimated using a combination of fundal height as measured by 
the midwife and last menstrual period (LMP) dates provided by the woman, where available. Women 
attending antenatal care for the first time after 28 weeks gestation were excluded from the trial. 
Women attending before 16 weeks gestation were screened for inclusion, given information about 
the trial and enrolled when they next attend between 16 and 28 weeks gestation. Women who were 
eligible and expressed an interest in the trial were subsequently enrolled and received an ultrasound 
scan using the SonoSite™ S180 machine (SonoSite, Inc, Bothell, Washington, USA) to accurately assess 
the gestational age of the pregnancy and identify multiple gestations. Alternatively the scan was done 
at a rescheduled appointment shortly after enrolment if it could not be performed on the day of 
enrolment. Ultrasound scans were conducted by a trained clinician, who was also the study 
investigator as well as the study nurses who had also received training by a clinical radiologist.  Any 
women identified as having multiple gestations at ultrasound scan were excluded from the study.  
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  Women already known to be HIV-positive were automatically excluded from the study. All 
women were offered HIV counselling and testing using rapid diagnostic tests, and if they refused or 
were found to be positive, were be excluded from the trial.  All potentially eligible women were tested 
for anaemia. If they are found to be severely anaemic (Hb ≤ 7 g/dL) they were excluded from the trial 
and referred to the nearest hospital for blood transfusion and appropriate treatment. A woman who 
was successfully treated for severe anaemia and attended the clinic again before 28 weeks gestation 
was deemed eligible for participation in the trial provided that she met all other inclusion criteria. 
Women with less severe anaemia were be included in the study and their anaemia treated by treating 
any cause identified and with ferrous sulphate 200-400mg twice daily for a month. A venous blood 
sample was used for both routine and study-specific tests. As venous sampling would not normally 
be included as part of care, consent for screening procedures that required venous blood samples 
was obtained before the blood draw.  
 Women were asked whether they planned to travel or migrate outside of the study area 
during the follow-up period. Those who planned to so were excluded. Women who were later found 
to be ineligible after they had signed the informed consent and initiated study procedures were 
excluded from the trial as screening failures immediately, but continued to receive all study-specific 
benefits and standard care.  
3.6.2 Informed consent procedures 
 A general introduction to the study and invitation to participate was provided by a study 
nurse during the antenatal talks at each clinic over the enrolment period.  More specific study 
information was provided in a consulting room (Annex 1). Participants were given leeway to consider 
the information including consultation with their spouses or immediate family, if required. Spousal 
involvement was encouraged in the woman’s participation in the study from as early as the 
consenting stage.  
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 There were three elements to consent for involvement (Annex 2); consent for eligibility 
screening; consent for inclusion in the trial; and consent for storage of blood samples. Consent for 
screening was sought from all women who appeared potentially eligible at the pre-screening stage, 
and was specific to procedures that are not normally undertaken as part of routine care. These 
included a 5ml venous blood draw taken before enrolment, which would be used to assess the woman 
for anaemia, and, if the test had not already been undertaken, HIV and syphilis, as well as for study-
specific tests if the women were found eligible.  
 Informed consent for inclusion in the trial was sought immediately before enrolment after 16 
weeks gestation. Women who made first contact before 16 weeks were potentially eligible received 
all relevant information at this time, and were asked for consent to be screened, but were not asked 
for their formal written consent for participation in the trial until their next attendance after 16 
weeks.  
 Each potential participant was given full and adequate oral and written information about 
the study, including all the known risks and any potential benefits, in their own local language. It was 
clearly stated that the participant would be free to withdraw from the study at any time for any 
reason without prejudice to future care, and with no obligation to give the reason for withdrawal. 
Participants were given the opportunity to ask questions and allowed time to consider the 
information provided.     
 Informed consent was documented on a written consent form signed by the participant and 
the person who conducted the informed consent discussion. If the participant was unable to write 
her signature then a thumbprint was used. If the subject was unable to read the information herself, 
full and comprehensive verbal information was communicated in the presence of an impartial 
witness. The witness signed the consent form to attest that information in the consent form was 
accurately explained and apparently understood by the participant, and that informed consent was 
freely given. 
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 Participants were asked for additional consent for the transport of blood sample outside of 
the country and the storage of blood samples for future research. Women who did not consent to the 
storage and transport of blood, or who withdraw their consent, were still allowed to participate in 
the trial.  In accordance with the laws of Malawi, a pregnant women aged 16 years or older is 
considered emancipated (332) and would be able to sign the consent form for themselves; no 
parental consent was required for emancipated minors. Either carbon copies or otherwise two 
identical consent forms were used per woman; one signed or thumb-printed consent form was kept 
on file by the study team and one given to the participant.   
3.6.3 Treatment allocation (Randomization) 
 Two randomization sequences were computer-generated by the study statistician at 
Liverpool School of Tropical Medicine, one for women in their first and second pregnancies and 
another for multigravidae. Variable block randomization was used, stratified by study site to ensure 
an equal proportion of participants in each intervention group from each site. The variable length of 
each block ensured that allocation concealment was fully maintained and allocation well distributed 
over the seasons. The allocation ratio for the two study arms was 1:1.  
 Recruitment was ‘competitive’ between study sites, meaning that the number of participants 
recruited at each site differed depending on the respective rates of enrolment. A sufficient number of 
randomization codes were generated for each site to allow for this.    
 Site specific randomization sequences stratified by gravidity were used to assign women to 
study arms. An independent person prepared opaque envelopes which were numbered sequentially 
with the allocated group code and details for that number inside. For each newly enrolled participant, 
an envelope from the correct sequence (according to gravidity group) was opened sequentially to 
identify the group that they are allocated to, thus concealing the upcoming allocation from the 
participants, clinic staff and study staff. The number on the envelope represented the study number 
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allocated to that participant and will became their unique identifier in the trial. Once assigned, a study 
number could not be used again, even if a participant discontinued. In the event a study number was 
allocated incorrectly, it was not reassigned and randomization continued with the next sequential 
number.   
 Administered treatments 
3.7.1 The study interventions  
 Participants received one of the following two interventions during the second and third 
trimesters of pregnancy; provided at each of the scheduled visits as directly observed treatment 
(DOT):  
IPTp-SP Group: Treatment with a treatment dose of three tablets of sulphadoxine-pyrimethamine, 
each containing sulphadoxine (500 mg) and pyrimethamine (25 mg). This is the standard and only 
drug of choice for IPTp in Africa.  
ISTp-DP Group: Screening for malaria was done using a combined Histidine – Rich Protein 2 (HRP-
2)/ plasmodium Lactate Dehydrogenase (pLDH) (P. falciparum/ pan-malaria) rapid diagnostic test 
(First Response® Malaria pLDH/HRP2 Combo Test, target antigen pLDH (pan); HRP2;  Premier 
Medical Corporation Ltd, USA). Each tablet of Dihydroartemisinin-piperaquine came as a fixed dose 
combination of 40 mg Dihydroartemisinin and 320 mg Piperaquine. Women were treated with 
dihydroartemisinin-piperaquine  (Sigma Tau) with 2-2.3 mg/kg/day dihydroartemisinin and 16 – 
18.3mg/kg/day Piperaquine for 3 days if RDT-positive. The daily number of tablets administered 
depended on the weight of the woman and was given to the nearest half tablet per recommendations 
by the manufacturer. All half tablets that remained after each clinic visit in the morning were stored 
in the drug inventory for drug accountability and were not administered to patients at subsequent 
antenatal clinic visits. 
80 
 
 All investigational medicinal products were sourced from GMP approved manufacturers. 
Upon receipt from the suppliers, all the drugs were stored at the clinical trials pharmacy unit with 
restricted access and temperature controlled environment at less than 30 degrees Celsius for long 
term storage.  Drugs were dispensed to the trial sites in cooler boxes at a maintained temperature of 
less than 40 degrees Celsius where upon reaching the trial sites, the drugs were stored in 
temperature monitored secured storage units and dispensed to patients in accordance with the 
treatment protocol.  Routine monitoring of drug inventory was undertaken at both the central trial 
pharmacy and trial sites to reconcile drug stocks. 
3.7.2 Case-management of clinical malaria 
Women in either group who attended scheduled study appointments with fever and 
parasitaemia confirmed by RDT were treated for malaria. In the case of women in the IPTp-
SP group, case-management treatment with Artemether - Lumefantrine (Coartem®, 
Novartis) in a fixed dose combination of 20mg Artemether and 120mf Lumefantrine with 4 
tablets per dose, 8 hours apart between the first two doses then 12 hours for the remaining 
4 doses, was given in place of the scheduled dose of SP. Women in the ISTp group were treated 
with DHA-PQ as direct observed treatment (DOT). DOT was not employed for women in the 
IPTp–SP arm who were being treated for symptomatic malaria.    
3.7.3  Other treatment and concomitant medication 
3.7.3.1 Treatments as part of routine care 
 All participants were offered routine antenatal care according to local policy and the 
principles of ‘focussed antenatal care’, including the provision of insecticide-treated bed nets (ITNs) 
free of charge. In addition, the routine antenatal care package in Malawi includes blood screening at 
the first appointment for syphilis, anaemia and HIV, and the provision of appropriate treatment for 
these conditions. Women diagnosed with symptomatic anaemia were treated in accordance to the 
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severity. In cases of symptomatic mild or moderate anaemia, women were prescribed an additional 
200mg of elemental iron as ferrous sulphate or if unavailable, ferrous folate, for one month. In the 
event of severe anaemia (haemoglobin <7g/dl), admission and blood transfusion was instituted at 
the referral health facility, followed by an additional 200mg of elemental iron once a day for one 
month after discharge.   In the event a woman was diagnosed with syphilis, she was requested to 
present the following day with her partner where after both then received 2.4 million units of 
benzathine penicillin G intramuscularly once a week for 3 weeks. If the spouse did not present for 
treatment, the women was still treated. Women diagnosed before or during the trial with HIV-
infection were excluded or withdrawn from the trial respectively and offered co-trimoxazole 
prophylaxis and counselling services in preparation for initiation of antiretroviral treatment in 
accordance to national guidelines and WHO recommendations. Blood screening for anaemia and HIV 
were also be repeated in the third trimester, as per standard of care in accordance to policy in Malawi 
(anaemia) and per new WHO guidelines (HIV).  
 As part of their antenatal care participants were given iron (200mg/day) and folic acid (0.4 
mg to 0.6 mg / day) supplements as well as tetanus vaccination as applicable. Presumptive treatment 
for Helminthic infestations was with an Albendazole 400 mg single dose for hookworm, trichuriasis 
and ascariasis. 
3.7.3.2 Treatments at unscheduled study visits 
Participants were encouraged to attend the study clinics if they felt unwell at any point 
outside the scheduled antenatal visit. All concomitant medications prescribed to participants during 
the study, or reported as used by the participants were recorded. Women diagnosed with 
symptomatic uncomplicated malaria were treated as described above. Rescue treatment with oral 
quinine, quinine sulfate dihydrate 600 mg every 8 hours for 7 days, was used in the event that a 
woman became symptomatic and parasiteamic again within 4 weeks. The exception was women in 
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the ISTp group who were attending their first or other routine appointments, would receive 
DHA-PQ if RDT-positive, with CoArtem reserved as second line therapy and oral quinine as 
third line. Women with severe malaria were admitted to hospital for treatment with 
intravenous quinine. 
3.7.3.3  Prohibited treatments 
Prohibited medication included antimalarial drugs not prescribed within the trial 
protocol, and other drugs with antimalarial properties including co-trimoxazole. Participants 
who took prohibited medications remained in the trial but were excluded from the per-
protocol analysis.  
 Use of long lasting insecticide treated bed nets (LLITNs) 
 All eligible participants were provided with a long lasting insecticide treated bed net at 
booking and were encouraged to consistently and correctly use the bed nets, not only for the duration 
of the trial, but also after their participation. Monitoring of LLITN use during the trial was based on 
self-reported compliance by the participant at scheduled study visits. These reports of LLITN use 
were not corroborated through observation at the house hold level. 
 Schedule of follow-up visits and procedures 
 A summary of the schedule of visits is provided in Figure 3.1 and Table 3.1 below. The detailed 
description of the timing and conduct of study visits is provided as follows: 
3.9.1 Antenatal booking visit 
 The first study visit immediately followed eligibility screening if a woman made contact with 
the study team between 16 and 28 weeks gestation. If a woman made her first contact before 16 
weeks gestation, the first study visit was conducted at their next appointment between 16 and 28 
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weeks gestation. Informed consent was obtained at the first contact visit after completion of 
eligibility screening and before enrolment.  
3.9.1.1 Enrolment  
 After informed consent had been granted participants were randomly allocated to receive 
either IPTp or ISTp as described earlier. Participants were informed of study intervention they have 
been allocated to. 
3.9.1.2 Baseline assessment 
A baseline assessment was conducted for each participant comprising demographic information, 
socioeconomic information, insecticide treated net (ITN) and indoor residual spraying use, medical 
and obstetric history, and clinical assessment. Any relevant information already collected during the 
screening process or at previous antenatal appointments for the same pregnancy was copied from 
the antenatal cards to avoid unnecessary duplication of work. 
 Study-relevant information recorded at the first visit included age; area of residence; prior 
use of ITNs; number of previous known pregnancies and number of previous births. Clinical 
assessment included height and weight, fundal height, reported date of last menstrual period and 
estimated gestation.  
 A 5 ml venous blood sample was taken and used for both routine and study-specific testing. 
This was obtained after consent for eligibility screening has been sought but before consent for 
enrolment in the trial. Women who had not been tested for HIV in their current pregnancy were 
tested and all women were assessed for anaemia and haemoglobin levels. Women not previously 
tested for syphilis in this pregnancy were tested and treated if positive. The same blood sample was 
used for l be prepared for later study-specific testing for malaria (blood smear microscopy and PCR) 
and other assays for related studies.  
84 
 
3.9.1.3 Study intervention 
 The first dose of IPTp-SP or RDT screening for ISTp-DP was administered to asymptomatic 
women at this visit. If women had symptomatic malaria, they were treated as described. 
3.9.1.4 Routine antenatal care and treatment of illness 
 Routine antenatal care and treatment of any illness identified at this visit were provided. This 
included provision of a suitable LLITN and advice on sleeping under the net for the duration of the 
pregnancy. 
3.9.1.5 Prior morbidities and medications in the current pregnancy 
 All participants were asked about any symptoms or illnesses they have had in the last month, 
and any medications taken.   
3.9.2 Second and third subsequent visits  
 A second clinic visits was scheduled between four and six weeks after the preceding visit with 
an additional third visit only for participants who were enrolled in the trial at between 16 and 23 
weeks gestation. 
3.9.2.1  Study interventions and care 
A subsequent dose of IPTp-SP or RDT screening for ISTp-DP was administered to 
asymptomatic women at this visit. If women had symptomatic malaria, they were treated as 
earlier described in section 3.7.2. Participants were asked about any symptoms or illnesses 
they have had since the last antenatal visit and any medications taken that had not been 
prescribed from the study clinic. 
All consenting participants had a venous blood sample taken, prepared and stored for 
later malaria testing using standard microscopy of blood smears and PCR of dried blood 
spots. Testing was done with the technicians blinded to the participant’s intervention arm.  
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Figure 3.1 Flow chart of participant study visits 
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Table 3.1 Table summary of study visits 
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Actions           
Eligibility confirmed X          
Consent X          
Randomization X          
IPTp or ISTp X X X X       
Measures           
Adherence monitoring     *Sub-
sample 
*Sub-
sample 
    
Tolerability/ adverse 
events 
 X X X *Sub-
sample 
*Sub-
sample 
    
Blood biochemistry       *Sub-
sample 
   
Full blood count       *Sub-
sample 
   
Blood drug levels       *Sub-
sample 
   
Immunology X   X    X   
Peripheral malaria 
microscopy and PCR 
X   X    X   
Peripheral malaria RDT        X   
Hb and anaemia** X**   X**       
Placental microscopy, 
RDT and PCR 
       X   
Placental histopathology        X   
Umbilical cord  blood 
RDT, microscopy and 
PCR 
       X   
Birth weight        X   
Gestational age        X   
Congenital anomalies        X X X 
Neonatal jaundice        X X  
Blood sample for storage X   X    X   
HIV**    X**       
Blood markers of 
malaria immunity and 
iron deficiency 
X       X   
*Women in the ISTp-DP group who were RDT-positive and treated with DHA-PQ  
**Routine care 
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3.9.3 Final antenatal visit 
A final third or fourth clinic visit was scheduled between 34 and 37 weeks gestation, 
at least four weeks after the previous visit. 
3.9.3.1 Study interventions and care 
In addition to procedures conducted during the interim visits, all women had their 
haemoglobin levels tested as point of care. Women found to be anaemic (Hb ≤ 11 µg/ L) were 
treated as appropriate. In addition, women were re-tested for HIV, as recommended in the 
latest WHO guidelines.(328) as well as having urine checked for protein and glucose.  
3.9.4 Day 3 and 14 post-treatment visit (RDT-positive women treated with DHA-PQ 
only) 
Women treated with DHA-PQ were asked to return to the clinic 3 and 14 days after the 
first dose was administered for assessment of safety. In case of the occurrence of a severe 
adverse event, a blood sample was taken to later have drug levels assayed.  A venous blood 
sample was at day 14 taken for assessment of full blood count (haemoglobin, white blood cell 
count, platelets); and biochemistry (bilirubin, alanine aminotransferase and creatine).  
3.9.5 Unscheduled visits during pregnancy 
 Participants were encouraged to visit the clinic in the event they felt unwell between 
scheduled appointments. Participants who presented between appointments were examined by 
study staff. Presenting symptoms, axillary temperature and blood pressure were recorded. A venous 
blood sample was taken for Hb measurement and malaria RDT and thick and thin microscopy smears. 
Women presenting with serious adverse events possibly associated with DHA-PQ had a 2 ml venous 
blood sample taken to measure blood drug levels. Any illness was treated as appropriate and 
according to standard local care.  
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3.9.6 Delivery visit 
 Women were encouraged to deliver on the maternity wards of the participating clinics, in 
which case they would have delivery assisted by a skilled birth attendant. A member of the study 
team would visit them on the ward and perform relevant examinations shortly after delivery. Women 
who delivered at home were identified and traced using a network of community health workers and 
were visited by a member of the study staff or encouraged to report to the research clinic within 48 
hours, to collect, as far as possible, the same information as women who had delivered at the health 
facility.   
3.9.6.1 Peripheral blood sampling  
 A 5 ml venous blood sample was taken from the mother and tested for malaria using RDT, 
standard microscopy and PCR; and tested for Hb concentration using hemocue. Women found to have 
malaria infection by RDT or microscopy, or anaemia (Hb ≤ 11 g/L) were treated in accordance with 
standard practice. 
3.9.6.2 Placental sampling  
 A placental blood sample was collected from the delivered placenta through an incision on 
the maternal side and collecting the pooled blood. This sample was tested for malaria using RDT, 
standard microscopy and PCR.  A 2cm x 2cm x 1cm specimen of placental tissue was taken from the 
maternal side for histopathology testing for current and past malarial infection. In addition, a roll of 
the amnion and chorion were taken for assessment of infection in these two areas.  
3.9.6.3 Umbilical cord sampling 
 An umbilical cord blood sample from the placental side of the cord was taken and tested for 
the fetal haemoglobin level as well as malaria infection using RDT, standard microscopy of blood 
smear and PCR.  If the pLDH line of the RDT was positive for malaria, microscopy would be prioritised 
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for within the next 24 hours to ascertain infection. In the event of microscopically proven 
parasitaemia, the baby was referred to the hospital for treatment of congenital malaria.  
3.9.6.4 Examination of the baby 
The baby was weighed using accurate digital scales and examined for vital status, 
presence of any significant congenital anomalies, and gestational age at birth using the 
Ballard’s score. After 24 hours, the baby was re-examined for the presence of jaundice. 
3.9.7 Postnatal visits 
 Maternal – neonate pairs were seen at the clinic around seven days after birth, if possible to 
correspond with the baby’s first vaccination visit. The baby was examined for the presence of 
jaundice and for any congenital anomalies that may have been missed at delivery. Babies with 
symptoms of malaria had blood samples taken from a heel prick for testing by RDT and treatment 
provided based on the RDT results. Standard postnatal advice and healthcare was given as needed 
for mother and baby. Women who did not attend the appointment were traced at home. Any infant 
deaths occurring before the visit were recorded and a verbal autopsy used to ascertain the likely 
cause of death.  Participants and their babies were again seen between six and eight weeks after birth, 
at their baby’s second vaccination visit with similar procedures being conducted as at the week 1 
post-natal visit. In addition, participants were also asked about their use of healthcare for the baby 
since birth. 
 Women were advised to present to the clinic in the event that themselves or their baby 
became unwell during the postnatal follow-up period. Any illness were treated as appropriate and 
according to standard local care.  
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 Clinical tests and Laboratory methods 
 The following diagnostic procedures were performed on blood and urine samples as 
stipulated in the respective visit procedures. All rapid diagnostic test were conducted in line with the 
manufacturer’s recommendations. 
3.10.1 Clinical tests 
3.10.1.1 Rapid diagnostic tests for malaria 
The First Response® Combo Malaria Ag (pLDH/HRP2) (Premier Medical Corporation, Ltd, India) 
test  was used for assessment of parasitaemia for point of care and screening. After confirmation of 
the participant’s identification number, the test kit was labeled with the participants ID and visit date. 
Blood obtained in accordance with procedures relevant to the visit was then used in order of 
specifications by the manufacturer and results interpreted as described in the Figure 3.2. 
3.10.1.2 Rapid diagnostic tests for syphilis and HIV 
 The SD BIOLINE Syphilis 3.0 test solid phase immunochromatographic assay for the 
qualitative detection of antibodies of all isotypes (IgG, IgM, IgA) against Treponema pallidum (TP) 
(Standard Diagnostics Inc., South Korea) was used for screening for syphilis. In accordance with 
current practice, HIV testing was facility based and conducted as per national guidelines trhough a 
two-step algorithm using Determine™ HIV-1/2 (Abbott Laboratories, US) and Uni-Gold™ 
Recombigen® HIV-1/2 (Trinity Biotech, UK). 
3.10.1.3 Haemoglobin assessment 
 The cuvette tip was placed on to the end of a syringe needle that was used to draw blood from 
the specimen site and the blood allowed to be drawn into the cuvette by capillary action. 
Haemoglobin was then assessed using the HemoCue machine (HemoCue® B-Haemoglobin, 
Angelholm Sweden). On a daily basis, the calibration control cuvette specific for the HemoCue 
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photometer was tested before participants’ testing. Values obtained were expected not to deviate 
from the assigned value on the control cuvette card by more than 0.3g/dl.  
 
Figure 3.2 First Response® Combo Malaria Ag (pLDH/HRP2) test procedures and interpretation of results 
 
 
 
 
3.10.1.4 Urine based tests for proteinuria and glycosuria 
 As part of screening for preeclampsia and gestational diabetes, women had urine dipstick 
tests performed (Seimens Multistix 10SG,  Seimens, UK). Urine dipsticks were also used as point of 
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care diagnostics for urinary tract infection and subsequent occurrences of hypertensive disorders in 
pregnancy. 
3.10.2 Laboratory tests 
3.10.2.1 Thick malaria blood smear  
3.10.2.1.1 Preparation 
 A slide was first labelled with the participant’s identification number, date of sample and the 
visit the sample was taken.  30 – 40 μl of whole blood was placed about 0.5 inches from the end of a 
1 – by 3 – inch glass microscope slide on a horizontal surface. An applicator was then used to spread 
the blood down the glass slide in the opposite direction to form a blood film down the length of the 
slide. Films were allowed to air dry for between 30 minutes and 1 hour in the horizontal position and 
protected from dust. Slides were then stained with diluted Giemsa stain (1:50, vol/vol) for 50 min, 
rinsed in buffered water for 3 to 5 min and allowed to air dry. 
3.10.2.1.2 Reporting and recording of results 
All results were written in a laboratory source book and were recorded onto a separate 
results CRF for data entry.  Once dry, a drop of immersion oil was applied to the center of the film 
using oil immersion objective (x 100 objective), an area that was stained and not too thick was 
selected and examined for the presence of asexual parasites. Examination of the slide consisted of 
counting against 200 high power fields before declaring the slide negative. Gametocytes were not 
counted as positive. If asexual stage parasites are identified before completing 200 high power fields, 
the number of parasites were then counted against the first 300 white blood cells, and the number of 
parasites against 300 white blood cells. Gametocytes were counted separately in a similar fashion. 
 A second microscopist (‘Second Reader’) read all the slides, blinded to the results of the first 
reader, and records their results in a Laboratory Book labeled ‘second reader’ and on the appropriate 
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laboratory form. In instances of discrepancies between the first microscopist (‘First Reader’) and the 
‘Second Reader’, a third microscopist (‘Third Reader’) read the slides that had conflicting results: 
Level of discrepancy that justifies a third reader were: Positive vs negative, Species difference, 
>400% difference in count if ‘First Reader’ count is less than 1000/200 WBC and >200% difference 
in count if ‘First Reader’ count is more than or equal to 1000/WBC. The ‘Third Reader’ recorded their 
results in the Laboratory Book labeled ‘third reader’ and on the appropriate laboratory form. The 
result of the third reader will be used as definitive result. In house quality control measures were 
effected to ensure consistent quality of microscopy. 
3.10.2.2 Placental impression smear microscopy 
3.10.2.2.1 Preparation 
 At delivery, the placenta was cleaned with running water to clear the placenta of the 
remaining blood and mucus from its surface, and then place it onto a flat surface with the maternal 
side facing upwards. A full thickness section of the placental tissue located in an off-centre position 
half way between the insertion of the umbilical cord and the edge of the placenta, was cut out. A 
parallel incision 1 cm away from the first one was made in the placenta and a 1.5 cm3 section of 
placenta removed. The section was lightly dried with a small piece of filter paper (2.5x2.5 cm 
approximately) and carefully pressed along the surface of a glass microscope slide three times. The 
slide was labelled with the participant’s identification number and date of the sample in pencil on the 
frosted area of the slide. 
 The smears were later fixed by dipping them in absolute methanol, which was followed by 
staining with diluted Giemsa stain (1:20, vol/vol) for 20 min. The slide was later washed briefly in 
buffered water and allowed to air dry before reading 
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3.10.2.2.2 Reporting and recording of results 
  The slide was examined under oil immersion objective with the number of parasitised red 
blood cells being counted against 500 red blood cells. Parasitaemia was reported as the proportion 
of parasitaemia as follows: Number of parasitised RBCs per 500 RBCs / 5 = % Parasitaemia. 
3.10.2.3 Placental histology  
3.10.2.3.1 Specimen preparation 
 Following initial cleaning of the placenta after delivery, a full thickness block of tissue about 
2 cm x 2cm x 1 cm deep was cut out from a location in an off-centre position half way between the 
insertion of the umbilical cord and the edge of the placenta, free of infarcted areas, and place it into 
30 mL 10% neutral buffered formalin in a 50 mL capped test tube at room temperature.  Both the 
tube and lid were labeled with the participant identification number, the date and time of collection 
as well as date and time of delivery. Samples were not kept for more than 24 hours before being 
delivered to the histology laboratory for further processing and reading. 
3.10.2.3.2 Further specimen preparation, reading and reporting of results 
 The placental sections were initially dehydrated through immersion in a series of alcohols, 
70%, 90% and 100% for 2 hours in each concentration, followed by clearing in two serial baths of 
toluene for 2 hours each. The sections were then impregnated with paraffin wax through a series of 
2 baths in liquid paraffin for 2 hours each. This was followed by embedding with molten wax and 
then sectioning with a rotary microtome. Sections were then placed on microscope slides and stained 
with haematoxylin and eosin. 
 Examination of placental histology slides and reporting were conducted as follows: 
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 The slides was first evaluated for the presence or absence of autolysis (characterised by poor 
preservation of the tissue, with absence of nuclei) and recorded as: 1=absent, 2=mild, 
3=moderate, 4=severe. 
 The presence or absence of formalin pigment was then examined (when present pigment is 
detected in a widespread location) and documented as: 1=absent, 2=mild, 3=moderate, 
4=abundant 
 The amount of maternal erythrocytes intervillous space was evaluated as : 1=absent, 2=scanty, 
3=moderate, 4=abundant 
 The presence or absence of deciduas basalis in the sample was evaluated as: 1=absent, 2=present 
 The present or absence of amnion in the sample: 1=absent, 2=present   
 The slide was then scanned at 400 magnification to examine for parasites in the intervillous 
space.  If parasites were identified, the percentage of the parasitised erythrocytes was calculated 
and recorded. 
 Hemozoin pigment was examined for at 100 magnification and subsequently repeated at 
magnification of 400 if none was identified. If pigment was identified, it’s location was reported 
as either in  
o Free macrophages alone, 
o Fibrin alone, or 
o Both fibrin and free macrophages 
The amount of pigment was then quantified as either: 
o Mild: very few spots identified focally, 
o Moderate: small spots diffusely distributed or coarse deposits focally located, or 
o Abundant: large and coarse spots diffusely distributed 
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 Abnormalities in the intervillous space were evaluated. Intervillous inflammation was examined 
for by magnification of any areas with most white cells. Magnification of 400 was used to count 
the number of white cells per area: 
o 1=absent 
o 2=1-10% 
o 3=>10%  
Inflammatory cells in the villous stroma were examined and quantified as  
o 1=0-1 
o 2=2-5 
o 3=6-10 
o 4=>10 
 The presence of calcifications was evaluated and reported as  1= absent, 2=minimal, 3=moderate, 
4=abundant 
 Chorioaminionitis was evaluated and reported as: 1=absent, 2=present, 3=not evaluable. 
3.10.2.4 Polymerase chain reaction for P. falciparum detection 
 Dry blood spots for PCR assays were prepared with Whatman’s #3 filter paper. The filter 
paper was labelled with the study ID number and date of sample. Using the pipette set at 40µl, 
approximately 40µl of whole blood was collected from a drawn blood sample and deposited in the 
center of the disc of Whatman’s filter paper. This was repeated until the four spots had been filled.  
Once the blood spots were made, the filter paper was set onto clean paper and left on a shelf to air 
dry in a cabinet. Filter papers were never approximated to each other to ensure that there was no 
cross contamination among specimens.  
 Once dry, the filter papers were individually stored in separate re-sealable Ziploc plastic bag 
labelled with patients ID number and the contents kept dry with a single packet of desiccant added 
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to prevent sample degradation due to moisture. The filter-paper samples were stored at room 
temperature pending shipping.  
 Samples were tested in duplicate in a real-time PCR assay that targeted the P. falciparum 
lactate dehydrogenase gene (pfldh). This is a single-copy gene. Samples were run on a 384-well plate, 
and each run included 10 standards with 3d7 gDNA at concentrations from 0.1ng/μL to 5x10-6 
ng/μL. Genomic DNA (gDNA) was extracted using a Chelex-100 protocol on three 5mm punches from 
a dried blood spot. gDNA specimens were tested in duplicate in a real-time PCR assay targeting the 
P. falciparum lactate dehydrogenase gene (pfldh) (242). Samples were tested on 384-well plates 
using a BioRad CFX384 Touch machine, threshold lines were set manually for each reaction plate, 
and quantitation cycle (Cq) values were computed using the Baseline subtracted curve fit setting. On 
each reaction plate was included a series of 10 standards in duplicate of P. falciparum strain 3D7 
gDNA in concentrations from 0.1ng/uL to 5x10-6ng/uL; the Cq values of these controls were used to 
construct standard curves to estimate parasite gDNA quantity in the clinical specimens. Each plate 
also included four negative controls with molecular-grade water in place of DNA, and all plates were 
prepared in a PCR hood using filtered pipet tips. 
 Data management 
 Source documents were the participants’ antenatal cards, delivery and birth records, 
laboratory results, and clinic records. All study-relevant data was transferred from the source 
documents to the case record forms (CRFs). In addition, some study specific data was recorded 
directly onto the CRF. Each participant had their own document file containing some of their original 
documents (e.g. print-out of automated laboratory results) and study specific CRFs. The investigators 
ensured that the CRFs were accurate, complete and legible.  
 The data recorded on the CRF was input into an electronic database using Cardiff Teleform 
Optical Mark Reader (OMR) v10.2 and managed by the data manager under the local PI in Malawi. 
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Data validation and verification were done to ensure that the data in the database corresponded with 
the CRFs and source documents. Data query sheets were raised and distributed by the data manager 
to the study team for resolution in a timely manner.          
 All documents were stored safely in confidential conditions. On all study-specific documents, 
other than the signed consent forms, the participant was referred to by their unique study participant 
number and initials, and not by name. 
 Safety monitoring and reporting of adverse events 
 Follow-up for symptomatic adverse events was focused on serious adverse events, adverse 
events serious enough to be reported to the study clinics through passive surveillance or requiring 
treatment, and the tolerability of the study drugs through direct observation at administration and 
as self-reported by the participants at visits.  
3.12.1 Reporting procedures for all adverse events 
 An independent physician based in Malawi was appointed by the trial sponsor to act as an 
independent safety monitor. All adverse events occurring during the study, observed by the 
investigator or reported by the participant, whether or not attributed to study medication, were 
recorded using Adverse Event Forms. The following information was recorded: description, date of 
onset and end date, severity, seriousness, action taken and outcome of the event.  
 The relationship of adverse events to the study medication and the expectedness of each 
suspected adverse event according to the Summary of Product Characteristics for SP and the 
Investigators Brochure for DHA-PQ was assessed by a medically qualified investigator and the 
independent safety monitor. In the event that the ISM disagreed with the investigator’s assessment, 
both opinions will be included in the report.  
 The investigator judged whether or not an adverse event was of sufficient severity to require 
discontinuation of the study treatment. If this occurred, or if the participant wished to withdraw due 
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to what they considered to be an intolerable adverse reaction, the participant was offered an end of 
study assessment and provided with appropriate medical care until symptoms ceased or the 
condition became stable. 
3.12.2 Reporting procedures for serious adverse events 
 The investigator reported all serious adverse events (SAEs) that occur in the course of the 
study to the ISM, the Data Safety and Monitoring Board, the local pharmaceutical regulators (PMPB) 
and the ethics review board (NHSRC) within 24 hours of the investigational site becoming aware of 
the event. All SAEs will be reported, whether or not they were deemed to be causally related to the 
study drugs. All SAEs were reported using a standard SAE reporting form.   
The immediate reports were followed within 24 hours by detailed, written reports with both reports 
identifying participants by their study ID number. In cases of doubt about whether an event fulfilled 
the criteria of serious, the case was reported to the ISM who proceeded to assess whether the event 
should be reported as an SAE.  
 All SAEs were reported by the investigator to the sponsor within 48 hrs of discovery or 
notification of the event. The sponsor was responsible for notifying the relevant external Ethics 
Committee (LSTM REC) and the trial Data Safety and Monitoring Board (DSMB). Detailed full SAE 
reports were provided to the DSMB to consider any action that may be needed in response to 
reported adverse events. 
 Overview of statistical methods for analysis 
3.13.1 Efficacy of ISTp – DP vs. IPTp-SP for the control of malaria in pregnancy 
 The primary efficacy analysis was based on the assessment of the superiority of ISTp-DP over 
IPTp-SP in women in their first and second pregnancies for the prevention of the primary endpoint. 
Similar analyses were undertaken for the additional primary outcome for women in their third to 
fifth pregnancies, and for the secondary efficacy outcomes.  
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3.13.1.1 Analytical populations 
 The primary efficacy analysis was based on modified intention (mITT) to treat which 
included all women who had been randomized into the trial and for whom there was a study outcome 
of interest. Women who were randomized but later classified as screening failures were excluded. 
The second level of analysis was by per protocol (PP) in which only women who contributed to the 
endpoint of interest and either: 
a. Received the study intervention (IPTp-SP or ISTp-DP) on at least three separate occasions at 
least four weeks apart and took >= 2/3 of the study doses on each occasion when measured; 
or  
b. Reached a study end-point before completion of the three-visit schedule but received the 
intervention at least once; or 
c. Received an approved alternative treatment for symptomatic malaria according to protocol 
that replaced the need for the scheduled intervention. 
Women were excluded from the PP analysis if they did not adhere to the study treatments, used 
prohibited medications or were screening failures. 
 A safety population was defined in order to evaluate potential adverse events between 
intervention arms. This group constituted all women who had received the study intervention (i.e. 
either IPTp-SP or ISTp, with DP if ever diagnosed with malaria) with sufficient follow-up time, 
defined as attending the at least one subsequent scheduled study visit after receiving the first 
intervention dose at enrolment.  
3.13.1.2 General analytical approach 
 Data from all three investigational sites was pooled as the study was conducted under a 
common protocol with the intention of pooling the data for analysis. All analysis was conducted and 
presented results stratified by gravidity group and overall (summary estimate for all gravidae 
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obtained by stratified analysis). Women were included in the gravidity strata that they were allocated 
to at enrolment. 
 Missing data for primary and secondary endpoints was not imputed. Missing values for 9 
covariates selected a priori (likely prognostic: gravidity, participant enrolment site, malaria status at 
enrolment, season during pregnancy, maternal height; less likely prognostic: haemoglobin status at 
enrolment, socioeconomic status, corrected gestational age at enrolment and educational status)   
was imputed for the covariate adjusted analysis of the primary endpoint.  
 Generalised linear models were used where appropriate to assess the effect of the 
intervention according to different characteristics of the participants. Treatment effects were 
expressed in terms of relative risk and risk difference for dichotomous variables and mean difference 
for continuous variables, and the corresponding 95% confidence intervals. Superiority was defined 
as a positive treatment effect that is greater in the ISTp group than the IPTp group, where the 95% 
confidence interval does not include the point of no difference (RR value of 1). 
 Both modified intention-to-treat and per-protocol analyses were undertaken for the efficacy 
analyses. The modified intention to treat analysis was the primary analysis to assess superiority. In 
the absence of evidence for superiority, the prospectively defined non-inferiority margin was 15% 
for adverse outcome or placental malaria in the intention to treat and per protocol populations 
(relative difference between endpoints of 15% (i.e. RR 0.85); e.g. 24.5% versus 28.8% for adverse 
birth outcome) (333).  
3.13.2 Effect of timing and frequency of submicroscopic parasitaemia and the 
reliability of RDTs for the detection of active placental malaria 
Binomial regression model was used to evaluate the relationship between the 
frequency and timing of sub-diagnostic parasitaemia and low birth weight. Sensitivity/ 
specificity and positive/negative predictive values were used to assess the reliability of the 
pLDH/HRP2 rapid diagnostic test from the peripheral maternal blood and placental blood for 
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detecting active placental malaria against placental histology as the reference standard test. Further 
details on the statistical considerations and methods are provided in the respective chapters. 
 Ethical considerations 
 The Investigators ensured the study was conducted in full conformity with relevant 
regulations and with the International Conference on Harmonization (ICH) guidelines for Good 
Clinical Practice (GCP) (CPMP/ICH/135/95) July 1996. The protocol, informed consent forms and 
participant information sheets were submitted to the research ethics committees at the College of 
Medicine (Blantyre, Malawi), the National Health Science Research Committee of the Malawi, 
Ministry of Health, and the Liverpool School of Tropical Medicine for approval. Prior to initiating the 
trial, written and dated approval were obtained from all relevant ethics committees. Any protocol 
amendments were submitted to the ethics committees before implementation. Progress reports, 
SUSAR reports and safety reports were submitted in accordance with local requirements.  
3.14.1 Informed consent and participant confidentiality 
 Informed consent was obtained before women were enrolled in the study as per Annex 2.  
The study staff ensured that participant anonymity was maintained. Participants were identified only 
by their study identification number and initials on the CRF and in any electronic database. All 
documents were stored securely and only accessible by study staff and other authorised personnel.  
3.14.2 Other ethical considerations 
3.14.2.1 Safety of the study drugs in pregnancy 
 Both SP and DHA-PQ are currently thought to be safe for the mother and foetus during the 
second and third trimesters of pregnancy. However, adverse events, particularly those associated 
with the study medication, were recorded and monitored throughout the trial. 
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3.14.2.2 Blood sampling 
 All examinations undertaken as part of this study were non-invasive, with the exception of 
blood sampling. Venous blood samples of 5 ml were taken as described in the trial procedures.  Blood 
sampling was likely inconvenient to the participants, and caused minor discomfort and bruising. In 
some aspects of the trial, venous blood sampling had the potential to directly benefit the participants 
or their babies as any malaria infection or anaemia detected as a result of the sampling would be 
treated as well as the avoiding of repeated finger pricking, which was deemed more uncomfortable.  
 The overall volume of blood collected from each participant was small, a maximum of 20 ml 
per woman over the course of the study. Only well trained nursing and laboratory staff were 
employed on the trial and new disposable needles and lancets will used for blood taking procedures, 
being safely discarded immediately after their use.  
3.14.2.3 Inclusion of young people under the age of 18 
 This study included young women below the age of 18 years. In Malawi, young pregnant 
women aged 15 or older are considered emancipated, and are legally able to consent on their own 
behalf to be included in a clinical trial. It was important to include young women in the trial, as 
adolescents are known to be particularly susceptible to malaria in pregnancy, and are therefore one 
of the groups that may potentially benefit the most from any improvements to practice in preventing 
adverse outcomes related to malaria in pregnancy. 
3.14.2.4 Reimbursement of costs 
 The study provided all study drugs, study procedures, study-related visits and reasonable 
medical expenses that were incurred as a result of the study including expenses for transport and a 
meal allowance for any study visits which were conducted over lunch times. 
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 Trial monitoring and GCP compliance (Quality assurance procedures) 
The study was conducted in accordance with the current approved protocol, ICH GCP, relevant 
regulations and standard operating procedures. Regular monitoring was performed in accordance 
with ICH GCP. The Research Support Centre of the College of Medicine provided the clinical 
monitoring on behalf of the sponsor with monitoring visits conducted prior to enrolment, shortly 
after the start of enrolment, and at periodic intervals during the trial, to ensure conduct according to 
the published protocol and any amendments.  
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4 CHAPTER FOUR: SCHEDULED INTERMITTENT SCREENING AND 
TREATMENT IN PREGNANCY (ISTP) FOR THE CONTROL OF MALARIA IN 
PREGNANCY IN MALAWI: A RANDOMIZED CONTROLLED TRIAL 
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 Results 
4.1.1 Baseline and patient disposition 
 Between 21 July 2011 and 18 March 2013, 3,214 women were screened for inclusion; 1,873 
women were randomized (paucigravidae=1155; multigravidae=718) and 1,743 (93.1%) were seen 
at delivery (Figure 4.1). Overall 6,504 of 6,942 (93.7%) scheduled antenatal follow-up visits were 
attended (Table 4.1) and 1,742 women (94.5%) attended all scheduled visits. Ultimately, 1,702 
(90.9% (ISTp=90.6%, IPTp=91.2%) contributed to the primary morbidity outcome and 1,653 
(88.3%) (ISTp=88.6%, IPTp=87.9%) to the primary outcome of malaria infection at delivery. The 
baseline characteristics were well balanced, within each gravidity strata and overall (Table 4.2). At 
baseline, about half of the women were infected with malaria parasites. In both arms, the median 
(IQR) follow-up time was 4.0 (3.2-4.7) months and median (range) number of scheduled visits was 4 
(1-4) (Table 4.1). In the ISTp-DP arm, 48.8%, 38.0%, 12.4% and 0.9% received 0, 1, 2, 3, courses of 
DP, respectively (Table 4.1). 
4.1.2 Primary outcome 
 Among paucigravidae, the prevalence of SGA/LBW/PT was similar in the ISTp-DP (33.7%) 
and IPTp-SP (30.6%) arms (RR=1.10, 95% CI 0.92-1.31, p=0.282, Figure 4.2). The prevalence was 
also similar between arms among multigravidae. 
 Among multigravidae, the risk of malaria at delivery was significantly higher in the ISTp-DP 
(34.9%) than in the IPTp-SP (27.2%) arm (RR=1.29 (1.02-1.63), p=0.037). This was also evident 
among paucigravidae and all gravidae. In absolute terms, the risk of malaria was increased in 
multigravidae by 7.8% (0.6-14.9) and amongst all gravidae by 7.9% (3.1-12.6) (Figure 4.2).  
 Similar results for both primary outcomes were obtained from covariate adjusted analyses, 
with and without imputation for missing values (Table 4.3), with per protocol population analysis 
(Table 4.4) and following sensitivity analysis that restricted analysis to birthweight obtained within 
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24 hours of delivery (Table 4.5). Results for the primary composite live birth outcome were also 
consistent across subgroups, including study sites, (Figures 4.3 and 4.4), although the increased risk 
of malaria at delivery appeared lowest in primigravidae (Figure 4.4).  However, Chikwawa and 
Madziabango, both high transmission areas, had significantly higher risk of primary outcome malaria 
infection at delivery, with no significant association noted for Mpemba (Figure 4.4). 
4.1.3 Secondary efficacy outcomes 
 Following enrolment, 45.8% had >=1 episode of malaria infection prior to delivery (PCR, 
microscopy or RDT) and 11.4% had >=1 episode of clinical malaria. These were similar in both arms 
(Figure 4.5Error! Reference source not found.). At delivery, 22.2% of women had peripheral 
alaria detected by PCR, RDT or microscopy. This was higher in the ISTp-DP arm (RR=1.34 [1.12-1.61], 
p=0.002, Figure 4.5), particularly for sub-patent infections (PCR-positive, RDT or microscopy-
negative, Figure 4.6). The overall prevalence of placental malaria detected by histology, PCR, RDT or 
microscopy was 38.0% and higher in the ISTp-DP arm: RR=1.16 (1.03-1.32), p=0.018 (Figure 4.5). 
The greatest difference was observed for acute rather than chronic or past histological infections 
(Figure 4.7). Congenital malaria was common (12.0%) in both groups (Figure 4.8).  
 At delivery, the mean haemoglobin concentration was higher (Table 4.6), and the prevalence 
of anaemia (Hb<11g/dL) lower in paucigravidae in the ISTp-DP arm relative to the ITPp-SP arm 
(Figure 4.5). The individual components of the primary endpoint are provided in Figure 4.8. LBW 
was more common in the ISTp-DP arm (RR=1.29 [0.97-1.71], p=0.079). 
4.1.3.1 Exploratory analysis of the effect of last antimalarial dosing prior to delivery on the 
risk of active malaria infection at delivery 
 There was no significant difference to the time of delivery from dosing of an antimalarial at 
the last visit prior to delivery between the SP, AL or DP (Table 4.7). Women who received DP and AL 
at the last visit prior to delivery had a higher risk of peripheral malaria compared to women who 
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received SP (RR=1.74 [1.16, 2.59], p=0.007 and RR=3.20 [2.09, 4.90], p<0.001 respectively, Table 
4.8). Receiving DP at the last visit was associated with a 46% lower risk of peripheral malaria at 
delivery than AL (29.9% vs 55.0%; RR=0.54 [0.32, 0.93], p=0.027 (Table 4.8).  
 Though not significant, there was an increased risk of active placental malaria in women who 
took DP than those who took SP at the last visit prior to delivery (RR=1.32 [0.99, 1.77], p=0.061, Table 
4.8) whilst AL was significantly associated with a higher risk of active placental malaria when 
compared to SP (RR=2.25 [1.72, 2.96], p<0.001). Receipt of DP was significantly associated with a 
lower risk of active placental malaria at delivery when compared to AL (RR=0.59 [0.40, 0.85], 
p=0.005). 
4.1.3.2 Risk of reinfection at the next scheduled clinic visit after treatment with 
dihydroartemisinin-piperaquine 
 Overall, 17% of women ever treated with dihydroartemesinin-piperaquine at a scheduled 
antenatal visit presented with reinfection by either malaria microscopy, RDT or PCR by the time of 
their next antenatal visit (Table 4.9). Though the risk of reinfection progressively increased, the 
absolute number of women being treated at each visit decreased. 
4.1.4 Adherence, tolerance, foetal loss, mortality and other safety outcomes 
 Overall DP was well tolerated (Table 4.10). There was no difference between arms in the 
number of maternal SAEs or deaths (Table 4.11). There were no severe cutaneous reactions. Foetal 
loss was highest in the ISTp-DP arm (2.6% vs 1.3%, Figure 4.8). Further stratified analysis within the 
ISTp-DP arm showed this was highest among women who had never received DP (i.e. pregnancies 
who remained RDT-negative throughout) (3.1% vs 2.2% in DP recipients, Table 4.11). Perinatal, 
neonatal and infant (by 6-8 weeks) mortality were also higher in the ISTp-DP arm (not significant) 
(Figure 4.8). Overall, foetal loss or infant death by the end of the follow-up period at 6-8 weeks 
occurred more often in the ISTp-DP (4.0%) than in the IPTp-SP (2.3%) arm (RR=1.76 [1.04-2.98], 
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p=0.036, Figure 4.4, Table 4.11). One case of neonatal jaundice was detected in the ISTp-DP arm (non 
DP-recipient) and none in the IPTp-SP arm. The frequency of congenital malformations was 1.5% 
and 1.0% in the ISTp-DP and ISTp-SP arm respectively (RR=1.44 (0.62-3.35), p=0.398) (1.5% vs 1.6% 
in non-DP vs DP-recipients within the ISTp-DP arm).  
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Figure 4.1:Participant flowchart 
 
 
ITT=Intention to treat, SGA/LBW/PT=composite of small-for-gestational Age (SGA), or low birthweight (LBW), or preterm (PT). 
a. One woman randomized to IPTp-SP was erroneously recorded as being in the ISTp-arm on her ANC card and as a result received ISTp-DP. She was included in the ITT population under 
the IPTp-SP arm. 
b. Screening failures were not followed to delivery and excluded from the modified ITT population 
c. Women lost to follow-up prior to delivery and women who withdrew consent were included in the modified ITT population and contributed to the antenatal follow-up analyses (e.g. 
incidence of malaria). 
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Table 4.1 Follow-up visits schedule (modified intention to treat population) 
 Paucigravidae  Multigravidae  All gravidae 
 ISTp-DP IPTp-SP  ISTp-DP IPTp-SP  ISTp-DP IPTp-SP 
 (n=571) (n=569)  (n=352) (n=352)  (n=923) (n=921) 
Planned No. of scheduled visits, including enrolment, excluding delivery,a No. (%) 
3 58 (10.2) 58 (10.2)  50 (14.2) 48 (13.6)  108 (11.7) 106 (11.5) 
4 513 (89.8) 511 (89.8)  302 (85.8) 304 (86.4)  815 (88.3) 815 (88.5) 
Total visits 2226 2218  1358 1360  3584 3578 
Possible No. of scheduled visits adjusted for early delivery, including enrolment, excluding delivery,b No. (%) 
1 4 (0.4) 5 (0.9)  0 (0) 0 (0)  4 (0.4) 5 (0.9) 
2 19 (3.3) 15 (2.6)  11 (3.1) 8 (2.3)  30 (3.3) 23 (2.5) 
3 90 (15.8) 79 (13.9)  64 (18.2) 68 (19.3)  154 (16.7) 147 (16.0) 
4 458 (80.2) 470 (82.6)  277 (78.7) 276 (78.4)  735 (79.6) 746 (81.0) 
Total visits 2144 2152  1322 1324  3466 3476 
Achieved number of scheduled visits, including enrolment, excluding delivery, No. (%) 
1 21 (3.7) 27 (4.7)  12 (3.4) 8 (2.3)  33 (3.6) 35 (3.8) 
2 38 (6.7) 34 (6.0)  22 (6.3) 26 (7.4)  60 (6.5) 60 (6.5) 
3 133 (23.3) 115 (20.2)  80 (22.7) 100 (28.4)  213 (23.1) 215 (23.3) 
4 379 (66.4) 393 (69.1)  238 (67.6) 218 (61.9)  617 (66.8) 611 (66.3) 
Total visits 2012 2012  1248 1232  3260 3244 
Number of DP or SP courses received, No. (%) 
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0 rev 1 (0.2)  230 (65.3) 0 (0)  450 (48.8) 1 (0.1) 
1 244 (42.7) 29 (5.1)  107 (30.4) 11 (3.1)  351 (38.0) 40 (4.3) 
2 99 (17.3) 39 (6.9)  15 (4.3) 27 (7.7)  114 (12.4) 66 (7.2) 
3 8 (1.4) 119 (20.9)  0 (0.0) 103 (29.3)  8 (0.9) 222 (24.1) 
4 0 381 (67.0)  0 211 (59.9)  0 592 (64.3) 
Total courses received 466 1988  137 1218  603 3206 
Person days contributed till delivery or till lost to follow-up, median (IQR) 
 117 (97-143) 117 (102-142)  115 (98-139) 116 (95-141)  116 (97-142) 117 (99-142) 
a. The number of scheduled visits was dependent on the gestational age at enrolment. This was either 4 visits (including enrolment) if women were enrolled between 16 
to 25 weeks gestation, or 3 visits if they were enrolled between 26 and 28 weeks gestation. 
b. Adjusted for early delivery (i.e. excludes all planned antenatal visits that could not have occurred because the pregnancy ended before that scheduled date) 
IQR=interquartile range 
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Table 4.2 Baseline characteristics (modified intention to treat population) 
  Paucigravidae  Multigravidae  All gravidae (pooled) 
  ISTp-DP IPTp-SP  ISTp-DP IPTp-SP  ISTp-DP IPTp-SP 
  (n=571) (n=569)  (n=352) (n=352)  (n=923) (n=921) 
Maternal characteristics                 
Study site         
 Madziabango 
21.9% 
(125/571) 
22.1% 
(126/569)  
31.3% 
(110/352) 
30.4% 
(107/352)  
25.5% 
(235/923) 
25.3% 
(233/921) 
 Mpemba 
51.5% 
(294/571) 
51.5% 
(293/569)  
54.3% 
(191/352) 
55.4% 
(195/352)  
52.6% 
(485/923) 
53.0% 
(488/921) 
 Chikwawa 
26.6% 
(152/571) 
26.4% 
(150/569)  
14.5% 
(51/352) 
14.2% 
(50/352)  
22.0% 
(203/923) 
21.7% 
(200/921) 
Maternal age (years) 19.5 (2.7) 19.6 (2.8)  27.3 (4.3) 27.5 (4.2)  22.5 (5.1) 22.6 (5.1) 
Marital status         
 Single 
8.1% 
(46/570) 
8.8% 
(50/569)  
2.0% 
(7/351) 0.3% (1/352)  5.8% (53/921) 
5.5% 
(51/921) 
 Married 
91.9% 
(524/570) 
91.2% 
(519/569)  
97.7% 
(343/351) 
99.1.% 
(349/352)  
94.1% 
(867/921) 
94.2% 
(868/921) 
 Widowed/separated/divorced 0.0% (0/570) 0.0% (0/569)  
0.3% 
(1/351) 0.6% (2/352)  0.1% (1/921) 0.2% (2/921) 
Used a bednet last night 
18.2% 
(104/571) 
17.0% 
(97/569)  
18.2% 
(64/351) 
24.1% 
(85/352)  
18.2% 
(168/922) 
19.8% 
(182/921) 
Schooling (years completed) 6.7 (3.4) 6.7 (3.3)  4.4(3.4) 4.4(3.9)  5.8(3.6) 5.9(3.7) 
SES index score (terciles)         
 Low 
34.7% 
(198/570) 
33.3% 
(189/567)  
33.3% 
(117/351) 
31.5% 
(111/352)  
34.2% 
(315/921) 
32.6% 
(300/919) 
 Medium 
31.2% 
(178/570) 
32.1% 
(182/567)  
37.0% 
(130/351) 
36.1% 
(127/352)  
33.4% 
(308/921) 
33.6% 
(309/919) 
 High 
34.0% 
(194/570) 
34.6% 
(196/567)  
29.6% 
(104/351) 
32.4% 
(114/352)  
32.4% 
(298/921) 
33.7% 
(310/919) 
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Rainfall 3 months before enrolment 
(average/month in millimetre) 67.2 (86.5) 66.1 (86.0)  67.6 (79.8) 66.6 (79.2)  67.3 (84.0) 66.3 (83.5) 
Pregnancy number (gravidity)         
 First 
54.5% 
(311/571) 
55.5% 
(316/569)  NA NA  
33.8% 
(311/921) 
34.3% 
(316/920) 
 Second 
45.5% 
(260/571) 
44.5% 
(253/569)  NA NA  
28.2% 
(260/921) 
27.5% 
(253/920) 
 Third NA NA  
44.0% 
(154/352) 
43.0% 
(151/351)  
16.7% 
(154/921) 
16.4% 
(151/920) 
 Fourth or higher NA NA  
56.0% 
(196/352) 
57.0% 
(200/351)  
21.3% 
(196/921) 
21.7% 
(200/920) 
Gestational age by ultrasound (days) 145.1(23.0) 144.5(22.4)  149.7(23.7) 149.1(23.8)  146.8(23.3) 146.2(23.0) 
Had a previous stillbirth/abortions 
5.1% 
(29/571) 
4.0% 
(23/569)  
14.2% 
(50/352) 
10.8% 
(38/352)  8.6% (79/923) 
6.6% 
(61/921) 
Maternal weight (kg) 54.1 (6.8) 54.4 (6.9)  56.1 (7.5) 57.0 (8.5)  54.8 (7.2) 55.4 (7.6) 
Maternal height (cm) 154 (4.8) 154 (5.0)  154 (5.2) 155 (5.0)  154 (5.0) 154 (5.0) 
Laboratory  findings                 
Haemoglobin (g/dL)  10.7 (1.5) 10.7 (1.5)    11.5 (1.3) 11.5 (1.3)   11.0 (1.5) 11.0 (1.4)  
Malaria infection          
  RDT 
 43.8% 
(250/571) NA    
19.4% 
(68/351)  NA    
34.5% 
(318/922)  NA  
 Microscopy 
17.7% 
(100/565) 
20.8% 
(117/562)  
11.8% 
(41/347) 
9.4% 
(33/351)  
15.5% 
(141/912) 
16.4% 
(150/913) 
 PCR 
51.3% 
(285/556) 
51.7% 
(290/561)  
33.1% 
(115/347) 
28.7% 
(98/342)  
44.3% 
(400/903) 
43.0% 
(388/903) 
 Microscopy or PCR 
52.5% 
(300/571) 
54.9% 
(312/568)  
36.4% 
(128/352) 
31.5% 
(111/352)  
46.4% 
(428/923) 
46.0% 
(423/920) 
Parasite densitya (median, IQR) 
1,000 (320-
7,200) 
2,427 (507-
9,600)  
320 (160-
3,200) 
907 (213-
4,267)  
800 (267-
5,867) 
2,400 (320-
8,000) 
Data are % (n/N), median (IQR), or mean (SD), unless otherwise indicated.  
SES=Socioeconomic Status, mm=millimetres rainfall (average per month), kg=kilograms, cm=centimetre, g/dL:=grams per decilitre, RDT=Rapid 
diagnostic test for malaria, PCR=Polymerase Chain Reaction, NA=Not Applicable 
Parasite density per/microliter assessed by microscopy  
 
 
116 
 
 
Figure 4.2Efficacy of ISTp-DP versus IPTp-SP on the composite primary outcomes of SGA, LBW and preterm birth and of malaria infection at delivery 
 
 
RR=Relative Risk, RD=crude Risk Difference. Adjusted RR obtained from multivariate log binomial regression models with missing values imputed and 
adjusting for study site, and 7 pre-specified covariates: malaria status at enrolment (binary), season during pregnancy (terciles based on average 
ranked rainfall during the last 6 month of pregnancy), maternal height (terciles), haemoglobin status at enrolment (terciles), maternal years of 
schooling (terciles), socio-economic status (terciles of SES Index calculated using Principal Component Analysis (PCA), gestational age at booking 
(binary based on median). 
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Table 4.3 Modified intention to treat analysis population, co-variate adjusted analysis of primary endpoint, with and without imputation for missing variables 
 
no/No (%) of patients with 
events 
Co-variate adjusted analysis 
No imputation for missing values 
Co-variate adjusted analysis 
Missing values for co-variates imputed 
Outcome ISTp-DP IPTp-SP 
Risk Ratio (95% CI), 
p-value  
Risk Difference (95% 
CI), p-value  
Risk Ratio(95% 
CI), p-value  
Risk Difference 
(95% CI), p-value 
SGA/LBW/PT        
 Paucigravidae 175/519 (33.7) 161/526 (30.6) 1.10 (0.93, 1.31), 
0.2727 
 2.17 (-3.34, 7.69), 0.4399  1.10 (0.93, 1.31), 
0.2552 
 2.27 (-3.23, 7.77), 0.4189 
 Multigravidae 79/330 (23.9) 85/327 (26.0) 0.89 (0.68, 1.16), 
0.3778 
 -3.96 (-10.55, 2.63), 
0.2391 
 0.89 (0.68, 1.16), 
0.3778 
 -3.96 (-10.55, 2.63), 
0.2391 
 All gravidae 254/849 (29.9) 246/853 (28.8) 1.03 (0.89, 1.19), 
0.6814 
 0.04 (-4.23, 4.32), 0.9856  1.03 (0.89, 1.19), 
0.6594 
 0.10 (-4.17, 4.37), 0.9638 
Malaria infection at 
delivery 
         
 Paucigravidae 293/512 (57.2) 251/510 (49.2) 1.13 (1.01, 1.26), 
0.0266 
 7.88 (1.97, 13.80), 0.0090  1.13 (1.02, 1.27), 
0.0237 
 8.03 (2.13, 13.94), 0.0077 
 Multigravidae 111/318 (34.9) 85/313 (27.2) 1.27 (1.01, 1.60), 
0.0419 
 8.17 (1.02, 15.32), 0.0252  1.27 (1.01, 1.60), 
0.0419 
 8.17 (1.02, 15.32), 0.0252 
 All gravidae 404/830 (48.7) 336/823 (40.8) 1.15 (1.04, 1.28), 
0.0060 
 7.21 (2.59, 11.84), 0.0022  1.15 (1.04, 1.28), 
0.0055 
 7.27 (2.65, 11.89), 0.0021 
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Table 4.4 Per protocol analysis population, unadjusted and co-variate adjusted analysis of primary endpoint, with missing values for co-variates imputed 
 
no/No (%) of patients 
with events Unadjusted analysis Co-variate adjusted analysis 
Outcome ISTp-DP IPTp-SP 
Risk Ratio 
(95% CI), p-value 
Risk Difference 
(95% CI), p-value 
Risk Ratio 
(95% CI), p-value 
Risk Difference 
(95% CI), p-value 
SGA/LBW/PT       
 Paucigravidae 123/439 
(28.0) 
109/444 
(24.5) 
1.16 (0.93, 1.43), 
0.1869 
3.05 (-2.57, 8.67), 
0.2874 
1.16 (0.94, 1.44), 
0.1738 
3.16 (-2.43, 8.76), 
0.2679 
 Multigravidae 55/276 
(19.9) 
55/267 
(20.6) 
0.94 (0.68, 1.32), 
0.7326 
-2.60 (-9.51, 4.32), 
0.4619 
0.94 (0.68, 1.32), 
0.7326 
-2.60 (-9.51, 4.32), 
0.4619 
 All gravidae 178/715 
(24.9) 
164/711 
(23.1) 
1.08 (0.90, 1.29), 
0.4253 
1.18 (-3.14, 5.51), 
0.5917 
1.08 (0.90, 1.29), 
0.4101 
1.22 (-3.10, 5.55), 
0.5789 
Malaria infection at 
delivery 
      
 Paucigravidae 241/429 
(56.2) 
199/428 
(46.5) 
1.21 (1.06, 1.38), 
0.0048 
9.83 (3.42, 16.25), 
0.0027 
1.19 (1.05, 1.35), 
0.0059 
10.00 (3.60, 16.40, 
0.0022 
 Multigravidae 88/264 
(33.3) 
64/259 
(24.7) 
1.35 (1.03, 1.77), 
0.0314 
8.58 (0.76, 16.40), 
0.0315 
1.36 (1.03, 1.78), 
0.0273 
8.58 (0.76, 16.40), 
0.0315 
 All gravidae 329/693 
(47.5) 
263/687 
(38.3) 
1.24 (1.10, 1.40), 
0.0006 
8.70 (3.69, 13.72), 
0.0007 
1.20 (1.07, 1.35), 
0.0017 
8.77 (3.76, 13.78), 
0.0006 
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Table 4.5 Sensitivity analysis to determine the effect of the use of corrected versus uncorrected birthweight, using the intention to treat analysis population 
 Corrected birthweight within 7 days of birth Un-corrected birthweight measured within 24 hours of delivery 
 
no/No (%) of women with 
events or  
No, mean (SD) 
Risk Ratio or Mean 
Difference 
(95% CI), p-value 
no/No (%) of women with events or  
No, mean (SD) Risk Ratio or Mean Difference 
(95% CI), p-value Outcome ISTp-DP IPTp-SP ISTp-DP IPTp-SP 
Birthweight       
 Paucigravidae 504; 2,859 
(412) 
508; 2,891 
(454) 
-32.32 (-85.72, 21.08),  
0.2355 
480; 2,853  
(406) 
488; 2,887  
(453) 
-34.81 (-88.93, 19.30),  
0.2073 
 Multigravidae 314; 3,020 
(421) 
310; 3,041 
(404) 
-20.56 (-85.23, 44.11),  
0.5333 
293; 3,010  
(418) 
298; 3,035  
(403) 
-25.03 (-91.13, 41.08),  
0.4581 
 All gravidae 818; 2,921 
(423) 
818; 2,948 
(442) 
-27.07 (-68.95, 14.80),  
0.2051 
773; 2,912  
(417) 
786; 2,944  
(440) 
-31.12 (-73.68, 11.44),  
0.1518 
LBW       
 Paucigravidae 77/504 (15.3) 59/508 (11.6) 1.32 (0.96, 1.80), 0.0890 74/480 (15.4) 56/488 (11.5) 1.34 (0.97, 1.86), 0.0736 
 Multigravidae 21/314 (6.7) 17/310 (5.5) 1.22 (0.66, 2.27), 0.5303 19/293 (6.5) 16/298 (5.4) 1.21 (0.63, 2.30), 0.5663 
 All gravidae 98/818 (12.0) 76/818 (9.3) 1.29 (0.97, 1.71), 0.0788 93/773 (12.0) 72/786 (9.2) 1.31 (0.98, 1.76), 0.0665 
SGA/LBW/PT       
 Paucigravidae 175/519 (33.7) 161/526 (30.6) 1.10 (0.92, 1.31), 0.2822 175/519 (33.7) 160/526 (30.4) 1.11 (0.93, 1.32), 0.2535 
 Multigravidae 79/330 (23.9) 85/327 (26.0) 0.92 (0.71, 1.20), 0.5431 79/330 (23.9) 85/327 (26.0) 0.92 (0.71, 1.20), 0.5431 
 All gravidae 254/849 (29.9) 246/853 (28.8) 1.04 (0.90, 1.20), 0.6254 254/849 (29.9) 245/853 (28.7) 1.04 (0.90, 1.21), 0.5881 
All birthweight in the primary analyses refer to corrected birthweights taken within 7 days (168 hours) after birth. Birthweights taken more than 24 
hours after delivery were corrected for the physiological fall in birth weight in breastfed infants occurring in the first days following deliver (334, 335). 
Birth weights taken 24-48h hours, and 48-168 hours after delivery were corrected by a factor +2% and +4%, respectively to obtain the estimated weight 
at birth (336, 337) . 
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Figure 4.3Subgroup analysis of the effect of ISTp-DP versus IPTp-SP on the composite primary outcomes of SGA, LBW and 
preterm birth 
 
 
RR=Relative Risk, Hb=haemoglobin, Season was defined by ranking the average rainfall in the 6 months prior 
to delivery.  
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Figure 4.4 Subgroup analysis of the effect of ISTp-DP versus IPTp-SP on the primary outcome malaria infection at delivery 
 
 
RR=Relative Risk, Hb=haemoglobin, Season was defined by ranking the average rainfall in the 6 months prior 
to delivery. The difference in treatment effect for malaria infection at delivery was greater in multigravidae 
and secundigravidae pooled (RR=1.30) than in primigravidae (RR=1.08) (p=0.08 for difference between 
subgroups). 
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Figure 4.5 Maternal secondary outcomes: anaemia and malaria 
 
a. Data for the incidence of malaria infection and clinical malaria represent the number of women with an 
event, the number of events, the person time follow-up and in brackets, the incidence rate per 100 person 
years 
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Figure 4.6 Patent and sub-patent malaria infection at delivery by microscopy, RDT or PCR 
 
 
* PCR positive and RDT or microscopy positive (patent) or RDT or microscopy negative (sub-patent) 
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Figure 4.7 Placental malaria infection by microscopy, RDT, PCR and placental histology 
 
 
* PCR positive or histology positive (active infection) and RDT or microscopy positive (patent) or RDT or 
microscopy negative (sub-patent) 
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Figure 4.8 Secondary outcomes newborn: birth outcomes and neonatal follow-up 
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Table 4.6 Effect of ISTp-DP vs IPTp-SP on mean haemoglobin, birthweight, gestational age and mean birthweight-for gestational age Z-score (crude analysis) 
 Number of women, 
mean (SD) 
 
Mean difference 
(95% CI) 
P-value 
Outcome ISTp-DP IPTp-SP   
 
Maternal haemoglobin (g/dL) last scheduled visit in 3rd trimester 
 Paucigravidae 408, 11.6 (1.3) 415, 11.4 (1.2) 0.12 (-0.05,0.29) 0.165 
 Multigravidae 262, 11.9 (1.1) 250, 11.8 (1.2) 0.09 (-0.11,0.30) 0.384 
 All gravidae 670, 11.7 (1.2) 665, 11.6 (1.2) 0.11 (-0.02,0.25) 0.090 
Maternal haemoglobin (g/dL) at delivery 
 Paucigravidae 503, 12.0 (1.6) 506, 11.7 (1.5) 0.22 (0.03, 0.41) 0.026 
 Multigravidae 314, 12.1 (1.5) 312, 12.1 (1.5) -0.09 (-0.33, 0.15) 0.466 
 All gravidae 817, 12.0 (1.6) 818, 11.9 (1.5) 0.10 (-0.05, 0.25) 0.179 
Foetal haemoglobin (g/dL) (cord blood) 
 Paucigravidae 472, 15.0 (2.4) 470, 14.9 (2.1) 0.10 (-0.18, 0.39) 0.478 
 Multigravidae 297, 14.7 (2.3) 291, 14.9 (2.3) -0.14 (-0.51, 0.23) 0.466 
 All gravidae 769, 14.9 (2.4) 761, 14.9 (2.2) 0.01 (-0.22, 0.24) 0.937 
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Table 4.6 Effect of ISTp-DP vs IPTp-SP on mean haemoglobin, birthweight, gestational age and mean birthweight-for gestational age Z-score (crude analysis) 
 Number of women, 
mean (SD) 
 
Mean difference 
(95% CI) 
P-value 
Outcome ISTp-DP IPTp-SP   
 
Mean birthweight (grams) 
 Paucigravidae 504, 2859 (412) 508, 2891 (454) -32.3 (-85.7, 21.1) 0.236 
 Multigravidae 314, 3020 (421) 310, 3041 (404) -20.6 (-85.2, 44.1) 0.533 
 All gravidae 818, 2921 (423) 818, 2948 (442) -27.1 (-69.0, 14.8) 0.205 
Gestational age (weeks) at birth 
 Paucigravidae 533, 38.0 (2.5) 532, 38.2 (2.4) -0.15 (-0.44, 0.15) 0.327 
 Multigravidae 338, 38.2 (2.2) 332, 38.5 (2.0) -0.28 (-0.59, 0.04) 0.083 
 All gravidae 871, 38.1 (2.4) 864, 38.3 (2.3) -0.20 (-0.41, 0.02) 0.076 
Birthweight for gestational age Z-score 
 Paucigravidae 501, 0.0 (0.9) 505, 0.1 (0.9) -0.06 (-0.18, 0.05) 0.280 
 Multigravidae 314, 0.3 (1.0) 309, 0.3 (0.9) 0.02 (-0.13, 0.17) 0.766 
 All gravidae 815, 0.1 (0.9) 814, 0.2 (1.0) -0.03 (-0.12, 0.06) 0.540 
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Table 4.7 Difference in number of days between antimalarial dosing and delivery 
Arm 
 
Number of women 
with event 
Mean (std.dev) 
 
Difference (95% CI), p-value 
 
 
Sulphadoxine-Pyrimethamine 
(SP) 
 
796 
 
19 (11.9) Reference  
 Artemether-Lumefantrine (AL)  21 21 (21.0)  -2 (-6.7, 3.5), 0.537  Reference 
 
Dihydroartemesinin-
Piperaquine (DP) 
 
70 
 
17 (9.6) 
 
 2 (-0.6, 5.2), 0.127  4 (-0.9, 8.6), 0.114 
 
Last visit prior to delivery may have been a scheduled or unscheduled visit. Peripheral malaria at delivery was defined as having parasiteamia detected 
by either malaria smear, RDT or PCR. Active placental malaria was defined as either acute or chronic placental infection 
 
 
 
 
 
 
 
 
129 
 
Table 4.8 Effect of antimalarial dosing at last visit prior to delivery on maternal peripheral parasiteamia and  active placental malaria 
Outcome 
 
no/No (%) of women with 
events 
Risk Ratio 
(95% CI), p-value 
Peripheral parasitaemia     
 Sulphadoxine-Pyrimethamine (SP) 
 
130/756 (17.2) 
 
Reference  
 Artemether-Lumefantrine (AL)  11/20 (55.0) 3.20 (2.09, 4.90), <0.001  Reference 
 Dihydroartemesinin-Piperaquine (DP) 
 
20/67 (29.9) 
 
1.74 (1.16, 2.59), 0.007 
 
 0.54 (0.32, 0.93), 0.027 
Active placental malaria     
 Sulphadoxine-Pyrimethamine (SP) 
 
249/748 (33.3) 
 
Reference  
 Artemether-Lumefantrine (AL)  15/20 (75.0) 2.25 (1.72, 2.96), <0.001  Reference 
 Dihydroartemesinin-Piperaquine (DP) 
 
29/66 (43.9) 
 
1.32 (0.99, 1.77), 0.061 
 
 0.59 (0.40, 0.85), 0.005 
 
Last visit prior to delivery may have been a scheduled or unscheduled visit. Peripheral malaria at delivery was defined as having parasiteamia detected 
by either malaria smear, RDT or PCR. Active placental malaria was defined as either acute or chronic placental infection 
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Table 4.9 Proportion of women reinfected by next antenatal visit after treatment with DP 
Visit after booking Number of women treated at 
prior visit 
Number of women reinfected at 
current visit † 
Proportion reinfected (%) 
    
1st  291 50 17 
2nd  29 8 28 
3rd 28 9 32 
Delivery 52 0 0 
Total 400 67 17 
    
 † Peripheral blood reinfection by either light microscopy, RDT or PCR positive 
 
Table 4.10 Adherence and tolerance of study drugs and regimen 
Outcome ISTp-DP IPTp-SP 
Number of women who did not tolerate DP or SP at least once (%)a 
 Paucigravidae 1/351 (0.3) 0/569 (0.0) 
 Multigravidae 1/122 (0.8) 0/352 (0.0) 
 All gravidae 2/473 (0.4) 0/921 (0.0) 
a. Defined as vomiting of primary and repeat dose, requiring alternative treatment with AL or parenteral antimalarials 
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Table 4.11 Foetal loss, perinatal and infant death among DP recipients and non-recipients in the ISTp-DP arm, compared with the IPTp-SP arm 
 
# with (at least one) event / # followed (%), or 
# events, # with (at least one) event/ # followed (%) 
Risk Ratio (95% CI), p-value 
Outcome 
ISTp-DP: 
DP-non-
recipients 
ISTp-DP: 
DP-recipients 
ISTp-DP 
total 
IPTP-SP ISTp-DP total  
vs  
IPTp-SP 
ISTp-DP non-DP- 
recipients vs 
DP-recipients 
ISTp-DP non-DP-
recipients vs 
IPTp-SP arm 
ISTp-DP DP-
recipients vs 
IPTp-SP arm 
Maternal SAEs (cumulative risk [% at least 1 event])     
 Paucigravidae 12/220 (5.5) 15/351 (4.3) 27/571 (4.7) 29/569 (5.1) 
0.93 (0.56, 1.55), 
0.7738 
1.28 (0.61, 2.68), 0.5182 1.07 (0.56, 2.06), 0.8390 
0.84 (0.46, 1.54), 
0.5708 
 Multigravidae 12/230 (5.2) 4/122 (3.3) 16/352 (4.5) 16/352 (4.5) 
1.00 (0.51, 1.97), 
1.0000 
1.59 (0.52, 4.83), 0.4121 1.15 (0.55, 2.38), 0.7112 
0.72 (0.25, 2.12), 
0.5519 
 All gravidae 24/450 (5.3) 19/473 (4.0) 43/923 (4.7) 45/921 (4.9) 
0.95 (0.63, 1.43), 
0.8190 
1.33 (0.74, 2.39), 0.3446 1.09 (0.67, 1.77), 0.7219 
0.82 (0.49, 1.39), 
0.4644 
Maternal deaths        
 Paucigravidae 0/220 (0.0) 0/351 (0.0) 0/571 (0.0) 1/569 (0.2) CBEa CBEa CBEa CBEa 
 Multigravidae 0/230 (0.0) 0/122 (0.0) 0/352 (0.0) 1/352 (0.3) CBEa CBEa CBEa CBEa 
 All gravidae 0/450 (0.0) 0/473 (0.0) 0/923 (0.0) 2/921 (0.2) CBEa CBEa CBEa CBEa 
Congenital malformations        
 Paucigravidae 3/195 (1.5) 6/333 (1.8) 9/528 (1.7) 8/529 (1.5) 1.13 (0.44, 2.90), 0.8039 0.85 (0.22, 3.38), 0.8218 1.02 (0.27, 3.80), 0.9796 
1.19 (0.42, 3.40), 
0.7436 
 Multigravidae 3/217 (1.4) 1/117 (0.9) 4/334 (1.2) 1/330 (0.3) 
3.95 (0.44, 35.17), 
0.2179 
1.62 (0.17, 15.38), 0.6756 4.56 (0.48, 43.58), 0.1874 
2.82 (0.18, 44.73), 
0.4621 
 All gravidae 6/412 (1.5) 7/450 (1.6) 13/862 (1.5) 9/859 (1.0) 1.44 (0.62, 3.35), 0.3980 0.94 (0.32, 2.76), 0.9050 1.39 (0.50, 3.88), 0.5295 
1.48 (0.56, 3.96), 
0.4298 
Foetal Loss         
 Paucigravidae 7/201 (3.5) 8/338 (2.4) 15/539 (2.8) 6/533 (1.1) 
2.47 (0.97, 6.32), 
0.0589 
1.47 (0.54, 4.00) 0.4487 3.09 (1.05, 9.09), 0.0401 
2.10 (0.74, 6.01), 
0.1653 
 Multigravidae 6/220 (2.7) 2/118 (1.7) 8/338 (2.4) 5/333 (1.5) 
1.58 (0.52, 4.77), 
0.4204 
1.61 (0.33, 7.85) 0.5563 1.82 (0.56, 5.88), 0.3193 
1.13 (0.22, 5.74), 
0.8839 
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Table 4.11 Foetal loss, perinatal and infant death among DP recipients and non-recipients in the ISTp-DP arm, compared with the IPTp-SP arm 
 
# with (at least one) event / # followed (%), or 
# events, # with (at least one) event/ # followed (%) 
Risk Ratio (95% CI), p-value 
Outcome 
ISTp-DP: 
DP-non-
recipients 
ISTp-DP: 
DP-recipients 
ISTp-DP 
total 
IPTP-SP ISTp-DP total  
vs  
IPTp-SP 
ISTp-DP non-DP- 
recipients vs 
DP-recipients 
ISTp-DP non-DP-
recipients vs 
IPTp-SP arm 
ISTp-DP DP-
recipients vs 
IPTp-SP arm 
 All gravidae 13/421 (3.1) 10/456 (2.2) 23/877 (2.6) 11/866 (1.3) 
2.06 (1.01, 4.21), 
0.0461 
1.41 (0.62, 3.18), 0.4098 2.43 (1.10, 5.38), 0.0284 
1.73 (0.74, 4.03), 
0.2073 
Miscarriage         
 Paucigravidae 3/201 (1.5) 2/338 (0.6) 5/539 (0.9) 2/533 (0.4) 
2.47 (0.48, 12.69), 
0.2681 
2.52 (0.43, 14.97), 0.3085 3.98 (0.67, 23.63), 0.1288 
1.58 (0.22, 11.14), 
0.6480 
 Multigravidae 2/220 (0.9) 0/118 (0) 2/338 (0.6) 1/333 (0.3) 
1.97 (0.18, 21.63), 
0.5790 
CBEa 3.03 (0.28, 33.18), 0.3646 CBEa 
 All gravidae 5/421 (1.2) 2/456 (0.4) 7/877 (0.8) 3/866 (0.3) 
2.30 (0.60, 8.88), 
0.2253 
2.71 (0.53, 13.88), 0.2323 3.43 (0.82, 14.28), 0.0905 
1.27 (0.21, 7.55), 
0.7957 
Stillbirth         
 Paucigravidae 4/198 (2.0) 6/336 (1.8) 10/534 (1.9) 4/531 (0.8) 
2.49 (0.78, 7.88), 
0.1217 
1.13 (0.32, 3.96), 0.8470 2.68 (0.68, 10.62), 0.1601 
2.37 (0.67, 8.34), 
0.1786 
 Multigravidae 4/218 (1.8) 2/118 (1.7) 6/336 (1.8) 4/332 (1.2) 
1.48 (0.42, 5.20), 
0.5392 
1.08 (0.20, 5.82), 0.9264 1.52 (0.38, 6.03), 0.5489 
1.41 (0.26, 7.58), 
0.6913 
 All gravidae 8/416 (1.9) 8/454 (1.8) 16/870 (1.8) 8/863 (0.9) 
1.98 (0.85, 4.61), 
0.1114 
1.09 (0.41, 2.88), 0.8599 2.07 (0.78, 5.49), 0.1416 
1.90 (0.72, 5.03), 
0.1959 
Infant SAEs (cumulative risk [% at least 1 event])    
 Paucigravidae 5/194 (2.6) 18/330 (5.5) 23/524 (4.4) 19/527 (3.6) 
1.22 (0.67, 2.21), 
0.5172 
0.47 (0.18, 1.25), 0.1317 0.71 (0.27, 1.89), 0.4982 
1.51 (0.81, 2.84), 
0.1976 
 Multigravidae 6/214 (2.8) 4/116 (3.4) 10/330 (3.0) 4/328 (1.2) 
2.48 (0.79, 7.84), 
0.1206 
0.81 (0.23, 2.82), 0.7446 2.30 (0.66, 8.05), 0.1930 
2.83 (0.72, 11.12), 
0.1369 
 All gravidae 11/408 (2.7) 22/446 (4.9) 33/854 (3.9) 23/855 (2.7) 
1.44 (0.85, 2.43), 
0.1754 
0.55 (0.27, 1.11), 0.0960 1.00 (0.49, 2.04), 0.9951 
1.83 (1.03, 3.25), 
0.0381 
Perinatal death 
 Paucigravidae 7/196 (3.6) 11/333 (3.3) 18/529 (3.4) 12/528 (2.3) 
1.50 (0.73, 3.08), 
0.2722 
1.08 (0.43, 2.74), 0.8695 1.57 (0.63, 3.93), 0.3343 
1.45 (0.65, 3.26), 
0.3635 
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Table 4.11 Foetal loss, perinatal and infant death among DP recipients and non-recipients in the ISTp-DP arm, compared with the IPTp-SP arm 
 
# with (at least one) event / # followed (%), or 
# events, # with (at least one) event/ # followed (%) 
Risk Ratio (95% CI), p-value 
Outcome 
ISTp-DP: 
DP-non-
recipients 
ISTp-DP: 
DP-recipients 
ISTp-DP 
total 
IPTP-SP ISTp-DP total  
vs  
IPTp-SP 
ISTp-DP non-DP- 
recipients vs 
DP-recipients 
ISTp-DP non-DP-
recipients vs 
IPTp-SP arm 
ISTp-DP DP-
recipients vs 
IPTp-SP arm 
 Multigravidae 6/216 (2.8) 2/118 (1.7) 8/334 (2.4) 4/330 (1.2) 
1.98 (0.60, 6.50), 
0.2622 
1.64 (0.34, 7.99), 0.5411 2.29 (0.65, 8.03), 0.1947 
1.40 (0.26, 7.54), 
0.6964 
 All gravidae 13/412 (3.2) 13/451 (2.9) 26/863 (3.0) 16/858 (1.9) 
1.62 (0.87, 2.99), 
0.1267 
1.09 (0.51, 2.33), 0.8149 1.69 (0.82, 3.48), 0.1536 
1.55 (0.75, 3.18), 
0.2377 
Neonatal death (by 4 weeks) 
 Paucigravidae 4/192 (2.1) 6/327 (1.8) 10/519 (1.9) 8/524 (1.5) 
1.26 (0.50, 3.17), 
0.6207 
1.14 (0.32, 3.97), 0.8425 1.36 (0.42, 4.48), 0.6083 
1.20 (0.42, 3.43), 
0.7313 
 Multigravidae 2/212 (0.9) 0/116 (0) 2/328 (0.6) 0/326 (0) CBEa CBEa CBEa CBE a 
 All gravidae 6/404 (1.5) 6/443 (1.4) 12/847 (1.4) 8/850 (0.9) 
1.51 (0.62, 3.66), 
0.3675 
1.10 (0.36, 3.37), 0.8723 1.58 (0.55, 4.52), 0.3954 
1.44 (0.50, 4.12), 
0.4978 
Infant death (by 6 to 8 weeks) 
 Paucigravidae 4/213 (1.9) 8/343 (2.3) 12/556 (2.2) 9/563 (1.6) 
1.35 (0.57, 3.18), 
0.4920 
0.81 (0.25, 2.64), 0.7207 1.17 (0.37, 3.77), 0.7867 
1.46 (0.57, 3.75), 
0.4323 
 Multigravidae 2/224 (0.9) 0/120 (0) 2/344 (0.6) 1/347 (0.3) 
2.02 (0.18, 22.15), 
0.5659 
CBEa 3.10 (0.28, 33.97), 0.3547 CBE, 0.5561 
 All gravidae 6/437 (1.4) 8/463 (1.7) 14/900 (1.6) 10/910 (1.1) 
1.42 (0.63, 3.17), 
0.3982 
0.79 (0.28, 2.27), 0.6680 1.25 (0.46, 3.42), 0.6643 
1.57 (0.62, 3.96), 
0.3365 
Foetal loss or infant death        
 Paucigravidae 11/220 (5.0) 16/351 (4.6) 27/571 (4.7) 15/569 (2.6) 
1.79 (0.96, 3.34), 
0.0649 
1.10 (0.52, 2.32), 0.8088 1.90 (0.88, 4.06), 0.0998 
1.73 (0.87, 3.45), 
0.1207 
 Multigravidae 8/230 (3.5) 2/122 (1.6) 10/352 (2.8) 6/352 (1.7) 
1.67 (0.61, 4.54), 
0.3173 
2.12 (0.46, 9.84), 0.3364 2.04 (0.72, 5.80), 0.1811 
0.96 (0.20, 4.70), 
0.9616 
 All gravidae 19/450 (4.2) 18/473 (3.8) 37/923 (4.0) 21/921 (2.3) 
1.76 (1.04, 2.98), 
0.0361 
1.11 (0.59, 2.09), 0.7471 1.85 (1.01, 3.41), 0.0478 
1.67 (0.90, 3.10), 
0.1052 
CBE=RR and 95% CI cannot be estimated 
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 Discussion 
 ISTp has been compared with IPTp-SP in two prior studies, but ours is the first to use DP and 
the first to evaluate the effects of ISTp among women that are protected by LLINs in areas with high 
malaria transmission and a high prevalence of parasite SP-resistant genotypes. Despite the high 
levels of resistance, ISTp-DP was not superior to the standard IPTp-SP regimen and was associated 
with more malaria at delivery, more LBW (p=0.067), and more foetal loss. Although the relative 
increase in malaria risk was modest, this resulted in an additional 8 out every 100 pregnancies being 
affected. These results suggest that ISTp-DP may not be a suitable alternative strategy to replace 
IPTp-SP in areas with high SP-resistance and may even predispose to unfavourable pregnancy 
outcomes. 
 Our efficacy findings are consistent with two previous non-inferiority trials conducted in 
areas in West Africa (338, 339). This consistency is surprising because of the marked geographic 
differences in prevailing SP resistance, which is high in Malawi but low in West Africa. In both West 
African studies, ISTp was non-inferior to IPTp-SP in the reduction in LBW among paucigravidae, 
though mean birthweights were higher in the IPTp-SP recipients than those receiving ISTp with 
amodiaquine-artesunate (p=0.06) (338) or AL (p=0.04) (339). Additionally, the incidence of clinical 
malaria was higher in the ISTp-AL arm compared to IPTp-SP. This was not observed in our trial, 
possibly reflecting the longer post-treatment prophylaxis with DP compared to AL. 
 The lack of superiority of ISTp-DP in the current trial may result from the ineffectiveness of 
ISTp as a strategy or from the continued effectiveness of IPTp-SP despite prevalent SP resistance. In 
our study area in Malawi, SP resistance was high, with 99% of parasites harbouring the “quintuple 
mutant” haplotype and 1.5% (209) to 4% (340) harbouring the additional pfdhps-A581G mutation, 
which classifies it as a high, but not yet super-resistant, area (341); therefore it is likely that IPTp-SP 
continued to provide some benefits, as has been observed in settings with similar parasite 
135 
 
populations (342, 343). Another factor likely contributing to continued effectiveness of IPTp-SP is 
our use of the frequent dosing regimen (3) now recommended by WHO, which may mitigate the 
shortening of post-treatment prophylaxis resulting from SP resistance (343). It would also be of 
interest to further explore whether SP, which also has broad antimicrobial activity, may have 
conferred additional protection from other pathogens (344). 
 Further to the surprising lack of difference in the overall efficacy of ISTp irrespective of 
significant differences in SP resistance with sites in West Africa presented above, transmission 
intensity may prove to be a significant determinant of the efficacy of ISTp owing to both sites having 
high transmission despite differences in SP resistance. With close to half of the women experiencing 
at least one episode of infection after enrolment, the evidence suggests an overall high transmission 
setting. It may be postulated that within a high transmission setting, a higher probability of infection 
occurs due to an increased frequency of exposure to infective bites, culminating in pregnant women 
having a higher risk of being infected and developing a significant biomass of parasites that lead to 
adverse pregnancy outcomes before they are diagnosed by RDT at the next antenatal visit. This is 
evident in the differences in the site specific primary malaria endpoints between two sites with 
moderate to high transmission and the one site with low transmission. It is likely that preceding 
studies utilising screening strategies, such as the Mass Screening and Treatment trials (345, 346), 
may have been informative in the consideration of screening in pregnancy to highlight the possible 
role of transmission intensity. Other than this, there would have very limited plausibility for the 
expected impact in pregnant populations. This is because the effect of the phenomenon of placental 
sequestration and gravidity dependent immunity would not have been observable in non-pregnant 
populations. In addition, screening and treatment approaches in non-pregnant populations are 
primarily targeted toward transmission reduction by detecting and treating the parasite reservoir as 
opposed to clinical outcomes which are of primary importance in pregnancy interventions 
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 Without any significant differences in the time between receiving DP, AL and SP at the last 
visit prior to delivery, the findings on the risk of peripheral and active placental malaria are rather 
surprising. The quintuple resistance genotype conferring SP resistance would be expected to reduce 
the treatment or prophylactic efficacy of SP (347) compared to DP and AL. As such, it would be 
expected that receipt of SP would be associated with a higher risk of peripheral and placental 
parasiteamia. Our findings do not support this expectation. Parasite density is known to be a 
predictor of parasitological failure in treatment studies (348). The use of DP and AL was indicated in 
patent or symptomatic infection, which would be characterised by higher parasite densities than 
with asymptomatic infection where SP was administered. It is therefore conceivable that parasite 
failure at delivery was due to differences in parasite densities at the time of administration of the 
antimalarial. Conversely, the results also suggest that SP continues confer a beneficial antimalarial 
effect despite high resistance levels resulting in low levels of parasiteamia and lower risks of parasite 
failure at delivery, likely through a mechanism of suppression of infection through the frequent doses 
over the  course of pregnancy (349).  
 ISTp-DP may have been ineffective owing to a failure to detect low-level parasitaemia. 
Conceptually, ISTp is intended to prevent both existing infections from progressing as well as new 
infections from occurring for up to 6 weeks after each DP course. The majority of antenatal infections 
were undetected by RDTs, thereby allowing sub-patent (RDT-negative, PCR-positive) infections to 
persist in the placenta. This was particularly noticeable among multigravidae, who tend to have 
lower density infections when infected. The overall sensitivity of RDT to detect PCR-positive 
infections during pregnancy was 44.9% in paucigravidae (51.6% in G1, 35.8% in G2) and 29.2% in 
multigravidae (Figure 5.3, section 5.2.2). This may explain the somewhat greater difference between 
treatment arms in malaria prevalence at delivery in multigravidae than primigravidae. The greater 
predisposition for active placental malaria at delivery than past or chronic infection may most likely 
be explained by the persistence of infections missed by RDT screening at the final visit prior to 
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delivery in the IST arm. By not treating these infections, they were left to either progress unfettered 
in the peripheral blood and seed in the placenta or were already present in the placenta and not 
cleared by treatment. This is in direct contrast to the SP arm where the routine administration of SP 
at the last visit would have cleared any present infections in the peripheral blood or placenta prior 
to delivery. 
 It is unlikely that suboptimal dosing or sub-therapeutic levels of DP would have contributed 
to the non-superior performance of ISTp-DP: each dose was supervised and there is no evidence that 
pregnancy alters the pharmacokinetics of DP to a degree that is requires dose adjustment (350). The 
same DP regimen was shown to be highly effective (PCR-corrected success rate: 98.8%) in a 
concurrent treatment trial conducted by the same team in this area using the same batch (172, 351). 
The progressive increase in the risk of reinfection following treatment with dihydroartemisinin-
piperaquine may have arisen as a result of women from transmission hot-spots presenting with 
frequent repeated infections. However, it cannot be determined whether the observed reinfections 
were due to reinfection or recrudescence. The lack of reinfection being detected at delivery could be 
attributed to the brief time frame between the last antenatal visit when the dose of DP was received 
and delivery, reflecting the acute treatment efficacy of DP. 
 The higher rate of foetal loss in the ISTp-DP arm (2.6% vs 1.3%) may reflect the 
ineffectiveness of ISTp to prevent malaria. There was no indication that this was related to DP toxicity 
as the risk was highest among pregnancies that had never received DP (3.1% vs 2.2%). Consistent 
with the recent 4-arm treatment trial comparing the 4 fixed dose ACTs in the case-management of 
malaria in pregnancy (351), DP was well tolerated. This is important as almost all RDT-positive 
women in our trial were asymptomatic and tolerance can be a major factor determining adherence. 
 ISTp is a labour intensive strategy, but it was highly acceptable to both patients and clinic 
staff. This finding was documented through a separate qualitative sub-study using in-depth 
interviews and focus-group discussions (Almond D, personal communications), corroborating 
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findings from similar acceptability studies in Ghana (352, 353). Although more frequent blood 
sampling was involved, women appreciated its importance and the fact that they could be shown the 
RDT test results. The venous sampling at antenatal booking was deemed more convenient than 
repeated finger pricks as it allowed health workers to tests for malaria, anaemia, syphilis and HIV 
testing with a single blood draw.  
 This study has a number of limitations. We did not conduct genotyping for SP resistance in 
individual women to determine the role of the dhps-A581G mutation. Furthermore, no molecular 
assessments were undertaken to differentiate recrudescence from reinfections needed to determine 
what fraction of infections in the IPTp-SP result from recrudescence due to sub-optimal clearance by 
SP. 
 IPTp-DP was not superior to the existing IPTp-SP regimen in this area with high SP resistance 
in southern Malawi. These results should be equally relevant to other areas in east and southern 
Africa with similar or lower levels of parasite SP resistance. In super-resistant settings, where 
alternative drugs that can replace SP for IPTp are lacking, ISTp-DP could be a potential interim 
solution. The identification for alternative drugs to replace SP remains a high research priority for 
the control of malaria in pregnancy before levels of SP resistance render IPTp-SP fully ineffective. 
Further considerations to the discussion of these findings and the implications thereof are presented 
in the overall discussion in Chapter 7.
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5 CHAPTER FIVE: THE EFFECT OF ASYMPTOMATIC PARASITAEMIA ON 
PREGNANCY OUTCOMES. 
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 Statistical consideration and analysis 
 The present analysis was based on a cohort of women from the ISTp arm of the prior 
presented clinical trial, the methods of which have been previously presented in Chapter 3. The 
objective of this analysis was to determine whether the lack of a superior performance by ISTp may 
have been partly attributable to low density peripheral blood infections missed by RDT but 
detectable by PCR over the course of the antenatal period. Specifically the analysis was undertaken 
to determine: 
1. The effect of timing of sub-RDT infections on the risk of maternal anaemia, placental 
malaria and adverse live birth outcomes, 
2. The effect of frequency of sub-RDT infections on the risk of maternal anaemia, placental 
malaria and adverse live birth outcomes, and 
3. The effect of patent RDT asymptomatic parasitaemia on maternal anaemia, placental 
malaria and adverse live birth outcomes.  
5.1.1 Exposures 
 For the purposes of this analysis, women were classified into the following infection statuses 
based on their overall experience of malaria infection over the course of their pregnancies, including 
at enrolment:  
1) No parasitaemia; RDT and PCR negative at all visits,  
2) Only asymptomatic sub-RDT parasitaemia; RDT negative but PCR positive at least  
   once, or were otherwise without parasitaemia (RDT and PCR negative) at any given 
   visit 
3) Only asymptomatic RDT patent parasitaemia; RDT and PCR positive only at least once, 
   or were otherwise without parasitaemia (RDT and PCR negative) at any given visit,     
   and 
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4)  Mixed infection experience; experienced at least one episode of asymptomatic sub-     
 RDT and one episode of asymptomatic patent and one episode of clinical malaria or any 
 combination of two such infections, through the course of pregnancy.  
RDT results were interpreted positive if the control line was visible and either the PAN (pLDH), Pf 
(HRP2) or both lines were visible following the manufacturer’s instructions on test conduct. 
The timing of infection was classified as second trimester only (corrected gestational age 13 – 
26 weeks), third trimester only (corrected gestational age > 26 weeks) or both. The frequency of 
infection was defined as either 1 episode or 2 or more episodes. 
5.1.2 Outcomes 
The following outcomes from the main trial were used to evaluate the effect of sub-RDT 
parasitaemia:  
1. any maternal anaemia (Hb < 11.0 g/dl),  
2. mean haemoglobin concentration at final scheduled antenatal visit,  
3. any placental malaria (active or chronic placental malaria),  
4. small for gestational age (SGA, corrected birthweight for corrected gestational age at birth < 
10th percentile),  
5. preterm birth (PTB, corrected  gestational age at delivery < 37 weeks) 
6. mean gestational age (corrected) 
7. low birth weight (LBW, corrected  birthweight at delivery < 2500 grams) 
8. mean birthweight (corrected) 
9. any adverse live birth outcomes (composite of SGA, PTB and LBW)  
5.1.3 Analyses 
 Analysis was performed with STATA version 13.0 software (Stata Corp., College Station, TX, 
USA). Categorical baseline characteristics were compared using the χ2 and Fisher’s exact tests. 
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Continuous variables were compared using the t-test. The diagnostic sensitivity of peripheral blood 
RDT was calculated with the user written programme stb59 sbe36_1 
(http://www.stata.com/stb/stb59). Univariate and multivariate analysis were conducted using 
generalized linear regression models with a log link, Poisson  distribution, and robust variance 
estimator (354, 355) to determine the crude and adjusted risk ratios between exposure status and 
outcome of interest, stratified by gravidity and overall. Crude and adjusted incidence rate ratios were 
calculated using Poisson regression models with robust standard errors as recommended by 
Cameron and Trivedi (356) and person years of follow-up as an offset. The t-test was used to 
determine the mean difference in continuous outcomes. All analyses were additionally stratified by 
gravidity. Two sided P-values were used and confidence intervals calculated at the 95% level. 
Statistical significance was set at P ≤ 0.05. 
 Women with mixed infections were excluded from the analysis. This was because the 
occurrence of several varying degrees of infections would not enable a clear distinction of the effect 
of a particular infection on its own, which was the objective of the analysis, with particular emphasis 
on determining the effect of asymptomatic sub-RDT infections that are postulated to be responsible 
for the less than superior performance of IST by being missed by the screening tool. 
 Results 
5.2.1 Study population and baseline characteristics 
 452 (49.0%) of the women enrolled in the ISTp arm were included in the analysis (Figure 
5.1) with data on haemoglobin at last scheduled antenatal visit and delivery visit available for 371 
(40.2%) and 443 (48.0%) respectively. 51% of the women enrolled in the ISTp arm in the main trial 
were excluded due to having mixed infection experiences. 
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5.2.2 Malaria infection and the diagnostic performance of peripheral blood RDT 
Less than half of the women in the IST arm prior to exclusion had evidence of malaria infection by 
either RDT or PCR (451/923, 48.9%). Amongst the cohort of women included in this analysis, any 
infection by RDT or PCR was 46.2%, n= 452.  Slightly under a third of all the women included in the 
analysis (29.0%, n = 452) were infected with malaria at enrolment by RDT (the corresponding figure 
in the overall sample of women in the ISTp arm was 318/922 (34.5%). The prevalence of infection 
by PCR at the same time point in this cohort was 44.5% (whilst the corresponding prevalence in the 
overall women from the IST arm was 44.3%, n=903). Malaria infection prevalence by both RDT and 
PCR were higher in paucigravidae at all visits but the prevalence of sub-RDT infection was 
consistently higher in multigravidae compared to paucigravidae (Figure 5.2). 
PCR was used as the gold standard against which the diagnostic sensitivity of the malaria RDT 
was assessed. The overall diagnostic sensitivity of peripheral blood RDT was 66.8% (95% C.I. 62.0, 
71.4%). The sensitivity was higher in primigravidae than secundi- and multigravidae (85.8%, 95% 
C.I. 79.8, 90.6% vs 57.8%, 95% C.I. 48.0, 67.2% vs 45.6%, 95% C.I. 36.3, 55.2% respectively) and this 
trend remained through pregnancy (Figure 5.3). 
5.2.3 Effect of asymptomatic parasitaemia on maternal outcomes 
5.2.3.1 Anaemia  
 Asymptomatic sub-RDT parasitaemia was not associated with an increased significantly 
increased risk of developing maternal anaemia compared to women who never experienced any 
parasitaemia (39.0 vs 37.4%, RR 1.04, 95% C.I. 0.78, 1.39, p-value = 0.779). This effect did not change 
after stratifying by gravidity (Table 5.2) and was not different by frequency (Table 5.3) and timing of 
sub-RDT infection (Table 5.4). 
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 No notable effect in timing of sub-RDT parasitaemia on the incidence of maternal anaemia 
(Tables 5.5 and 5.6) or difference in mean haemoglobin concentration at last scheduled antenatal 
visit (Tables 5.7 and 5.8) was observed. 
 
Figure 5.1 Participant flow chart 
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Table 5.1 Baseline patient characteristics overall and by parasitaemia class 
Characteristic    Overall 
 
(N=452) 
No 
parasitaemia 
(n=155) 
Only 
asymptomatic 
sub-RDT 
parasitaemia 
(n=141)  
Only asymptomatic 
RDT Patent 
parasitaemia 
(n=156) 
Age (years)  mean (sd)  22.9 (5.2) 24.1 (5.5) 23.9 (4.8) 20.8 (4.6) 
Gestational age (corrected, in weeks) mean (sd)  20.6 (3.0) 19.9 (2.4) 21.0 (3.0) 20.9 (3.5) 
Gravidity     Paucigravidae (%)  56.0 45.2 49.7 72.4 
Own bednet (%)  18.1 20.7 12.8 20.5 
Haemoglobin (g/dl) mean (sd)  11.1 (1.5) 11.6 (1.4) 11.5 (1.3) 10.4 (1.5) 
Anaemia (Hb < 11.0 g/dl) (%)  40.0 27.1 29.1 62.8 
Socioeconomic      
                                   Residence        
 Rural 99.3 99.4 99.3 99.4 
 Urban 0.2 0.0 0.0 0.6 
 Peri-urban 0.5 0.6 0.7 0.0 
                                   Income category      
 Low 31.9 28.4 36.9 31.9 
 Medium 35.5 32.3 36.1 35.5 
 High 32.6 39.4 27.0 32.6 
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Figure 5.2 Malaria prevalence across antenatal visits stratified by gravidity 
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Figure 5.3 RDT sensitivity by study visit and gravidity 
 
 
 
 
 
After adjustment for covariates, there was a significantly increased incidence of maternal anaemia 
with 2 or more episodes of sub-RDT infection in multigravidae (1,511.1 vs 952.2/1,000 person-years, 
IRR 2.17, 95% C.I. 1.12, 4.21, p-value = 0.021) (Table 5.10). 
 In contrast to sub-RDT infections, asymptomatic patent RDT parasitaemia significantly 
increased the risk of any maternal anaemia (67.3 vs 37.4%, RR 1.80, 95% C.I. 1.43, 2.27, p-value < 
0.001). This effect was mostly apparent in paucigravidae (74.3 vs 44.3%, RR 1.68, 95% C.I. 1.26, 2.23, 
p-value < 0.001) and marginally significant in multigravidae (48.8 vs 31.8%, RR 1.54, 95% C.I. 0.99, 
2.38, p-value = 0.054). There was an increased incidence of maternal anaemia with asymptomatic 
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patent RDT parasitaemia (Table 5.6) in both gravidity strata and overall, but this was lost after 
adjustment for covariates. Paucigravidae with asymptomatic patent RDT parasitaemia had a 
significantly lower mean haemoglobin at the last scheduled antenatal visit (11.8 vs 11.3g/dl, mean 
difference 0.44, 95% C.I. 0.04, 0.84, p-value = 0.033) (Table 5.7). 
5.2.3.2 Placental malaria 
 Asymptomatic sub-RDT parasitaemia was associated with an almost two-fold increased risk 
of any placental malaria at delivery (38.8 vs 20.4%, RR 1.90, 95% C.I. 1.28, 2.82, p-value = 0.002)  
(Table 5.11), which was consistent both in pauci- and multigravidae (45.2 vs 23.4%, RR 1.93, 95% 
C.I. 1.14, 3.25, p-value = 0.014 and 32.8 vs 17.8%, RR 1.84, 95% C.I. 1.01, 3.37, p-value = 0.046 
respectively) though this was statistically non-significant in multigravidae after adjusting for 
covariates. The strength of this association was evident with infection during the third trimester, 
further increased if infection occurred in the second and third trimester, and with 2 or more episodes 
of infection (Tables 5.12 and 5.13).   
 Asymptomatic patent RDT infection was also significantly associated with a more than two 
and a half fold higher risk of placental malaria overall (55.6 vs 20.4%, RR 2.72, 95% C.I. 1.90, 3.91,p-
value < 0.001) and by gravidity. There was strong evidence of this increased overall risk even after 
adjustment for covariates.  
5.2.4 Effect of asymptomatic parasitaemia on live birth fetal outcomes 
5.2.4.1 Composite adverse live birth outcome (LBW/SGA/PTB) 
 The risk of any adverse live birth outcome was significantly increased by asymptomatic sub-
RDT parasitaemia (26.5 vs 12.8%, RR 2.06, 95% C.I. 1.23, 3.42, p-value = 0.005; Table 5.14). Two or 
more episodes of asymptomatic sub-RDT parasitaemia were associated with a significantly increased 
risk of composite adverse live birth outcome in paucigravidae whilst only having one episode 
conferred a significantly elevated risk in multigravidae (Table 5.15). By timing, asymptomatic sub-
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RDT infection was associated with higher risk of composite adverse live birth outcome when 
occurring in the second or third trimester (Table 5.16).   
 Asymptomatic patent RDT parasitaemia was associated with a close to 3 fold increased risk 
of any adverse live birth outcome, though the risk was higher in multigravidae than paucigravidae 
(33.3 vs 8.5%, RR 3.90,95% C.I. 1.70, 8.95, p-value = 0.001 and 38.8 vs 18.2, RR 2.14, 95% C.I. 1.21, 
3.77, p-value = 0.009 respectively) (Table 5.14). 
5.2.4.2 Small for gestational age 
 There were no evident significant associations of small for gestational age any asymptomatic 
infection overall or when stratified by gravidity (Table 5.17). Neither the timing nor frequency of 
asymptomatic sub-RDT infection had a significant bearing on the risk of small for gestational age 
even when stratified by gravidity (Tables 5.18 and 5.19). 
5.2.4.3 Low birthweight 
 Asymptomatic sub-RDT parasitaemia did not increase the risk of low birthweight (Table 
5.20) and this was not amended by timing or frequency amongst paucigravidae or multigravidae 
(Tables 5.21 and 5.22). Furthermore, there was no statistically significant difference in mean 
birthweight with women who never experienced any parasitaemia (Tables 5.23, 5.24 and 5.25).  
 Asymptomatic patent RDT infection was associated with a more than 2 fold risk of low 
birthweight (19.1 vs 6.5%, RR 2.96, 95% C.I. 1.44, 6.06, p-value =0.003). Babies born to women 
without any infection over the course of pregnancy had a significantly higher mean birthweight by 
172.2 grams compared to babies born to women with at least 1 asymptomatic patent malaria 
infection only through follow-up (3,010.3 vs 2,838.1g,  95% C.I. 75.5, 268.8, p-value < 0.001).  
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 Table 5.2 Risk of any maternal anaemia (Hb <11.0g/dl) by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of 
women 
(N) 
Number of 
women with at 
least one event 
(n) 
Risk  
 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-
value 
Adjusted risk 
ratio    (95% C.I) 
P-value 
G1-2      †  
No parasitaemia (reference) 70 31 31/70     (44.3) - - - - 
Only asymptomatic sub-
RDT parasitaemia 70 28 28/70     (40.0) 0.90 (0.61, 1.33) 0.609 0.92 (0.54, 1.54) 0.740 
Only asymptomatic RDT 
Patent parasitaemia 113 84 84/113   (74.3) 1.68 (1.26, 2.23) < 0.001 0.98 (0.64, 1.52) 0.939 
        
G3+      †  
No parasitaemia (reference) 85 27 27/85     (31.8) - - - - 
Only asymptomatic sub-
RDT parasitaemia 71 27 27/71     (38.0) 1.19 (0.78, 1.84) 0.414 1.14 (0.66, 1.99) 0.635 
Only asymptomatic RDT 
Patent parasitaemia 43 21 21/43     (48.8) 1.54 (0.99, 2.38) 0.054 0.94 (0.51, 1.73) 0.846 
        
All      ‡  
No parasitaemia (reference) 155 58 58/155    (37.4) - - - - 
Only asymptomatic sub-
RDT parasitaemia 141 55 55/141    (39.0) 1.04 (0.78, 1.39) 0.779 1.00 (0.69, 1.46) 0.976 
Only asymptomatic RDT 
Patent parasitaemia 156 105 105/156  (67.3) 1.80 (1.43, 2.27) < 0.001 0.97 (0.69, 1.36) 0.865 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.3 Risk of any maternal anaemia (Hb <11.0g/dl) by number of episodes of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women 
(N) 
Number of 
women with at 
least one event 
(n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-
value 
Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 70 31 31/70     (44.3) - - - - 
   1 episode  50 24 24/50     (48.0) 1.08 (0.73, 1.60) 0.686 0.99 (0.80, 1.22) 0.901 
   2+ episodes 20 4 4/20       (20.0) 0.45 (0.18, 1.13) 0.089 0.64 (0.41, 0.99) 0.045 
        
G3+      †  
No parasitaemia (reference) 85 27 27/85    (31.8) - - - - 
   1 episode  47 18 18/47    (38.3) 1.21 (0.75, 1.95) 0.445 0.99 (0.75, 1.32) 0.964 
   2+ episodes 24 9 9/24      (37.5) 1.18 (0.64, 2.16) 0.591 1.65 (0.92, 2.98) 0.095 
        
All 
     ‡  
No parasitaemia (reference) 155 58 58/155    (37.4) - - - - 
   1 episode  97 42 42/97      (43.3) 1.16 (0.85, 1.57) 0.350 0.99 (0.83, 1.18) 0.870 
   2+ episodes 44 13 13/44      (29.5) 0.79 (0.48, 1.30) 0.355 1.08 (0.74, 1.59) 0.689 
 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.4 Risk of any maternal anaemia (Hb <11.0g/dl) by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women 
(N) 
Number of 
women with at 
least one event 
(n) 
Risk 
 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-
value 
Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 70 31 31/70      (44.3) - - - - 
   Second trimester only  31 11 11/31      (35.5) 0.80 (0.47, 1.38) 0.424 0.85 (0.65, 1.10) 0.211 
   Third trimester only 32 14 14/32      (43.8) 0.99 (0.62, 1.59) 0.960 0.99 (0.76, 1.30) 0.947 
   Second and Third trimester 7 3 3/7           (42.9) 0.97 (0.39, 2.37) 0.943 0.87 (0.66, 1.16) 0.353 
        
G3+      †  
No parasitaemia (reference) 85 27 27/85      (31.8) - - - - 
   Second trimester only  23 8 8/23        (34.8) 1.09 (0.58, 2.08) 0.782 1.10 (0.69, 1.76) 0.683 
   Third trimester only 30 14 14/30      (46.7) 1.47 (0.90, 2.41) 0.127 1.07 (0.78, 1,47) 0.681 
   Second and Third trimester 18 5 5/18        (27.8) 0.87 (0.39, 1.96) 0.745 1.47 (0.68, 3.21) 0.532 
        
All      ‡  
No parasitaemia (reference) 155 58 58/155    (37.4) - - - - 
   Second trimester only  54 19 19/54      (35.2) 0.94 (0.62, 1.43) 0.772 0.94 (0.74, 1.20) 0.615 
   Third trimester only 62 28 28/62      (45.2) 1.21 (0.86, 1.70) 0.281 1.02 (0.83, 1.25) 0.871 
   Second and Third trimester 25 8 8/25        (32.0) 0.86 (0.47, 1.57) 0.614 1.16 (0.73, 1.86) 0.530 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.5 Incidence of maternal anaemia (Hb <11.0g/dl) by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia level Number 
of 
women 
Total 
number of 
events 
Total 
person-
years 
follow-up 
Incidence 
rate (/1,000 
pyrs) 
Crude incidence 
rate ratio   
(95% C.I) 
P-
value 
Adjusted  
incidence rate 
ratio   (95% 
C.I) 
P-value 
G1-2 
      †  
No parasitaemia (reference) 70 49  33.98 1,442.0 - - - - 
Only asymptomatic sub-
RDT parasitaemia 70 41 32.45 1,263.5 0.88 (0.56, 1.37) 0.565 0.86 (0.67, 1.10) 0.232 
Only asymptomatic RDT 
Patent parasitaemia 113 115 51.80 2,220.1 1.54 (1.08, 2.20) 0.018 0.82 (0.66, 1.02) 0.082 
 
        
G3+ 
      †  
No parasitaemia (reference) 85 40 42.01 952.15 - - - - 
Only asymptomatic sub-
RDT parasitaemia 71 46 31.85 1,444.27 1.52 (0.90, 2.55) 0.115 1.36 (0.95, 1.94) 0.092 
Only asymptomatic RDT 
Patent parasitaemia 43 27 18.25 1,479.45 1.55 (0.93, 2.60) 0.093 0.93 (0.67, 1.27) 0.639 
 
        
All 
      ‡  
No parasitaemia (reference) 155 89 75.99 1,171.2 - - - - 
Only asymptomatic sub-
RDT parasitaemia 141 87 64.30 1,353.0 1.16 (0.82, 1.63) 0.411 1.07 (0.85, 1.35) 0.562 
Only asymptomatic RDT 
Patent parasitaemia 156 142 70.05 2,027.1 1.73 (1.30, 2.31) < 0.001 0.87 (0.72, 1.06) 0.178 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.6 Incidence of maternal anaemia (Hb <11.0g/dl) by  timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia level Number 
of 
women 
Total 
number of 
events  
Total 
person-
years 
follow-up 
Incidence 
rate (/1,000 
pyrs) 
Crude incidence 
rate ratio  (95% 
C.I) 
P-
value 
Adjusted  
incidence rate 
ratio   (95% C.I) 
P-value 
G1+2       †  
No parasitaemia (reference) 70 49 33.98 1,442.02 - - - - 
   Second trimester only  31 16 14.42 1,109.57 0.77 (0.42, 1.42) 0.403 0.84 (0.60, 1.18) 0.314 
   Third trimester only 32 20 14.89 1,343.18 0.93 (0.54, 1.60) 0.797 0.87 (0.65, 1.16) 0.348 
   Second and Third trimester 7 5 3.13 1,597.44 1.11 (0.41, 2.96) 0.841 0.88 (0.58, 1.35) 0.573 
         
G3+       †  
No parasitaemia (reference) 85 40 42.01 952.15 - - - - 
   Second trimester only  23 14 10.59 1,322.00 1.39 (0.60, 3.23) 0.446 1.42 (0.78, 2.58) 0.251 
   Third trimester only 30 22 12.75 1,725.49 1.81 (1.02, 3.21) 0.041 1.12 (0.81, 1.56) 0.482 
   Second and Third trimester 18 10 8.51 1,175.09 1.23 (0.50, 3.06) 0.651 2.02 (0.86, 4.79) 0.109 
         
All       ‡  
No parasitaemia (reference) 155 89 75.99 1,171.2 - - - - 
   Second trimester only  54 30 25.00 1,200.0 1.02 (0.61, 1.71) 0.927 1.06 (0.75, 1.50) 0.749 
   Third trimester only 62 42 27.64 1,519.5 1.30 (0.87, 1.92) 0.196 0.98 (0.77, 1.24) 0.856 
   Second and Third trimester 25 15 11.65 1,287.6 1.10 (0.56, 2.17) 0.784 1.50 (0.88, 2.56) 0.135 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.7 Difference in mean Haemoglobin  at last scheduled antenatal visit by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean Hb at last scheduled 
antenatal visit (sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 70 11.8 (1.20) - - 
Only asymptomatic sub-
RDT parasitaemia 54 11.9 (1.34) -0.10 (-0.55, 0.35) 0.655 
Only asymptomatic RDT 
Patent parasitaemia 78 11.3 (1.28) 0.44 (0.04, 0.84) 0.033 
     
G3+     
No parasitaemia (reference) 85 11.9 (1.12) - - 
Only asymptomatic sub-
RDT parasitaemia 55 11.8 (1.21) 0.07 (-0.33, 0.46) 0.743 
Only asymptomatic RDT 
Patent parasitaemia 29 12.1 (1.14) -0.25 (-0.73, 0.23) 0.308 
     
All     
No parasitaemia (reference) 155 11.8 (1.16) - - 
Only asymptomatic sub-
RDT parasitaemia 109 11.9 (1.27) -0.01 (-0.31, 0.28) 0.933 
Only asymptomatic RDT 
Patent parasitaemia 107 11.6 (1.29) 0.28 (-0.02, 0.58) 0.063 
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Table 5.8 Difference in mean Hb  at last scheduled antenatal visit  by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean gestational age at delivery 
(sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 70 11.8 (1.20) - - 
   Second trimester only  23 12.1 (1.34) -0.28 (-0.87, 0.31)  0.349 
   Third trimester only 27 11.8 (1.24) -0.02 (-0.56, 0.53) 0.945 
   Second and Third trimester 4 11.4 (2.14) 0.35 (-0.93, 1.64) 0.586 
     
G3+     
No parasitaemia (reference) 85 11.9 (1.12) - - 
   Second trimester only  15 12.1 (1.18) -0.18 (-0.81, 0.45) 0.577 
   Third trimester only 24 11.7 (1.31) 0.22 (-0.31, 0.76) 0.411 
   Second and Third trimester 16 11.8 (1.12) 0.06 (-0.55, 0.67) 0.850 
     
All     
No parasitaemia (reference) 155 11.8 (1.16) - - 
   Second trimester only  38 12.1 (1.26) -0.22 (-0.64, 0.20) 0.299 
   Third trimester only 51 11.7 (1.26) 0.10 (-0.27, 0.48) 0.589 
   Second and Third trimester 20 11.8 (1.32) 0.09 (-0.46, 0.64) 0.751 
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Table 5.9 Difference in mean Hb  last scheduled antenatal visit  by frequency of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean gestational age at delivery 
(sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 70 11.8 (1.20) - - 
   1 episode  40 11.8 (1.36) -0.04 (-0.54, 0.45) 0.872 
   2+ episodes 14 12.1 (1.30) -0.28 (-0.99, 0.43) 0.433 
     
G3+     
No parasitaemia (reference) 85 11.9 (1.12) - - 
   1 episode  34 11.9 (1.28) -0.03 (-0.50, 0.44) 0.906 
   2+ episodes 21 11.7 (1.11) 0.22 (-0.32, 0.76) 0.427 
     
All     
No parasitaemia (reference) 155 11.8 (1.16) - - 
   1 episode  74 11.9 (1.12) -0.02 (-0.36, 0.31) 0.884 
   2+ episodes 35 11.8 (1.18) 0.01 (-0.42, 0.44)0.952  
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Table 5.10 Incidence of maternal anaemia (Hb <11.0g/dl) by number of episodes of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia level Number 
of 
women 
Total 
number of 
events  
Total 
person-
years 
follow-up 
Incidence 
rate (/1,000 
pyrs) 
Crude incidence 
rate ratio  (95% 
C.I) 
P-
value 
Adjusted  
incidence rate 
ratio   (95% 
C.I) 
P-value 
G1+2 
      †  
No parasitaemia (reference) 70 49 33.98 1,442.02 - - - - 
   1 episode  50 35 23.20 1,508.62 1.05 (0.66, 1.65) 0.845 0.92 (0.71, 1.19) 0.508 
   2+ episodes 20 6 9.25 648.65 0.45 (0.16, 1.23) 0.120 0.63 (0.38, 1.04) 0.072 
         
G3+ 
      †  
No parasitaemia (reference) 85 40 42.01 952.15 - - - - 
   1 episode  47 29 20.61 1,407.08 1.47 (0.82, 2.66) 0.193 1.13 (0.78, 1.62) 0.517 
   2+ episodes 24 17 11.25 1,511.11 1.59 (0.79, 3.18) 0.193 2.17 (1.12, 4.21) 0.021 
         
All 
      ‡  
No parasitaemia (reference) 155 89 75.99 1,171.2 - - - - 
   1 episode  97 64 43.80 1,461.2 1.25 (0.87, 1.80) 0.235 1.00 (0.80, 1.26) 0.982 
   2+ episodes 44 23 20.50 1,122.0 0.96 (0.54, 1.70) 0.882 1.34 (0.86, 2.08) 0.192 
 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.11 Risk of  any placental malaria by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number 
of 
women 
(N) 
Number of 
women 
with event 
(n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-
value 
Adjusted risk 
ratio    (95% 
C.I) 
P-
value 
G1+2      †  
No parasitaemia (reference) 64 15 
15/64     
(23.4) - - - - 
Only asymptomatic sub-RDT parasitaemia 62 28 
28/62     
(45.2) 1.93 (1.14, 3.25) 0.014 1.89 (1.14, 3.15) 0.014 
Only asymptomatic RDT Patent parasitaemia 103 64 
64/103   
(62.1) 2.65 (1.69, 4.24) < 0.001 2.14 (1.32, 3.48) 0.002 
        
G3+      †  
No parasitaemia (reference) 73 13 
13/73     
(17.8) - - - - 
Only asymptomatic sub-RDT parasitaemia 67 22 
22/67     
(32.8) 1.84 (1.01, 3.37) 0.046 1.50 (0.82, 2.73) 0.186 
Only asymptomatic RDT Patent parasitaemia 39 15 
15/39     
(38.5) 2.16 (1.14, 4.07) 0.017 1.71 (0.87, 3.33) 0.117 
        
All      ‡  
No parasitaemia (reference) 137 28 
28/137     
(20.4) - - - - 
Only asymptomatic sub-RDT parasitaemia 129 50 
50/129     
(38.8) 1.90 (1.28, 2.82) 0.002 1.77 (1.20, 2.61) 0.004 
Only asymptomatic RDT Patent parasitaemia 142 79 
79/142     
(55.6) 2.72 (1.90, 3.91) < 0.001 2.00 (1.37, 2.93) <0.001 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.12 Risk of  any placental malaria by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 15 15/64     (23.4) - - - - 
   Second trimester only  25 7 7/25       (28.0) 1.19 (0.55, 2.58) 0.651 1.22 (0.57, 2.61) 0.601 
   Third trimester only 30 16 16/30     (53.3) 2.28 (1.30, 3.97) 0.004 2.14 (1.24, 3.69) 0.006 
   Second and Third trimester 7 5 5/7         (71.4) 3.05 (1.60, 4.24) 0.001 3.04 (1.66, 5.58) < 0.001 
        
G3+      †  
No parasitaemia (reference) 73 13 13/73     (17.8) - - - - 
   Second trimester only  23 3 3/23       (13.0) 0.73 (0.22, 2.35) 0.601 0.64 (0.19, 2.18) 0.473 
   Third trimester only 29 11 11/29     (37.9) 2.13 (1.08, 4.20) 0.029 1.64 (0.82, 3.27) 0.162 
   Second and Third trimester 15 8 8/15       (53.3) 2.99 (1.51, 5.94) 0.002 2.69 (1.38, 5.23) 0.004 
        
All      ‡  
No parasitaemia (reference) 137 28 28/137     (20.4) - - - - 
   Second trimester only  48 10 10/48       (20.8) 1.02 (0.54, 1.94) 0.953 0.97 (0.51, 1.84) 0.924 
   Third trimester only 59 27 27/59       (45.8) 2.24 (1.45, 3.45) < 0.001 1.99 (1.31, 3.04) 0.001 
   Second and Third trimester 22 13 13/22       (59.1) 2.89 (1.79, 4.67) < 0.001 3.07 (1.93, 4.87) < 0.001 
 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.13 Risk of  any placental malaria by number of episodes of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 15 15/64      (23.4) - - - - 
   1 episode  43 16 16/43      (37.2) 1.59 (0.88, 2.86) 0.125 1.51 (0.85, 2.67) 0.160 
   2+ episodes 19 12 12/19      (63.2) 2.69 (1.54, 4.73) 0.001 2.85 (1.66, 4.90) < 0.001 
 
       
G3+      †  
No parasitaemia (reference) 73 13 13/73      (18.8) - - - - 
   1 episode  46 13 13/46      (28.3) 1.59 (0.81, 3.12) 0.181 1.22 (0.62, 2.42) 0.565 
   2+ episodes 21 9 9/21        (42.9) 2.41 (1.20, 4.84) 0.014 2.19 (1.11, 4.31) 0.023 
        
All 
     ‡  
No parasitaemia (reference) 137 28 28/137     (20.4) - - - - 
   1 episode  89 29 29/89       (32.6) 1.59 (1.02, 2.49) 0.040 1.42 (0.92, 2.20) 0.118 
   2+ episodes 40 21 21/40       (52.5) 2.57 (1.65, 4.00) < 0.001 2.69 (1.76, 4.12) < 0.001 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.14 Risk of composite adverse livebirth outcome (SGA/PTB/LBW)  by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 12 12/66     (18.2) - - - - 
Only asymptomatic sub-
RDT parasitaemia 66 18 18/66     (27.3) 1.50 (0.79, 2.87) 0.220 1.57 (0.81, 3.04) 0.178 
Only asymptomatic RDT 
Patent parasitaemia 103 40 40/103   (38.8) 2.14 (1.21, 3.77) 0.009 1.69 (0.94, 3.07) 0.082 
        
G3+      †  
No parasitaemia (reference) 82 7 7/82        (8.5) - - - - 
Only asymptomatic sub-
RDT parasitaemia 70 18 18/70      (25.7) 3.01 (1.33, 6.80) 0.008 3.59 (1.53, 8.40) 0.003 
Only asymptomatic RDT 
Patent parasitaemia 42 14 14/42      (33.3) 3.90 (1.70, 8.95) 0.001 
4.99 (2.11, 
11.80) < 0.001 
        
All      ‡  
No parasitaemia (reference) 148 19 19/148   (12.8) - - - - 
Only asymptomatic sub-
RDT parasitaemia 136 36 36/136   (26.5) 2.06 (1.24, 3.42) 0.005 2.09 (1.25, 3.48) 0.005 
Only asymptomatic RDT 
Patent parasitaemia 145 54 54/145   (37.2) 2.90 (1.81, 4.64) < 0.001 2.51 (1.52, 4.13) < 0.001 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.15 Risk of  composite adverse livebirth outcome (SGA/PTB/LBW) by number of episodes of sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 12 12/66    (18.2) - - - - 
   1 episode  48 11 11/48    (22.9) 1.26 (0.61, 2.61) 0.535 1.33 (0.63, 2.78) 0.454 
   2+ episodes 18 7 7/18      (38.9) 2.14 (0.99, 4.64) 0.054 2.23 (1.02, 4.88) 0.044 
        
G3+      †  
No parasitaemia (reference) 82 7 7/82      (8.5) - - - - 
   1 episode  46 14 14/46    (30.4) 3.57 (1.55, 8.21) 0.003 
4.55 (1.91, 
10.83) 0.001 
   2+ episodes 24 4 4/24      (16.7) 1.95 (0.62, 6.13) 0.252 2.13 (0.65, 6.93) 0.209 
        
All      ‡  
No parasitaemia (reference) 148 19 19/148   (12.8) - - - - 
   1 episode  94 25 25/94     (26.6) 2.07 (1.21, 3.55) 0.008 2.10 (1.22, 3.64) 0.008 
   2+ episodes 42 11 11/42     (26.2) 2.04 (1.05, 3.95) 0.034 2.06 (1.06, 3.98) 0.032 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.16 Risk of composite adverse livebirth outcome (SGA/PTB/LBW) by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 12 12/66    (18.2) - - - - 
   Second trimester only  28 7 7/28      (25.0) 1.38 (0.60, 3.13) 0.448 1.52 (0.67, 3.49) 0.319 
   Third trimester only 32 8 8/32      (25.0) 1.38 (0.62, 3.03) 0.430 1.38 (0.63, 3.05) 0.420 
   Second and Third trimester 6 3 3/6        (50.0) 2.75 (1.06, 7.12) 0.037 2.70 (1.10, 6.59) 0.029 
        
G3+      †  
No parasitaemia (reference) 82 7 7/82       (8.5) - - - - 
   Second trimester only  23 8 8/23       (34.8) 
4.07 (1.65, 
10.07) 0.002 
4.67 (1.83, 
11.88) 0.001 
   Third trimester only 29 7 7/29       (24.1) 2.83 (1.08, 7.39) 0.034 
3.80 (1.39, 
10.40) 0.009 
   Second and Third trimester 18 3 3/18       (16.7) 1.95 (0.56, 6.85) 0.296 2.07 (0.56, 7.69) 0.276 
        
All      ‡  
No parasitaemia (reference) 148 19 19/148   (12.8) - - - - 
   Second trimester only  51 15 15/51     (29.4) 2.29 (1.26, 4.17) 0.007 2.34 (1.27, 4.29) 0.006 
   Third trimester only 61 15 15/61     (24.6) 1.92 (1.04, 3.52) 0.036 1.90 (1.02, 3.51) 0.041 
   Second and Third trimester 24 6 6/24       (25.0) 1.95 (0.87, 4.38) 0.107 2.03 (0.91, 4.53) 0.084 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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By gravidity, there was a significant difference in birthweights amongst paucigravidae in favor of 
babies born to women who never had malaria infection (2,928.5 vs 2, 802.8g, mean difference 125.7g, 
95% C.I. 1.49, 249.88, p-value = 0.047) and a lower but non-significant difference in multigravidae 
(3,080.0 vs 2,927.2g, mean difference 152.8, 95% C.I. -11.90,  317.60, p-value = 0.069). 
5.2.4.4 Preterm Birth 
 There was an elevated risk of preterm delivery with asymptomatic sub-RDT parasitaemia in 
both paucigravidae (21.2 vs 4.6%, RR 4.67, 95% C.I. 1.40, 15.50, p-value = 0.012) and multigravidae 
(17.1 vs 3.7%, RR 4.69, 95% C.I. 1.37, 15.99, p-value 0.014) (Table 5.26). The timing of asymptomatic 
infection was significantly associated with increased risk in paucigravidae in the second trimester 
only or infection occurred in the second and third trimester. This association was however only 
significant in multigravidae if infection occurred in either the second trimester or third trimester 
only (Table 5.27). Any number of episodes of asymptomatic sub-RDT infection in paucigravidae was 
significantly associated with an increased risk of preterm delivery but only one and not 2 or more 
episodes were associated with a raised risk amongst multigravidae (Table 5.28). 
 On average, babies born to women without any parasitaemia were 0.69 weeks older than 
those born to women with any asymptomatic sub-RDT parasitaemia (39.0 vs 38.3 weeks, 95% C.I. 
0.33, 1.05, p-value < 0.001). This effect, though slightly varied, was constant in each gravidity strata 
(Table 5.29).  Amongst paucigravidae, there was a significant difference in the mean gestational age 
at delivery if infection occurred in the second and third trimester and with more than 2 episodes. 
Comparatively, infection in either the second trimester or third trimester only and only 1 episode of 
infection was associated with significantly earlier fetal age at delivery in multigravidae (Tables 5.30 
and 5.31).
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Table 5.17 Risk of  SGA (corrected birthweight < 10th percentile for gestational age) by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number 
of women 
(N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-
value 
G1+2      †  
No parasitaemia (reference) 64 8 8/64      (12.5) - - - - 
Only asymptomatic sub-
RDT parasitaemia 62 4 4/62      (6.5) 0.52 (0.16, 1.63) 0.260 0.56 (0.17, 1.83) 0.342 
Only asymptomatic RDT 
Patent parasitaemia 101 16 16/101  (15.8) 1.27 (0.57, 2.79) 0.557 1.09 (0.47,2.52) 0.835 
        
G3+      †  
No parasitaemia (reference) 75 5 5/75      (6.7) - - - - 
Only asymptomatic sub-
RDT parasitaemia 66 6 6/66      (9.1) 1.36 (0.43, 4.28) 0.595 1.73 (0.50, 5.95) 0.386 
Only asymptomatic RDT 
Patent parasitaemia 40 5 5/40      (12.5) 1.88 (0.58, 6.11) 0.297 2.59 (0.76, 8.89) 0.130 
        
All      ‡  
No parasitaemia (reference) 139 13 13/139     (9.4) - - - - 
Only asymptomatic sub-
RDT parasitaemia 128 10 10/128     (7.8) 0.84 (0.38, 1.84) 0.655 0.93 (0.41, 2.09) 0.854 
Only asymptomatic RDT 
Patent parasitaemia 141 21 21/141     (14.9) 1.59 (0.83, 3.06) 0.162 1.52 (0.76, 3.06) 0.240 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.18 Risk of  SGA (corrected birthweight < 10th percentile for gestational age) by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 8 8/64       (12.5) - - - - 
   Second trimester only  26 0 0/26       (0.0) 
2.20e-07 (1.03e-
07, 4.67e-07)  0.000 
2.05e-07 (9.05e-
08, 4.63e-07) 0.000 
   Third trimester only 30 4 4/30       (13.3) 1.07 (0.35, 3.27) 0.910 1.16 (0.37, 3.69) 0.798 
   Second and Third trimester 6 0 0/6          (0.0) 
2.20e-07 (7.82e-
08, 6.16e-07) 0.000 
2.08e-07 (6.91e-
08, 6.28e-07) 0.000 
        
G3+      †  
No parasitaemia (reference) 75 5 5/75        (6.7) - - - - 
   Second trimester only  23 2 2/23        (8.7) 1.30 (0.27, 6.31) 0.741 1.45 (0.31, 6.82) 0.638 
   Third trimester only 28 2 2/28        (7.1) 1.07 (0.22, 5.23) 0.932 1.50 (0.30, 7.58) 0.625 
   Second and Third trimester 15 2 2/15        (13.3) 2.00 (0.43, 9.40) 0.380 2.71 (0.45, 16.1) 0.274 
        
All      ‡  
No parasitaemia (reference) 139 13 13/139     (9.4) - - - - 
   Second trimester only  49 2 2/49         (4.1) 0.44 (0.10, 1.87) 0.264 0.46 (0.11, 2.01) 0.302 
   Third trimester only 58 6 6/58         (10.3) 1.11 (0.44, 2.77) 0.830 1.24 (0.50, 3.09) 0.646 
   Second and Third trimester 21 2 2/21         (9.5) 1.02 (0.25, 4.20) 0.980 1.28 (0.30, 5.43) 0.738 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.19 Risk of  SGA (corrected birthweight < 10th percentile for gestational age) by number of episodes of asymptomatic  sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk 
ratio   (95% 
C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2 
     †  
No parasitaemia (reference) 64 8 8/64       (12.5) - - - - 
   1 episode  44 2 2/44       (4.6) 0.36 (0.81, 1.64) 0.188 0.39 (0.84, 1.76) 0.218 
   2+ episodes 18 2 2/18       (11.1) 0.89 (0.21, 3.83) 0.875 1.06 (0.25, 4.53) 0.934 
        
G3+ 
     †  
No parasitaemia (reference) 75 5 5/75        (6.7) - - - - 
   1 episode  45 4 4/45        (8.9) 1.33 (0.38, 4.73) 0.656 1.62 (0.46, 5.71) 0.449 
   2+ episodes 21 2 2/21        (9.5) 1.43 (0.30, 6.87) 0.656 1.98 (0.34, 11.47) 0.447 
        
All 
     ‡  
No parasitaemia (reference) 139 13 13/139     (9.4) - - - - 
   1 episode  89 6 6/89         (6.7) 0.72 (0.28, 1.83) 0.491 0.77 (0.31, 1.94) 0.581 
   2+ episodes 39 4 4/39         (10.3) 1.10 (0.38, 3.18) 0.865 1.33 (0.44, 4.03) 0.610 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.20 Risk of  Low birth weight (corrected weight at deliver < 2.50 kg )  by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 6 6/64    (9.4) - - - - 
Only asymptomatic sub-RDT 
parasitaemia 62 4 4/62    (6.5) 0.69 (0.20, 2.33) 0.548 0.76 (0.23, 2.51) 0.654 
Only asymptomatic RDT 
Patent parasitaemia 101 22 22/101 (21.8) 2.32 (0.99, 5.43) 0.051 1.68 (0.71, 3.98) 0.236 
        
G3+      †  
No parasitaemia (reference) 75 3 3/75     (4.0) - - - - 
Only asymptomatic sub-RDT 
parasitaemia 66 5 5/66     (7.6) 1.89 (0.47, 7.65) 0.370 2.41 (0.49, 11.81) 0.278 
Only asymptomatic RDT 
Patent parasitaemia 40 5 5/40     (12.5) 
3.13 (0.78, 
12.46) 0.106 4.48 (1.24, 16.24) 0.022 
        
All      ‡  
No parasitaemia (reference) 139 9 9/139    (6.5) - - - - 
Only asymptomatic sub-RDT 
parasitaemia 128 9 9/128    (7.0) 1.09 (0.44, 2.65) 0.856 1.18 (0.47, 2.92) 0.725 
Only asymptomatic RDT 
Patent parasitaemia 141 27 27/141  (19.1) 2.96 (1.44, 6.06) 0.003 2.39 (1.12, 5.10) 0.024 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.21 Risk of Low birth weight (corrected weight at deliver < 2.50 kg ) by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 6 6/64    (9.4) - - - - 
   Second trimester only  26 1 1/26    (3.9) 0.41 (0.05, 3.26) 0.399 0.46 (0.06, 3.70) 0.469 
   Third trimester only 30 3 3/10    (10.0) 1.07 (0.29, 3.99) 0.924 1.14 (0.33, 3.99) 0.837 
   Second and Third trimester 6 0 0/6      (0.0) 
2.18e-06 (7.21e-
07, 6.60e-06) 0.000 
8.02e-07 (2.43e-
07, 2.65e-06) 0.000 
        
G3+      †  
No parasitaemia (reference) 72 3 3/71     (4.0) - - - - 
   Second trimester only  23 2 2/23     (8.7) 
2.17 (0.38, 
12.29) 0.380 
2.69 (0.43, 
16.82) 0.291 
   Third trimester only 28 2 2/28     (7.1) 
1.79 (0.31, 
10.18) 0.514 
2.39 (0.32, 
17.68) 0.394 
   Second and Third trimester 15 1 1/15     (6.7) 
1.67 (0.18, 
15.05) 0.649 
1.99 (0.17, 
23.32) 0.585 
        
All      ‡  
No parasitaemia (reference) 139 9 9/139    (6.5) - - - - 
   Second trimester only  49 3 3/49      (6.1) 0.95 (0.27, 3.36) 0.931 1.00 (0.27, 3.66) 0.994 
   Third trimester only 58 5 5/58      (8.6) 1.33 (0.47, 3.81) 0.593 1.44 (0.50, 4.13) 0.493 
   Second and Third trimester 21 1 1/21      (4.8) 0.74 (0.10, 5.53) 0.765 0.86 (0.11, 6.51) 0.886 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.22 Risk of Low birth weight (corrected weight at deliver < 2.50 kg ) by number of episodes  of sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% 
C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 64 6 6/64    (9.4) - - - - 
   1 episode  44 2 2/44    (4.6) 0.48 (0.10, 2.30) 0.362 0.50 (0.11, 2.25) 0.370 
   2+ episodes 18 2 2/18    (11.1) 1.19 (0.26, 5.40) 0.836 1.57 (0.35, 7.02) 0.557 
        
G3+S      †  
No parasitaemia (reference) 75 3 3/75     (4.0) - - - - 
   1 episode  45 3 3/45     (6.7) 1.67 (0.35, 7.94) 0.521 
2.15 (0.36, 
12.73) 0.398 
   2+ episodes 21 2 2/21     (9.5) 
2.38 (0.42, 
13.39) 0.325 2.94 (0.4917.56) 0.236 
        
All      ‡  
No parasitaemia (reference) 139 9 9/139    (6.5) - - - - 
   1 episode  89 5 5/89      (5.6) 0.87 (0.30, 2.51) 0.793 0.92 (0.31, 2.70) 0.882 
   2+ episodes 39 4 4/39      (10.3) 1.58 (0.51, 4.88) 0.423 1.81 (0.58, 5.71) 0.309 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.23 Difference in mean birthweight  by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean corrected birthweight g (sd) Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 64 2,928.5 (348.40) - - 
Only asymptomatic sub-RDT 
parasitaemia 62 2,922.1 (367.64) 6.37 (-119.89, 132.64) 0.921 
Only asymptomatic RDT 
Patent parasitaemia 101 2,802.8 (419.69) 125.69 (1.49, 249.88) 0.047 
     
G3+     
No parasitaemia (reference) 75 3,080.0 (405.65) - - 
Only asymptomatic sub-RDT 
parasitaemia 66 3,104.6 (449.38) -24.61 (-166.98, 117.77) 0.733 
Only asymptomatic RDT 
Patent parasitaemia 40 2,927.15 (458.78) 152.85 (-11.90, 317.60) 0.069 
     
All     
No parasitaemia (reference) 139 3,010.25 (386.52) - - 
Only asymptomatic sub-RDT 
parasitaemia 128 3,016.33 (420.31) -5.97 (-103.19, 91.25) 0.904 
Only asymptomatic RDT 
Patent parasitaemia 141 2,838.09 (433.14) 172.16 (75.54, 268.78) < 0.001 
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Table 5.24 Difference in mean birthweight  by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean corrected birthweight (sd) Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 64 2,928.5 (348.40) - - 
   Second trimester only  26 2,983.2 (379.87) -54.7 (-219.94, 110.63) 0.513 
   Third trimester only 30 2,867.0 (363.67) 61.5 (-93.75, 216.75) 0.433 
   Second and Third trimester 6 2,933.3 (350.23) -4.8 (-301.78, 292.11) 0.974 
     
G3+     
No parasitaemia (reference) 75 3,080.0 (405.65) - - 
   Second trimester only  23 3,116.1 (498.11) -36.1 (-238.87, 166.70) 0.725 
   Third trimester only 28 3,138.3 (454.54) -58.3 (-242.49, 125.92) 0.532 
   Second and Third trimester 15 3,024.1 (373.93) 55.9 (-169.40, 281.14) 0.623 
     
All     
No parasitaemia (reference) 139 3,010.2 (386.52) - - 
   Second trimester only  49 3,045.6 (439.74) -35.3 (-166.71, 96.10) 0.597 
   Third trimester only 58 2,998.0 (428.78) 12.3 (-110.83, 135.39) 0.844 
   Second and Third trimester 21 2,998.2 (360.98) 12.1 (-165.22, 189.33) 0.893 
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Table 5.25 Difference in mean birthweight by frequency of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean corrected birthweight (sd) Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 64 2,928.5 (348.40) - - 
   1 episode  44 2,944.8 (374.38) -16.3 (-155.77, 123.13) 0.817 
   2+ episodes 18 2,866.7 (354.80) 61.8 (-123.87, 247.54) 0.510 
     
G3+     
No parasitaemia (reference) 75 3,080.0 (405.65) - - 
   1 episode  45 3,125.4 (453.90) -45.4 (-203.66, 112.90) 0.571 
   2+ episodes 21 3,060.1 (449.47) 19.9 (-183.70, 223.51) 0.847 
     
All     
No parasitaemia (reference) 139 3,010.2 (386.52) - - 
   1 episode  89 3,036.1 (423.42) -25.9 (-133.22, 81.48) 0.635 
   2+ episodes 39 2,970.8 (414.95) 39.4 (-101.06, 179.91) 0.580 
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Table 5.26 Risk of  Preterm Birth (corrected gestational age at birth < 37 completed weeks ) by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 3 3/66     (4.6) - - - - 
Only asymptomatic sub-
RDT parasitaemia 66 14 14/66   (21.2) 4.67 (1.40, 15.50) 0.012 4.84 (1.46, 16.10) 0.010 
Only asymptomatic RDT 
Patent parasitaemia 103 27 27/103 (26.2) 5.77 (1.82, 18.30) 0.003 4.08 (1.22, 13.66) 0.022 
        
G3+      †  
No parasitaemia (reference) 82 3 3/82      (3.7) - - - - 
Only asymptomatic sub-
RDT parasitaemia 70 12 12/70    (17.1) 4.69 (1.37, 15.99) 0.014 5.41 (1.61, 18.22) 0.006 
Only asymptomatic RDT 
Patent parasitaemia 42 13 13/42    (31.0) 8.46 (2.54, 28.15) <0.001 
11.31 (3.35, 
38.23) < 0.001 
        
All      ‡  
No parasitaemia (reference) 148 6 6/148     (4.1) - - - - 
Only asymptomatic sub-
RDT parasitaemia 136 26 26/136   (19.1) 4.72 (2.00, 11.12) < 0.001 4.57 (1.94, 10.73) < 0.001 
Only asymptomatic RDT 
Patent parasitaemia 145 40 40/145   (27.6) 6.80 (2.97, 15.57) < 0.001 6.01 (2.52, 14.30) < 0.001 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.27 Risk of  Preterm Birth (corrected gestational age at birth < 37 completed weeks ) by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 3 3/66     (4.6) - - - - 
   Second trimester only  28 6 6/28     (21.4) 4.71 (1.26, 17.58) 0.021 5.36 (1.44, 20.00) 0.012 
   Third trimester only 32 5 5/32     (15.6) 3.44 (0.87, 13.54) 0.077 3.37 (0.88, 12.97) 0.077 
   Second and Third trimester 6 3 3/6       (50.0) 
11.00 (2.80, 
43.19) 0.001 9.54 (2.61, 34.92) 0.001 
        
G3+      †  
No parasitaemia (reference) 82 3 3/82     (3.7) - - - - 
   Second trimester only  23 6 6/23     (26.1) 7.13 (1.92, 26.42) 0.003 8.74 (2.44, 31.28) 0.001 
   Third trimester only 29 5 5/29     (17.2) 4.71 (1.20, 18.56) 0.027 6.47 (1.69, 24.82) 0.006 
   Second and Third trimester 18 1 1/18     (5.6) 1.52 (0.17, 13.85) 0.711 1.38 (0.15, 12.64) 0.773 
        
All      ‡  
No parasitaemia (reference) 148 6 6/148     (4.1) - - - - 
   Second trimester only  51 12 12/51     (23.5) 5.80 (2.29, 14.68) < 0.0001 6.03 (2.41, 15.10) < 0.0001 
   Third trimester only 61 10 10/61     (16.4) 4.04 (1.54, 10.65) 0.005 3.79 (1.44, 9.98) 0.007 
   Second and Third trimester 24 4 4/24       (16.7) 4.11 (1.25, 13.52) 0.020 3.69 (1.12, 12.14) 0.032 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.28 Risk of  Preterm Birth (corrected gestational age at birth < 37 completed weeks ) by number of episodes  of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of 
women (N) 
Number of 
women with 
event (n) 
Risk 
n/N (%) 
Crude risk ratio   
(95% C.I) 
P-value Adjusted risk 
ratio    (95% C.I) 
P-value 
G1+2      †  
No parasitaemia (reference) 66 3 3/66     (4.6) - - - - 
   1 episode  48 8 8/48     (16.7) 3.67 (1.02, 13.14) 0.046 3.82 (1.06, 13.79) 0.041 
   2+ episodes 18 6 6/18     (33.3) 7.33 (2.02, 26.56) 0.002 7.61 (2.19, 26.41) 0.001 
        
G3+      †  
No parasitaemia (reference) 82 3 3/82     (3.7) - - - - 
   1 episode  46 10 10/46   (21.7) 5.94 (1.72, 20.57) 0.005 8.06 (2.43, 26.67) 0.001 
   2+ episodes 25 2 2/25     (8.3) 2.28 (0.40, 12.91) 0.352 2.17 (0.39, 11.98) 0.372 
        
All      ‡  
No parasitaemia (reference) 148 6 6/148     (4.1) - - - - 
   1 episode  94 18 18/94     (19.1) 4.72 (1.94, 11.48) 0.001 4.75 (1.95, 11.55) 0.001 
   2+ episodes 42 8 8/42       (19.0) 4.70 (1.72, 12.81) 0.002 4.22 (1.56, 11.39) 0.005 
† adjusted for all baseline characteristics excluding gravidity 
‡ adjusted for all baseline characteristics including gravidity 
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Table 5.29 Difference in mean gestational age at delivery by  asymptomatic sub-patent RDT and asymptomatic patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean gestational age at delivery 
(sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 67 38.9 (1.20) - - 
Only asymptomatic sub-
RDT parasitaemia 67 38.3 (1.76) 0.60 (0.09,1.12) 0.022 
Only asymptomatic RDT 
Patent parasitaemia 106 37.7 (2.35) 1.18 (0.57, 1.79) < 0.001 
     
G3+     
No parasitaemia (reference) 84 39.0 (1.34) - - 
Only asymptomatic sub-
RDT parasitaemia 71 38.2 (1.89) 0.76 (0.25, 1.28) 0.004 
Only asymptomatic RDT 
Patent parasitaemia 42 37.8 (2.14) 1.22 (0.60, 1.83) < 0.001 
     
All     
No parasitaemia (reference) 151 39.0 (1.28) - - 
Only asymptomatic sub-
RDT parasitaemia 138 38.3 (1.82) 0.69 (0.33, 1.05) < 0.001 
Only asymptomatic RDT 
Patent parasitaemia 148 37.8 (2.28) 1.21 (0.79, 1.63) < 0.001 
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Table 5.30 Difference in mean gestational age at delivery by timing of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean gestational age at delivery 
(sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 67 38.9 (1.20) - - 
   Second trimester only  28 38.4 (1.81) 0.57 (-0.05, 1.20) 0.073 
   Third trimester only 32 38.5 (1.58) 0.43 (-0.14, 1.00) 0.134 
   Second and Third trimester 7 37.4 (2.28) 1.50 (0.45, 2.55) 0.006 
     
G3+     
No parasitaemia (reference) 84 39.0 (1.34) - - 
   Second trimester only  23 38.3 (1.72) 0.70 (0.04, 1.37) 0.039 
   Third trimester only 30 38.0 (2.32) 1.02 (0.33, 1.72) 0.004 
   Second and Third trimester 18 38.6 (1.18) 0.41 (-0.26, 1.09) 0.230 
     
All     
No parasitaemia (reference) 151 39.0 (1.28) - - 
   Second trimester only  51 38.3 (1.75) 0.63 (0.19, 1.09) 0.006 
   Third trimester only 62 38.2 (1.97) 0.72 (0.27, 1.17) 0.002 
   Second and Third trimester 25 38.3 (1.60) 0.71 (0.14, 1.27) 0.015 
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Table 5.31 Difference in mean gestational age at delivery by frequency of asymptomatic sub-patent RDT parasitaemia 
Parasitaemia Number of women (N) Mean gestational age at delivery 
(sd) 
Mean difference   (95% C.I) P-value 
G1+2     
No parasitaemia (reference) 67 38.9 (1.20) - - 
   1 episode  48 38.5 (1.62) 0.45 (-0.72, 0.97) 0.091 
   2+ episodes 19 37.9 (2.05) 0.99 (0.26, 1.73)  0.009 
     
G3+     
No parasitaemia (reference) 84 39.0 (1.34) - - 
   1 episode  47 38.1 (2.12) 0.92 (0.32, 1.51) 0.003 
   2+ episodes 24 38.5 (1.32) 0.47 (-0.15, 1.08) 0.135 
     
All     
No parasitaemia (reference) 151 39.0 (1.28) - - 
   1 episode  95  38.3 (1.88) 0.68 (0.29, 1.08) < 0.001 
   2+ episodes 43 38.3 (1.68) 0.70 (0.23, 1.17) 0.004 
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 There was strong evidence of a raised risk of preterm delivery with asymptomatic patent RDT 
parasitaemia (27.6 vs 4.1%, RR 6.80, 95% C.I. 2.97, 15.57, p-value < 0.001).  Babies born to mothers 
who never had parasitaemia were more than a week older on average at delivery compared to those 
born to mothers with at least one episode of asymptomatic patent infection (39.0 vs 37.8 weeks, 
mean difference 1.21, 95% C.I. 0.79, 1.63 weeks, p-value < 0.001).  
5.2.5 Discussion 
 In our analysis, we found that asymptomatic RDT parasitaemia had different effects on 
pregnancy outcomes in both the mother and foetus depending on its characterization by RDT 
detection. Asymptomatic sub-RDT infection only was associated with an increased risk of any 
adverse live birth outcome, largely as a result of the significantly higher risk of preterm birth in 
women with such infections. In addition, asymptomatic sub-RDT infection was associated with a 
higher risks of any placental malaria, and this was observed in both pauci- and multigravidae. 
 The risk of preterm birth and placental malaria was elevated with asymptomatic infection in 
the second or third trimester. A frequency of two or more episodes of infection were significantly 
associated with higher risks for preterm birth and placental malaria in paucigravidae whilst these 
were significantly increased in multigravidae with only one episode of asymptomatic sub-RDT 
infection. 
 Asymptomatic but patent RDT infections detected during at least one antenatal visit was 
associated with higher risk for maternal anaemia, placental malaria, low birth weight and preterm 
delivery. Pregnancies exposed to patent RDT infection also had lower haemoglobin at the final 
scheduled antenatal visit, lower mean birthweights and earlier deliveries. There was however no 
significant association with small for gestational age by either type of asymptomatic infection. 
 The results from this study showed a clear trend in a reduction in the prevalence of RDT 
patent malaria infection with subsequent antenatal visits especially when compared to the initial 
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booking visit. This may be due to the effect of screening and treating out RDT-positive infection 
women, most of which were detected during the first visit, followed by further treatment at each 
subsequent visit, such that fewer women would be parasiteamic by the next visit.   
 Treating out RDT infection may not be the sole reason for the observed decline in patent RDT 
infections. Early publications have demonstrated a similar trend in reduction in patent malaria 
prevalence in settings with alternative chemoprevention strategies (357). In a weekly prospective 
and initial chemoprevention naïve pregnancy cohort study in western Kenya, the prevalence of 
microscopically detectable malaria infection was highest at first antenatal visit between 91 and 112 
days gestation then tended to taper to lower levels by delivery. This was postulated to be as a result 
of subsequent higher recovery rates from previous infections, markedly after 98 days gestation, than 
the occurrence of new infections. It was stated that this came about as a result of “women losing their 
age dependent immunity at the beginning of pregnancy then to reacquire it within the space of 9 
months”.     This phenomenon has been attributed in recent studies from Benin and Cameroon, to the 
development of VAR2CSA antibody expression as a function of gestational age (358, 359). 
 A second explanation for the reduction in patent RDT infection may lie in the distribution of 
bed nets at the enrolment visit. A previous study conducted in western Kenya showed ITNs reduced 
the incidence of malaria parasitaemia by 38% over the course of pregnancy (360).  Furthermore, a 
systematic review of the effect of insecticide treated bed nets demonstrated that in two trials, there 
was a reduction in the time to first parasitaemia, clinical malaria and geometric mean parasite 
densities among paucigravidae protected by ITNs (361).  
 The sensitivity of malaria RDTs to detect parasitaemia in the peripheral blood is largely 
influenced by parasite density and improves with higher parasite densities especially above 200 
parasites /ul ((362-364). The trend in reduction of the sensitivity in the RDT to detect peripheral 
parasitaemia may also be as a result of the evolving maternal immune system over the course of same 
pregnancy, limiting the number and density of infections probably due to an amelioration of cytokine 
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and hormonal mechanisms initially mounted to prevent the rejection of the fetal allograft in early 
pregnancy. A marked increase in corticosteroids, that impede cell mediated malaria immunity, in the 
third trimester (244) may explain the rise in parasitaemia evident at delivery. Consequently this 
means that RDTs are more useful early in pregnancy at the first antenatal visit, with less utility in the 
period in-between. This limitation of only being able to reliably diagnose malaria parasitaemia at 
higher parasite densities at a single point early in pregnancy poses a significant disadvantage to pre-
emptively diagnosing and treating malaria parasitaemia at levels before pathophysiological 
processes that culminate in adverse pregnancy events are set in motion during the overall course of 
pregnancy.  
 In a cross sectional study, asymptomatic malaria infections were demonstrated to be 
associated with maternal anaemia (365). Our findings have been consistent with these previous 
results but have further demonstrated that asymptomatic infections not detected by RDT are not 
associated with maternal anaemia possibly owing to the low density of such infections. Conversely, 
it was asymptomatic patent RDT infections that were associated with maternal anaemia and this may 
be likely due to higher parasite densities which have been shown to be strongly correlated with 
maternal anaemia (366) over the course of pregnancy possibly due to an induction of increased 
splenic destruction of infected red blood cells in a dose dependent manner.  
 High parasite densities have been associated with  decreased birthweight and increased risk 
of low birthweight (367, 368) as a result of either reduced availability of nutrients to the foetus due 
to nutrient depletion during pathophysiological processes of localized infection or mechanical 
blockage via placental membrane thickening following inflammatory reactions (96). The results from 
our analysis did not find any association of asymptomatic sub-RDT parasitaemia with low 
birthweight or mean birthweight. This may suggests that the pathophysiological processes leading 
to low birthweight are dependent on higher parasite densities as asymptomatic infections detected 
by RDT had an increased risk for low birthweight and significant difference in birthweight, which 
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may be enacted in a manner dependant on the timing and frequency of such infections (369). Some 
studies have reported an increased risk of low birthweight with malaria infection in the first 
trimester (370, 371). This aspect of timing of infection was not evaluated in the current analysis as 
women were recruited in the second trimester. It may be possible that sub-RDT infections in the first 
trimester and chronically carried through pregnancy could result in low birthweight from 
intrauterine growth restriction following a prolonged carriage of low lying infection. However, 
neither form of asymptomatic infection was associated with small for gestational age which is rather 
surprising. This may indicate that asymptomatic malaria infection may not play a directly significant 
role in intrauterine growth restriction but may be facilitated through other placental microbiotas, 
such as bacteria, that are supported in the presence of malaria infection. Previous evidence has 
demonstrated that malaria infection is a significant risk factor for invasive non-typhoid salmonella 
infection in children and these infections commonly occur as coinfections (372-374).    
 Acute high density malaria infections, often associated with constitutional symptoms, have 
been shown to increase the risk of preterm delivery (375) especially in low transmission settings. 
The risk for preterm delivery in high transmission settings, such as from the where the cohort of this 
analysis were drawn, is associated with chronic malaria infection (376). The exact mechanism is not 
clear but may be associated with gradual increase in cytokines due to the persistence of parasitaemia 
that remains untreated that precipitate the labor cascade (377). The findings in our analysis 
demonstrate that both asymptomatic sub-RDT parasitaemia and patent RDT infection were 
associated with preterm delivery. The effect of timing and frequency of asymptomatic sub-RDT 
parasitaemia was strikingly similar in associations with preterm birth and any placental malaria 
when examined by gravidity. 
 Our results are consistent with findings from recently published results from cross-sectional 
studies from the DRC and Burkina Faso that found that asymptomatic RDT infections increased the 
odds of maternal anaemia (365, 378). However, given the prospective nature of our study population, 
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this association was true for women having at least one episode of asymptomatic patent RDT 
infection. Our data may additionally suggest that by the time of diagnosis of levels of parasitaemia 
associated with anaemia, this may be too late as the damage would have already been done. This is 
further supported by the findings that sub-RDT infection was not associated with maternal anaemia, 
neither by timing nor by frequency.  
 In the midst of the growing interest in intermittent screening and treatment for the control 
of malaria in pregnancy as an alternative strategy to intermittent presumptive treatment with SP in 
current areas of malaria endemicity where SP is failing or have no currently recommended drug 
strategy, very few studies have evaluated the impact of asymptomatic infections on pregnancy 
outcomes to warrant the importance of screening for asymptomatic infection and more so, the 
consequences of missed infections. Our findings indicate that asymptomatic infections have a 
significant impact on pregnancy outcomes. Low density infections that are missed by RDT have 
adverse consequences on fetal outcomes whilst patent infections, representing higher degrees of 
parasitaemia bear significant consequences on maternal and fetal outcomes which may indicate a 
delay in addressing clinically significant parasitaemia by the time of diagnosis.  These findings 
therefore indicate that if screening were to be incorporated as part of a viable strategy for the control 
of malaria in pregnancy in order to prevent adverse pregnancy outcomes, the screening test should 
be able to detect low levels of parasitaemia before reaching asymptomatic patent levels where it 
would be too late to intervene. Where asymptomatic sub-RDT infection is associated with adverse 
pregnancy outcomes such as with preterm delivery, a screening strategy would not be ideal and a 
presumptive treatment strategy with an efficacious agent would be more favourable.  
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6 CHAPTER SIX: THE PERFORMANCE OF HISTIDINE RICH PROTEIN 2 
(HRP2)/ PLASMODIUM LACTASE DEHYDROGENASE (PLDH) MALARIA 
RAPID DIAGNOSTIC TEST TO DETECT ACTIVE PLACENTAL MALARIA; 
IMPLICATIONS FOR THE EFFICACY OF INTERMITTENT SCREENING AND 
TREATMENT FOR THE CONTROL OF MALARIA IN PREGNANCY WITH 
PLACENTAL SEQUESTRATION 
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 Statistical considerations and analyses 
6.1.1 Rationale 
 P.falciparum is the only currently known species of malaria to sequester in the placenta with 
characteristic morphological features on histological examination. Because of this phenomenon, 
peripheral parasiteamia underestimates the overall density of infection in pregnant women due to 
the sequestration of a potentially significant biomass in the placenta (379-382). Because of this 
density mismatch presented by peripheral parasiteamia and the density dependant reliability of RDT 
performance, intermittent screening and treatment may miss treating a significant mass of 
parasiteamia that would lead to adverse pregnancy outcomes. 
6.1.2 Approach 
 The study was imbedded in the larger clinical trial comparing the efficacy and safety of 
intermittent screening and treatment to intermittent presumptive treatment in pregnancy with 
Sulphadoxine – Pyrimethamine for the control of malaria in pregnancy. The trial and its methods 
have been described in chapter 3 including laboratory methods for light microscopy, histology, RDT 
and PCR evaluations. The power of this analysis was thus based on the number of deliveries from the 
parent trial for which RDT (First Response® Combo Malaria Ag (pLDH/HRP2); Premier Medical 
Corporation, Ltd, India) results at delivery and placental histology were available. Thus a separate 
sample size calculation was not conducted for this sub-analysis. Where applicable, guidelines in 
accordance to the Standard of Reporting of Diagnostic Accuracy (STARD) statement were followed 
to report results.   
6.1.3 Analyses 
 Stata version 13 (StataCorp, College Station, Texas) with the user written programme stb59 
sbe36_1 (http://www.stata.com/stb/stb59) was used to calculate the sensitivity, specificity, positive 
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predictive value and negative predictive value, and their 95% confidence intervals. The positive and 
negative likelihood ratios, and diagnostic odds ratio (DOR) were calculated from a Microsoft Excel™ 
2013 (Microsoft Corporation, Redmond, Washington) online confidence interval calculator 
(http://www.pedro.org.au/english/downloads/confidence-interval-calculator/). The DOR is 
a measure of the effectiveness of a diagnostic test given by the ratio of the odds of a true positive 
result to the odds of a false positive.  Placental histology was considered the gold standard. The 
sensitivities of diagnostics tests within and between samples were compared using McNemar’s test 
for correlated proportions (383-385) . Statistical significance was set at α of 0.05.  
 Results 
6.2.1 Patient disposition 
 Of the 1,873 women enrolled in the trial 1,261 (67.3%) were included in the analysis, having 
complete data at delivery on peripheral malaria RDT, light microscopy and PCR, and placental 
malaria detected by RDT, LM, PCR, placental histology and placental impression smears (Figure 6.2).  
The mean age (SD) was 22.6 (5.0) years and 60.6% of the women were paucigravidae. The majority 
of women (99.4%) resided in a rural setting.  All the women reported having used an insecticide 
treated net during the current pregnancy with 99.5% having slept under an insecticide treated net 
24 hours prior to delivery. Less than 1% of the women reported having felt ill prior to delivery since 
the last study visit with 0.32% diagnosed with clinical malaria at delivery.  The prevalence of 
peripheral parasitaemia was 8.6%, 2.3% and 20.6% by RDT, LM and PCR respectively. 26.7% of the 
women had evidence of placental infection, 11.6% of which was active infection. By light microscopy, 
P.falciparum accounted for the vast majority of infections (93.1%) with P.malariae contributing the 
remainder of infections. Mixed infections were not detected. 
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6.2.2 Performance of peripheral blood malaria rapid diagnostic test for detection of 
active placental malaria (acute or chronic) 
 The sensitivity of peripheral blood RDT was 48.0%, with specificity, PPV, NPV, LR+, LR- and 
DOR values of 96.5%, 64.2%, 93.4%,  13.7, 0.54 and 25.4 respectively (Table 6.1). Comparative 
performance measures for peripheral blood LM and PCR were higher compared to RDT. PCR was 
more sensitive than RDT (64.4 vs 47.9%, difference 16.4%, 95% C.I. 8.40, 24.5%, p < 0.001) and LM 
(64.4 vs 16.4%, difference 47.9%, 95% C.I. 38.9, 57.0%, p < 0.001). RDT was more sensitive than LM 
(48.0 vs 16.4%; difference 31.5%, 95% C.I. 22.4, 40.6%, p < 0.001).  
6.2.3 Performance of RDT, LM and PCR in placental blood to detect active placental 
malaria detected by histology 
 From placental blood samples, the sensitivity, specificity, PPV, NPV, LR+, LR- and DOR for 
RDT was 34.3%, 98.8%, 79.4%, 92.0%, 29.4, 0.67 and 44.2 respectively (Table 6.2). LM and PCR 
evaluation of placental blood to detect active placental malaria were further compared to RDT.   As 
with peripheral blood, PCR remained more sensitive than RDT (67.8 vs 34.2%, difference 33.6%, 95% 
C.I. 24.3, 42.8%, p < 0.001) and LM (67.8 vs 5.5%; difference 62.3%, 95% C.I. 53.4,  71.3%, p < 0.001). 
RDT was significantly more sensitive than LM (34.2 vs 5.5%, difference 28.8%, 95% C.I. 20.5, 37.0%, 
p < 0.001). 
6.2.4 Performance of diagnostic tests between peripheral and placental blood 
samples 
 The sensitivity for PCR to detect active placental infections was similar between placental 
and peripheral blood samples (67.8 vs 64.4%, difference 3.42%, 95% C.I. -4.7, 11.2%, p = 0.369). 
However, for both RDT and LM, sensitivity was lower in the placental sample than the peripheral 
blood sample (34.3 vs 48.0 %: difference -13.7%, 95% C.I. -21.1, -6.3%, p < 0.001) and (5.5 vs 16.4%, 
difference 11.0%, 95% C.I. -17.4, -4.5%, p < 0.001).  
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Figure 6.1 Participant flow chart for diagnostic accuracy eligibility 
 
 
 
 
 
 
 
 
1,873 women randomized
1,722 (91.9 %) delivered
150 (8%) excluded
- 20 (13.3%) missed delivery visit
- 29 (19.3%) trial screening failure
- 40 (26.7%) withdrawal consent before delivery
- 61 (40.7%) loss to follow-up before delivery
1,261 (67.3%) eligible for analysis
1,261 matched samples 
available for analysis
461 (24.6%) excluded ⋝ 1 of the following
- no peripheral blood samples result for 
malaria RDT (RDT)
thick smear microscopy (LM)
malaria detection PCR (PCR)
- no placental blood samples results for
malaria RDT (RDT)
thick smear microscopy (LM)
malaria detection PCR (PCR)
- no results for placental histology
- no results for placental impression smear
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6.2.5 Association of placental parasite density and the risk of low birth weight 
 Overall, placental parasitaemia was associated with LBW (Chi 2, P = 0.007), with an almost 
1.5 times increased risk (crude RR 1.47, 95% C.I. 1.16, 1.86, p = 0.001) than having no placental 
parasitaemia. The risk ratio for LBW increased with placental parasite density, with a statistically 
significant effect above 100 parasites/500RBC (crude RR 3.98, 95% C.I 1.78, 8.94, p = 0.001). This 
was a mainly pronounced effect amongst paucigravidae with risk in multigravidae not being 
significant (Table 6.3). 
6.2.6 Peripheral malaria rapid diagnostic test performance by placental parasite 
density 
 The influence of placental parasite density on the sensitivity of peripheral RDT to diagnose 
active placental malaria showed an increase in sensitivity with an increase in the placental parasite 
density though this increase was minimal above 50parasites/500RBC (Table 6.4).  Comparatively, at 
a density of >100parasites / 500 RBC, PCR demonstrated a sensitivity of 91.3%, 95% C.I. 72.0, 98.9%. 
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Table 6.1 Summary performance measures of diagnostic tests for peripheral parasitaemia to detect active placental malaria by placental histology 
Index 
test Performance parameter (95% C.I) 
 Sensitivity Specificity PPV NPV LR+ LR- DOR 
RDT 
48.0 (39.6 – 
56.4) 
96.5 (95.3 – 
97.5) 
64.2 (54.5 – 
73.2) 
93.4 (91.8 – 
94.8) 
13.7 (9.6 – 
19.5) 
0.54 (0.56 – 
0.63) 
25.4 (16.1 – 
40.1) 
        
LM 
16.4 (10.8 - 
23.5) 
99.6 (99.0 - 
99.9) 
82.8 (64.2 -  
94.2) 
90.1 (88.3 -  
91.7) 
36.7(14.2 – 
94.6) 
0.83 (0.78 – 
0.90) 
43.7 (16.4 – 
116.5) 
        
PCR 
64.4 (56.0 - 
72.1) 
85.1 (82.9 - 
87.2) 
36.1 (30.3 - 
42.3) 
94.8 (93.2 -  
96.1)   4.3 (3.6 – 5.2) 
0.42 (0.34 – 
0.52) 
10.3 (7.09 – 
15.1) 
                
 
Table 6.2 Summary performance measures of diagnostic tests for peripheral parasitaemia to detect active placental malaria 
Index 
test Performance parameter (95% C.I) 
 Sensitivity Specificity PPV NPV LR+ LR- DOR 
RDT 
34.3 (26.6 – 
42.6) 
98.8 (98.0 – 
99.4) 
79.4 (67.3 – 
88.5) 
92.0 (90.3 – 
93.5) 
29.4 (16.4 – 
52.7) 
0.67 (0.59 – 
0.75) 
44.2 (23.2 – 
84.1) 
        
LM 5.5 (2.4 - 10.5) 
99.6 (99.1 -  
99.9) 
66.7 (34.9 -  
90.1) 
89.0 (87.1 -  
90.6) 
15.2 (4.7 – 
50.1) 
0.95 (0.91 – 
0.99) 
16.1 (4.8 – 
54.2) 
        
PCR 
67.8 (59.6 -  
75.3) 
87.7(85.6 -  
89.6) 
42.0 (35.6 -  
48.3) 
95.4 (94.0 -  
96.6) 5.5 (4.6 – 6.7) 
0.37 (0.29 – 
0.47) 
15.0 (10.2 – 
22.2) 
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Table 6.3 Association of placental parasite density and low birthweight, stratified by gravidity 
Placental parasite  
density (n/ 500 RBCs) 
 
Total Number 
of women 
Number of 
women with 
LBW outcome 
Risk Crude Risk  
Ratio  (95% 
C.I) 
P-value Adjusted 
Risk  Ratio 
(95% C.I)† 
P-value 
G1+2        
0 (reference) 724 95 95/724     (13.1) - - - - 
1 - 50 69 7 7/69         (10.1) 0.75 (0.33, 1.68) 0.482 0.68 (0.29, 
1.68) 
0.366 
51 - 100 26 5 5/26         (19.2) 1.58 (0.58, 4.28) 0.372 1.14 (0.39, 
3.28) 
0.814 
>100 22 8 8/22         (36.4) 3.78 (1.55, 9.26) 0.004 2.53 (0.91, 
7.06) 
0.076 
G3+        
0 (reference) 498 29 29/498     (5.8) - - - - 
1 - 50 30 4 4/30          (13.3) 2.49 (0.81, 7.61) 0.110 2.20 (0.70, 
6.86) 
0.176 
51 - 100 4 0 0/4            (0.0) - - - - 
>100 7 1 1/7            (14.3) 2.70 (0.31, 23.1) 0.366 2.20 (0.25, 
19.8) 
0.481 
All        
0 (reference) 1,222 124 124/1,222 (10.2) - - - - 
1 - 50 99 11 11/99         (11.1) 1.11 (0.58, 2.13) 0.761 0.94 (0.47, 
1.85) 
0.850 
51 - 100 30 5 5/30           (16.7) 1.77 (0.67, 4.71) 0.252 1.13 (0.40, 
3.14) 
0.822 
>100 29 9 9/29           (31.0) 3.98 (1.78, 8.94) 0.001 2.54 (1.03, 
6.25) 
0.043 
 
† adjusted for maternal age, number of scheduled interventions received, use of bednet, pregnancy season and socioeconomic status 
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Table 6.4 Peripheral mRDT performance by placental parasite density, stratified by gravidity 
Placental parasite density (n/ 500 RBCs) 
 
Total positives by 
reference test 
Positive by RDT Sensitivity (95% C.I) 
G1+2    
1 - 50 26 18 18/26, 69.2% (48.2, 85.7%) 
51 - 100 18 12 12/18, 66.7% (41.0, 86.7%) 
>100 21 14 14/21, 66.7% (43.0, 85.4%) 
    
G3+    
1 - 50 6 3 3/6,     50.0% (11.8, 88.2%) 
51 - 100 4 3 3/4,     75.0% (19.4, 99.4%) 
>100 2 2 2/2,   100.0% (15.8, 
100.0%) 
    
All    
1 - 50 32 21 21/32, 65.6% (46.8, 81.4%) 
51 - 100 22 15 15/22, 68.2% (45.1, 86.1%) 
>100 23 16 16/23, 69.6% (47.1, 86.8%) 
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 Discussion 
 The utility of RDTs in malaria control has largely been targeted toward the diagnosis of 
symptomatic malaria to guide initiation of appropriate treatment (141). Consequently the vast 
majority of studies that have evaluated the performance of RDTs have been within the context of 
symptomatic malaria, which is usually accompanied by higher peripheral parasite densities than 
among asymptomatic women (386, 387) . Within this regard, RDTs, more especially combination 
HRP2/pLDH, have demonstrated very high performance characteristics (293, 388, 389). Though a 
key susceptible group for malaria infection, the evaluation of RDT performance in pregnant women 
has largely remained limited (390) but has demonstrated equal reliability to guide malaria treatment 
as in non-pregnant populations (382, 391, 392). The predominant localization of the biomass of 
P.falciparum malaria in the placenta during the second and third trimesters of pregnancy presents a 
challenge for the detection of infection sequestered in the placenta by LM but an opportunity for the 
utility of RDTs. Most studies that have examined the performance of RDTs against this phenomenon 
have used PCR as the reference test (382). This study is one of the few to date that have compared 
RDT performance against active placental malaria by placental histology as the reference test for the 
diagnosis of malaria in pregnancy. 
 The results of the current study show a high proportion of predominantly P.falciparum 
asymptomatic peripheral and placental malaria infections at delivery. This is  in line with results from 
previous studies (393). Furthermore, the present observations suggest, similar to prior studies, that 
a large proportion of asymptomatic parasitaemia is largely missed by light microscopy (394, 395). 
As with many studies, RDT consistently detected more peripheral (283, 396-398) and placental (391, 
399, 400) parasitaemia, though this observation differed with other studies that have found RDTs to 
be inferior to expert microscopy (392) . 
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 Placental histology presents the optimal reference standard for the assessment of the 
performance of diagnostic tests for active placental malaria (93). The sequestration of viable 
P.falciparum through infected erythrocytes presents a twofold problem for diagnosis of malaria in 
pregnancy. Firstly, it effectively reduces the density of parasites in the peripheral circulation thus 
reducing the available concentration of parasites for detection by a diagnostic tests.  Secondly, it is 
likely that the higher concentration of the malaria biomass in the placenta is sufficient enough to 
perpetrate continued pathophysiological changes leading to adverse pregnancy outcomes. 
Consequently there is poor detection of malaria biomass causing significant damage to the mother 
and unborn child.  The low performance of otherwise robust peripheral symptomatic malaria 
diagnostics to detect active placental malaria are therefore not surprising.   
 An interesting observation in this study was the significant reduction in the sensitivity of RDT 
and expert microscopy to detect active placental infection from the peripheral blood to the placental 
blood. It could be postulated that this could be due to the reduced available biomass for detection in 
the immediate environment of sequestration whereas in the peripheral blood, the biomass would be 
easier detectable. PCR however proved to be constant in its sensitivity in both milieu, demonstrating 
significant diagnostic reliability irrespective of sampling site. As such, a PCR method based on 
peripheral blood is just as good as sampling at site. The observed poor sensitivity of placental blood 
RDT and LM agree with one known published study to date that used placental histology as the gold 
standard test. In this study from eastern Sudan in an area of unstable malaria transmission (391) 
amongst symptomatic pregnant women who would essentially have higher parasite densities, the 
mean (SD) geometric parasite density was 8,897.8 (1031.0) rings/μl. RDT and PCR had sensitivity 
17.5% and 6.5% whilst LM did not detect any malaria. This was despite the same tests having high 
sensitivities for peripheral malaria with LM as the gold standard. However the study did not evaluate 
the sensitivity of peripheral blood diagnosis for active placental malaria nor did it compare whether 
sensitivity differed between the peripheral and placental blood. The findings of the current study 
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demonstrate higher performance indices, independent of prevalence, than the findings from the 
study from Sudan. This may lie in the fact that in unstable areas of transmission, pregnant women 
have poorly developed anti-malarial immunity and therefore symptomatic malaria is easily induced 
at lower parasite densities. This is opposed to the setting of the current study where though 
asymptomatic, pregnant women harbored higher parasite densities. 
 This analysis also sought to elucidate if there was a relationship between placental infection 
density and the performance of peripheral blood RDT. By adopting the placental parasite density 
from the placental impression smear as a proxy measure of the density of sequestered placental 
malaria, there was a strong association between the density of infection and sensitivity of RDT. In 
addition, it was shown that the risk of LBW with active PM was determined to be significant at >100 
parasites/ 500 sequestered RBCs.  
 The study was not without limitations. The greater test performance by RDTs compared to 
expert microscopy may be argued to be as a result of poor microscopy technique. Though the 
microscopy methods employed a robust protocol to ensure quality assurance with a second and third 
microscopist employed to verify results of the first reader, poor microscopy results may have still 
emanated from the absence of verification of readings by the lack of external quality assessment as 
independent assessment of the quality of microscopy. Secondly, the analysis was likely 
underpowered due to the small number of events of interest in respective analyses as evident by the 
large confidence intervals in some cases.  
 From these results, HRP2/pLDH combination RDTs miss a burden of malaria infection in 
pregnancy after establishment of the placenta due to poor sensitivity to detect parasiteamia 
sequestered in the placenta. More consistent and sensitive diagnostics methods would therefore be 
required to catch this missed burden of parasiteamia if screening were to be an effective tool for the 
control of malaria related morbidity in pregnancy.  
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7 CHAPTER SEVEN: GENERAL DISCUSSION AND CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“I never quit until I get what I’m after. Negative results are just what I’m after. They are just as 
valuable to me as positive results.” – Thomas A. Edison 
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 An estimated US$ 2.7 billion in international and domestic funding was directed toward the 
global effort to eliminate malaria in 2013 (24). These efforts have contributed to an overall 30% drop 
in malaria incidence globally from 2000 to 2013, with Africa registering 4% above the global average 
decrease in incidence over the same period, signifying the great impact of current efforts in Africa. It 
is through these concerted efforts that the Millennium Development Goal 6, target C (halted and 
begun to reverse the incidence of malaria by 2015) has been attained. However, as funding 
commitments remain below the US$ 5.1 billion benchmark required to successfully control and 
eliminate malaria, it is apparent that malaria will remain a significant public health problem in the 
current 94 countries registered with the WHO as having ongoing malaria transmission. 
 Despite the general penetration of interventions for the control of malaria in Africa having 
registered significant improvements with an estimated universal coverage of 49% of all people at 
risk of malaria accessing an insecticide treated bed-net, the uptake of Intermittent Preventative 
Treatment with Sulphadoxine-Pyrimethamine (IPTp-SP), an essential intervention specifically 
tailored to pregnant women, remains extremely low. A staggering 42.8% of 35 million pregnant 
women at risk of malaria are reported not to have received a single dose of preventative treatment 
for malaria in 2013 (24) despite the continued proven efficacy of Sulphadoxine-Pyrimethamine 
against alternative regimens, in the context of growing SP resistance. Given the simplicity of 
implementation of IPTp-SP but the surprising low uptake, it is imperative that any strategy to replace 
IPTp-SP should not only have superior efficacy and safety, but also be cost effective, acceptable and 
scalable. 
 The efficacy of intermittent screening and treatment for the control of 
malaria in pregnancy 
 The concept of intermittent screening and treatment for the control of malaria in pregnancy 
is based on the assumptions that;  
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a) Screening detects parasitaemia that would result in adverse pregnancy outcomes if left 
unchecked. 
b) Any parasitaemia not detected would not pose a risk on adverse pregnancy outcomes,  
c) By the time of detection of significant levels of parasitaemia, pathological processes that lead to 
adverse pregnancy outcomes have not been fully established,  
d) Treatment with an efficacious antimalarial would halt progression of detected parasitaemia to a 
critical mass and thus reduces the risk of infections resulting in the irreversible 
pathophysiological processes that lead to adverse birth outcomes and  
e) The post treatment prophylactic effect would sufficiently retard any reinfection and thus 
reducing therisk of malaria mediated pathophysiological processes that adversely affect the 
pregnancy until the next antenatal visit. 
 The findings of the efficacy and safety trial comparing ISTp-DP against IPTp-SP have 
demonstrated that ISTp-DP is not superior to IPTp-SP in an area of moderate to high malaria 
transmission with near saturation of quintuple SP mutations and low level (1.5%) sextuple mutants.  
Further analyses have suggested this lack of superiority may be as a result of a contravention in the 
earlier assumptions regarding ISTp as outlined below.  
7.1.1 Asymptomatic P.falciparum infection in pregnancy and diagnostic reliability of 
RDTs  
 Results from Chapter 5 have shown that asymptomatic infections have a significant bearing 
on pregnancy outcomes, however, asymptomatic sub-RDT infections (i.e. those missed by RDTs) 
appear to have a limited influence on most pregnancy outcomes except for preterm delivery. The 
majority of patent asymptomatic RDT infections during pregnancy were detected at enrolment 
(69.9%, N = 299) with most women experiencing only 1 episode (91.3%, N = 275) through the course 
of pregnancy. This seems to suggest that by the time of presentation for their first antenatal visit, 
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most women have already experienced significant parasitaemia with possibly irreversible 
consequences to pregnancy outcomes.  
 As such exposure reduction interventions in early pregnancy would be required in order to 
avoid pregnancies from adopting a trajectory toward unfavorable outcomes, an effect which cannot 
be addressed in light of current practice as SP is contraindicated in the first trimester when malaria 
infection is greatest in pregnancy. Further studies would be required to substantiate the effect of 
malaria infection in the first trimester and the impact of intervening at this time point of later 
pregnancy outcomes.  
 Despite the current lack of safe chemo-prevention strategies to protect pregnancies at risk in 
endemic areas in the first trimester, LLITNs provide a strategic reprieve in protecting early 
pregnancies from the complications of malaria infection as they have been shown to reduce the 
incidence of parasitaemia and clinical malaria in pregnancy, independent of use of IPTp-SP (161). 
With only 30% of households having an ITN for people who slept in the household, and 62% of 
pregnant women reported to having slept under an ITN the night before the Malaria Indicator Survey 
(187), there is a significant gap in coverage of utilisation of ITNs in early pregnancy (proxy by the 
proportion of households having an ITN the for people who slept in the household the night before), 
prior increased utilization upon initiation of antenatal visits where LLITNs are provided. This 
signifies that active distribution of LLITNs at the community level would provide wider coverage and 
protection of early pregnancies prior to the initiation of antenatal care.  The current local 
programmatic drive toward universal LLITN coverage not only tackles population level transmission 
reduction but also, by virtue of providing wider coverage beyond recognised target high risk groups, 
also provides protection to not yet identified high risk groups such as pregnant women in the first 
trimester which will reduce the burden of infection by the first antenatal visit and the adverse effects 
on pregnancy that would have either wise been set in motion prior to targeted interventions that 
would be accessed from the first antenatal visit.  
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7.1.2 Implications of the performance of malaria Rapid Diagnostic Tests for the 
control of pregnancy associated malaria due to placental sequestration 
 The very low sensitivity of peripheral blood RDTs to detect active placental infection as 
shown in Chapter 6 implies that such localized infections largely remain undetected through 
pregnancy. As such the adverse localized effects of placenta sequestration proceed unfettered in 
screening approach with an RDT. The role of uncleared parasitaemia and the advantage of an 
efficacious antimalarial has been demonstrated in a recent publication from work conducted in 
western Kenya where dihydroartemisinin-piperaquine was used for IPTp, showing significantly 
lowered risks of both peripheral and placental infections than sulphadoxine-pyrimethamine (401), 
clearly showing that efficacious drugs administered appropriately clear the adverse effects of low 
density infections by treating peripheral infection so  preventing seed to the placenta or clearing 
already sequestered infections in the placenta.  
 Sulphadoxine-Pyrimethamine: Is there more to what meets the eye? 
 Sulphadoxine-Pyrimethamine consists of a sulfonamide antibiotic (Sulphadoxine) and 
antiprotozoal (Pyrimethamine) components. It is closely related to the broad spectrum antibiotic 
drug, Trimethoprim-Sulfamethoxazole (Cotrimoxazole) which has similar constitutional moieties 
and is used for the prevention of bacterial and protozoal opportunistic infections in HIV infection. 
Given the relatedness of the two compounds and the dual efficacy of Cotrimoxazole on bacterial 
infections and malaria, it may be postulated that SP exhibits similar antibiotic effects in addition to 
its antimalarial properties. 
 The antibacterial effects of SP in pregnancy have not been subject to full investigation and 
literature is sparse. The intrinsic antibacterial property of SP against bacterial pathogens common in 
pregnancy has been previously explore in-vitro and was shown to be highly active against several 
pathogens (344). There is a paucity of studies that have sought to evaluate the in-vivo efficacy of SP 
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on ascending genitourinary tract infections in pregnancy or the non-malarial placental biome of the 
placenta at delivery in order to characterize the importance of non-malarial infections of the placenta 
on fetal outcomes and neonatal survival. Only one recently published study from Gabon sought to 
establish the in-vivo efficacy of SP to reduce the prevalence of group B Streptococcus (GBS) in 
pregnant women (402) the results of which showed that SP did not reduce GBS colonization in-vivo.  
In this efficacy study, it may be indeed possible that in addition to the longer treatment malaria 
prophylaxis with IPTp-SP due to more frequent dosing (403), there was an additional beneficial 
antibacterial treatment effect at the level of the placenta through efficacy on bacterial biomes other 
than GBS. 
 Intermittent Screening and Treatment or Intermittent Testing and 
Treatment? 
 The concept of screening as a strategy for the reduction of disease associated morbidity and 
mortality is based on the potential benefits of early detection of asymptomatic preclinical disease or 
disease precursors and administration of an effective intervention. Accordingly, the ten point Wilson-
Jungner criteria for appraising the validity of a screening programme is essential in considering the 
viability of a screening strategy (323) though recent alternatives have been proposed after a review 
of the  Wilson-Jungner criteria in the current scientific dispensation (324-327). 
 Within the context of malaria prevention in pregnancy, the lack of a superior effect in 
preventing adverse pregnancy outcomes as demonstrated in this trial may be partially explained by 
a breach in the consideration of Wilson-Jungner criteria in this application.  
 The concept of screening for malaria infection in pregnancy meets 6 of the proposed criteria: 
Criteria 1: Malaria in pregnancy is a recognised public health problem in tropical and mostly 
underdeveloped countries with devastating consequences for the pregnant woman, unborn child, 
and early childhood survival and development (2, 96). 
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Criteria 2: Current WHO recommendations for the treatment of symptomatic malaria infection are 
with ACTs. The concept of treatment of asymptomatic infection with the IPTp-SP strategy proves that 
treating presumed asymptomatic infections are beneficial to pregnancy outcomes. The use of an ACT 
to clear asymptomatic infection in the current environment of declining SP efficacy is therefore a 
rational alternative. 
Criteria 3: In accordance with WHO recommendations, focused antenatal care at all cadres of health 
facilities provides opportune access points for interventions in pregnancy and favorable outcomes 
(404). However, as observed with IPTp-SP, several factors interplay that hinder access to FANC 
services by pregnant women (405, 406).  
Criteria 8: As a strategy, it is agreed that there is a dire need for alternative preventive interventions 
for malaria infection in pregnant women and as such any infected pregnant women is a candidate for 
treatment. 
Criteria 9: Costs of screening for malaria in pregnancy include the cost of RDTs, equipment, personal 
training, test administration time and space. In light of the reduced efficacy of IPTp-SP, a screening 
strategy that would be superior in malaria prevention would be cost effective.  
Criteria 10: Intermittent screening and treatment is based on routine screening at predefined 
intervals over the course of the pregnancy until delivery in order to detect pre-effective infections 
for treatment. 
 The following failures in the remaining 4 criteria present the limitations of IST and propose 
further considerations in order to make ISTp more appropriate for the intended purposes: 
Criteria 4:  The pathophysiology of malaria in pregnancy and how pathological processes are related 
to adverse birth outcomes are poorly understood (407, 408). As such, it is not possible to define a 
reliable detectable preclinical phase (DPCP) of disease. 
Criteria 5: In light of 4 above, an appropriate and cost-effective test cannot be recommended. By 
default, it may be postulated that the most sensitive diagnostic test for malaria infection would be 
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the best bet. However, as demonstrated in Chapter 6, PCR suffers from a considerable limitation in 
sensitivity to diagnose infection when parasites sequester in the placenta, which may effectually be 
the DPCP. 
Criteria 6: RDTs have been widely accepted and have changed the landscape for appropriate case 
management of malaria. RDTs were designed for the diagnosis of symptomatic malaria to guide 
appropriate treatment administration. From Chapter 5, it is evident that RDTs have limitations when 
used as a screening tests for diagnosing asymptomatic parasitaemia. More sensitive assays that may 
be applied in field settings such as LAMP may be more promising for detecting low level 
asymptomatic infections (362, 409-411).  
Criteria 7: The natural history of malaria in pregnancy is not fully understood. Despite many studies 
evaluating effects in the second and third trimester, pathophysiological processes of malaria 
infection in the first trimester have not been sufficiently explored. 
 Findings from this work suggest that IST with current RDTs detect relevant levels of 
parasitaemia associated with adverse birth outcomes. As such the current strategy may be termed 
“intermittent diagnosis and treatment” since no preclinical stage of disease can be detected and 
treatment does not necessarily seem to thwart the progression to adverse pregnancy outcomes. 
 Despite these limitations, an effective screening strategy holds great potential for value 
addition to antenatal care as it could be easily be integrated into current existing screening strategies 
in pregnancy such as HIV and syphilis, with the potential to integrate other point of care diagnostics 
for reproductive tract infections such as chlamydia, in a compact microarray or panel. This benefit 
would be further potentiated if a screening strategy were to be implemented in the first trimester of 
pregnancy. 
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 Cost effectiveness, acceptability and scalability 
 Ancillary studies to the main efficacy trial, which have not been presented in this thesis, were 
conducted to determine the cost effectiveness and acceptability of ISTp as a strategy. Evaluation of 
the efficacy results from the main trial showed that ISTp was not a cost effective strategy. Significant 
cost drivers were the RDTs and cost of dihydroartemisinin-piperaquine and only a dramatic loss in 
the efficacy of SP would turn the cost benefit ratio in favor of ISTp-DP.  
 Findings of the acceptability study identified that although obstacles to the successful 
implementation of ISTp-DP were acknowledged by health workers and pregnant women, overall 
both groups considered ISTp as an acceptable alternative to IPTp-SP. The main obstacles to 
acceptability for health workers were concerns over resources, stock and adherence to DHA-PQ. 
Pregnant women were generally receptive to ISTp, providing they are able to attend ANC and their 
expectations were met. IST demonstrated an ability to be easily integrated into the pre-existing 
antenatal structure and had potential to be scaled up as a policy. 
 Recommendations 
 Local transmission dynamics and drug resistance patterns are major determinants of 
appropriate strategies for the control of malaria transmission and infection during pregnancy (412). 
As such, one size will not fit all. Further to ecological factors determining the force of infection in any 
given setting, the implementation of programmes geared toward malaria eradication (413) will 
influence at what point strategy changes for malaria control in pregnancy would be appropriate 
(414) so as to be in tandem with the changing transmission landscape.  
7.5.1 Intermittent screening and treatment: “To be or not to be….?” 
 As shown by findings in chapter 5 and 6, the utility of ISTp is limited by the reduced ability of 
RDTs to detect pre-patent levels of asymptomatic parasitaemia in the peripheral blood, especially 
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during the course of subsequent antenatal visits (Chapter 5), and sequestered parasitaemia in the 
placenta that would warrant treatment (Chapter 6). This is further compounded by the fact that the 
intervention was implemented after the most vulnerable period to infection i.e. the first trimester 
where it may have had a more significant impact. 
 Screening however may not be a totally irrelevant tool for malaria control in pregnancy. 
Within the current treatment recommendations by the WHO advising for the cautious use of ACTs 
solely for treatment purposes, screening would detect relevant levels of parasitaemia that would 
warrant treatment. Based on results from chapter 5, asymptomatic patent infection in pregnancy 
could warrant consideration as an indication for treatment in line with WHO recommendations for 
the use of ACTs.  
 Of note was the much higher overall prevalence of patent and sub-patent infections and the 
better performance of mRDTs during the initial booking visit, especially in primigravidae. Given the 
dependency of gestational timing on reliability of RDTs to detect parasitaemia, IST with an ACT may 
be employed as part of hybrid strategies relevant to local transmission settings within the context of 
very high SP resistance, and in the absence of better alternatives such as IPTp with alternative 
antimalarials such as DP that may require a further 2 to 3 years of research. In low transmission 
settings, screening may be employed as a ‘single screen and treat’ (SST) strategy as the risk of 
subsequent patent infection was shown to be much lower during progressive antenatal visits, as is 
the national policy in Indonesia (189). In high transmission settings, intermittent screening would 
be employed as part of a mixed screening and presumptive treatment model as the risk of infection 
remains high in such settings, with women requiring constant chemo-protection.  In this approach, 
women would be screened at each antenatal visit and treated with an ACT if RDT positive or given 
SP if RDT negative. Such a hybrid strategy was recently introduced in Tanzania, and has been used in 
parts of Kenya, albeit haphazardly, for some years now. 
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7.5.2 Alternative strategies 
 Malaria interventions for the control of malaria in pregnancy are strongly dependent on the 
broader transmission dynamics in the population and drug resistance patterns. As such, due to the 
variability in transmission and implementation of malaria eradication programmes between 
endemic countries, no one size will fit all and individual policies must be tailored accordingly. 
 The results from this study strongly suggest that in areas of moderate to high transmission, a 
presumptive treatment approach with an efficacious antimalarial would be best suitable. However, 
as previously highlighted, to date there are a limited number of efficacious drug options well placed 
to replace SP for IPTp. However, the efficacy, safety and tolerability of dihydroartemisinin-
piperaquine has made it a potential candidate for use as IPTp.  
 A study evaluating IPTp-DP in Kenya has been recently completed, the results of which are 
pending publication (238). A previous study evaluating monthly IPT with DP in Ugandan children 
displayed remarkably results in reducing the incidence of clinical malaria, asymptomatic 
parasitaemia and anaemia (415) demonstrating the great potential this strategy may have in 
pregnancy and improving maternal and fetal outcomes.  
 A significant draw back with any intervention involving DP is the three day course required 
for the administration of treatment. In light of treatment most likely to be taken at home over three 
days, there is the concern that adherence may be poor and treatment courses not completed which 
could result in sub-optimal plasma concentrations. Though this in itself may not warrant a significant 
fear of the development of drug resistance as pregnant women form a small proportion of the 
population, the storage and sharing of drugs in communities is not uncommon (416, 417) which 
could likely perpetuate sub-optimal drug levels in the larger population and drive the development 
of artemisinin drug resistance, similar to antibiotic resistance (418). 
 In areas where the prevalence of SP mutations is low, irrespective of transmission intensity, 
IPTp-SP may still be considered a viable and cost effective strategy. The results from this ISTp-DP 
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efficacy study demonstrate that IPTp-SP continues to be an effective in the absence of more cost 
effective alternatives in areas of near saturation of the quintuple SP mutation, low prevalence of the 
sextuple mutants and moderate to high malaria transmission. Daily cotrimoxazole prophylaxis may 
be considered in settings with a high prevalence of sextuple mutants as cotrimoxazole prophylaxis 
remains efficacious against malaria infection and is not hindered by SP resistance mutations despite 
concerns of cross-resistance.   
7.5.3 Molecular monitoring of high level SP resistance markers 
 The additional dhps A581G mutation to the quintuple mutation confers very high grade 
resistance and near total SP treatment failure. It would thus be imperative that monitoring of this 
mutation in addition to the K540E marker for quintuple mutation be included as part of routine 
malaria surveys to aptly provide indication for possible policy changes to ensure adequate protection 
of pregnant women and their off-spring from the consequences of malaria infection during 
pregnancy.      
 Current and Future research 
7.6.1 The role of the bacterial placental biome on pregnancy outcomes and potential 
effect of adjunct antibacterial therapy in malaria interventions in pregnancy 
  Intercellular bacterial infections have been recognised to contribute substantially to adverse 
pregnancy outcomes and neonatal infections (419).  Despite evidence of a synergistic relationship 
between malaria and some bacterial infections in other settings, this has not been fully explored in 
pregnancy, especially in settings where malaria and bacterial infections overlap.  Studies that have 
co-opted antibacterial regimens as part of combination treatment with an antimalarial have seldom 
investigated the effect on the bacterial biome of the placenta and whether this contributed to the 
observed pregnancy outcomes.  
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 In a placebo-controlled trial of oral azithromycin for the prevention of preterm delivery in 
southern Malawi, routine prophylaxis did not have a significantly different effect on preterm birth, 
birthweight maternal anaemia, malaria infection or perinatal mortality (420). No placental histology 
was reported from this trial. Contrary to these findings, two randomized control clinical trials have 
found the use of azithromycin with SP to have beneficial effects on pregnancy outcomes. An earlier 
trial from Malawi found reduced risk of preterm birth and low birthweight with monthly SP and two 
prophylactic doses of azithromycin (421). A more recent trial from Papua New Guinea found that the 
addition of Azithromycin to IPTp-SP reduced preterm delivery and low birthweight with a reduction 
in the carriage of gonorrhoea as well (422). The use of azithromycin was associated with reduced 
carriage of other bacterial pathogens (423).  
In an expert review on combination therapy for the prevention of malaria and genitourinary 
tract infections in pregnancy, the addition of an antibacterial to an antimalarial, such as 
azithromycin with chloroquine would be essential to address the adverse effects of both malaria 
and bacterial infections on pregnancy outcomes (230), particular in the early pregnancy when 
most regimens are contraindicated. With these results, the consideration of adding adjunct 
antibiotic therapy to a promising routine intervention for the prevention of malaria in pregnancy 
would be warranted. 
7.6.2 Intermittent presumptive treatment in pregnancy with an Artemisinin 
combination therapy in the first trimester 
 The limited alternatives to replace SP for IPTp has prompted great interest in the use of ACTs 
for malaria prevention in pregnancy due to their high treatment efficacy, post treatment prophylaxis, 
safety and tolerability (172, 424). The greatest burden of malaria infection in pregnancy has been 
shown to occur in the first trimester commonly between 9 and 16 weeks of gestation when most 
interventions have been contraindicated save for chloroquine and azithromycin. A growing body of 
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evidence appears to suggest that ACTs do not confer any higher risk of adverse events in pregnancy 
when administered in the first trimester (171, 425, 426). 
 More evidence is required on the safety of first trimester administration of ACTs as well as 
the effect of repeated dosing in pregnancy as current evidence remains small. Results from a repeat 
fix dose treatment study in children from Uganda with Artesunate-Amodiaquine (ASAQ) and 
Artemether-Lumefantrine (AL) have shown no remarkable adverse effects and are considered safe 
(427). The major concern with repeated dosing of Dihydroartemisinin-piperaquine  is with the risk 
of prolonged QT interval (180, 428) that may lead to torsade’s de pointes (TdP) after successive 
accumulation of Piperaquine in a dose dependant manner (429) via blockade of the IKr (rapidly 
depolarising potassium ion) channels. However, in several single dose studies that have noted 
prolonged QT intervals following DP administration, such prolongations have been transient and 
resolved by day 7 post treatment with no deaths ascribed to TdP (430, 431).  
 The potential ramifications of proven safety of first trimester administration as well as 
multiple dose administration would enable the use of an efficacious intervention against malaria in 
pregnancy at the period when pregnancies are most vulnerable to malaria infection. In addition, the 
provision of chemo-intervention, which has been viewed as a motivational factor for ANC attendance 
as part of keeping the pregnancy safe from malaria (406, 432, 433) could encourage early attendance. 
7.6.3 Chemoprevention for HIV infected pregnant women and interactions between 
ACTs and ARVs in pregnancy 
 Pregnant women with HIV infection are at an increased risk of malaria infection and more 
likely to suffer from untoward pregnancy outcomes due to the combined and synergistic 
consequences of HIV and malaria infection (51, 434, 435). Current recommendations for the control 
of malaria in pregnancies complicated by HIV infection exclude IPTp-SP as women receive daily 
cotrimoxazole prophylaxis for the prevention of opportunistic infections which provides additional 
protection from malaria infection (436, 437).  Furthermore, as cotrimoxazole and SP are both 
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sulphonamide drugs, co-administration presents an increased risk for sulphonamide derived side 
effects especially severe cutaneous reactions (438-440).  
 Due to their related mode of action as antimalarials by similarly inhibiting the dhfr (via 
Trimethoprim and Pyrimethamine components)and dhps (via Sulfamethoxazole and Sulphadoxine) 
enzymes essential to parasite metabolism (441), rising SP resistance has raised concerns regarding 
the continued efficacy of daily cotrimoxazole for prevention of malaria related morbidity in HIV 
infected pregnant women and as a source of sustained drug pressure fueling continued selection 
pressure for SP resistant parasites. Despite results from in-vitro studies suggesting cross resistance 
(442), findings from previous field studies have demonstrated this not to be the case (443, 444) and 
cotrimoxazole chemoprophylaxis remains efficacious (445, 446). A recent published multicenter 
study however, demonstrated that with the addition of a IPT administered Mefloquine to daily 
cotrimoxazole prophylaxis, improved malaria prevention but was associated with higher   viral loads 
and mother to child transmission of HIV (237).  
 Despite revised WHO recommendations to initiate ARTs in pregnant and breast-feeding 
women irrespective of CD4 count or WHO staging (447), cotrimoxazole prophylaxis has remained a 
key policy recommendation for HIV management amongst pregnant women especially where 
malaria transmission remains moderate to high (malaria prevalence greater than 10% among 
children aged 2-9 years old).  Given evidence of the additional benefit of malaria prevention by the 
inclusion of a non-SP IPTp regimen, evaluating the use of an ACT for IPTp in HIV infected pregnant 
women would be warranted. Little is known about the interactions of ACTs and ARVs and a study to 
evaluate drug-drug interactions and the impact on infection and pregnancy outcomes is important.  
 Overall conclusion and recommendations 
 The findings of the work undertaken in this thesis strongly indicate that intermittent 
screening and treatment for the control of malaria in pregnancy in an areas of moderate to high 
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malaria transmission and near saturation of high grade SP resistance is not a suitable alternative to 
intermittent preventive treatment with SP for the control of malaria in pregnancy, and may even 
predispose to adverse maternal and fetal outcomes. These results are consistent with similar trials 
conducted in Western Kenya and West Africa. The failure of ISTp may be attributed to the 
infrequency of screening (approximately monthly) to pick up significant infections in a high 
transmission setting and from the failure of the current generation of malaria RDTs to detect chronic 
low-level parasitemia that are only detectable by PCR, allowing parasites to persist from weeks to 
months in the placenta. Furthermore, the results suggest that SP remains at least partially effective 
at improving birthweights and preventing pregnancy loss. The surprisingly resilient beneficial effect 
of SP may reflect a partial antimalarial effect that may be insufficient to clear parasites (treatment 
effect), but enough to provide some prophylactic benefit in these semi-immune women by 
suppressing parasite densities in the placenta (rather than clearing them) to sufficiently low levels 
to reduce in part, the harmful effects of malaria infection in pregnancy. Furthermore, it is possible 
that the residual beneficial effect of SP, could also reflect its broad antimicrobial activity conferring 
some protection against undetected bacterial infections, particularly gram-positive bacteria (448), 
or due to an effect on either the gut or vaginal microbiota.  
 In light of the consistent failure of ISTp to demonstrate any beneficial effect on pregnancy 
outcomes, it is strongly recommended that ISTp should not be considered as a viable strategy to 
replace IPTp-SP for the control of malaria in pregnancy in areas of moderate to high transmission 
and low to high SP resistance. However, within settings of low transmission or near elimination, 
screening may prove to be a viable and cost effective alternative. The current resilience of SP offers 
a window of opportunity for the continued use of IPTp-SP until superior interventions are developed 
and verified, though within a limited time period owing to the rapid emergence of more aggressive 
resistant strains characterised by the A581G mutation.  
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 Within this window of opportunity, it is essential to monitor how fast it would be closing by 
incorporating molecular monitoring of the A581G mutation. Furthermore,  as it is apparent from this 
trial that within a setting of moderate to high malaria transmission, continuous protection from 
infection be provided to pregnant women, it is imperative that not only alternative drug regimens for 
IPTp be identified and verified for use in both HIV-seronegative and –seropositive women, but also 
that there is a need for enhanced efforts to accelerate malaria transmission reduction through 
increased coverage of current vector control strategies, and innovative reservoir and vector 
elimination interventions to reduce the transmission burden at the larger population level.       
215 
 
8 REFERENCES 
 
1. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of 
pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 2010;7(1):e1000221. 
2. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and 
burden of malaria in pregnancy. The Lancet Infectious Dis. 2007;7(2):93-104. 
3. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent 
preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-
pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 
2013;309(6):594-604. 
4. McClure EM, Goldenberg RL, Dent AE, Meshnick SR. A systematic review of the impact of 
malaria prevention in pregnancy on low birth weight and maternal anemia. Int J Gynaecol Obstet. 
2013;121(2):103-9. 
5. Rijken MJ, De Livera AM, Lee SJ, Boel ME, Rungwilailaekhiri S, Wiladphaingern J, et al. 
Quantifying low birth weight, preterm birth and small-for-gestational-age effects of malaria in 
pregnancy: a population cohort study. PLoS One. 2014;9(7):e100247. 
6. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth weight in sub-Saharan 
Africa. Clin Microbiol Rev. 2004;17(4):760-9. 
7. Guyatt HL, Snow RW. Malaria in pregnancy as an indirect cause of infant mortality in sub-
Saharan Africa. Trans R Soc Trop Med Hyg. 2001;95(6):569-76. 
8. McDonald CR, Elphinstone RE, Kain KC. The impact of placental malaria on 
neurodevelopment of exposed infants: a role for the complement system? Trends Parasitol. 
2013;29(5):213-9. 
216 
 
9. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an 
old problem with present consequences. Malar J. 2014;13:271. 
10. Walther B, Miles DJ, Crozier S, Waight P, Palmero MS, Ojuola O, et al. Placental malaria is 
associated with reduced early life weight development of affected children independent of low birth 
weight. Malar J. 2010;9:16. 
11. WHO. WHO policy brief for the implementation of intermittent preventive treatment of 
malaria in pregnancy using sulphadoxine-pyrimethamine (IPTP-SP). Geneva, Switzerland: World 
Health Organization, 2014. 
12. WHO. Guidelines for the treatment of malaria: second edition. Geneva: World Health 
Organization; 2010. 
13. WHO. A strategic framework for malaria prevention and control during pregnancy in the 
African Region. Brazzaville: World Health Organization Regional Office for Africa, 2004. 
14. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the 
efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic 
review. JAMA. 2007;297(23):2603-16. 
15. Kayentao K, Garner P, Maria van Eijk A, et al. Intermittent preventive therapy for malaria 
during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth 
weight in africa: Systematic review and meta-analysis. JAMA. 2013;309(6):594-604. 
16. Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent Preventive Treatment in 
Pregnant Women Is Associated with Increased Risk of Severe Malaria in Their Offspring. PLoS One. 
2013;8(2):e56183. 
17. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent Treatment to 
Prevent Pregnancy Malaria Does Not Confer Benefit in an Area of Widespread Drug Resistance. Clin 
Infect Dis. 2011;53(3):224-30. 
217 
 
18. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. 
Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant 
women who receive preventive treatment. Proc Natl Acad Sci. 2009;106(22):9027-32. 
19. ter Kuile FO, Larsen DA, Roper C, Koshy G, Taylor SD, Meghna , Eisele T, et al. Impact of 
sulphadoxine-pyrimethamine resistance on the effectiveness of Intermittent Preventive Therapy for 
malaria in pregnancy (IPTp) in Africa: A systematic review and meta-analysis. Unpublished. 
20. United Nations General Assembly. United Nations Millennium Declaration. Resolution 
adopted. United Nations, 2000. 
21. Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680-
5. 
22. Gallup J, Sachs J. The economic burden of malaria. Am J Trop Med Hyg. 2001;64(1 suppl):85-
96. 
23. Malaney P, Spielman A, Sachs J. THE MALARIA GAP. Am J Trop Med Hyg. 2004;71(2 
suppl):141-6. 
24. World Health Organization. World Malaria Report 2014. Geneva: World Health Organization, 
2014. 
25. Guyatt HL, Snow RW. Impact of Malaria during Pregnancy on Low Birth Weight in Sub-
Saharan Africa. Clin Microbiol Rev. 2004;17(4):760-9. 
26. Van Geertruyden J-P, Thomas F, Erhart A, D’Alessandro U. THE CONTRIBUTION OF MALARIA 
IN PREGNANCY TO PERINATAL MORTALITY. Am J Trop Med Hyg. 2004;71(2 suppl):35-40. 
27. Roll Back Malaria. The contribution of malaria control to maternal and newborn health 2014 
[cited 2015 22 March]. Available from: 
http://www.rollbackmalaria.org/ProgressImpactSeries/report17.html. 
28. Ansell J, Hamilton KA, Pinder M, Walraven GE, Lindsay SW. Short-range attractiveness of 
pregnant women to Anopheles gambiae mosquitoes. Trans R Soc Trop Med Hyg. 2002;96(2):113-6. 
218 
 
29. Le Hesran JY, Cot M, Personne P, Fievet N, Dubois B, Beyeme M, et al. Maternal placental 
infection with Plasmodium falciparum and malaria morbidity during the first 2 years of life. Am J 
Epidemiol. 1997;146(10):826-31. 
30. Malhotra I, Dent A, Mungai P, Wamachi A, Ouma JH, Narum DL, et al. Can prenatal malaria 
exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS 
Med. 2009;6(7):e1000116. 
31. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, et al. Maternal malaria and 
gravidity interact to modify infant susceptibility to malaria. PLoS Med. 2005;2(12):e407. 
32. Schwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandji ST, Newman RD, et al. Placental 
malaria increases malaria risk in the first 30 months of life. Clin Infect Dis. 2008;47(8):1017-25. 
33. Cornet M, Le Hesran JY, Fievet N, Cot M, Personne P, Gounoue R, et al. Prevalence of and risk 
factors for anemia in young children in southern Cameroon. Am J Trop Med Hyg. 1998;58(5):606-11. 
34. van Eijk AM, Ayisi JG, Ter Kuile FO, Misore AO, Otieno JA, Kolczak MS, et al. Malaria and human 
immunodeficiency virus infection as risk factors for anemia in infants in Kisumu, western Kenya. Am 
J Trop Med Hyg. 2002;67(1):44-53. 
35. Reed SC, Wirima JJ, Steketee RW. Risk factors for anemia in young children in rural Malawi. 
Am J Trop Med Hyg. 1994;51(2):170-4. 
36. Owens Sea. Placental malaria and gravidity interact to modify infant susceptibility to malaria. 
Arch Dis Child. 2009;91:507-8. 
37. UNICEF. New York: United Nations Population Division, & United Nations Statistics Division; 
2013 [updated 27 December 2013; cited 2015 04 March]. Available from: 
http://www.unicef.org/infobycountry/malawi_statistics.html. 
38. Emina JBO, Madise N, Kuepie M, Zulu EM, Ye Y. Identifying HIV most-at-risk groups in Malawi 
for targeted interventions. A classification tree model. BMJ Open. 2013;3(5). 
219 
 
39. Kazembe LN, Kleinschmidt I, Holtz TH, Sharp BL. Spatial analysis and mapping of malaria risk 
in Malawi using point-referenced prevalence of infection data. Int J Health Geogr. 2006;5:41. 
40. Mzilahowa T, Hastings IM, Molyneux ME, McCall PJ. Entomological indices of malaria 
transmission in Chikhwawa district, Southern Malawi. Malar J. 2012;11:380-. 
41. Spiers AA MT, Atkinson D, McCall PJ. The malaria vectors of the Lower Shire Valley, Malawi. 
Malawi Med J. 2002(14):4-7. 
42. Mzilahowa T, Ball AJ, Bass C, Morgan JC, Nyoni B, Steen K, et al. Reduced susceptibility to DDT 
in field populations of Anopheles quadriannulatus and Anopheles arabiensis in Malawi: evidence for 
larval selection. Med Vet Entomol. 2008;22(3):258-63. 
43. Wondji CS, Coleman M, Kleinschmidt I, Mzilahowa T, Irving H, Ndula M, et al. Impact of 
pyrethroid resistance on operational malaria control in Malawi. Proc Natl Acad Sci U S A. 
2012;109(47):19063-70. 
44. Lindblade KA, Mwandama D, Mzilahowa T, Steinhardt L, Gimnig J, Shah M, et al. A cohort study 
of the effectiveness of insecticide-treated bed nets to prevent malaria in an area of moderate 
pyrethroid resistance, Malawi. Malar J. 2015;14(1):31. 
45. Rantala A-M, Taylor SM, Trottman PA, Luntamo M, Mbewe B, Maleta K, et al. Comparison of 
real-time PCR and microscopy for malaria parasite detection in Malawian pregnant women. Malar J. 
2010;9:269-. 
46. Taylor SM, Antonia AL, Chaluluka E, Mwapasa V, Feng G, Molyneux ME, et al. Antenatal Receipt 
of Sulfadoxine-Pyrimethamine Does Not Exacerbate Pregnancy-Associated Malaria Despite the 
Expansion of Drug-Resistant Plasmodium falciparum: Clinical Outcomes From the QuEERPAM Study. 
Clin Infect Dis. 2012;55(1):42-50. 
47. Hochman S, Kim K. The Impact of HIV and Malaria Coinfection: What Is Known and Suggested 
Venues for Further Study. Interdisciplinary perspectives on infectious diseases. 2009;2009:617954. 
220 
 
48. Brentlinger PE, Behrens CB, Micek MA. Challenges in the concurrent management of malaria 
and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis. 2006;6(2):100-11. 
49. van Eijk AM, Ayisi JG, ter Kuile FO, Misore AO, Otieno JA, Rosen DH, et al. HIV increases the 
risk of malaria in women of all gravidities in Kisumu, Kenya. AIDS (London, England). 
2003;17(4):595-603. 
50. Keen J, Serghides L, Ayi K, Patel SN, Ayisi J, van Eijk A, et al. HIV impairs opsonic phagocytic 
clearance of pregnancy-associated malaria parasites. PLoS Med. 2007;4(5):e181. 
51. ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, van Eijk AM, et al. The 
burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women 
in sub-saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):41-54. 
52. Ayisi JG, van Eijk AM, Newman RD, ter Kuile FO, Shi YP, Yang C, et al. Maternal malaria and 
perinatal HIV transmission, western Kenya. Emerg Infect Dis. 2004;10(4):643-52. 
53. Mwapasa V, Rogerson SJ, Molyneux ME, Abrams ET, Kamwendo DD, Lema VM, et al. The effect 
of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in 
pregnant Malawian women. AIDS (London, England). 2004;18(7):1051-9. 
54. Briand V, Badaut C, Cot M. Placental malaria, maternal HIV infection and infant morbidity. 
Ann Trop Paediatr. 2009;29(2):71-83. 
55. Inion I, Mwanyumba F, Gaillard P, Chohan V, Verhofstede C, Claeys P, et al. Placental malaria 
and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis. 
2003;188(11):1675-8. 
56. Ayouba A, Badaut C, Kfutwah A, Cannou C, Juillerat A, Gangnard S, et al. Specific stimulation 
of HIV-1 replication in human placental trophoblasts by an antigen of Plasmodium falciparum. AIDS 
(London, England). 2008;22(6):785-7. 
221 
 
57. Renzaho AM. Mortality rates, prevalence of malnutrition, and prevalence of lost pregnancies 
among the drought-ravaged population of Tete Province, Mozambique. Prehosp Disaster Med. 
2007;22(1):26-34. 
58. Gresham E, Byles JE, Bisquera A, Hure AJ. Effects of dietary interventions on neonatal and 
infant outcomes: a systematic review and meta-analysis. Am J Clin Nutr. 2014;100(5):1298-321. 
59. Abu-Saad K, Fraser D. Maternal Nutrition and Birth Outcomes. Epidemiol Rev. 2010;32(1):5-
25. 
60. Rayco-Solon P, Fulford AJ, Prentice AM. Differential effects of seasonality on preterm birth 
and intrauterine growth restriction in rural Africans. Am J Clin Nutr. 2005;81(1):134-9. 
61. Caulfield LE, Richard SA, Black RE. Undernutrition as an underlying cause of malaria 
morbidity and mortality in children less than five years old. Am J Trop Med Hyg. 2004;71(2 
Suppl):55-63. 
62. Landis SH, Lokomba V, Ananth CV, Atibu J, Ryder RW, Hartmann KE, et al. Impact of maternal 
malaria and under-nutrition on intrauterine growth restriction: a prospective ultrasound study in 
Democratic Republic of Congo. Epidemiol Infect. 2009;137(2):294-304. 
63. Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute F, Osman N, et al. An autopsy study of 
maternal mortality in Mozambique: the contribution of infectious diseases. PLoS Med. 2008;5(2):e44. 
64. Singh K, Moran A, Story W, Bailey P, Chavane L. Acknowledging HIV and malaria as major 
causes of maternal mortality in Mozambique. Int J Gynaecol Obstet. 2014;127(1):35-40. 
65. William T, Jelip J, Menon J, Anderios F, Mohammad R, Awang Mohammad TA, et al. Changing 
epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malar J. 
2014;13:390. 
66. Yusof R, Lau YL, Mahmud R, Fong MY, Jelip J, Ngian HU, et al. High proportion of knowlesi 
malaria in recent malaria cases in Malaysia. Malar J. 2014;13:168. 
222 
 
67. Barber BE, Bird E, Wilkes CS, William T, Grigg MJ, Paramaswaran U, et al. Plasmodium 
knowlesi Malaria During Pregnancy. J Infect Dis. 2015;211(7):1104-10. 
68. Duffy PE. Plasmodium in the placenta: parasites, parity, protection, prevention and possibly 
preeclampsia. Parasitology. 2007;134(Pt 13):1877-81. 
69. Arango E, Maestre A, Carmona-Fonseca J. [Effect of submicroscopic or polyclonal Plasmodium 
falciparum infection on mother and gestation product: systematic review]. Rev Bras Epidemiol. 
2010;13(3):373-86. 
70. Ataide R, Mayor A, Rogerson SJ. Malaria, primigravidae, and antibodies: knowledge gained 
and future perspectives. Trends Parasitol. 2014;30(2):85-94. 
71. Thellin O, Coumans B, Zorzi W, Igout A, Heinen E. Tolerance to the foeto-placental 'graft': ten 
ways to support a child for nine months. Current opinion in immunology. 2000;12(6):731-7. 
72. Piccinni MP. T cell tolerance towards the fetal allograft. J Reprod Immunol. 2010;85(1):71-5. 
73. Brabin BJ, Johnson PM. Placental malaria and pre-eclampsia through the looking glass 
backwards? J Reprod Immunol. 2005;65(1):1-15. 
74. Taylor-Robinson AW. Regulation of immunity to Plasmodium: implications from mouse 
models for blood stage malaria vaccine design. Exp Parasitol. 2010;126(3):406-14. 
75. Hamer DH, Mwanakasale V, MacLeod WB, Chalwe V, Mukwamataba D, Champo D, et al. Two-
Dose versus Monthly Intermittent Preventive Treatment of Malaria with Sulfadoxine-Pyrimethamine 
in HIV-Seropositive Pregnant Zambian Women. J Infect Dis. 2007;196(11):1585-94. 
76. Fievet N, Moussa M, Tami G, Maubert B, Cot M, Deloron P, et al. Plasmodium falciparum 
induces a Th1/Th2 disequilibrium, favoring the Th1-type pathway, in the human placenta. J Infect 
Dis. 2001;183(10):1530-4. 
77. Rogerson SJ, Brown HC, Pollina E, Abrams ET, Tadesse E, Lema VM, et al. Placental Tumor 
Necrosis Factor Alpha but Not Gamma Interferon Is Associated with Placental Malaria and Low Birth 
Weight in Malawian Women. Infect Immun. 2003;71(1):267-70. 
223 
 
78. Moore JM, Nahlen BL, Misore A, Lal AA, Udhayakumar V. Immunity to placental malaria. I. 
Elevated production of interferon-gamma by placental blood mononuclear cells is associated with 
protection in an area with high transmission of malaria. J Infect Dis. 1999;179(5):1218-25. 
79. Suguitan AL, Jr., Leke RG, Fouda G, Zhou A, Thuita L, Metenou S, et al. Changes in the levels of 
chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect 
Dis. 2003;188(7):1074-82. 
80. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol. 2006;28(1-
2):51-60. 
81. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune 
responses against malaria. Trends Parasitol. 2008;24(12):578-84. 
82. Serghides L, Patel SN, Ayi K, Kain KC. Placental Chondroitin Sulfate A–Binding Malarial 
Isolates Evade Innate Phagocytic Clearance. J Infect Dis. 2006;194(1):133-9. 
83. Rieger H, Yoshikawa HY, Quadt K, Nielsen MA, Sanchez CP, Salanti A, et al. Cytoadhesion of 
Plasmodium falciparum–infected erythrocytes to chondroitin-4-sulfate is cooperative and shear 
enhanced. Blood. 2014;125(2):383-91. 
84. Fowkes FJ, McGready R, Cross NJ, Hommel M, Simpson JA, Elliott SR, et al. New insights into 
acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis. 
2012;206(10):1612-21. 
85. Duffy PE, Fried M. Malaria in the pregnant woman. Curr Top Microbiol Immunol. 
2005;295:169-200. 
86. Mayor A, Rovira-Vallbona E, Machevo S, Bassat Q, Aguilar R, Quinto L, et al. Parity and 
placental infection affect antibody responses against Plasmodium falciparum during pregnancy. 
Infect Immun. 2011;79(4):1654-9. 
87. Umbers AJ, Stanisic DI, Ome M, Wangnapi R, Hanieh S, Unger HW, et al. Does Malaria Affect 
Placental Development? Evidence from In Vitro Models. PLoS One. 2013;8(1):e55269. 
224 
 
88. Silver KL, Zhong K, Leke RGF, Taylor DW, Kain KC. Dysregulation of Angiopoietins Is 
Associated with Placental Malaria and Low Birth Weight. PLoS One. 2010;5(3):e9481. 
89. Conroy AL, Silver KL, Zhong K, Rennie M, Ward P, Sarma JV, et al. Complement activation and 
the resulting placental vascular insufficiency drives fetal growth restriction associated with placental 
malaria. Cell Host Microbe. 2013;13(2):215-26. 
90. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P, et al. Evidence for the 
involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med. 2004;200(9):1197-203. 
91. Parekh FK, Davison BB, Gamboa D, Hernandez J, Branch OH. Placental histopathologic 
changes associated with subclinical malaria infection and its impact on the fetal environment. Am J 
Trop Med Hyg. 2010;83(5):973-80. 
92. Ismail MR, Ordi J, Menendez C, Ventura PJ, Aponte JJ, Kahigwa E, et al. Placental pathology in 
malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol. 2000;31(1):85-
93. 
93. Muehlenbachs A, Fried M, McGready R, Harrington WE, Mutabingwa TK, Nosten F, et al. A 
Novel Histological Grading Scheme for Placental Malaria Applied in Areas of High and Low Malaria 
Transmission. J Infect Dis. 2010;202(10):1608-16. 
94. Chotivanich K, Udomsangpetch R, Suwanarusk R, Pukrittayakamee S, Wilairatana P, Beeson 
JG, et al. Plasmodium vivax adherence to placental glycosaminoglycans. PLoS One. 2012;7(4):e34509. 
95. Souza RM, Ataide R, Dombrowski JG, Ippolito V, Aitken EH, Valle SN, et al. Placental 
histopathological changes associated with Plasmodium vivax infection during pregnancy. PLoS Negl 
Trop Dis. 2013;7(2):e2071. 
96. Uneke CJ. Impact of Placental Plasmodium falciparum Malaria on Pregnancy and Perinatal 
Outcome in Sub-Saharan Africa: II: Effects of Placental Malaria on Perinatal Outcome; Malaria and 
HIV. Yale J Biol Med. 2007;80(3):95-103. 
225 
 
97. Umbers AJ, Boeuf P, Clapham C, Stanisic DI, Baiwog F, Mueller I, et al. Placental Malaria-
Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation. J 
Infect Dis. 2011;203(4):561-9. 
98. Muehlenbachs A, Mutabingwa TK, Edmonds S, Fried M, Duffy PE. Hypertension and maternal-
fetal conflict during placental malaria. PLoS Med. 2006;3(11):e446. 
99. Mockenhaupt FP, Ulmen U, von Gaertner C, Bedu-Addo G, Bienzle U. Diagnosis of placental 
malaria. J Clin Microbiol. 2002;40(1):306-8. 
100. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. 
Nature. 1998;395(6705):851-2. 
101. Megnekou R, Staalsoe T, Taylor DW, Leke R, Hviid L. Effects of Pregnancy and Intensity of 
Plasmodium falciparum Transmission on Immunoglobulin G Subclass Responses to Variant Surface 
Antigens. Infect Immun. 2005;73(7):4112-8. 
102. Guyatt HL, Snow RW. The epidemiology and burden of Plasmodium falciparum-related 
anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg. 2001;64(1-2 Suppl):36-
44. 
103. Schrier RW, Fassett RG, Ohara M, Martin PY. Pathophysiology of renal fluid retention. Kidney 
Int Suppl. 1998;67:S127-32. 
104. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated 
by the prohormone convertase furin. Blood Cells Mol Dis. 2008;40(1):132-8. 
105. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-
86. 
106. Khalafallah AA, Dennis AE. Iron Deficiency Anaemia in Pregnancy and Postpartum: 
Pathophysiology and Effect of Oral versus Intravenous Iron Therapy. J Pregnancy. 
2012;2012:630519. 
226 
 
107. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong'echa JM. Severe Malarial 
Anemia: Innate Immunity and Pathogenesis. Int J Biol Sci. 2011;7(9):1427-42. 
108. Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L. Severe malarial anemia of 
low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. 
Blood. 2005;107(3):1192-9. 
109. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 
as a marker of self on red blood cells. Science (New York, NY). 2000;288(5473):2051-4. 
110. Safeukui I, Correas JM, Brousse V, Hirt D, Deplaine G, Mule S, et al. Retention of Plasmodium 
falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood. 
2008;112(6):2520-8. 
111. Luxemburger C, McGready R, Kham A, Morison L, Cho T, Chongsuphajaisiddhi T, et al. Effects 
of Malaria during Pregnancy on Infant Mortality in an Area of Low Malaria Transmission. Am J 
Epidemiol. 2001;154(5):459-65. 
112. Newman RD, Hailemariam A, Jimma D, Degifie A, Kebede D, Rietveld AE, et al. Burden of 
malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a 
nonepidemic year. J Infect Dis. 2003;187(11):1765-72. 
113. Adegnika AA, Verweij JJ, Agnandji ST, Chai SK, Breitling LP, Ramharter M, et al. Microscopic 
and sub-microscopic plasmodium falciparum infection, but not inflammation caused by infection is 
associated with low birth weight. Am J Trop Med Hyg. 2006;75(5):798-803. 
114. Le Hesran JY, Cot M, Personne P, Fievet N, Dubois B, Beyeme M, et al. Maternal placental 
infection with Plasmodium falciparum and malaria morbidity during the first 2 years of life. Am J 
Epidemiol. 1997;146(10):826-31. 
115. Cot M, Le Hesran JY, Staalsoe T, Fievet N, Hviid L, Deloron P. Maternally transmitted 
antibodies to pregnancy-associated variant antigens on the surface of erythrocytes infected with 
227 
 
Plasmodium falciparum: relation to child susceptibility to malaria. Am J Epidemiol. 2003;157(3):203-
9. 
116. Malhotra I, Dent A, Mungai P, Wamachi A, Ouma JH, Narum DL, et al. Can prenatal malaria 
exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS 
Med. 2009;6(7):e1000116. 
117. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, et al. Maternal malaria and 
gravidity interact to modify infant susceptibility to malaria. PLoS Med. 2005;2(12):e407. 
118. Kalanda BF, Verhoeff FH, Chimsuku L, Harper G, Brabin BJ. Adverse birth outcomes in a 
malarious area. Epidemiol Infect. 2006;134(3):659-66. 
119. Watson-Jones D, Weiss HA, Changalucha JM, Todd J, Gumodoka B, Bulmer J, et al. Adverse 
birth outcomes in United Republic of Tanzania--impact and prevention of maternal risk factors. 
Bulletin of the World Health Organization. 2007;85(1):9-18. 
120. Verhoeff FH, Le Cessie S, Kalanda BF, Kazembe PN, Broadhead RL, Brabin BJ. Post-neonatal 
infant mortality in Malawi: the importance of maternal health. Ann Trop Paediatr. 2004;24(2):161-
9. 
121. Schwarz NG, Adegnika AA, Breitling LP, Gabor J, Agnandji ST, Newman RD, et al. Placental 
malaria increases malaria risk in the first 30 months of life. Clin Infect Dis. 2008;47(8):1017-25. 
122. Adegnika AA, Kohler C, Agnandji ST, Chai SK, Labuda L, Breitling LP, et al. Pregnancy-
associated malaria affects toll-like receptor ligand-induced cytokine responses in cord blood. The J 
Infect Dis. 2008;198(6):928-36. 
123. Asante KP, Owusu-Agyei S, Cairns M, Dodoo D, Boamah EA, Gyasi R, et al. Placental malaria 
and the risk of malaria in infants in a high malaria transmission area in ghana: a prospective cohort 
study. J Infect Dis. 2013;208(9):1504-13. 
228 
 
124. Apinjoh TO, Anchang-Kimbi JK, Mugri RN, Njua-Yafi C, Tata RB, Chi HF, et al. Determinants of 
Infant Susceptibility to Malaria During the First Year of Life in South Western Cameroon. Open Forum 
Infect Dis. 2015;2(1). 
125. Bardaji A, Sigauque B, Sanz S, Maixenchs M, Ordi J, Aponte JJ, et al. Impact of malaria at the 
end of pregnancy on infant mortality and morbidity. J Infect Dis. 2011;203(5):691-9. 
126. Steketee RW. Pregnancy, Nutrition and Parasitic Diseases. J Nutr. 2003;133(5):1661S-7S. 
127. Verhoef H, West CE, Veenemans J, Beguin Y, Kok FJ. Stunting may determine the severity of 
malaria-associated anemia in African children. Pediatrics. 2002;110(4):e48. 
128. Deen JL, Walraven GE, von Seidlein L. Increased risk for malaria in chronically malnourished 
children under 5 years of age in rural Gambia. J Trop Pediatr. 2002;48(2):78-83. 
129. O'Neil-Dunne I, Achur RN, Agbor-Enoh ST, Valiyaveettil M, Naik RS, Ockenhouse CF, et al. 
Gravidity-Dependent Production of Antibodies That Inhibit Binding of Plasmodium falciparum-
Infected Erythrocytes to Placental Chondroitin Sulfate Proteoglycan during Pregnancy. Infect Immun. 
2001;69(12):7487-92. 
130. Walker PGT, Griffin JT, Cairns M, Rogerson SJ, van Eijk AM, ter Kuile F, et al. A model of parity-
dependent immunity to placental malaria. Nat Commun. 2013;4:1609. 
131. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an 
old problem with present consequences. Malar J. 2014;13(1):1-10. 
132. Recker M, Bouma MJ, Bamford P, Gupta S, Dobson AP. Assessing the burden of pregnancy-
associated malaria under changing transmission settings. Malar J. 2009;8:245. 
133. Nosten F, Rogerson SJ, Beeson JG, McGready R, Mutabingwa TK, Brabin B. Malaria in 
pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol. 2004;20(9):425-32. 
134. Greenwood BM. Immune responses to sporozoite antigens and their relationship to naturally 
acquired immunity to malaria. Bull World Health Organ. 1990;68 Suppl:184-90. 
229 
 
135. Steketee RW, Wirima JJ, Bloland PB, Chilima B, Mermin JH, Chitsulo L, et al. Impairment of a 
pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human 
immunodeficiency virus type-1. Am J Trop Med Hyg. 1996;55(1 Suppl):42-9. 
136. Newman RD, Hailemariam A, Jimma D, Degifie A, Kebede D, Rietveld AEC, et al. Burden of 
Malaria during Pregnancy in Areas of Stable and Unstable Transmission in Ethiopia during a 
Nonepidemic Year. J Infect Dis. 2003;187(11):1765-72. 
137. Ndyomugyenyi R, Magnussen P. Malaria morbidity, mortality and pregnancy outcome in 
areas with different levels of malaria transmission in Uganda: a hospital record-based study. Trans R 
Soc Trop Med Hyg. 2001;95(5):463-8. 
138. Boudova S, Cohee LM, Kalilani-Phiri L, Thesing PC, Kamiza S, Muehlenbachs A, et al. Pregnant 
women are a reservoir of malaria transmission in Blantyre, Malawi. Malar J. 2014;13:506. 
139. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, et al. Increased 
Gametocytemia after Treatment: An Early Parasitological Indicator of Emerging Sulfadoxine-
Pyrimethamine Resistance in Falciparum Malaria. J Infect Dis. 2008;197(11):1605-13. 
140. Fehintola FA, Balogun ST, Adeoye SB. Intermittent Preventive Treatment during Pregnancy 
with Sulphadoxine-Pyrimethamine May Promote <i>Plasmodium falciparum</i> 
Gametocytogenesis. Med Princ Pract. 2012;21(1):63-7. 
141. WHO. Guidelines for the treatment of malaria. Second edition. Geneva: World Health 
Organization, 2010. 
142. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, Sawa P, et al. Revisiting the circulation 
time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration 
of gametocyte carriage and the effect of gametocytocidal drugs. Malar J. 2010;9:136. 
143. Nevill CG, Some ES, Mung'ala VO, Mutemi W, New L, Marsh K, et al. Insecticide-treated bednets 
reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med 
Int Health. 1996;1(2):139-46. 
230 
 
144. Premji Z, Lubega P, Hamisi Y, McHopa E, Minjas J, Checkley W, et al. Changes in malaria 
associated morbidity in children using insecticide treated mosquito nets in the Bagamoyo district of 
coastal Tanzania. Trop Med Parasitol. 1995;46(3):147-53. 
145. Snow RW, Lindsay SW, Hayes RJ, Greenwood BM. Permethrin-treated bed nets (mosquito 
nets) prevent malaria in Gambian children. Trans R Soc Trop Med Hyg. 1988;82(6):838-42. 
146. Müller O, Traoré C, Kouyaté B, Yé Y, Frey C, Coulibaly B, et al. Effects of insecticide-treated 
bednets during early infancy in an African area of intense malaria transmission: a randomized 
controlled trial. Bulletin of the World Health Organization. 2006;84(2):120-6. 
147. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane 
Database Syst Rev. 2004(2):Cd000363. 
148. Eisele TP, Larsen D, Steketee RW. Protective efficacy of interventions for preventing malaria 
mortality in children in Plasmodium falciparum endemic areas. Int J Epidemiol. 2010;39 Suppl 1:i88-
101. 
149. Thomson MC, D'Alessandro U, Bennett S, Connor SJ, Langerock P, Jawara M, et al. Malaria 
prevalence is inversely related to vector density in The Gambia, West Africa. Trans R Soc Trop Med 
Hyg. 1994;88(6):638-43. 
150. Sexton JD, Ruebush TK, 2nd, Brandling-Bennett AD, Breman JG, Roberts JM, Odera JS, et al. 
Permethrin-impregnated curtains and bed-nets prevent malaria in western Kenya. Am J Trop Med 
Hyg. 1990;43(1):11-8. 
151. Curtis CF, Jana-Kara B, Maxwell CA. Insecticide treated nets: impact on vector populations 
and relevance of initial intensity of transmission and pyrethroid resistance. J Vector Dis. 2003;40(1-
2):1-8. 
152. Kulkarni MA, Malima R, Mosha FW, Msangi S, Mrema E, Kabula B, et al. Efficacy of pyrethroid-
treated nets against malaria vectors and nuisance-biting mosquitoes in Tanzania in areas with long-
term insecticide-treated net use. Trop Med Int Health. 2007;12(9):1061-73. 
231 
 
153. Smithuis FM, Kyaw MK, Phe UO, van der Broek I, Katterman N, Rogers C, et al. The effect of 
insecticide-treated bed nets on the incidence and prevalence of malaria in children in an area of 
unstable seasonal transmission in western Myanmar. Malar J. 2013;12(1):1-15. 
154. Coleman PG, Goodman CA, Mills A. Rebound mortality and the cost-effectiveness of malaria 
control: potential impact of increased mortality in late childhood following the introduction of 
insecticide treated nets. Trop Med Int Health. 1999;4(3):175-86. 
155. Eisele TP, Lindblade KA, Wannemuehler KA, Gimnig JE, Odhiambo F, Hawley WA, et al. Effect 
of sustained insecticide-treated bed net use on all-cause child mortality in an area of intense 
perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2005;73(1):149-56. 
156. Louis VR, Bals J, Tiendrebeogo J, Bountogo M, Ramroth H, De Allegri M, et al. Long-term effects 
of malaria prevention with insecticide-treated mosquito nets on morbidity and mortality in African 
children: randomised controlled trial. Trop Med Int Health. 2012;17(6):733-41. 
157. Shulman CE, Dorman EK, Talisuna AO, Lowe BS, Nevill C, Snow RW, et al. A community 
randomized controlled trial of insecticide-treated bednets for the prevention of malaria and anaemia 
among primigravid women on the Kenyan coast. Trop Med Int Health. 1998;3(3):197-204. 
158. ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kariuki SK, et al. 
Reduction of malaria during pregnancy by permethrin-treated bed nets in an area of intense 
perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2003;68(4 Suppl):50-60. 
159. Gamble C, Ekwaru JP, ter Kuile FO. Insecticide-treated nets for preventing malaria in 
pregnancy. Cochrane Database Syst Rev. 2006(2):Cd003755. 
160. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, et al. Malaria prevention in 
pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional 
datasets in Africa. Lancet Infect Dis. 2012;12(12):942-9. 
232 
 
161. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-Treated Nets for the Prevention of 
Malaria in Pregnancy: A Systematic Review of Randomised Controlled Trials. PLoS Med. 
2007;4(3):e107. 
162. Lindblade KA, Mwandama D, Mzilahowa T, Steinhardt L, Gimnig J, Shah M, et al. A cohort study 
of the effectiveness of insecticide-treated bed nets to prevent malaria in an area of moderate 
pyrethroid resistance, Malawi. Malar J. 2015;14(1):1-15. 
163. WHO. Insecticide-treated mosquito nets: a WHO position statement. Geneva: World Health 
Organization, 2007. 
164. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. Decreasing Burden of Malaria in 
Pregnancy in Malawian Women and Its Relationship to Use of Intermittent Preventive Therapy or 
Bed Nets. PLoS One. 2010;5(8):e12012. 
165. WHO. WHO recommendations for achieving universal coverage with long-lasting insecticidal 
nets in malaria control. World Health Organization, 2013 2013. Report No. 
166. Zarocostas J. Malaria treatment should begin with parasitological diagnosis where possible, 
says WHO. BMJ. 2010;340:c1402. 
167. Reyburn H. New WHO guidelines for the treatment of malaria. BMJ. 2010;340:c2637. 
168. Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, et al. Rapid diagnostic tests for 
diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries. 
Cochrane Database Syst Rev. 2014;12:Cd011431. 
169. Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert 
Opin Pharmacother. 2014;15(15):2219-54. 
170. Visser BJ, Wieten RW, Kroon D, Nagel IM, Belard S, van Vugt M, et al. Efficacy and safety of 
artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J. 
2014;13:463. 
233 
 
171. Dellicour S, Hall S, Chandramohan D, Greenwood B. The safety of artemisinins during 
pregnancy: a pressing question. Malar J. 2007;6:15. 
172. Nambozi M, Mulenga M, Halidou T, Tagbor H, Mwapasa V, Phiri LK, et al. Safe and efficacious 
artemisinin-based combination treatments for African pregnant women with malaria: a multicentre 
randomized control trial. Reprod Health. 2015;12:5. 
173. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-
piperaquine. Trans R Soc Trop Med Hyg. 2007;101(9):858-66. 
174. Rijken MJ, McGready R, Boel ME, Barends M, Proux S, Pimanpanarak M, et al. 
Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum 
malaria in pregnancy: a preliminary report. Am J Trop Med Hyg. 2008;78(4):543-5. 
175. Price Ric N DG, Nosten Francois. Antimalarial Therapies in Children from Papua New 
Guinea. N Engl J Mede. 2009;360(12):1254-5. 
176. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 
2003;89(11):1363-72. 
177. White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549-58. 
178. Moore BR, Benjamin JM, Salman S, Griffin S, Ginny E, Page-Sharp M, et al. Effect of co-
administered fat on the tolerability, safety and pharmacokinetic properties of dihydroartemisinin-
piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents 
Chemother. 2014. 
179. Karunajeewa H, Lim C, Hung T-Y, Ilett KF, Denis MB, Socheat D, et al. Safety evaluation of fixed 
combination piperaquine plus dihydroartemisinin (Artekin®) in Cambodian children and adults 
with malaria. Br J Clin Pharmacol. 2004;57(1):93-9. 
180. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, et al. Electrocardiographic Safety 
Evaluation of Dihydroartemisinin–Piperaquine in the Treatment of Uncomplicated falciparum 
Malaria. Am J Trop Med Hyg. 2007;77(3):447-50. 
234 
 
181. Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, et al. Efficacy of Two versus Three-
Day Regimens of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Military Personnel 
in Northern Cambodia: An Open-Label Randomized Trial. PLoS One. 2014;9(3):e93138. 
182. WHO. WHO policy brief for the implementation of intermittent preventive treatment of 
malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) Geneva, Switzerland: World 
Health Organization; 2014 [cited 2015 22 March]. Available from: 
http://www.who.int/malaria/publications/atoz/policy_brief_iptp_sp_policy_recommendation/en/. 
183. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, 
adolescents and adults: recommendations for a public health approach. Geneva: 2006. 
184. WHO. World Malaria Report 2013. Geneva, Switzerland: World Health Organization; 2013. 
185. van Eijk AM, Hill J, Larsen DA, Webster J, Steketee RW, Eisele TP, et al. Coverage of 
intermittent preventive treatment and insecticide-treated nets for the control of malaria during 
pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. 
Lancet Infect Dis. 2013;13(12):1029-42. 
186. National Malaria Control Programme (NMCP) II. Malawi Malaria Indicator Survey (MIS) 2012. 
Lilongwe, Malawi: 2012. 
187. National Malaria Control Programme (NMCP) II. Malawi Malaria Indicator Survey (MIS) 2014. 
In: International NaI, editor. Lilongwe, Malawi and Calverton, Maryland2014. 
188. Andrews KG, Lynch M, Eckert E, Gutman J. Missed opportunities to deliver intermittent 
preventive treatment for malaria to pregnant women 2003-2013: a systematic analysis of 58 
household surveys in sub-Saharan Africa. Malar J. 2015;14(1):521. 
189. ISRCTN registry. STOPMiP: Intermittent Screening and Treatment Or intermittent Preventive 
therapy for the control of Malaria in Pregnancy in Indonesia: BioMed Central; 2015 [cited 2015 27 
April]. Available from: http://www.isrctn.com/ISRCTN34010937. 
235 
 
190. Plotkin M, Said K, Msellem MI, Chase RP, Hendler N, Khamis AR, et al. Placental Malaria Is 
Rare Among Zanzibari Pregnant Women Who Did Not Receive Intermittent Preventive Treatment in 
Pregnancy. Am J Trop Med Hyg. 2014;91(2):367-73. 
191. Maiga OM, Kayentao K, Traoré BT, Djimde A, Traoré B, Diallo M, et al. Superiority of 3 Over 2 
Doses of Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine for the Prevention of 
Malaria During Pregnancy in Mali: A Randomized Controlled Trial. Clin Infect Dis. 2011;53(3):215-
23. 
192. Mace KE, Chalwe V, Katalenich BL, Nambozi M, Mubikayi L, Mulele CK, et al. Evaluation of 
sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy: a 
retrospective birth outcomes study in Mansa, Zambia. Malar J. 2015;14:69. 
193. Mosha D, Chilongola J, Ndeserua R, Mwingira F, Genton B. Effectiveness of intermittent 
preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, 
maternal anaemia and birthweight in areas with high and low malaria transmission intensity in 
Tanzania. Trop Med Int Health. 2014;19(9):1048-56. 
194. Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, et al. Randomized Trial 
of 2-Dose versus Monthly Sulfadoxine-Pyrimethamine Intermittent Preventive Treatment for 
Malaria in HIV-Positive and HIV-Negative Pregnant Women in Malawi. J Infect Dis. 2006;194(3):286-
93. 
195. Cot M, Le Hesran JY, Miailhes P, Esveld M, Etya'ale D, Breart G. Increase of birth weight 
following chloroquine chemoprophylaxis during the first pregnancy: results of a randomized trial in 
Cameroon. Am J Trop Med Hyg. 1995;53(6):581-5. 
196. Wellems TE, Plowe CV. Chloroquine-Resistant Malaria. J Infect Dis. 2001;184(6):770-6. 
197. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of 
antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing 
236 
 
peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J 
Trop Med Hyg. 1994;51(5):515-22. 
198. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, et al. Intermittent 
sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a 
randomised placebo-controlled trial. Lancet. 1999;353(9153):632-6. 
199. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. 
Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant 
women who receive preventive treatment. Proc Natl Acad Sci U S A. 2009;106(22):9027-32. 
200. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to 
prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin 
Infect Dis. 2011;53(3):224-30. 
201. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J 
Trop Med Hyg. 2007;77(6 Suppl):181-92. 
202. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine-sulfadoxine 
resistance in Plasmodium falciparum: what next? Trends Parasitol. 2001;17(12):582-8. 
203. Fohl LM, Roos DS. Fitness effects of DHFR-TS mutations associated with pyrimethamine 
resistance in apicomplexan parasites. Mol Microbiol. 2003;50(4):1319-27. 
204. Mockenhaupt FP, Teun Bousema J, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, et al. 
Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine 
treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health. 2005;10(9):901-
8. 
205. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. 
Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment 
of Plasmodium falciparum malaria. J Infect Dis. 2002;185(3):380-8. 
237 
 
206. Tan KR, Katalenich BL, Mace KE, Nambozi M, Taylor SM, Meshnick SR, et al. Efficacy of 
sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy, Mansa, 
Zambia. Malar J. 2014;13:227. 
207. Taylor SM, Antonia AL, Chaluluka E, Mwapasa V, Feng G, Molyneux ME, et al. Antenatal Receipt 
of Sulfadoxine-Pyrimethamine Does Not Exacerbate Pregnancy-Associated Malaria Despite the 
Expansion of Drug-Resistant Plasmodium falciparum: Clinical Outcomes From the QuEERPAM Study. 
Clin Infect Dis. 2012;55(1):42-50. 
208. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, et al. High resistance of 
Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence 
of dhps resistance mutation at Codon 581. PLoS One. 2009;4(2):e4569. 
209. Gutman J, Kalilani L, Taylor S, Zhou Z, Wiegand RE, Thwai KL, et al. The A581G Mutation in 
the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of 
Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. The J Infect Dis. 
2015. 
210. Minja DTR, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, et al. 
Plasmodium falciparum Mutant Haplotype Infection during Pregnancy Associated with Reduced 
Birthweight, Tanzania. Emerg Infect Dis. 2013;19(9):1446-54. 
211. Arinaitwe E, Ades V, Walakira A, Ninsiima B, Mugagga O, Patil TS, et al. Intermittent 
preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional 
study from Tororo, Uganda. PLoS One. 2013;8(9):e73073. 
212. WHO. WHO Policy recommendation on intermittent preventive treatment during infancy 
with sulphadoxine-pyrimethamine (IPTi-SP) for Plasmodium falciparum malaria control in Africa. 
Geneva, Switzerland: World Health Organization, 2010. 
213. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V. Anti-
folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and 
238 
 
dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum 
parasite populations. Malar J. 2010;9:247. 
214. Venkatesan M, Alifrangis M, Roper C, Plowe CV. Monitoring antifolate resistance in 
intermittent preventive therapy for malaria. Trends Parasitol. 
2013;29(10):10.1016/j.pt.2013.07.008. 
215. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of 
chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. 
J Infect Dis. 2003;187(12):1870-5. 
216. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, et al. Recovery of chloroquine 
sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter 
gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg. 
2003;68(4):413-5. 
217. Ndiaye M, Faye B, Tine R, Ndiaye JL, Lo A, Abiola A, et al. Assessment of the molecular marker 
of Plasmodium falciparum chloroquine resistance (Pfcrt) in Senegal after several years of 
chloroquine withdrawal. Am J Trop Med Hyg. 2012;87(4):640-5. 
218. Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, et al. 
Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. 
J Infect Dis. 2015. 
219. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. Temporal trends of 
sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum 
parasites from pregnant women in western Kenya. Malar J. 2012;11:134. 
220. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum crossresistance 
between trimethoprim and pyrimethamine.Lancet. 2001;358(9287):1066-7. 
221. Hastings IM, Watkins WM. Intensity of malaria transmission and the evolution of drug 
resistance. Acta Trop. 2005;94(3):218-29. 
239 
 
222. Mharakurwa S, Kumwenda T, Mkulama MA, Musapa M, Chishimba S, Shiff CJ, et al. Malaria 
antifolate resistance with contrasting Plasmodium falciparum dihydrofolate reductase (DHFR) 
polymorphisms in humans and Anopheles mosquitoes. Proc Natl Acad Sci U S A. 
2011;108(46):18796-801. 
223. Mharakurwa S, Sialumano M, Liu K, Scott A, Thuma P. Selection for chloroquine-sensitive 
Plasmodium falciparum by wild Anopheles arabiensis in Southern Zambia. Malar J. 2013;12:453. 
224. Alifrangis M, Lemnge MM, Ronn AM, Segeja MD, Magesa SM, Khalil IF, et al. Increasing 
prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area 
with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am 
J Trop Med Hyg. 2003;69(3):238-43. 
225. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV. Return of 
chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible 
parasites. J Infect Dis. 2010;202(5):801-8. 
226. Nkhoma S, Molyneux M, Ward S. Molecular surveillance for drug-resistant 
Plasmodiumfalciparum malaria in Malawi. Acta Trop. 2007;102(2):138-42. 
227. Njagi JK, Magnussen P, Estambale B, Ouma J, Mugo B. Prevention of anaemia in pregnancy 
using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of 
Kenya: a randomized controlled trial. Trans R Soc Trop Med Hyg. 2003;97(3):277-82. 
228. ClinicalTrials.gov. Chloroquine for Malaria in Pregnancy: U.S. National Institutes of Health; 
2015 [cited 2015 27 April]. Available from: https://clinicaltrials.gov/ct2/show/NCT01443130. 
229. Chico RM, Pittrof R, Greenwood B, Chandramohan D. Azithromycin-chloroquine and the 
intermittent preventive treatment of malaria in pregnancy. Malar J. 2008;7:255. 
230. Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for 
protection against malaria and sexually transmitted infections in pregnancy. EExpert Opin Drug 
Metab Toxicol. 2011;7(9):1153-67. 
240 
 
231. ClinicalTrials.gov. Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The 
Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum 
Parasitemia In Africa: U.S. National Institutes of Health; 2015 [cited 2015 27 April]. Available from: 
https://clinicaltrials.gov/ct2/show/study/NCT01103713?term=NCT01103713&rank=1. 
232. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of Repeated 
Treatment of Pregnant Women with Sulfadoxine-Pyrimethamine and Azithromycin on Preterm 
Delivery in Malawi: A Randomized Controlled Trial. Am J Trop Med Hyg. 2010;83(6):1212-20. 
233. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS, et al. Sulphadoxine-
pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a 
randomised controlled trial. BMC Med. 2015;13:9. 
234. Clerk CA, Bruce J, Affipunguh PK, Mensah N, Hodgson A, Greenwood B, et al. A randomized, 
controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, 
or the combination in pregnant women in Ghana. J Infect Dis. 2008;198(8):1202-11. 
235. Briand V, Bottero J, Noel H, Masse V, Cordel H, Guerra J, et al. Intermittent treatment for the 
prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial 
comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis. 2009;200(6):991-1001. 
236. Gonzalez R, Mombo-Ngoma G, Ouedraogo S, Kakolwa MA, Abdulla S, Accrombessi M, et al. 
Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: 
a multicentre randomized controlled trial. PLoS Med. 2014;11(9):e1001733. 
237. Gonzalez R, Desai M, Macete E, Ouma P, Kakolwa MA, Abdulla S, et al. Intermittent preventive 
treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole 
prophylaxis: a multicenter randomized placebo-controlled trial. PLoS Med. 2014;11(9):e1001735. 
238. ClinicalTrials.gov. Efficacy of Intermittent Screening and Treatment or Intermittent 
Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-
Pyrimethamine for the Control of Malaria in Pregnancy in Kenya (STOP MiP KENYA): U.S. National 
241 
 
Institutes of Health; 2014 [cited 2015 27 April]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT01669941. 
239. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A Review of Malaria 
Diagnostic Tools: Microscopy and Rapid Diagnostic Test (RDT). Am J Trop Med Hyg. 2007;77(6 
Suppl):119-27. 
240. Coleman RE, Sattabongkot J, Promstaporm S, Maneechai N, Tippayachai B, Kengluecha A, et 
al. Comparison of PCR and microscopy for the detection of asymptomatic malaria in a Plasmodium 
falciparum/vivax endemic area in Thailand. Malar J. 2006;5:121. 
241. Erdman LK, Kain KC. Molecular diagnostic and surveillance tools for global malaria control. 
Travel Med Infect Dis. 2008;6(1-2):82-99. 
242. Rantala AM, Taylor SM, Trottman PA, Luntamo M, Mbewe B, Maleta K, et al. Comparison of 
real-time PCR and microscopy for malaria parasite detection in Malawian pregnant women. Malar J. 
2010;9:269. 
243. Cohee LM, Kalilani-Phiri L, Boudova S, Joshi S, Mukadam R, Seydel KB, et al. Submicroscopic 
malaria infection during pregnancy and the impact of intermittent preventive treatment. Malar J. 
2014;13:274. 
244. Doolan DL, Dobaño C, Baird JK. Acquired Immunity to Malaria. Clin Microbiol Rev. 
2009;22(1):13-36. 
245. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the 
immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol. 
2003;133(2):145-52. 
246. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual acquisition 
of immunity to severe malaria with increasing exposure. Proc Biol Sci. 2015;282(1801). 
242 
 
247. Woodberry T, Minigo G, Piera KA, Amante FH, Pinzon-Charry A, Good MF, et al. Low-level 
Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in 
healthy volunteers. J Infect Dis. 2012;206(3):333-40. 
248. Ibitokou SA, Boström S, Brutus L, Tuikue Ndam N, Vianou B, Agbowaï C, et al. Submicroscopic 
Infections with Plasmodium falciparum during Pregnancy and Their Association with Circulating 
Cytokine, Chemokine, and Cellular Profiles. Clin Vaccine Immunol. 2014;21(6):859-66. 
249. Wilson NO, Bythwood T, Solomon W, Jolly P, Yatich N, Jiang Y, et al. Elevated Levels of IL-10 
and G-CSF Associated with Asymptomatic Malaria in Pregnant Women. Infect Dis Obstet Gynecol. 
2010;2010:7. 
250. Hugosson E, Montgomery SM, Premji Z, Troye-Blomberg M, Björkman A. Higher IL-10 levels 
are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol. 
2004;26(3):111-7. 
251. Othoro C, Lal AA, Nahlen B, Koech D, Orago ASS, Udhayakumar V. A Low Interleukin-10 Tumor 
Necrosis Factor-α Ratio Is Associated with Malaria Anemia in Children Residing in a Holoendemic 
Malaria Region in Western Kenya. J Infect Dis. 1999;179(1):279-82. 
252. Agudelo OM, Aristizabal BH, Yanow SK, Arango E, Carmona-Fonseca J, Maestre A. 
Submicroscopic infection of placenta by Plasmodium produces Th1/Th2 cytokine imbalance, 
inflammation and hypoxia in women from north-west Colombia. Malar J. 2014;13:122. 
253. Singh N, Bharti PK, Singh MP, Singh R, Yeboah-Antwi K, Desai M, et al. What is the burden of 
submicroscopic malaria in pregnancy in central India? Pathog Glob Health. 2015;109(1):30-8. 
254. Walker-Abbey A, Djokam RR, Eno A, Leke RF, Titanji VP, Fogako J, et al. Malaria in pregnant 
Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections 
and multiple parasite genotypes. Am J Trop Med Hyg. 2005;72(3):229-35. 
243 
 
255. Cottrell G, Moussiliou A, Luty AJ, Cot M, Fievet N, Massougbodji A, et al. Submicroscopic 
Plasmodium falciparum Infections Are Associated With Maternal Anemia, Premature Births, and Low 
Birth Weight. Clin Infect Dis. 2015. 
256. Mockenhaupt FP, Rong B, Till H, Eggelte TA, Beck S, Gyasi-Sarpong C, et al. Submicroscopic 
Plasmodium falciparum infections in pregnancy in Ghana. Trop Med Int Health. 2000;5(3):167-73. 
257. Arango EM, Samuel R, Agudelo OM, Carmona-Fonseca J, Maestre A, Yanow SK. Molecular 
Detection of Malaria at Delivery Reveals a High Frequency of Submicroscopic Infections and 
Associated Placental Damage in Pregnant Women from Northwest Colombia. Am J Trop Med Hyg. 
2013;89(1):178-83. 
258. Mutanda AL, Cheruiyot P, Hodges JS, Ayodo G, Odero W, John CC. Sensitivity of fever for 
diagnosis of clinical malaria in a Kenyan area of unstable, low malaria transmission. Malar J. 
2014;13:163. 
259. Muhe L, Oljira B, Degefu H, Enquesellassie F, Weber MW. Clinical algorithm for malaria during 
low and high transmission seasons. Arch Dis Child. 1999;81(3):216-20. 
260. Kallander K, Nsungwa-Sabiiti J, Peterson S. Symptom overlap for malaria and pneumonia--
policy implications for home management strategies. Acta Trop. 2004;90(2):211-4. 
261. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, et al. 
Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 
2004;329(7476):1212. 
262. Jelinek T, Grobusch MP, Schwenke S, Steidl S, von Sonnenburg F, Nothdurft HD, et al. 
Sensitivity and specificity of dipstick tests for rapid diagnosis of malaria in nonimmune travelers. J 
Clin Microbiol. 1999;37(3):721-3. 
263. Gerstl S, Dunkley S, Mukhtar A, De Smet M, Baker S, Maikere J. Assessment of two malaria 
rapid diagnostic tests in children under five years of age, with follow-up of false-positive pLDH test 
results, in a hyperendemic falciparum malaria area, Sierra Leone. Malar J. 2010;9:28. 
244 
 
264. Endeshaw T, Gebre T, Ngondi J, Graves PM, Shargie EB, Ejigsemahu Y, et al. Evaluation of light 
microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: 
a household survey in Ethiopia. Malar J. 2008;7:118. 
265. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, Hill AVS. Thick blood film 
examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates 
parasite density. Malar J. 2006;5:104-. 
266. CDC. Malaria Diagnosis (U.S.) - Microscopy Atlanta, USA: Centers for Disease Control and 
Prevention; 2012 [updated 9 November 2012; cited 2015 28 March]. Available from: 
http://www.cdc.gov/malaria/diagnosis_treatment/diagnosis.html. 
267. McKenzie FE, Sirichaisinthop J, Miller RS, Gasser RA, Jr., Wongsrichanalai C. Dependence of 
malaria detection and species diagnosis by microscopy on parasite density. Am J Trop Med Hyg. 
2003;69(4):372-6. 
268. Maguire JD, Lederman ER, Barcus MJ, O'Meara WA, Jordon RG, Duong S, et al. Production and 
validation of durable, high quality standardized malaria microscopy slides for teaching, testing and 
quality assurance during an era of declining diagnostic proficiency. Malar J. 2006;5:92. 
269. Johnston SP, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, da Silva AJ. PCR as a 
confirmatory technique for laboratory diagnosis of malaria. J Clin Microbiol. 2006;44(3):1087-9. 
270. Singh B, Kim Sung L, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, et al. A large focus 
of naturally acquired Plasmodium knowlesi infections in human beings. Lancet. 
2004;363(9414):1017-24. 
271. Cox-Singh J, Davis TM, Lee KS, Shamsul SS, Matusop A, Ratnam S, et al. Plasmodium knowlesi 
malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis. 
2008;46(2):165-71. 
272. Clendennen TE, 3rd, Long GW, Baird JK. QBC and Giemsa-stained thick blood films: diagnostic 
performance of laboratory technologists. Trans R Soc Trop Med Hyg. 1995;89(2):183-4. 
245 
 
273. Lenz D, Kremsner PG, Lell B, Biallas B, Boettcher M, Mordmuller B, et al. Assessment of LED 
fluorescence microscopy for the diagnosis of Plasmodium falciparum infections in Gabon. Malar J. 
2011;10:194. 
274. Ochola LB, Vounatsou P, Smith T, Mabaso MLH, Newton C. The reliability of diagnostic 
techniques in the diagnosis and management of malaria in the absence of a gold standard. Lancet 
Infect Dis. 2006;6(9):582-8. 
275. She RC, Rawlins ML, Mohl R, Perkins SL, Hill HR, Litwin CM. Comparison of 
immunofluorescence antibody testing and two enzyme immunoassays in the serologic diagnosis of 
malaria. J Travel Med. 2007;14(2):105-11. 
276. Duo-Quan W, Lin-Hua T, Zhen-Cheng G, Xiang Z, Man-Ni Y. Application of the indirect 
fluorescent antibody assay in the study of malaria infection in the Yangtze River Three Gorges 
Reservoir, China. Malar J. 2009;8:199. 
277. Noedl H, Yingyuen K, Laoboonchai A, Fukuda M, Sirichaisinthop J, Miller RS. Sensitivity and 
specificity of an antigen detection ELISA for malaria diagnosis. Am J Trop Med Hyg. 2006;75(6):1205-
8. 
278. WHO. Malaria rapid diagnostic test performance: results of WHO product testing of malaria 
RDTs: round 1 (2008). Geneva, Switzerland: World Health Organization, 2008. 
279. Bell D, Peeling RW. Evaluation of rapid diagnostic tests: malaria. Nat Rev Micro. 2006. 
280. WHO. Malaria Rapid Diagnostic Tests: Accuracy of results: World Health Organization; 2005 
[cited 2015 26 March]. Available from: 
http://www.wpro.who.int/malaria/sites/rdt/whatis/action.html. 
281. Hopkins H, Bebell L, Kambale W, Dokomajilar C, Rosenthal PJ, Dorsey G. Rapid diagnostic tests 
for malaria at sites of varying transmission intensity in Uganda. J Infect Dis. 2008;197(4):510-8. 
246 
 
282. Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, et al. Determinants of the accuracy 
of rapid diagnostic tests in malaria case management: evidence from low and moderate transmission 
settings in the East African highlands. Malar J. 2008;7:202. 
283. Minja DT, Schmiegelow C, Oesterholt M, Magistrado PA, Bostrom S, John D, et al. Reliability of 
rapid diagnostic tests in diagnosing pregnancy-associated malaria in north-eastern Tanzania. Malar 
J. 2012;11:211. 
284. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of 
P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria 
rapid diagnostic tests. PLoS One. 2010;5(1):e8091. 
285. Maltha J, Gamboa D, Bendezu J, Sanchez L, Cnops L, Gillet P, et al. Rapid diagnostic tests for 
malaria diagnosis in the Peruvian Amazon: impact of pfhrp2 gene deletions and cross-reactions. PLoS 
One. 2012;7(8):e43094. 
286. Kumar N, Pande V, Bhatt RM, Shah NK, Mishra N, Srivastava B, et al. Genetic deletion of HRP2 
and HRP3 in Indian Plasmodium falciparum population and false negative malaria rapid diagnostic 
test. Acta Trop. 2013;125(1):119-21. 
287. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, et al. Pfhrp2 and pfhrp3 polymorphisms 
in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. 
Malar J. 2013;12:34. 
288. Ho MF, Baker J, Lee N, Luchavez J, Ariey F, Nhem S, et al. Circulating antibodies against 
Plasmodium falciparum histidine-rich proteins 2 interfere with antigen detection by rapid diagnostic 
tests. Malar J. 2014;13:480. 
289. Iqbal J, Sher A, Rab A. Plasmodium falciparum histidine-rich protein 2-based immunocapture 
diagnostic assay for malaria: cross-reactivity with rheumatoid factors. J Clin Microbiol. 
2000;38(3):1184-6. 
247 
 
290. Mtove G, Hendriksen IC, Amos B, Mrema H, Mandia V, Manjurano A, et al. Treatment guided 
by rapid diagnostic tests for malaria in Tanzanian children: safety and alternative bacterial 
diagnoses. Malar J. 2011;10:290. 
291. Meatherall B, Preston K, Pillai DR. False positive malaria rapid diagnostic test in returning 
traveler with typhoid fever. BMC Infect Dis. 2014;14:377. 
292. CDC. Malaria Diagnosis (U.S.) – Rapid Diagnostic Test Atlanta, USA: Centers for Disease 
Control and Prevention; 2014 [updated 14 July 2014; cited 2015 28 March]. Available from: 
http://www.cdc.gov/malaria/diagnosis_treatment/rdt.html. 
293. Mouatcho JC, Goldring JPD. Malaria rapid diagnostic tests: challenges and prospects. J Med 
Microbiol. 2013;62(Pt 10):1491-505. 
294. Tanizaki R, Kato Y, Iwagami M, Kutsuna S, Ujiie M, Takeshita N, et al. Performance of Rapid 
Diagnostic Tests for Plasmodium ovale Malaria in Japanese Travellers. Trop Med Health. 
2014;42(4):149-53. 
295. Foster D, Cox-Singh J, Mohamad DS, Krishna S, Chin PP, Singh B. Evaluation of three rapid 
diagnostic tests for the detection of human infections with Plasmodium knowlesi. Malar J. 
2014;13:60. 
296. Kantele A, Jokiranta TS. Review of Cases With the Emerging Fifth Human Malaria Parasite, 
Plasmodium knowlesi. Clin Infect Dis. 2011;52(11):1356-62. 
297. Jeremiah SS, Janagond AB, Parija SC. Challenges in diagnosis of Plasmodium knowlesi 
infections. Trop Parasitol. 2014;4(1):25-30. 
298. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin Microbiol 
Infect. 2013;19(5):399-407. 
299. WHO. Summary results of WHO product testing of malaria RDTs: Round 1-5 (2008-2013). 
Geneva, Switzerland: World Health Organization, 2013. 
248 
 
300. UNITAID. Malaria Diagnostics Technology and Market Landscape. 2nd Edition. Geneva, 
Switzerland: World Health Organization, 2014. 
301. Schachterle SE, Mtove G, Levens JP, Clemens EG, Shi L, Raj A, et al. Prevalence and Density-
Related Concordance of Three Diagnostic Tests for Malaria in a Region of Tanzania with 
Hypoendemic Malaria. J Clin Microbiol. 2011;49(11):3885-91. 
302. Wangai LN, Karau MG, Njiruh PN, Sabah O, Kimani FT, Magoma G, et al. Sensitivity of 
Microscopy Compared to Molecular Diagnosis of P. Falciparum: Implications on Malaria Treatment 
in Epidemic Areas in Kenya. African J Infect Dis. 2011;5(1):1-6. 
303. Fransisca L, Kusnanto JH, Satoto TBT, Sebayang B, Supriyanto ᅟ, Andriyan E, et al. 
Comparison of rapid diagnostic test Plasmotec Malaria-3, microscopy, and quantitative real-time PCR 
for diagnoses of Plasmodium falciparum and Plasmodium vivax infections in Mimika Regency, Papua, 
Indonesia. Malar J. 2015;14:103. 
304. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human 
malaria parasite species in field samples by the polymerase chain reaction and detection of a high 
prevalence of mixed infections. Mol Biochem Parasitol. 1993;58(2):283-92. 
305. Lucchi NW, Poorak M, Oberstaller J, DeBarry J, Srinivasamoorthy G, Goldman I, et al. A new 
single-step PCR assay for the detection of the zoonotic malaria parasite Plasmodium knowlesi. PLoS 
One. 2012;7(2):e31848. 
306. Link L, Bart A, Verhaar N, van Gool T, Pronk M, Scharnhorst V. Molecular Detection of 
Plasmodium knowlesi in a Dutch Traveler by Real-Time PCR. J Clin Microbiol. 2012;50(7):2523-4. 
307. Bosman P, Stassijns J, Nackers F, Canier L, Kim N, Khim S, et al. Plasmodium prevalence and 
artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional 
population-based study. Malar J. 2014;13:394. 
249 
 
308. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular 
marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50-5. 
309. Alker AP, Mwapasa V, Meshnick SR. Rapid real-time PCR genotyping of mutations associated 
with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Antimicrob Agents 
Chemother. 2004;48(8):2924-9. 
310. Mishra S, Raj DK, Hazra RK, Dash AP, Supakar PC. An efficient PCR--SSCP-based method for 
detection of a chloroquine resistance marker in the PfCRT gene of Plasmodium falciparum. Trans R 
Soc Trop Med Hyg. 2006;100(3):243-7. 
311. Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S. Malaria diagnosis: a brief review. 
Korean J Parasitol. 2009;47(2):93-102. 
312. Chaikitgosiyakul S, Rijken MJ, Muehlenbachs A, Lee SJ, Chaisri U, Viriyavejakul P, et al. A 
morphometric and histological study of placental malaria shows significant changes to villous 
architecture in both Plasmodium falciparum and Plasmodium vivax infection. Malar J. 2014;13:4. 
313. Eusebi P. Diagnostic accuracy measures. Cerebrovasc Dis. 2013;36(4):267-72. 
314. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and using 
sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008;56(1):45-50. 
315. Harper R, Reeves B. Reporting of precision of estimates for diagnostic accuracy: a review. 
BMJ. 1999;318(7194):1322-3. 
316. Deeks JJ, Altman DG. Sensitivity and specificity and their confidence intervals cannot exceed 
100%. BMJ. 1999;318(7177):193-4. 
317. Shiu S-Y, Gatsonis C. The predictive receiver operating characteristic curve for the joint 
assessment of the positive and negative predictive values. Philosophical Transactions of the Royal 
Society of London A: Mathematical, Physical and Engineering Sciences. 2008;366(1874):2313-33. 
318. Coulthard MG. Quantifying how tests reduce diagnostic uncertainty. Arch Dis Child. 
2007;92(5):404-8. 
250 
 
319. BMJ. Diagnostic test studies: assessment and critical appraisal: BMJ Publishing; 2014 [cited 
2015 30 March]. Available from: 
http://clinicalevidence.bmj.com/x/set/static/ebm/toolbox/665061.html. 
320. Šimundić A-M. Measures of diagnostic accuracy: basic definitions. Med Biol Sci. 
2008;22(4):61-5. 
321. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD 
statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 
2003;138(1):W1-12. 
322. Bossuyt PMM. STARD Statement: Still Room for Improvement in the Reporting of Diagnostic 
Accuracy Studies. Radiology. 2008;248(3):713-4. 
323. Sheehy AM, Coursin DB, Gabbay RA. Back to Wilson and Jungner: 10 Good Reasons to Screen 
for Type 2 Diabetes Mellitus. Mayo Clin Proc. 2009;84(1):38-42. 
324. Harris R, Sawaya GF, Moyer VA, Calonge N. Reconsidering the Criteria for Evaluating 
Proposed Screening Programs: Reflections From 4 Current and Former Members of the U.S. 
Preventive Services Task Force. Epidemiol Rev. 2011;33(1):20-35. 
325. Forman J, Coyle F, Levy-Fisch J, Roberts P, Terry S, Legge M. Screening criteria: the need to 
deal with new developments and ethical issues in newborn metabolic screening. J Community Genet. 
2013;4(1):59-67. 
326. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the 
genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 
2008;86(4):317-9. 
327. Petros M. Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public 
health in the era of genetic screening? Genet Med. 2012;14(1):129-34. 
328. WHO. Delivering HIV test results and messages for re-testing and counselling in adults. 
Geneva: World Health Organization, 2010. 
251 
 
329. Tako EA, Zhou A, Lohoue J, Leke R, Taylor DW, Leke RF. Risk factors for placental malaria and 
its effect on pregnancy outcome in Yaounde, Cameroon. Am J Trop Med Hyg. 2005;72(3):236-42. 
330. Katz J, Lee AC, Kozuki N, Lawn JE, Cousens S, Blencowe H, et al. Mortality risk in preterm and 
small-for-gestational-age infants in low-income and middle-income countries: a pooled country 
analysis. Lancet. 2013;382(9890):417-25. 
331. Bennett A, Kazembe L, Mathanga DP, Kinyoki D, Ali D, Snow RW, et al. Mapping Malaria 
Transmission Intensity in Malawi, 2000–2010. Am J Trop Med Hyg. 2013;89(5):840-9. 
332. Malawi. Ministry of Health. Guidelines for paediatric HIV testing and counselling, Malawi. 
Lilongwe: Ministry of Health; 2007. vi, 25 p. p. 
333. CPMP. Points to consider on switching between superiority and non-inferiority (Committee 
for Proprietory Medicinal Products). Br J Clin Psychol. 2001;52:223-8. 
334. Noel-Weiss J, Courant G, Woodend AK. Physiological weight loss in the breastfed neonate: a 
systematic review. Open Med. 2008;2(4):e99-e110. 
335. Flaherman VJ, Kuzniewicz MW, Li S, Walsh E, McCulloch CE, Newman TB. First-day weight 
loss predicts eventual weight nadir for breastfeeding newborns. Arch Dis Child Fetal Neonatal Ed. 
2013;98(6):F488-92. 
336. Greenwood BM, Greenwood AM, Snow RW, Byass P, Bennett S, Hatib-N'Jie AB. The effects of 
malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of 
pregnancy. Trans R Soc Trop Med Hyg. 1989;83(5):589-94. 
337. D'Alessandro U, Langerock P, Bennett S, Francis N, Cham K, Greenwood BM. The impact of a 
national impregnated bed net programme on the outcome of pregnancy in primigravidae in The 
Gambia. Trans R Soc Trop Med Hyg. 1996;90(5):487-92. 
338. Tagbor H, Bruce J, Agbo M, Greenwood B, Chandramohan D. Intermittent screening and 
treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised 
controlled non-inferiority trial. PLoS One. 2010;5(12):e14425. 
252 
 
339. Tagbor H, Cairns M, Bojang K, Coulibaly SO, Kayentao K, Williams JE, et al. A non-inferiority, 
individually randomised trial of intermittent screening and treatment: an alternative approach to the 
control of malaria in pregnancy. PLoS One. 2015 (in press). 
340. Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, et al. 
Persistence of sulfadoxine-pyrimethamine resistance despite reduction of drug pressure in Malawi. 
J Infect Dis. 2015. 
341. Naidoo I, Roper C. Mapping 'partially resistant', 'fully resistant', and 'super resistant' malaria. 
Trends Parasitol. 2013;29(10):505-15. 
342. ter Kuile FO, et al. Impact of sulphadoxine-pyrimethamine resistance on the effectiveness of 
Intermittent Preventive Therapy for malaria in pregnancy (IPTp) in Africa: A systematic review and 
meta-analysis. Report for WHO ERG. 2013. 
343. Desai M, Gutman J, Taylor S, Wiegand R, Khairallah C, Kayentao K, et al. Impact of sulfadoxine-
pyrimethamine resistance on effectiveness of intermittent preventive therapy in pregnancy at 
clearing peripheral blood plasmodium falciparum parasites and preventing low birth weight: A 
prospective, multi-country observational study across Africa. Submitted. 
344. Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of 
intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of 
sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J. 2010;9:303. 
345. Cook J, Xu W, Msellem M, Vonk M, Bergstrom B, Gosling R, et al. Mass screening and treatment 
on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce 
malaria incidence in Zanzibar. J Infect Dis. 2015;211(9):1476-83. 
346. von Seidlein L. The Failure of Screening and Treating as a Malaria Elimination Strategy. PLoS 
Med. 2014;11(1):e1001595. 
347. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J. 
2008;7:9-. 
253 
 
348. Dorsey G, Gasasira AF, Machekano R, Kamya MR, Staedke SG, Hubbard A. The impact of age, 
temperature, and parasite density on treatment outcomes from antimalarial clinical trials in 
Kampala, Uganda. Am J Trop Med Hyg. 2004;71(5):531-6. 
349. Vallely A, Vallely L, Changalucha J, Greenwood B, Chandramohan D. Intermittent preventive 
treatment for malaria in pregnancy in Africa: what's new, what's needed? Malar J. 2007;6:16. 
350. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J, Laochan N, et al. Pharmacokinetics 
of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated 
Falciparum Malaria. Antimicrob Agents Chemother. 2011;55(12):5500-6. 
351. The Pregnancy and Artemisinin-based Combination Treatments (PREGACT) study group, 
Tinto H, Traoré/Coulibaly M, Tahita MC, Valéa I, Mwapasa V, et al. The safety and efficacy of four 
artemisinin-based combination treatments in African pregnant women with malaria [submitted]. 
352. Pell C, Menaca A, Chatio S, Hodgson A, Tagbor H, Pool R. The acceptability of intermittent 
screening and treatment versus intermittent preventive treatment during pregnancy: results from a 
qualitative study in Northern Ghana. Malar J. 2014;13:432. 
353. Smith Paintain L, Antwi GD, Jones C, Amoako E, Adjei RO, Afrah NA, et al. Intermittent 
screening and treatment versus intermittent preventive treatment of malaria in pregnancy: provider 
knowledge and acceptability. PLoS One. 2011;6(8):e24035. 
354. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am 
J Epidemiol. 2004;159(7):702-6. 
355. Cummings P. Methods for estimating adjusted risk ratios. Stata Journal. 2009;9(2):175-96. 
356. Cameron AC TP. Microeconometrics Using Stata. College Station (TX): Stata Press; 2009. 
357. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 
1983;61(6):1005-16. 
358. Tutterrow YL, Salanti A, Avril M, Smith JD, Pagano IS, Ako S, et al. High Avidity Antibodies to 
Full-Length VAR2CSA Correlate with Absence of Placental Malaria. PLoS One. 2012;7(6):e40049. 
254 
 
359. Ndam NT, Denoeud-Ndam L, Doritchamou J, Viwami F, Salanti A, Nielsen MA, et al. Protective 
Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin. Emerg Infect Dis. 
2015;21(5):813-23. 
360. Ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kariuki SK, et al. 
Reduction of malaria during pregnancy by  Perimethrin-treated bed nets in an area of intense 
perennial malaria transmission in western Kenya. Am J Trop Med Hyg. 2003;68(4 suppl):50-60. 
361. Gamble C, Ekwaru PJ, Garner P, ter Kuile FO. Insecticide-Treated Nets for the Prevention of 
Malaria in Pregnancy: A Systematic Review of Randomised Controlled Trials. PLoS Med. 
2007;4(3):e107. 
362. Mouatcho JC, Goldring JP. Malaria rapid diagnostic tests: challenges and prospects. J Med 
Microbiol. 2013;62(Pt 10):1491-505. 
363. Moody A. Rapid Diagnostic Tests for Malaria Parasites. Clin Microbiol Rev. 2002;15(1):66-78. 
364. McMorrow ML, Aidoo M, Kachur SP. Malaria rapid diagnostic tests in elimination settings—
can they find the last parasite? Clin Microbiol Infect. 2011;17(11):1624-31. 
365. Matangila JR, Lufuluabo J, Ibalanky AL, Inocencio da Luz RA, Lutumba P, Van Geertruyden JP. 
Asymptomatic Plasmodium falciparum infection is associated with anaemia in pregnancy and can be 
more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, Democratic 
Republic of the Congo. Malar J. 2014;13:132. 
366. Ndyomugyenyi R, Magnussen P. Anaemia in pregnancy: Plasmodium falciparum infection is 
an important cause in primigravidae in Hoima district, western Uganda. Ann Trop Med Parasitol. 
1999;93(5):457-65. 
367. Malhotra I, Dent A, Mungai P, Muchiri E, King CL. Real-Time Quantitative PCR for Determining 
the Burden of Plasmodium falciparum Parasites during Pregnancy and Infancy. J Clin Microbiol. 
2005;43(8):3630-5. 
255 
 
368. Ayoola OO, Gemmell I, Omotade OO, Adeyanju OA, Cruickshank JK, Clayton PE. Maternal 
Malaria, Birth Size and Blood Pressure in Nigerian Newborns: Insights into the Developmental 
Origins of Hypertension from the Ibadan Growth Cohort. PLoS One. 2011;6(9):e24548. 
369. Kalilani L, Mofolo I, Chaponda M, Rogerson SJ, Meshnick SR. The effect of timing and 
frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and 
maternal anemia. Trans R Soc Trop Med Hyg. 2010;104(6):416-22. 
370. Valea I, Tinto H, Drabo MK, Huybregts L, Sorgho H, Ouedraogo JB, et al. An analysis of timing 
and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, 
anaemia and perinatal mortality in Burkina Faso. Malar J. 2012;11:71. 
371. Cottrell G, Mary J-Y, Barro D, Cot M. The importance of the period of malarial infection during 
pregnancy on birth weight in tropical Africa. Am J Trop Med Hyg. 2007;76(5):849-54. 
372. Takem EN, Roca A, Cunnington A. The association between malaria and non-typhoid 
Salmonella bacteraemia in children in sub-Saharan Africa: a literature review. Malar J. 2014;13:400. 
373. Church J, Maitland K. Invasive bacterial co-infection in African children with Plasmodium 
falciparum malaria: a systematic review. BMC Med. 2014;12:31. 
374. Maltha J, Guiraud I, Kaboré B, Lompo P, Ley B, Bottieau E, et al. Frequency of Severe Malaria 
and Invasive Bacterial Infections among Children Admitted to a Rural Hospital in Burkina Faso. PLoS 
One. 2014;9(2):e89103. 
375. Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, et al. The sick 
placenta-the role of malaria. Placenta. 2004;25(5):359-78. 
376. Stanisic DI, Moore KA, Baiwog F, Ura A, Clapham C, King CL, et al. Risk factors for malaria and 
adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria 
transmission area of Papua New Guinea. Trans R Soc Trop Med Hyg. 2015. 
377. Takem EN, D’Alessandro U. Malaria in Pregnancy. Mediterranean Journal of Hematology and 
Infectious Diseases. 2013;5(1):e2013010. 
256 
 
378. Douamba Z, Bisseye C, Djigma FW, Compaor, #xe9,  TR, et al. Asymptomatic Malaria 
Correlates with Anaemia in Pregnant Women at Ouagadougou, Burkina Faso. J Biomed Biotechnol. 
2012;2012:6. 
379. Anchang-Kimbi JK, Achidi EA, Nkegoum B, Sverremark-Ekstrom E, Troye-Blomberg M. 
Diagnostic comparison of malaria infection in peripheral blood, placental blood and placental 
biopsies in Cameroonian parturient women. Malar J. 2009;8:126. 
380. Leke RF, Djokam RR, Mbu R, Leke RJ, Fogako J, Megnekou R, et al. Detection of the Plasmodium 
falciparum antigen histidine-rich protein 2 in blood of pregnant women: implications for diagnosing 
placental malaria. J Clin Microbiol. 1999;37(9):2992-6. 
381. Mayor A, Moro L, Aguilar R, Bardaji A, Cistero P, Serra-Casas E, et al. How hidden can malaria 
be in pregnant women? Diagnosis by microscopy, placental histology, polymerase chain reaction and 
detection of histidine-rich protein 2 in plasma. Clin Infect Dis. 2012;54(11):1561-8. 
382. Kattenberg JH, Ochodo EA, Boer KR, Schallig HD, Mens PF, Leeflang MM. Systematic review 
and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria 
in pregnant women. Malar J. 2011;10:321. 
383. Tamhane A. Matched-Sample Analysis: Sensitivity, Specificity, and P Values. Clin Infect Dis. 
2008;46(3):474-5. 
384. Kim S, Lee W. Does McNemar’s test compare the sensitivities and specificities of two 
diagnostic tests? Stat Methods Med Res. 2014. 
385. Alfred N, Lovette L, Aliyu G, Olusegun O, Meshak P, Jilang T, et al. Optimising Mycobacterium 
tuberculosis detection in resource limited settings. BMJ Open. 2014;4(3). 
386. Njama-Meya D, Kamya MR, Dorsey G. Asymptomatic parasitaemia as a risk factor for 
symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health. 2004;9(8):862-8. 
257 
 
387. Ilombe G, Maketa V, Mavoko HM, da Luz RI, Lutumba P, Van geertruyden JP. Performance of 
HRP2-based rapid test in children attending the health centre compared to asymptomatic children 
in the community. Malar J. 2014;13:308. 
388. Bharti PK, Silawat N, Singh PP, Singh MP, Shukla M, Chand G, et al. The usefulness of a new 
rapid diagnostic test, the First Response Malaria Combo (pLDH/HRP2) card test, for malaria 
diagnosis in the forested belt of central India. Malar J. 2008;7:126. 
389. Hendriksen ICE, Mtove G, Pedro AJ, Gomes E, Silamut K, Lee SJ, et al. Evaluation of a PfHRP2 
and a pLDH-based Rapid Diagnostic Test for the Diagnosis of Severe Malaria in 2 Populations of 
African Children. Clin Infect Dis. 2011;52(9):1100-7. 
390. Fried M, Muehlenbachs A, Duffy PE. Diagnosing malaria in pregnancy: an update. Expert 
review of anti-infective therapy. 2012;10(10):1177-87. 
391. Kashif AH, Adam GK, Mohmmed AA, Elzaki SE, AbdelHalim AM, Adam I. Reliability of rapid 
diagnostic test for diagnosing peripheral and placental malaria in an area of unstable malaria 
transmission in Eastern Sudan. Diagn Pathol. 2013;8:59. 
392. Kyabayinze DJ, Tibenderana JK, Nassali M, Tumwine LK, Riches C, Montague M, et al. Placental 
Plasmodium falciparum malaria infection: operational accuracy of HRP2 rapid diagnostic tests in a 
malaria endemic setting. Malar J. 2011;10:306. 
393. Matangila J, Lufuluabo J, Ibalanky A, Inocêncio da Luz R, Lutumba P, Van Geertruyden J-P. 
Asymptomatic Plasmodium falciparum infection is associated with anaemia in pregnancy and can be 
more cost-effectively detected by rapid diagnostic test than by microscopy in Kinshasa, Democratic 
Republic of the Congo. Malar J. 2014;13(1):1-10. 
394. Mayor A, Moro L, Aguilar R, Bardají A, Cisteró P, Serra-Casas E, et al. How Hidden Can Malaria 
Be in Pregnant Women? Diagnosis by Microscopy, Placental Histology, Polymerase Chain Reaction 
and Detection of Histidine-Rich Protein 2 in Plasma. Clin Infect Dis. 2012;54(11):1561-8. 
258 
 
395. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic Infection in Plasmodium 
falciparum-Endemic Populations: A Systematic Review and Meta-Analysis. J Infect Dis. 
2009;200(10):1509-17. 
396. Azikiwe CCA, Ifezulike CC, Siminialayi IM, Amazu LU, Enye JC, Nwakwunite OE. A comparative 
laboratory diagnosis of malaria: microscopy versus rapid diagnostic test kits. Asian Pac J Trop 
Biomed. 2012;2(4):307-10. 
397. Batwala V, Magnussen P, Hansen KS, Nuwaha F. Cost-effectiveness of malaria microscopy and 
rapid diagnostic tests versus presumptive diagnosis: implications for malaria control in Uganda. 
Malar J. 2011;10:372. 
398. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, et al. Rapid diagnostic 
tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in 
Tanzania: randomised trial.BMJ.2007-02-22 23:05:50. 403 p. 
399. Singer LM, Newman RD, Diarra A, Moran AC, Huber CS, Stennies G, et al. Evaluation of a 
malaria rapid diagnostic test for assessing the burden of malaria during pregnancy. Am J Trop Med 
Hyg. 2004;70(5):481-5. 
400. Singh N, Saxena A, Awadhia SB, Shrivastava R, Singh MP. Evaluation of a rapid diagnostic test 
for assessing the burden of malaria at delivery in India. Am J Trop Med Hyg. 2005;73(5):855-8. 
401. Desai M, Gutman J, L'Lanziva A, Otieno K, Juma E, Kariuki S, et al. Intermittent screening and 
treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus 
intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during 
pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. 
Lancet. 2015;386(10012):2507-19. 
402. Capan-Melser M, Mombo Ngoma G, Akerey-Diop D, Basra A, Wurbel H, Groger M, et al. 
Evaluation of intermittent preventive treatment of malaria against group B Streptococcus 
colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of 
259 
 
sulfadoxine/pyrimethamine versus mefloquine. The Journal of antimicrobial chemotherapy. 
2015;70(6):1898-902. 
403. Luntamo M, Rantala A-M, Meshnick SR, Cheung YB, Kulmala T, Maleta K, et al. The Effect of 
Monthly Sulfadoxine-Pyrimethamine, Alone or with Azithromycin, on PCR-Diagnosed Malaria at 
Delivery: A Randomized Controlled Trial. PLoS One. 2012;7(7):e41123. 
404. Berhan Y, Berhan A. Antenatal Care as a Means of Increasing Birth in the Health Facility and 
Reducing Maternal Mortality: A Systematic Review. Ethiop J Health Sci. 2014;24(0 Suppl):93-104. 
405. Hill J, Hoyt J, van Eijk AM, D'Mello-Guyett L, Ter Kuile FO, Steketee R, et al. Factors affecting 
the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: 
a systematic review and meta-analysis. PLoS Med. 2013;10(7):e1001488. 
406. Hill J, Kayentao K, Achieng F, Diarra S, Dellicour S, Diawara SI, et al. Access and Use of 
Interventions to Prevent and Treat Malaria among Pregnant Women in Kenya and Mali: A Qualitative 
Study. PLoS One. 2015;10(3):e0119848. 
407. Rogerson SJ, Hviid L, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and 
immunity. Lancet Infect Dis. 2007;7(2):105-17. 
408. Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in pregnancy: linking immunity and 
pathogenesis to prevention. Am J Trop Med Hyg. 2007;77(6 Suppl):14-22. 
409. Sema M, Alemu A, Bayih AG, Getie S, Getnet G, Guelig D, et al. Evaluation of non-instrumented 
nucleic acid amplification by loop-mediated isothermal amplification (NINA-LAMP) for the diagnosis 
of malaria in Northwest Ethiopia. Malar J. 2015;14:44. 
410. Polley SD, Mori Y, Watson J, Perkins MD, González IJ, Notomi T, et al. Mitochondrial DNA 
Targets Increase Sensitivity of Malaria Detection Using Loop-Mediated Isothermal Amplification. J 
Clin Microbiol. 2010;48(8):2866-71. 
411. WHO. WHO Evidence Review Group on Malaria Diagnosis in Low Transmission Settings. 
Geneva, Switzerland: World Health Organization, 2014. 
260 
 
412. Snow RW. Global malaria eradication and the importance of Plasmodium falciparum 
epidemiology in Africa. BMC Med. 2015;13:23. 
413. Liu J, Modrek S, Gosling RD, Feachem RGA. Malaria eradication: is it possible? Is it worth it? 
Should we do it? Lancet Glob Health. 2013;1(1):e2-e3. 
414. Hay SI, Smith DL, Snow RW. Measuring malaria endemicity from intense to interrupted 
transmission. Lancet Infect Dis. 2008;8(6):369-78. 
415. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, et al. Impact of 
Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine on Malaria in Ugandan 
Schoolchildren: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2014;58(10):1404-12. 
416. Ocan M, Bbosa GS, Waako P, Ogwal-Okeng J, Obua C. Factors predicting home storage of 
medicines in Northern Uganda. BMC Public Health. 2014;14:650. 
417. Petersen EE, Rasmussen SA, Daniel KL, Yazdy MM, Honein MA. Prescription medication 
borrowing and sharing among women of reproductive age. J Womens Health (Larchmt). 
2008;17(7):1073-80. 
418. Planta MB. The role of poverty in antimicrobial resistance. J Am Board Fam Med. 
2007;20(6):533-9. 
419. Baud D, Greub G. Intracellular bacteria and adverse pregnancy outcomes. Clin Microbiol 
Infect. 2011;17(9):1312-22. 
420. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, et al. The APPLe 
Study: A Randomized, Community-Based, Placebo-Controlled Trial of Azithromycin for the 
Prevention of Preterm Birth, with Meta-Analysis. PLoS Med. 2009;6(12):e1000191. 
421. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of repeated treatment 
of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in 
Malawi: a randomized controlled trial. Am J Trop Med Hyg. 2010;83(6):1212-20. 
261 
 
422. Unger HW, Ome-Kaius M, Wangnapi RA, Umbers AJ, Hanieh S, Suen CS, et al. Sulphadoxine-
pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a 
randomised controlled trial. BMC Med. 2015;13(1):9. 
423. Unger HW, Aho C, Ome-Kaius M, Wangnapi RA, Umbers AJ, Jack W, et al. Impact of intermittent 
preventive treatment in pregnancy with azithromycin-containing regimens on maternal 
nasopharyngeal carriage and antibiotic sensitivity of Streptococcus pneumoniae, Haemophilus 
influenzae, and Staphylococcus aureus: a cross-sectional survey at delivery. J Clin Microbiol. 
2015;53(4):1317-23. 
424. Manyando C, Kayentao K, D'Alessandro U, Okafor HU, Juma E, Hamed K. A systematic review 
of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum 
malaria during pregnancy. Malar J. 2012;11:141. 
425. Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B. Safety of artemether-
lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J. 2014;13:197. 
426. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ. Pharmacovigilance of 
artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar J. 
2012;11:225. 
427. Yeka A, Lameyre V, Afizi K, Fredrick M, Lukwago R, Kamya MR, et al. Efficacy and Safety of 
Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of 
Uncomplicated Malaria in Ugandan Children. PLoS One. 2014;9(12):e113311. 
428. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, et al. Randomized, Double-Blind, 
Placebo-Controlled Clinical Trial of a Two-Day Regimen of Dihydroartemisinin-Piperaquine for 
Malaria Prevention Halted for Concern over Prolonged Corrected QT Interval. Antimicrob Agents 
Chemother. 2014;58(10):6056-67. 
262 
 
429. Darpo B, Ferber G, Siegl P, Laurijssens B, Macintyre F, Toovey S, et al. Evaluation of the QT 
effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the 
treatment of uncomplicated malaria. Br J Clin Pharmacol. 2015:n/a-n/a. 
430. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C, et al. Dihydroartemisinin-
piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a 
randomised, non-inferiority trial. PLoS One. 2009;4(11):e7871. 
431. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, 
randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum 
malaria in Asia. PLoS One. 2010;5(7):e11880. 
432. Mpanga V, Maluwa, A. , Kafulafula, U. , Pindani, M. and Bultemeier, K. Comprehension of Risk 
Factors of Malaria during Pregnancy among Pregnant Women Attending Antenatal Care in Malawi. 
Open J Nurs. 2014;4:896-905. 
433. Kiwuwa MS, Mufubenga P. Use of antenatal care, maternity services, intermittent 
presumptive treatment and insecticide treated bed nets by pregnant women in Luwero district, 
Uganda. Malar J. 2008;7:44. 
434. Wumba RD, Zanga J, Aloni MN, Mbanzulu K, Kahindo A, Mandina MN, et al. Interactions 
between malaria and HIV infections in pregnant women: a first report of the magnitude, clinical and 
laboratory features, and predictive factors in Kinshasa, the Democratic Republic of Congo. Malar J. 
2015;14:82. 
435. Turner AN, Tabbah S, Mwapasa V, Rogerson SJ, Meshnick SR, Ackerman WEt, et al. Severity of 
maternal HIV-1 disease is associated with adverse birth outcomes in Malawian women: a cohort 
study. J Acquir Immune Defic Syndr. 2013;64(4):392-9. 
436. Denoeud-Ndam L, Zannou DM, Fourcade C, Taron-Brocard C, Porcher R, Atadokpede F, et al. 
Cotrimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria 
263 
 
in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr. 
2014;65(2):198-206. 
437. Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Phiri K, Fitzgerald M, Mwapasa V. Marked 
Reduction in Prevalence of Malaria Parasitemia and Anemia in HIV-Infected Pregnant Women Taking 
Cotrimoxazole With Or Without Sulfadoxine-Pyrimethamine Intermittent Preventive Therapy during 
Pregnancy in Malawi. J Infect Dis. 2011. 
438. Gimnig JE, MacArthur JR, M’bang'ombe M, Kramer MH, Chizani N, Stern RS, et al. Severe 
cutaneous reactions to sulfadoxine-purimethamine and trimethoprim-sulphamethoxazole in 
Blantyre district, Malawi. Am J Trop Med Hyg. 2006;74(5):738-43. 
439. Sevene E, Gonzalez R, Menendez C. Current knowledge and challenges of antimalarial drugs 
for treatment and prevention in pregnancy. Expert Opin Pharmacother. 2010;11(8):1277-93. 
440. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: 
safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7(2):136-44. 
441. Manyando C, Njunju EM, D’Alessandro U, Van geertruyden J-P. Safety and Efficacy of Co-
Trimoxazole for Treatment and Prevention of Plasmodium falciparum Malaria: A Systematic Review. 
PLoS One. 2013;8(2):e56916. 
442. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance 
between trimethoprim and pyrimethamine. Lancet. 2001;358(9287):1066-7. 
443. Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, Otieno K, et al. Does cotrimoxazole 
prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant 
pathogens in Kenyan adults? Am J Trop Med Hyg. 2008;79(3):320-30. 
444. Malamba SS, Mermin J, Reingold A, Lule JR, Downing R, Ransom R, et al. Effect of 
cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the 
selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected 
household members. Am J Trop Med Hyg. 2006;75(3):375-80. 
264 
 
445. Klement E, Pitche P, Kendjo E, Singo A, D'Almeida S, Akouete F, et al. Effectiveness of co-
trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-
Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis. 2014;58(5):651-9. 
446. Mbeye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, Wandeler G. Cotrimoxazole 
prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and 
meta-analysis. Trop Med Int Health. 2014;19(9):1057-67. 
447. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing 
HIV infection. Geneva, Switzerland: World Health Organization, 2013. 
448. Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of 
intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of 
sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J. 2010;9(1):303. 
 
  
265 
 
9 ANNEXES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
266 
 
 Annex 1: STARD checklist for the reporting of studies of diagnostic 
accuracy 
 (Version January 2003) 
Section and Topic Item 
# 
 On page # 
TITLE/ABSTRACT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic accuracy (recommend MeSH 
heading 'sensitivity and specificity'). 
 
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic 
accuracy or comparing accuracy between tests or across participant 
groups. 
 
METHODS    
Participants 3 The study population: The inclusion and exclusion criteria, setting and 
locations where data were collected. 
 
 4 Participant recruitment: Was recruitment based on presenting symptoms, 
results from previous tests, or the fact that the participants had received 
the index tests or the reference standard? 
 
 5 Participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in item 3 and 4? If not, 
specify how participants were further selected. 
 
 6 Data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study)? 
 
Test methods 7 The reference standard and its rationale.  
 8 Technical specifications of material and methods involved including how 
and when measurements were taken, and/or cite references for index 
tests and reference standard. 
 
 9 Definition of and rationale for the units, cut-offs and/or categories of the 
results of the index tests and the reference standard. 
 
 10 The number, training and expertise of the persons executing and reading 
the index tests and the reference standard. 
 
 11 Whether or not the readers of the index tests and reference standard 
were blind (masked) to the results of the other test and describe any 
other clinical information available to the readers. 
 
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, 
and the statistical methods used to quantify uncertainty (e.g. 95% 
confidence intervals). 
 
 13 Methods for calculating test reproducibility, if done.  
RESULTS    
Participants 14 When study was performed, including beginning and end dates of 
recruitment. 
 
 15 Clinical and demographic characteristics of the study population (at least 
information on age, gender, spectrum of presenting symptoms). 
 
 16 The number of participants satisfying the criteria for inclusion who did or 
did not undergo the index tests and/or the reference standard; describe 
why participants failed to undergo either test (a flow diagram is strongly 
recommended). 
 
Test results 17 Time-interval between the index tests and the reference standard, and 
any treatment administered in between. 
 
 18 Distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition. 
 
 19 A cross tabulation of the results of the index tests (including 
indeterminate and missing results) by the results of the reference 
standard; for continuous results, the distribution of the test results by the 
results of the reference standard. 
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 20 Any adverse events from performing the index tests or the reference 
standard. 
 
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty 
(e.g. 95% confidence intervals). 
 
 22 How indeterminate results, missing data and outliers of the index tests 
were handled. 
 
 23 Estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done. 
 
 24 Estimates of test reproducibility, if done.       
DISCUSSION 25 Discuss the clinical applicability of the study findings.  
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 Annex 2: Patient information sheet (English version only) 
 The University Of Malawi College Of Medicine and the Liverpool School of Tropical Medicine 
are jointly doing a research study. We invite you to take part in this study. Before you decide whether 
to take part, it is important for you to understand why the study is being done and what it will involve. 
Please take the time to read the following information carefully. Ask us if there is anything that is not 
clear and if you would like more information. 
 
What is the purpose of the study? 
 Malaria is a common cause of anaemia (lack of blood) in pregnancy and can cause the baby 
to be born small and weak. Sometimes you can have malaria without feeling sick. To help prevent 
malaria in pregnancy, you would usually be given three tablets of sulphadoxine-pyrimethamine (SP 
or Fansidar) three or four times during pregnancy when you visit the clinic after you first feel the 
baby move. This strategy is called IPTp-SP, which stands for Intermittent Preventive Treatment in 
pregnancy with Sulphadoxine-Pyrimethamine. 
 Malaria parasites are now becoming resistant to SP, meaning that the drug may not work as 
well as it used to. We want to evaluate a new strategy for control of malaria in pregnancy called ISTp. 
ISTp stands for Intermittent Screening and Treatment in pregnancy, and consists of testing women 
for malaria three or four times during pregnancy, and, if they have malaria, treating them with a drug 
called dihydroartemisinin-piperaquine  (DHA-PQ), which is used to cure malaria. We want to 
compare the new strategy (ISTp) with IPTp-SP given three or four times. 
 
Why have I been chosen? 
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 We need women who are between 16 and 28 weeks pregnant, and who would normally be 
scheduled to receive IPTp-SP, to take part in this study. If you are less than 16 weeks pregnant, we 
would like you to join the study after you are 16 weeks pregnant, when you next come to the clinic.  
 
What will happen if I want to take part? 
If you think you would like to be in this study, we will first invite you to be screened, to see if 
you are suitable. If you agree we will first take a small amount of blood from your arm (about a 
teaspoon) and test it for anaemia and HIV, unless you have already had an HIV test in this pregnancy. 
Either then or later (perhaps after you join the study) we will do an ultrasound scan of your baby. An 
ultra-sound scan is a test which shows a moving picture of the baby inside you. You will be asked to 
lie down, a cool gel will be spread over your belly and a small machine will be moved gently over it. 
We will use the ultrasound picture to know when your baby is due to be born. Ultra-sound scans are 
completely painless and harmless to you and the baby. They are very common in Europe and 
America.   
If the blood tests show that you are suitable for this study, and you agree to take part, we will 
ask you some questions about your health. We will do a physical examination, measure your weight, 
and copy some information from your health passport and from the lab books. We will use the rest 
of blood sample that we have already taken to find out whether you have malaria, and the nurse will 
also do all the other routine tests that pregnant women usually have, unless you have already had 
these tests. If you consent, we will also send some of this blood sample abroad for special tests of 
your body’ resistance against the malaria parasite (immunity) and the resistance of the parasite. We 
will try not to prick your arm again at this appointment. The examination and tests will take about 
ten minute’s altogether.  
You will then open an envelope with a piece of paper inside which describes which treatment 
you will get. The treatment you get is decided by chance, like flipping a coin. It will be either: 
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- Group 1 - ISTp 
If you are in this group, we will test the blood sample for malaria using a rapid diagnostic test. The 
test results will take about 15 minutes. If the results show that you have malaria, we will give you 
DHA-PQ tablets to take in the clinic and some more tablets to take at home on the following day and 
the day after that. If you are given DHA-PQ, a fieldworker may visit you at home on the second day 
after your appointment to ask whether you have taken the tablets and whether you had any problems 
with them. You will only receive DHA-PQ if you have malaria. 
Or 
- Group 2 - IPTp-SP (current standard of care) 
If you are in this group you will be given three tablets of SP to take at the clinic. You will not be tested 
for malaria. 
 You will then be asked to return to the study clinic around two or three more times, when 
you will be given the same treatment that you received on your first visit. If you are tested for malaria 
at one of these visits we will take only a tiny amount of blood from a finger prick. At one of these 
visits, we will ask you for an additional blood sample, taken from a finger, which we will test for 
malaria at the end of the study. We will also use this 
blood sample to test you for anaemia. If we test you 
and find that you have anaemia, we will treat your 
anaemia at this visit.   
When you come for your clinic visits we will give you 
enough money for transport to and from the clinic 
and, if you miss lunch, for a light meal. You will also 
receive all other health care that pregnant women 
attending the clinic would usually receive. 
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We would like you to give birth to your baby in the maternity ward of the clinic so that we 
can check how you and the baby are doing. After your baby is born we will check the placenta for 
malaria (see picture).  
We will take a blood sample from your arm and test it for malaria, your level of immunity to malaria, 
and anaemia. We will measure your baby’s weight and give the baby a health check. If you want to 
give birth to your baby at home, we would like you to inform us as soon as possible when the baby is 
born, so we can visit you at home and collect information for the study.  
We would like to see you again with your baby when baby is seven days old and again when 
they are about six to eight weeks old, to check that you and your baby are still doing well. You will 
not need to make an extra journey to the clinic, as we will see you when you bring your baby for their 
routine vaccinations.  
If you are in the study, we would prefer that you do not take any medicine that is not provided by the 
clinic. If you feel unwell during the study you can come to the clinic. You will be seen by a qualified 
member of staff free of charge and will be given any treatment that you need.  
The information collected will be used by staff involved in the study and by scientists in 
Malawi and abroad. It will be kept confidential. Names and addresses will not appear on any of the 
study reports.  
 
What if I don’t want to be in the study? 
If you decide not to be in the study, you will receive all the usual health care that pregnant 
women attending the clinic usually receive. This will include getting three tablets of SP when you 
visit the clinic at least two times during pregnancy after you first feel the baby move, and again 
several times later in your pregnancy. You can change your mind and withdraw from the study at any 
time, and you do not have to give a reason if you do not want to.  
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What are the possible disadvantages and risks of taking part?    
 DHA-PQ is a very effective treatment for malaria. It has already been tested in pregnant 
women after 13 weeks of pregnancy and it does not seem to cause any harm to women or their babies. 
However, it is still quite a new drug and we cannot be completely sure that it will not have any side-
effects. If you appear to suffer bad side-effects during the study, we will stop your treatment with 
DHA-PQ. All babies will be given a thorough health check and any problems will be recorded. The 
study will be stopped if we suspect that DHA-PQ is causing health problems in the babies 
SP has been widely used during pregnancy, is very safe, and is given to all pregnant 
women who attend clinics in Malawi. You will also be given SP if you do not take part in the 
study.  
If do you become ill after taking DHA-PQ or SP, and we think it might be because of the drug, we may 
stop your treatment (not give you the same drug again) but if this happens we would still like you to 
continue in the study. 
 When we take blood, you may get a small bruise or mild pain on the finger or arm where the 
blood is taken. There is also a very small chance of infection; the chance is very small because we 
always use clean materials. 
 The study will require you to make more trips to the clinic than usual, which may be 
inconvenient. However, we will give you money to pay for the travel costs.    
Thank you very much for your time. Would you like to be screened to join the study? 
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 Annex 3: Study informed consent forms (English version only) 
9.3.1 Consent for screening 
Screening will involve taking a small sample of blood from your arm for testing, and possibly also an 
ultrasound scan. 
 
If you agree to be screened, this does not mean that you have to agree to be in the study, you can 
change your mind at any time. 
 
The above study has been explained to me and I agree to be screened to see if I am suitable to be in 
the study. 
Participant’s statement: sign or thumbprint on the appropriate line.  If the participant does not wish 
to consent, form should not be signed. 
 
The above has been explained 
to me 
I agree to be part of this study   
 
 
 
Participant’s name: 
 
Participant ’s signature: Date: (day/month/year) 
 
 
                                      
Witness’ statement (optional, except for illiterate participants): 
The above consent was explained and the woman agreed to be screened: 
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Witness’ name 
 
 
Witness’ signature Date: (day/month/year) 
 
                                         
Investigator’s name: 
 
Investigator ’s signature: Date: (day/month/year) 
 
 
 
9.3.2 Consent for inclusion in the study 
The above study has been explained to me and I agree to join. 
•   I have been told about the risks of and benefits of being in the study. 
•   I have been told that it is up to me if I want to join the study and that I can leave the study any 
time I want without any consequences for me and my baby.   
•   I agree to have a home visit by the study staff if I am not able to come to the study clinic. 
Participant’s statement: sign or thumbprint on the appropriate line.  If the participant does not wish 
to consent, form should not be signed. 
The above has been 
explained to me 
I agree to be part of this study   
 
Participant’s name: 
 
Participant ’s signature: Date: (day/month/year) 
 
                                       
Witness’ statement (optional, except for illiterate participants): 
The above consent was explained and the woman agreed to join the study: 
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Witness’ name 
 
Witness’ signature Date: (day/month/year) 
 
                                     
Investigator’s name: Investigator ’s signature: Date: (day/month/year) 
 
 
Contacts 
If you later have questions or concerns about your participation in this study, you may speak 
with one of our staff. If you have any questions about the study, or you feel your child has been 
harmed, please contact Dr. Linda Kalilani-Phiri at the College of Medicine, Private Bag 360, Blantyre 
3 or at phone number 01919776.  If you have any questions about your rights as a study participant, 
or if you want to talk about the study with someone who is not part of this research project, please 
contact Prof Mfutso-Bengo at the College of Medicine, Private Bag 360, Blantyre 3 or phone number 
01877291. 
9.3.3 Consent for transportation and storage of blood samples 
 
We would like to send part of the blood sample abroad for special tests of your body’ resistance 
against the malaria parasite (immunity) and the resistance of the parasite. We do not have the 
equipment to be able to do these tests in Malawi at present. 
We would also like to store a part of the blood sample collected in this research in case there 
are additional tests that we wish to perform after the study is over. The sample will be sent to the 
USA and stored there. We will not store your samples without your permission. 
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If you allow us to transport and store your samples, you may change your mind and withdraw 
up to one month after you complete the study. If you would like your samples to be removed 
from storage, you may contact Dr. ______________________ at phone number _______________. 
One month after you complete the study, we will remove your name from the blood 
samples sent for storage.  After your name is removed, we will not be able to take your 
samples out of storage if you change your mind.  Also, we will not be able to report any future 
test results to you.   
You can be in the study even if you do not want blood samples stored. 
Please check one of the boxes below to indicate whether you do or do not allow us to store 
your blood. 
 NO, I wish my blood samples to be destroyed immediately. 
 
        YES, I give permission for my blood samples to be stored anonymously  
 
Participant’s statement: sign or thumbprint on the appropriate line.  If the participant does not wish 
to consent, form should not be signed. 
 
The above has been explained 
to me 
I agree to be part of this study   
 
 
 
Participant’s name: 
 
Participant ’s signature: Date: (day/month/year) 
 
 
 
 
Witness’ statement (optional, except for illiterate participants): 
The above consent was explained and the woman agreed to join the study: 
 
Witness’ name 
 
Witness’ signature Date: (day/month/year) 
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Investigator’s name: 
 
Investigator ’s signature: Date: (day/month/year) 
 
 
 
 
